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ABSTRACT 
 
PRIMATE PROTEOMIC COMPOSITION OF SEMINAL PLASMA AND PROSTATE-
SPECIFIC TRANSGLUTAMINASE ACTIVITY IN RELATION TO SEXUAL SELECTION. 
 
 
 
By 
Amanda M. Colvin Zielen 
December 2017 
 
Dissertation supervised by Dr. Michael I. Jensen-Seaman 
Humans (Homo sapiens), chimpanzees (Pan troglodytes), and gorillas (Gorilla gorilla) 
have diverse mating systems with varying levels of sperm competition. Several seminal plasma 
genes have been claimed to evolve under positive selection, while others are altered or lost. This 
study aims to identify biologically relevant differences among seminal plasma proteomes of 
primates in relation to mating systems and previous genomic studies. Seminal plasma from three 
individuals of each species were run in triplicate in shotgun liquid chromatography – tandem 
mass spectrometry (LC-MS/MS) and confirmed with Western blots. Over 7,000 peptides were 
identified across all individuals; 168 proteins were identified with high confidence, 70 seminal 
plasma proteins were identified for human, 64 proteins for chimpanzee, and 34 proteins for 
gorilla. The gorilla seminal plasma proteome has higher variation among individuals and many 
proteins involved in semen coagulation and liquefaction have been lost. Chimpanzees have 
 v 
approximately 7-fold higher prostate specific transglutaminase (TGM4) expression than humans. 
TGM4 was not detected in gorillas, supporting pseudogenization of this gene. The structural 
semenogelin proteins, SEMG1 and SEMG2, were detected in high abundance in only one of 
three gorilla individuals, and in all three human and chimpanzee individuals. Chimpanzees have 
significantly higher expression of SEMG1 (~2.5-fold) compared to human; whereas, they only 
produce a small amount of SEMG2; ~6.5 –fold less than humans. Chimpanzees have roughly 34-
fold higher expression of a serine protease inhibitor, SERPINA3 (Serpin Family A Member 3), 
than humans. SERPINA3 paralogs, SERPINA1 and SERPINA5, also have increased expression 
(~2.5 –fold) compared to human, and only SERPINA1 was detected in gorilla. SERPINAs may 
delay protease dissolution of the copulatory plug in chimpanzees. Recombinant human TGM4 
and the reconstructed ancestral TGM4 sequence of our last common ancestor (LCA) with 
chimpanzees (the human-chimpanzee ancestor) proteins were produced and incubated with 
casein and monodansylcaverdine to determine enzymatic activity. The human-chimpanzee 
ancestor TGM4 had higher activity compared to human TGM4. Considering the importance of 
TGM4 in semen coagulation and copulatory plug formation in chimpanzee, the increased activity 
of the human-chimpanzee ancestor TGM4 may be indicative of elevated female promiscuity of 
our LCA, perhaps similar to a chimp-like mating system. 
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CHAPTER 1: Introduction 
1.1 Hominid evolution and physiology 
1.1.1 Hominid phylogeny 
 Hominoids, or apes, are divided into two families: hylobatidae (gibbons) and hominidae 
(hominids) and diverged from old world monkeys approximately 20 million years ago (mya).  
The hominids, or great apes, consist of human (Homo sapiens), chimpanzee (Pan troglodytes), 
bonobo (Pan paniscus), western and eastern gorilla (Gorilla gorilla and Gorilla beringei, 
respectively), and orangutan (Pongo pygmaeus) species (Figure 1.1). The major divergences 
within the hominid clade arose approximately 15 million years ago (orangutan), 7 Mya (gorilla), 
and 6 Mya (human-chimpanzee split) (Chen and Li, 2001). The taxonomic ranks assigned to 
some hominoid groups and their divergence times remain somewhat contentious, while the 
branching order is nearly universally accepted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Hominid phylogenic tree 
Orangutan diverged approximately 15 million years ago (mya) from the other hominids. Gorilla separated from the 
human-chimpanzee clade approximately 7 Mya, and the human / chimpanzee split occurred 6 Mya. Chimpanzee and 
Bonobo were separated geographically by the Congo River approximately 2 Mya, which led to speciation.  
Note: All photos are personal or available for free usage.  
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Orangutan 
Gorilla 
Chimpanzee Bonobo 
Human 
2 Mya 
 2 
1.1.2 Hominid physiology 
 The extant primates have multiple universal morphological characters, which distinguish 
them from other mammals. Perhaps the most known, is that primates have opposable thumbs and 
big toes, which allow them to grasp and hold objects with ease. Furthermore on all digits, the 
primates’ nails are flattened as opposed to claws seen in other mammals. The olfactory region in 
primates has been greatly reduced in most species, which allows for the expansion of the 
cerebrum. The areas of the brain that correlate with hand-eye coordination and stereoscopic 
vision (forward facing eyes) are enhanced compared to other mammals. Primates also have 
slower reproduction rates than mammals of similar size, which is a result of having an extended 
infant/juvenile stage in offspring. Typically primate species only have one to three offspring per 
pregnancy, and hominids usually only have one (Fleagle, 2013). My research mainly focuses on 
the hominids: human, chimpanzee, and gorilla species; therefore, they will be discussed in more 
detail.   
1.1.2.1 Gorilla species, biogeography, and life history 
 There are two species of gorilla, the western gorilla (Gorilla gorilla) and eastern gorilla 
(Gorilla beringei), existing in two distinct geographical ranges north and east of the Congo River 
basin, separated by about 1000 kilometers. Western gorillas are found throughout west Central 
Africa, as far north as southern Nigeria. Eastern gorillas are found east of the Congo River basin 
to the extreme north and southwestern edges of Rwanda and Uganda (Mitchell and Gonder, 
2013). The western gorilla comprises two subspecies: the western lowland gorilla (G. g. gorilla) 
and the Cross River gorilla (G. g. dielhi). The eastern gorilla comprises two subspecies: the 
eastern lowland gorilla (G. b. graueri) and the mountain gorilla (G. b. beringei) (Das et al., 
2014).  
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 Gorilla is the largest living primate, with females weighing up to 98 kg and males up to 
181 kg in the wild (Miller-Schroeder, 1997). In general, gorillas have black skin with thick dark 
brown or black hair covering their body, except for their face, hands, feet, and the male chest 
(Rowe, 1996). Dominant males, or silverbacks, have a pronounced sagittal crest and distinct 
gray, or “silver”, patch of hair on their backs and posterior end (Groves, 2004). Gorillas walk on 
their finger knuckles of the two digits closest to the thumb. This leaves the hand open, allowing 
them to carry objects as they walk on all fours (Fleagle, 2013).  
 Around six years of age, females experience menarche, or their first menstrual cycle.  
However, female gorillas remain infertile for two years post menarche. Female gorillas first 
parturition, or their first delivery, is around ten years of age (Czekala and Robbins, 2001). 
Gorilla infant stage is up to three years, and then they begin their juvenile stage (3-6 years of 
age), which shows a decrease in maternal grooming, weaning, and no longer sleeping in a nest 
with the mother (Stewart, 2001). Because of their long period of maternal dependence, gorilla 
mothers can expect to invest years caring for their altricial offspring, which coincides with their 
interbirth span of approximately 4 years (Czekala and Robbins, 2001). Although male gorillas do 
not take an active role in caring for infants, they are essential for their socialization, often 
associating with older infants and juveniles, and fighting off aggressive adult males (Stewart, 
2001). It is difficult to assess male gorilla reproductive maturity because they can be fertile 
before exhibiting secondary physical sexual characteristics (like gray hair). Males between the 
ages of 8 and 12 are called blackbacks (Robbins et al., 2004). Usually by age 12 or 13, males can 
be considered silverbacks, but most will not reach their full adult size until the age of 15 
(Czekala and Robbins, 2001). 
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1.1.2.2 Chimpanzee species, biogeography, and life history 
 Chimpanzees live north of the Congo River, and their congeneric species, bonobo, lives 
to the south. There are currently three geographically defined chimpanzee subspecies: P.t. 
troglodytes from central Africa, P.t. schweinfurthii from east Africa, and P. t. verus from west 
Africa (Ely et al., 2005). Although a fourth subspecies, P.t. vellerosus, located in northern 
Cameroon and Nigeria was proposed, it has not become widely accepted (Gonder et al., 1997).  
 Chimpanzees are black or dark brown in skin and hair color, have beards, and can 
become bald.  They are born with a pale face and hands, which darken with age (Rowe, 1996). 
Chimpanzees have a less pronounced snout and sagittal crest, and are smaller, as a male 
chimpanzee’s average weight is 34-70 kg and females are typically between 26-50 kg in the wild 
(Nowak, 1999). Chimpanzees are quadrupedal knuckle walkers, and walk with open hands, like 
gorilla (Fleagle, 2013). Chimpanzees have limited bipedalism, and are also able to be arboreal 
(Doran, 1996). 
 Female chimpanzees experience menarche between 8-11 years of age, although they 
typically have their first offspring around 13 years of age, which coincides with female natal 
dispersal. The interbirth interval is about four to six years, with a life span of about 40 years in 
the wild (Atsalis and Videan, 2009) In chimpanzees, hierarchy is mediated by male dominance, 
where the more dominant males copulate more than the less dominant males (Goodall, 1986; 
Whiten et al., 1999). Chimpanzee females may covertly, forced or willingly, leave the group 
with another male and/or mate with males from neighboring groups (Vigilant et al., 2001). 
Though these behaviors increase the female’s chance of reproductive success, they also increase 
the chance of male mediated infanticide of their offspring (Nishida and Kawanaka, 1985).  
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1.1.2.3 Human evolution and life history 
 Although the only extant hominin is modern humans (Homo sapiens), there are multiple 
extinct hominins that are on our lineage after the human-chimpanzee split (~6 Mya). The earliest 
hominin fossils were found in eastern and southern Africa from the Pliocene, and possibly as 
early as the late Miocene (Robson and Wood, 2008). Ardipithecus fossils have been found in 
eastern Africa and have been dated 4.2 - 5.8 Mya. Australopithecus fossils were found in eastern 
and southern Africa from the time period of 1.9 - 4.2 Mya. Paranthropus most likely lived 
between 1.2 – 2.7 Mya, and their fossils were mostly found in eastern and southern Africa. The 
genus Homo dates back to 2.3 Mya, and its species have a wide distribution of fossils found in 
Africa, Europe, Asia, and Indonesia (Potts, 2013). Genetic evidence supports an African origin 
of modern human (Homo sapiens), as well as at least two instances of admixture with other 
species of archaic humans (Homo neanderthalensis and Homo sapiens ssp. denisova) once 
modern humans had radiated out of Africa (Green et al., 2010; Reich et al., 2010).  
 Humans are unique from other apes with long legs, upright bodies, and large brains. Hair 
color in human populations ranges between shades of black, red, brown, and white; skin color 
ranges between multiple shades of brown. Men often have beards, but beard density and 
coverage varies greatly. Although hair covers the majority of the human body, most of it is 
shorter, fragile, less pigmented, and less dense than in other primates. This has led to the humans 
being described as the “naked ape”, or simply hairless (Newman, 1970; Pagel and Bodmer, 
2003). The human brain is bigger with an enlarged cranium, which lacks well-defined brow 
ridges and crests. In addition, human canine tooth size is greatly reduced, our premolars are 
wider, and often the third molar is absent or reduced in size (Fleagle, 2013). Human weight 
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varies, but on average humans are 42 to 78 kg. Men, on average, are 1.2 times heavier than 
women, and 1.06 times taller (Fleagle, 2013; Dixson, 2009) 
 Human females experience menarche between 9 and 13 years of age, and unlike other 
primates, will go through reproductive senescence, commonly known as menopause, around 50 
years of age. Females will then continue to live several decades as a post-reproductive individual 
(Kuhle, 2007). Human male fertility develops during the same time frame as females. Though 
different human societies have describable natal dispersal, there is no real gender-specific trend, 
with humans of both genders dispersing as well as maintaining familial relationships throughout 
life (Fleagle, 2013). 
1.2 Evolution of reproductive proteins  
1.2.1 Prediction of selection 
 Genes involved in reproduction have shown positive selection and rapid divergence 
among diverse animal groups as a result of sexual selection (Koisol et al., 2008; Ramm et al., 
2008; 2009). As selection has different effects on synonymous (dS) and nonsynonymous (dN) 
substitution rates, estimation of these rates is used to understand the selective forces (purifying, 
neutral, or positive) of sequences coding for proteins.  
 Synonymous and nonsynonymous nucleotide changes occur in a protein sequence. The 
encoded amino acid remains the same in synonymous base substitutions, while the amino acid is 
changed in nonsynonymous substitutions. The dN/dS value is calculated as the ratio of the rate of 
nonsynonymous substitutions divided by the rate of synonymous substitutions (dN/dS). A dN/dS 
value equal to 1 is consistent with the gene experiencing neutral evolution because the rate of 
nonsynonymous change is equal to the rate of synonymous change. If the dN/dS value is less 
than 1, then the gene is likely experiencing purifying selection. The rate of nonsynonymous 
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change is less than rate of synonymous change because the gene’s function is important, and 
nonsynonymous changes tend to be deleterious and selected against. A dN/dS value greater than 
1 is indicative of positive selection, in the form of recurrent selective sweeps. In this case, the 
rate of nonsynonymous change is greater than the rate of synonymous change because multiple 
changes in the amino acid sequence are adaptive. Defining selective forces using dN/dS ratios 
may be misleading as relaxation of selective constraint (i.e., pseudogenization, loss of function, 
etc.,) can appear as positive selection. For example, the mammalian insulin gene is highly 
conserved across species and dN/dS ratios indicate rapid positive selection in guinea pig and 
chinchilla insulin, while it is later argued that it is due to the absence of the zinc ion in their 
insulin and corresponding relaxation of conserved sites involved with zinc (King, 1969; Kimura, 
1986; Opazo et al., 2005).  
 Nonsynonymous substitutions are more likely to change the function of a protein than 
synonymous substitutions because they ultimately change the amino acid composition. However, 
some synonymous substitutions may affect protein abundance and interactions through codon 
usage bias, changes in regulatory binding sites, and changes in translation synthesis and folding 
(Sauna and Kimchi-Sarfaty, 2011). Some nonsynonymous changes are considered conservative 
(or neutral) and others are considered radical. The ratio of radical to conservative amino acid 
changes are used in predicting selection upon protein sequences in a similar fashion to how 
nonsynonymous/synonymous changes are used with gene sequences. Radical changes can be 
classified by volume and polarity, charge, or Grantham’s distance (1974): a physiochemical 
measure. Many human disease Amino Acid Substitution (AAS) prediction methods find 
radical/conservative ratios useful in a context of protein structure and sequence (Ng and 
Henikoff, 2006). Mutations that affect function are usually at evolutionarily conserved sites or 
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buried in protein structure (Saunders and Baker, 2002). Disease causing AASs are overabundant 
at conserved sites (Miller and Kumar, 2001) and 83% of disease causing mutations affect protein 
stability (Wang and Moult, 2001).  
1.2.2 Evolution of proteins with activity 
 Functional protein sequences are often located near other functional sequences (Keefe 
and Szostak, 2001; Taverna and Goldstein, 2002). However, mutations far away from catalytic 
active sites can influence protein function (Spiller et al., 1999; Shimotohno et al., 2001). A large 
fraction of random substitutions do not detectably change structure and function of a protein; 
they are usually modest and additive (Shortle and Lin, 1985; Pakula et al., 1986; Loeb et al., 
1989; Serrano et al., 1993; Bloom et al., 2006), yet small changes in structure or chemical 
properties can have substantial effects on catalytic function (Romero and Arnold, 2009). This 
may be explained by the reduction of fitness effects (either positive or negative) as an enzyme 
reaches optimal efficiency (Hartl et al., 1985). Most random mutations are considered 
destabilizing (Pakula et al., 1986; Matthews, 1995; Kumar et al., 2006). It has been shown that 
natural proteins are marginally stable with free energies (ΔG) between -5 and -15 kcal/mol 
(Fersht, 1999). If a mutation does not shift the thermodynamic stability of the overall protein it 
may persist.  
 Compensatory mutations are common in adaptive evolution and occur in the same gene 
as a deleterious mutation (Wang et al., 2002; Poon and Chao, 2005). Usually ten to twelve 
compensatory mutations are required for each deleterious mutation in a protein. A single amino 
acid change that is favorable in one protein dimension (function, stability, etc.) is most likely 
negative in other dimensions. Therefore, adaptive change in function probably demands a series 
of events to restore biochemical constraints (DePristo et al., 2005). However, globally expressed 
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protein-folding chaperones and heat shock proteins may offset unfavorable mutations in various 
adaptive proteins, reducing the number of gene-specific compensatory mutations, which is 
evident when they are inhibited or overexpressed (Rutherford, 2003; Sangster et al., 2004).  
 Most contemporary enzymes are thought to have evolved from promiscuous functions of 
ancestral proteins (Babtie et al., 2010). A promiscuous activity is an enzyme’s ability to catalyze 
an alternative function that is not its primary function. If promiscuous activity of a protein is 
physiologically insignificant to the overall function and stability of the protein, the promiscuous 
activity could persist (Jensen, 1976; O’Brien and Herschlag, 1999; Khersonsky et al., 2006). 
Promiscuous activities are usually less efficient than the primary function of an enzyme (O’Brien 
and Herschlag, 1999; Wolfenden, 2006; Jonas and Hollfelder, 2008; Tawfik, 2010). Promiscuity 
could play a biological role in organismal survival to environmental changes, and has been 
shown to contribute to observed tolerance of gene deletion in metabolic pathways (Kim and 
Copley, 2007). An experimental study of dehydroxyacetone kinase (DHAK) in Citrobacter 
freundii showed changes in amino acid composition had little effect on native enzymatic activity 
but increased promiscuous activity nearly 50-fold (Sánchez‐Moreno et al., 2009). Promiscuous 
activity can occur in numerous ways such as substrate similarities in hydrophobic binding, 
substrates utilizing the same catalytic functional groups, or the influence of different metal 
cofactors in active sites (Wang et al., 2003; Khersonsky and Tawfik, 2005; Afriat et al., 2006; 
Villiers and Hollfelder, 2009). 
 Evolutionary protein biochemists propose a conceptual framework for protein evolution 
similar to Wright’s adaptive landscape metaphor. Neutral Networks conceptualize a protein 
sequence space where one functional protein is linked to all other functional proteins that have a 
single nucleotide difference (Smith, 1970; Huynen et al., 1996; Tiana et al., 2000). Therefore, 
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evolution can move one mutation at a time (an adaptive walk) through a continuous network of 
functional proteins. Otherwise, mutations would always lead to lower fitness (Smith, 1970). 
Mutations that spread through neutral genetic drift may impact future evolution through altering 
the functional neutral network (DePristo et al., 2005). Therefore neutral and adaptive protein 
evolution may be coupled through protein thermodynamics and the ever changing neutral 
network (Bloom et al., 2007; Bloom and Arnold, 2009).   
 Proteins are undeniably complex and have to balance promiscuity, functionality, and 
stability to survive. Protein evolution depends on two critical factors: 1) induction of new 
phenotypic functions by a relatively low number of mutations (the simplest evolutionary path) 
and 2) reduction of lethality from beneficial mutations, in essence compensatory or back 
mutations (Aharoni et al., 2005). Utilizing neutrality tests, the prevalence of advantageous and 
compensatory mutations would be identified as positive selection (through increased abundance 
of nonsynonymous mutations), which would prove beneficial as a first indicator of protein 
evolution. Though the neutral theory may not be entirely correct, nor the statistical neutrality 
tests error free, they may provide a basis for identifying selection. However, neutrality tests can 
also produce false negative and positive results, and it is extremely important for further 
investigation. Nearly neutral mutations may increase a protein’s robustness, or ability to 
withstand additional (maybe beneficial) mutations (Bloom et al., 2006; Bloom et al., 2007). 
These nearly neutral mutations may open new paths for adaptation, including but not limited to 
optimizing functions, increasing promiscuity, or through gene duplication division of function.  
1.2.3 Eukaryotic regulation and its role in protein evolution 
 King and Wilson suggested that evolutionary changes between species could not come 
from protein sequence changes alone, as sequence similarity is high, particularly between human 
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and chimpanzee, yet the expression is quite different (1975). They hypothesized that the 
differences must be due to gene regulation. Regulation of genes occurs at every stage from DNA 
transcription to the final product, protein. Initiation of transcription is intensely regulated by both 
DNA sequences (cis-regulatory) and DNA-binding proteins (trans-regulatory). The basic 
genomic structure of a gene includes a promoter with a TATA box and transcription start site 
(TSS) commonly upstream of the first exon. However, additional cis-regulatory sequences, like 
enhancers, silencers, or insulators may be involved, and are usually located away from the gene 
(Maston, 2006). DNA mutations in these cis-regulatory regions can drastically affect the 
expression of their associated gene; whereas mutations in trans-regulatory factors would affect 
the expression of many genes involved in a pathway, or general transcription. Therefore, trans-
regulatory factors are most likely conserved and slow evolving, while cis-regulatory regions still 
have constraint, they are able to evolve faster than trans-regulatory factors (Arnone and 
Davidson, 1997).  
 After a eukaryotic gene is transcribed, pre-mRNA undergoes processing that ultimately 
affects the expression of the protein. Pre-mRNA transcripts can be alternatively spliced, which 
results in different isoforms of proteins. Depending on particular conditions one isoform may be 
expressed over another. The 5’cap and 3’ poly-A tail aid in mRNA stability, and the longer the 
mRNA is stable, the longer the transcript is used to produce protein (Proudfoot et al., 2002). In 
addition, a protein’s function and abundance is regulated through post-translational 
modifications, such as phosphorylation, glycosylation, lipidation, and ubiquitination. Essentially, 
a protein’s activity and function can evolve through regulation, protein-coding sequences, or a 
combination of the two. Though this dissertation focuses mainly on species differences in 
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abundance or function of proteins, these results should be supplemented with research addressing 
how those changes developed.  
1.3 Sexual selection 
 Darwin originally described sexual selection as the advantage some individuals have over 
others (of the same sex) in a species with respect to reproduction alone (Darwin, 1859; 1883). 
Darwin focused on “secondary characteristics” which involve ornamentation to attract mates or 
physical characteristics to combat other individuals, which today is often associated with 
precopulatory sexual selection. Though these attributes help acquire mates, there is also a behind 
the scenes battle of the sexes, referred to as postcopulatory sexual selection. Jones and 
Rattlerman suggested that “sexual selection arises from differences in reproductive success 
caused by competition for access to mates or fertilization opportunities” (2009). This modified 
definition incorporates both precopulatory and postcopulatory sexual selection (Table 1.1), 
which will be further defined in the following subsections. 
Table 1.1: Types of sexual selection and their anatomical and physiological adaptations 
 Precopulatory 
(Mating success) 
Postcopulatory 
(Fertilization success) 
Intersexual selection Female choice Female cryptic choice 
 • Nuptial gifts 
• Courtship (visual or 
vocal displays) 
• Ornamentation 
• ‘Healthier males’ 
• Modifying pH levels 
• Growing eggs to maturity 
• Preparing uterus for 
implantation 
• Allowing completion of 
copulation 
• Ejecting sperm 
Intrasexual selection Male to male combat Sperm competition 
 • Sexual dimorphism 
• Competition weaponry  
• Canines 
• Antlers 
• Increased levels of 
testosterone 
• Increasing sperm viability 
• Faster sperm motility 
• Stimulation of the reproductive 
tract 
• Formation of copulatory plug 
• Suppression of female chemical 
and immunological challenges 
to sperm 
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 In most cases of intersexual selection the female is the ‘choosey’ gender, while males are 
competitive for mates, and if given the opportunity, are more likely to mate with any female 
(Table 1.1). This gender bias in reproductive strategies seems likely due to the fundamental 
asymmetry of sex. In many species, females typically have a relatively large investment in 
producing offspring, beginning with using a lot of energy to produce a limited number of eggs, 
while their male counterparts can produce millions of sperm with ease. In addition to differences 
in gamete investment, females provide extensive care to offspring. However, there are several 
species where the sex roles are reversed and the males have a larger investment in offspring, like 
seahorses, where males are choosier and females become competitive (Berglund et al., 2005). 
1.3.1 Precopulatory strategies 
 Precopulatory strategies are mechanisms occurring before insemination, which increase a 
male’s chance of mating with a female. Both males and females influence the probability of 
individual females obtaining the sperm from certain male individuals. Mating success is 
determined by the number of successful matings an individual has over their lifetime.  
1.3.1.1 Intersexual precopulatory strategies 
 Female choice is the main form of precopulatory intersexual selection. A female may 
choose a mate for direct or indirect benefits. Direct benefits would include, but are not limited to, 
parental care, nuptial gifts, and territory defense. An indirect benefit is mating with a male that 
has perceived superior genes to aid in offspring survivability (Jones and Ratterman, 2009). These 
sexual signals come in many forms: acoustic (mating calls), visual (coloration or appendages), 
and chemical (i.e. pheromones), which provide information to females about male quality and 
potential mating benefits. 
 14 
 Fisher proposed that this type of ‘artificial selection’ by the female could lead to runaway 
selection, where if certain traits have a selective advantage in males, and become more prevalent 
in the population, then females will also evolve genes to prefer that phenotype (1915). If sexual 
selection was the only selective pressure, this ‘runaway selection’ could continue indefinitely 
with the males’ evolving more elaborate ornamentations and the females’ preference evolving to 
favor the extreme. Sexual selection is not the only prevalent force; thus, there must be an upper 
limit to ornamentation that intersects with an individual’s ability to survive (Pomiankowski and 
Iwasa, 1998).  
  Sometimes elaborate signals provide accurate information about the individual’s health, 
and other times they are falsely representative. An example of a ‘honest’ signal is that the 
survival of offspring positively correlates with the number of eye spots in a male peacock’s tail 
(Møller and Petrie, 2002; Loyau et al., 2005). In fiddler crabs, females prefer males with a larger 
claw; which also warns other males to choose their battles. If a fiddler loses its claw, it is able to 
regenerate a new claw to signal its ability to fight; however, the regenerated claw is a false 
signal, as it is actually weak (Backwell et al., 2000).  
1.3.1.2 Intrasexual precopulatory strategies 
 Precopulatory intrasexual selection includes male to male combat. Species that are 
adapted through intrasexual selection are typically sexually dimorphic (Gould and Gould, 1989), 
where males have an enlarged body size and enhanced fighting appendages. Male gorillas are 
much larger than females with well-developed muscles and strong jaws to aid in combat, in order 
to protect his territory and sole reproductive access of his harem of females. In addition to large 
size, animals have competition weaponry, Examples of competition weaponry include: large 
teethed claws in fiddler crabs, antlers in ungulates, tusks in walruses, and horned mandibles in 
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many beetle species (Emlen, 2008). While enlarged competition weaponry certainly aids in 
competition success, in return, they can be costly to the individual by requiring a lot of nutrition 
or maintenance, or the appendage weight and size could impede common tasks, like locomotion 
or eating, which are essential to survival.  
1.3.2 Postcopulatory strategies 
 Postcopulatory strategies increase a male’s probability of fertilizing the egg. The number 
of progeny sired per copulation describes fertilization success. Both males and females have 
adapted strategies suited for their respective reproductive goals in the battlegrounds of the female 
reproductive tract.  
1.3.2.1 Intersexual postcopulatory strategies 
 Intersexual postcopulatory strategies are those that involve cryptic female choice. These 
are female controlled processes that modulate a male’s chance for insemination. It is considered 
‘cryptic’ because it is hidden in the female reproductive tract (Birkhead and Pizzari, 2001). Some 
female controlled processes are modified pH levels, growing more eggs to maturity, producing 
eggs with more nutrients, preparing the uterus for implantation, ejecting sperm, and allowing 
completion of copulation (Eberhard, 2009). When seminal fluid enters the female reproductive 
tract, several alterations occur in the female. In some species, there is an increased clearance of 
microorganisms and extra spermatozoa, the maternal immune response is activated, tissue is 
remodeled, and cytokines and growth factors, are activated for pre-implantation embryo growth 
development (Robertson et al., 2002; Robertson, 2005).  
 Seminal plasma significance in uterine clearance has been studied in livestock species, 
and has indicated that increased inflammatory response to seminal plasma is positively correlated 
with implantation success (Robertson et al., 2002). The increased inflammatory response 
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increases the number of phagocytic cells in the cervix. Phagocytic cells target microorganisms 
and sperm with abnormal morphologies. The female reproductive tract may inactivate and 
sequester sperm to favor genetically superior or phenotypically more competent sperm 
(Robertson, 2005). It is inevitable that some viable spermatozoa will be destroyed as well.  
 Immunoregulatory molecules present in the seminal plasma, like TGFβ, protect the 
majority of sperm surface antigens from feminine rejection. In mice, TGFβ1 is originally 
inactive in the seminal vesicles and it becomes activated in the female uterus (Robertson, 2005). 
TGFβ was identified as the principle active immune component in human seminal plasma. This 
promotes partner-specific embryo implantation and is considered to be “priming.” The female 
reproductive tract is primed for an individual male until their immunoregulatory molecules are 
cleared (Robertson et al., 2002).  
1.3.2.2 Intrasexual postcopulatory strategies 
 Sperm competition is the major form of male-male postcopulatory intrasexual selection. 
Sperm competition was originally defined as “competition between the sperm of two or more 
males for the fertilization of a given set of ova” (Parker, 1970). Sperm competition strategies 
include increasing sperm viability, faster sperm mobility and capacitation, stimulation of the 
female reproductive tract, suppression of female chemical and immunological challenges to 
sperm, and in some species the formation of a copulatory plug (Ramm, 2008). A copulatory plug 
is a semi-solid gelatinous ejaculate that produces a barrier in the female reproductive tract, which 
is thought to aid in fertilization or have a “chastity-belt” function by blocking access to the ova 
from future mating males (Dixson and Anderson, 2004). In mammalian species with increased 
female promiscuity, there is heightened sperm competition. Increased sperm competition leads to 
changes in sperm morphology and abundance, physiological anatomy, and behavior in males.  
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 Sperm morphology and number are influenced by increased sperm competition. Sperm 
tend to be slightly smaller with a larger midpiece for better movement in species with high sperm 
competition (Dixon and Anderson, 2004; Ramm et al., 2009). The mitochondria that are required 
for flagellar movement are located in the midpiece, which would explain increased midpiece 
volume, for faster motility. In primates, midpiece volume has been correlated with mating 
systems and relative testis size (Figure 1.2: B; Anderson and Dixson, 2002; Dixson and 
Anderson, 2004). Under increased sperm competition, males have a higher sperm count, larger 
volume of ejaculate, and a greater number of ejaculations than species with lower sperm 
competition. There is a fitness cost to increased sperm production, and male gametic investment 
should reflect species levels of female promiscuity and degree of sperm competition (Ramm et 
al., 2008). 
  To amplify spermatogenesis production, seminiferous tubular tissue is expanded, 
resulting in larger testes size in relation to body weight. This has been shown in some bats 
(Hosken, 1997), porpoises (Fontaine and Barrette, 1997), primates (Short, 1979; Harcourt et al., 
1981; Harcourt et al., 1995; Kappeler, 1997), metatherian mammals (Rose et al., 1997; Taggart 
et al., 1998), and eutherian mammals (Kenagy and Trombulak, 1986). Mammalian species with 
larger relative testes have been shown to produce higher sperm count per ejaculate, and within 
species those with larger relative testes size have increased reproductive success (Dixson, 1998). 
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Figure 1.2: Primate sperm competition phenotypes 
A) Primates in multi-male mating systems (orange circles) have relatively large testes compared to body size than 
males with single-male mating systems (blue circles). Data are from Harcourt et al., 1981 and the graph was redrawn 
from Dixson, 2012. B) Sperm midpiece volume is correlated with relative testes to body size ratio. Primates with 
multi-male mating systems have a larger midpiece volume and a larger testes to body size ratio. The graph was 
redrawn from Dixson, 2012, which Dixson incorporated data from their previous publications. C) Average 
frequency of ejaculations in primate genera having 1) multiple partner mating systems (blue bar, n=6) compared to 
single partner mating systems (black bar, n=6), and 2) large relative testes size (orange bar, n=5) compared to small 
relative testes sizes (white bar, n=7). Primates of multi-male mating systems and those with a relatively large testes 
to body size ratio ejaculate more frequently (**p <0.01; (Mann–Whitney U-test)) than primates of single-male 
mating systems and those with a smaller testes to body size ratio, respectively. This graph was redrawn from Dixson 
and Anderson, 2004; which incorporated unpublished data and data from Dixson, 1995. D) Chimpanzee and 
macaque, primates with multi-partner mating systems (orange bars), have increased velocity of sperm compared to 
human and gorilla, with single-male mating systems (blue bars). This graph was redrawn and modified from 
Nascimento et al., 2008. 
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 Anatomical reproductive features may be reduced or lost in species with relatively low 
sperm competition. There are significant anatomical differences between single-partner and 
multi-partner mating systems, which are associated with penile length, baculum length, and 
distal complexity (Figure 1.3; Dixson, 2009). A human-specific loss of regulatory DNA in front 
of the androgen receptor locus was hypothesized to have led to the loss of male penile spines in 
humans. It was concluded that this regulatory DNA deletion was not deleterious to humans 
because of our mostly monogamous mating system (McLean et al., 2001). However, these 
anatomical traits are also associated with copulation time, which has not been well correlated 
with mating systems. In species with shorter copulation times, the penile bone has been reduced 
or lost. This has been shown in hyenas, humans, and tarsiers. Likewise, in species with longer 
copulation times, mammals have an elongated penile bone, which has been shown in some 
pinnepeds, bats, stumptail macaques, and galagos (Dixson and Anderson, 2004). 
Figure 1.3: Morphological penile differences among multi-partner and single-partner 
mating systems  
Penile morphologies are more complex in primate genera where females mate with multiple males (multi-male / 
multi-female or dispersed mating systems, defined as multi-partner) than genera where females typically mate with a 
single male during estrus (monogamous or polygynous mating systems, defined as single partner). Data are from 48 
primate genera and show the number of genera that received either a 4 or 5 (on a 5 point scale) for various traits (*p 
<0.05). Graph was redrawn from Dixson (2012) and data was from Dixson, 2009.  
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1.4 Primate sperm competition, physiology, and seminal plasma proteins 
1.4.1 Primate mating systems, sperm competition, and reproductive physiology 
 Gorillas (Gorilla gorilla) have a polygynous mating system where multiple females mate 
with a single dominant male during estrus (Watts, 1990). A gorilla troop usually has a silverback 
male, several females, and dependent offspring, with an average size of 10 individuals with a 
maximum of 20. The smallest group size begins with one male and one female (Harcourt, 1978). 
The troop may also include a young reproductive subordinate male, or ‘black back’, from within 
the group for a short period of time (Robbins et al., 2005). The subordinate males in the group 
form non-threating relationships with the females consisting of protection, food, and grooming. 
Conversely, they try to sneak fertilizations with estrous females, which are often interrupted by 
the silverback who may guard the females from these advances (Watts, 1996). These subordinate 
males may migrate from the group alone, in search of a mate, wait for the dominant male to die, 
or leave with a non-related female group member (Bradley et al., 2005). Mountain gorillas are 
unique in that some groups may have two related, or unrelated reproductively successful 
silverbacks, with a dominant silverback siring the majority, but not all, of the offspring (Bradley 
et al., 2005). Gorilla sperm competition is likely to be low and gorillas have relatively small 
ejaculate volume (Seager et al., 1982; Dixson, 1997).  
 Chimpanzees (Pan troglodytes) have multi-male/multi-female mating systems, where a 
female will mate with multiple males in rapid succession during estrus (White, 1996). During 
estrus, female chimpanzees exhibit prominent “sexual swelling” of the urogenital skin, 
presumably to attract males. Groups have many adult males with high levels of male kinship, and 
many adult females with little to no kinship. Chimpanzees have a fission-fusion society (Fleagle, 
2013; White, 1996; Dixson, 2012) with small foraging groups regularly splitting and rejoining. 
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Chimpanzees and closely related bonobos (Pan paniscus) are the only hominoids to form a 
copulatory plug and produce a relatively large volume of ejaculate (Dixson, 1997; Dorus et al., 
2004; Dixson and Anderson, 2004). 
 The human mating system is a challenge to classify due to societal differences, but most 
humans are monogamous or polygynous, where we define monogamy as the tendency to mate 
with a single male during any given cycle (Marlowe, 2000). Humans, when compared to all other 
primates, have the most diversity in their social organization (Fleagle, 2013). Notably, humans of 
both genders participate in fission-fusion, where often familial members will separate themselves 
from their mates and offspring to participate in activities with other individuals of both genders 
before returning to their familial unit (Aureli et al., 2008). Humans live in many social settings, 
with any number of individuals that are related or unrelated, male or female, and of various ages. 
There are cultural constraints specific to each population that determine how humans 
interact/live within their environment, and how they think about their interactions (Costa et al., 
2001; Özer et al., 2013, Fleagle, 2013). The aforementioned variability makes it difficult to 
categorize humans into any one social or mating system (Fleagle, 2013). Relative testis weight to 
body size suggests that humans are polygynous, but with more sperm competition than gorillas 
(Harcourt et al., 1981; Dixson 2009). Using sperm midpiece volume and mitochondrial density, 
humans look more monandrous than chimpanzee (Anderson and Dixson, 2002; Anderson et al., 
2007). Humans have sexually dimorphic characteristics, where males are larger than females and 
have facial hair, a more muscular build, an enlarged larynx, and a deepened voice (Dixson, 
2012). This dissertation will consider humans as mostly monogamous with relatively moderate 
levels of sperm competition, compared to low levels of sperm competition in gorilla, and higher 
levels of sperm competition in chimpanzees.  
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 Although these are generalizations, mating systems with higher female promiscuity are 
projected to have higher sperm competition (Karr and Picnick, 1999; Dixson and Anderson, 
2001; Birkhead and Pizzari, 2002). Primate species that experience high sperm competition have 
been shown to have larger testes to body size ratio (Figure 1.2: A; Harcourt et al., 1981). Sperm 
midpiece volume, likely important in sperm motility, is positively correlated with relative testes 
size (Figure 1.2: B; Anderson and Dixson, 2002; Dixson and Anderson, 2004). Similarly, 
seminal vesicles are larger in species with higher sperm competition (Dixson, 1997). The number 
of ejaculations (Figure 1.2: C; Dixson, 1995; Dixson and Anderson, 2004), concentration of 
motile sperm, volume of sperm midpiece, and movement of sperm increase (Figure 1.2: D; 
Nascimento et al., 2008) with higher sperm competition. 
Figure 1.4: Summary of hominid mating systems, sperm competition, and physiology 
This summary presentation is original and visually describes mating system, ejaculate volume and consistency, 
relative testes size, level of sexual size dimorphism, and relative level of sperm competition of hominids (reviewed 
in section 1.4.1). For testes weight to body size ratio, the size of the circles represent the relative size of testes, with 
the larger circles indicating a larger ratio. For male to female body size, the male/female symbols represent 
approximate size of each gender in relation to the other. Section 1.1 provides more detail about body size differences 
of these primates.  
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1.4.2 Seminal plasma proteins 
 Semen is the product of five main organs in primates: the testes, epididymis, prostate, 
seminal vesicles, and the Cowper gland (Mann and Lutwak-Mann, 2012). Seminal plasma, the 
liquid portion of semen separated from spermatozoa, affects various aspects of fertilization, 
including: sperm motility, female immunological suppression, female receptivity, sperm storage, 
and copulatory plug formation. Seminal plasma provides energy and buffers the acidity of the 
vagina, containing proteins, lipids, sugars, potassium, sodium, calcium, magnesium, and zinc 
(Owen and Katz, 2005).  
  Proteomic studies show that seminal plasma proteins vary between individuals in 
humans and rodents (Oliva et al., 2008; Ramm et al., 2008); however, there is a need for 
proteomic studies assessing differences between species. Currently, there has only been one 
other study conducted on non-human primate seminal plasma, and as of yet, it has only been 
written in a dissertation (Claw, 2013). They reported that the most abundant proteins across 
multiple primate species were involved in semen coagulation and liquefaction, and particularly 
the copulatory plug pathway for some mating systems with high female promiscuity. These 
proteins were semenogelin 1 and 2, prostate specific transglutaminase, kallikrein related 
peptidase 3, and prostatic acid phosphatase; at least one of these proteins was within the top five 
most abundant proteins in each species, despite the associated mating system (Claw, 2013). The 
aforementioned abundant seminal plasma proteins are important to all subsequent chapters of 
this dissertation; therefore, they will be discussed extensively in this introduction chapter.  
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1.4.2.1 Semenogelin proteins 
1.4.2.1.1	Structure	of	SEMG1	and	SEMG2	genes	
 The human semenogelin genes, SEMG1 and SEMG2, are duplicated genes located 
adjacent to one another on human chromosome 20. The locus in which they are located is called 
the Wap four-disulfide core (WFDC) domain locus, which contains the semenogelin genes, PI3, 
EPPIN, SLPI, 3 SPINT genes, and 11 WFDC genes (Peter et al., 1998; Clauss et al., 2002). Both 
SEMG1 and SEMG2 have a conserved gene structure consisting of three exons (Figure 1.5:A; 
Ulvsbäck et al., 1992). The first exon has a leader and a signal peptide coding sequence, the 
second exon encodes for the entire secreted peptide sequence, and the third exon is non-coding. 
The timing of the gene duplication, which resulted in primate SEMG1 and SEMG2, is estimated 
to be 61 million years ago and is perhaps thought to be the result of homologous recombination 
between LINE - L1 elements (Lundwall, 1996). 
 SEMG1 and SEMG2 genes vary in length among and within primate species due to 
expansion of 180 base pair repetitive units in the second exon. These repetitive units account for 
greater than 80% of the coding sequence, and are split into three groups based on sequence 
similarity (Lundwall and Lazure, 1995). Exon 2 of human SEMG1 has two (a and b) of each type 
of 60 amino acid repeats (I, II, and III) and exon 2 of human SEMG2 has four (a, b, c, and d) 
repeats of type I, two (a, b) repeats of type II, two (a, b) repeats of type III (Figure 1.5:B; Lilja 
and Lundwall, 1992). Type I repetitive units are the putative sites for transglutaminase cross-
linking activity (Zalensky et al., 1993; Robert et al., 1997; Ulvsbäck and Lundwall, 1997; Robert 
and Gagnon, 1999), which is believed to be important in the functionality of the SEMG proteins; 
it is interesting that the SEMGs differ among species mainly in the number of type I repeats. The 
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number of repeats in exon 2 of SEMG1 is more variable than the number of repeats in SEMG2 
across primates (Figure 1.5:C; Jensen-Seaman and Li, 2003).  
 Since the duplication in primates, the SEMGs have undergone numerous rearrangements, 
pseudogenizations, open reading frame expansions, deletions, and homogenizations. This is often 
a trademark of duplicated gene fate, where conservation of both genes in the ancestral form is 
rare. Neo-functionalization may occur when one of the genes gains a new function, but most 
commonly, sub-functionalization occurs with function preservation in one gene and 
complementary loss of function in the other gene (Zhang, 2003). Several deletions have occurred 
in New World monkeys; the cotton-top tamarin (Saguinus oedipus) only has SEMG1 due to the 
deletion of the SEMG2 gene by insertion of a LINE1 element (Ulvsbäck and Lundwall, 1997; 
Lundwall and Olsson, 2001). The owl monkey (Atous nancymaae) has a single chimeric 
semenogelin due to an Alu insertion, which resulted in a SEMG1-like exon 1 and intron 1 and a 
SEMG2-like exon 2, intron 2, and exon 3 (Hurle et al., 2007).  
 There is a wide distribution of premature stop codons within the protein coding sequence 
(Figure 1.5: D) among the primates. Only human, orangutan, vervet, colobus, and the marmoset 
seem to have full-length functional copies of both SEMGs. Chimpanzees, bonobos, and baboons 
have a premature stop codon in the coding region of SEMG2 and gibbons have a premature stop 
codon in SEMG1 (Jensen-Seaman and Li, 2003; Dorus et al., 2004; Hurle et al., 2007). Gorillas 
have premature stop codons in exon 2 of both SEMGs; in SEMG1, gorillas are polymorphic for 
three premature stop codons, in SEMG2 they are polymorphic for two premature stop codons 
(Jensen-Seaman and Li, 2003).  
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Figure 1.5: SEMGs genomic and protein structure 
A) Schematic of SEMG1 (blue) and SEMG2 (red) on the q arm of human chromosome 20 (12-13.1). Both paralogs 
have three exons, with the solid color region representing either the signal peptide or protein coding sequence, and 
the outlined regions represent regulatory regions. SEMG1 is 2.7 kb in length, there is 11.5 kilobases between 
paralogs, and SEMG2 is 3.1 kb in length (UCSC genome browser). B) Schematic of human SEMG1 (blue) and 
SEMG2 (red) proteins and location of 60 amino acid repeats: I, II, and II (Lilja and Lundwall, 1992). C) SEMG1 
has variability in amino acid repeats across hominoid species. Expansion of Ia repeats are numbered, with orangutan 
having the most (Jensen-Seaman and Li, 2003). D) SEMG1 and SEMG2 genes have premature stop codons located 
in some of the hominoid species. Black symbols indicate fixed premature stop codons located in either SEMG1 
(blue) or SEMG2 (red) exons; whereas, white symbols represent polymorphic premature stop codons (Jensen-
Seaman and Li, 2003). All figures are original or redrawn from sources indicated above.  
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linages (Table 1.2; Dorus et al., 2004). Strikingly, the pattern of selection on both genes seems to 
correlate with higher levels of polyandry, or female promiscuity, and the degree of semen 
coagulation (Dorus et al., 2004) with the more rapidly evolving lineages being those that have 
the highest level of sperm competition.  
Table 1.2: Rates of SEMG2 evolution compared to species level of polyandry*  
Species Mating system Mean number of male partners per estrus 
dN/dS 
 
Gorilla Polygynous ~1 0.61 
Colobus monkey Polygynous ~1 0.70 
Gibbon Monogamous ~1 0.89 
Orangutan Dispersed 1-2 0.88 
Human Various 1-2 0.91 
Macaque Multi-male / Multi-female ~3 1.28 
Chimpanzee Multi-male / Multi-female ~8 2.52 
 *Reproduced from Dorus et al., 2004 
1.4.2.1.2	Expression	and	function	of	Semenogelin	proteins	
 SEMG1 and SEMG2 are mainly expressed in the seminal vesicles in vast quantity 
(Bjartell et al., 1996; Lundwall et al., 2002; Koistinen et al., 2002; Yoshida et al., 2003), but also 
have expression (although lower) in the vas deferens, prostate, epididymis, and trachea. In 
addition to the above, SEMG1 has some expression in the gastro-intestinal tract and skeletal 
muscle, while SEMG2 has some expression in the kidney and testes (Lundwall et al., 2002).  
 In humans, the semenogelin paralogs share 78% identity in their amino acid sequence 
(Lilja et al., 1989); however, they differ in molecular weight by approximately 20 kilodaltons 
(kDa). SEMG2 is between 71 and 76 kDa (depending on glycosylation state) and SEMG1 is 
approximately 52 kDa (Lilja et al., 1985; Lilja and Lundwall, 1992; Malm et al., 1996). Non-
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covalent interactions and the covalent cross-linking of semenogelins generate a coagulum, which 
is stabilized by zinc and traps spermatozoa (Jonsson et al, 2006; Malm et al., 2007). In addition 
to semen coagulation, the semenogelins have known functions in inhibiting sperm motility 
(Robert and Gagnon, 1995), sperm capacitation (de Lamirande et al., 2001), and antimicrobial 
properties (Bourgeon et al., 2004; Edström et al., 2008; Mitra et al., 2010). Upon ejaculation 
semenogelin proteins adhere to the surface of the sperm and form an eppin complex through 
covalent crosslinkage. The eppin complex provides antimicrobial protection for sperm (Mitra et 
al, 2010; O’Rand et al., 2011).  
 After seminal coagulation, the SEMGs are cleaved by seminal fluid peptidases, KLK3 
(Kallikrein related peptidase 3, also known as PSA; Lilja, 1985) and to a lesser extent by ACPP 
(Prostate acid phosphatase, also known as PAP; Brillard-Bourdet, et al. 2002), facilitating 
liquefaction of semen. Semenogelins are a specific substrate for KLK3 and are rapidly 
fragmented when in solution together (Peter et al., 1998; Robert and Gagnon, 1999; Jonsson et 
al., 2006). The cleavage of semenogelin releases bound and trapped spermatozoa (Robert et al., 
1997; Flori et al., 2008).  
1.4.2.2 Prostate specific transglutaminase  
 Prostate specific transglutaminase (TGM4) is a calcium dependent enzyme involved in 
semen coagulation and copulatory plug formation by crosslinking semenogelin (SEMG1 and 
SEMG2) proteins at glutamine and lysine residues (Greenberg et al., 1991; Folk, 1983; Esposito 
and Caputo, 2004). The gene coding for TGM4 is located on human chromosome 3 (Dubbink et 
al., 1996; Dubbink et al., 1998).  In gibbons, gorillas, and other species with relatively low sperm 
competition, TGM4 has become a pseudogene (Clark and Swanson, 2005; Carnahan and Jensen-
Seaman, 2008; Tian et al., 2009). TGM4 knockout mice had reduced fertility and were unable to 
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form a copulatory plug, a common phenotype in mice (Dean, 2013).  The expression of TGM4 
can be upregulated by retinoic acid (Pasquali et al., 1999; Rivera-Gonzalez et al., 2012) and is 
down regulated by the steroid hormone androgen (Dubbink et al., 1998; Rivera-Gonzalez et al., 
2012). 
1.4.2.3 Kallikrein related peptidase 
 Kallikrein related peptidase (KLK3), otherwise known as prostate specific antigen (PSA) 
is a trypsin-like serine protease involved in semen liquefaction by cleaving semenogelin 
(SEMG1 and SEMG2) proteins at serine residues (Lilja et al., 1987; Jonsson et al., 2005; 
Jonsson et al., 2006; Lundwall and Brattsand, 2008; Andrade et al., 2010). KLK3 originated from 
a gene duplication of KLK2 approximately 42 million years ago (Olsson et al., 2004). A study 
has identified chimeric KLK3-KLK2 fusion genes in Gorilla (Gorilla gorilla) and gibbon 
(Nomascus leucogenys), a result of gene duplication and relaxation of selective pressures 
(Marques et al., 2012). Active and functional KLK2 and KLK3 genes are associated with higher 
female promiscuity (chimpanzees), while the dysfunction of one or both genes is associated with 
lower female promiscuity or monogamy (Marques et al., 2012).  
 Kallikreins are known to work in cooperation with one another in proteolytic cascade 
pathways, with one KLK activating another (Pampalakis and Sotiropoulou, 2007). KLK2 self-
activates, and then cleaves and activates proenzyme KLK3 in the liquefaction process of seminal 
plasma (Pampalakis and Sotiropoulou, 2007; Lundwall and Brattsand, 2008). KLK2 and KLK3 
are expressed in the prostate (Lovgren et al., 1997). KLK3 is mostly studied in association with 
prostate cancer because increasing levels of KLK3 (PSA – prostate specific antigen) is a clinical 
indication of prostate cancer (Schieferstein, 1999; Loeb and Catalona, 2007). Though KLK3 has 
been studied in association with fertility, there have not been any significant findings in humans; 
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moreover, mice knockout models are fertile. However, there is a slight negative correlation 
between sperm motility and KLK3, and a negative correlation of KLK3 to fructose concentration 
(Schieferstein, 1999). 
1.4.2.4 Prostatic acid phosphatase ACPP 
 Tissues such as the prostate, brain, kidney, liver, lung, muscle, placenta, salivary gland, 
spleen, thyroid, and thymus express prostatic acid phosphatase (ACPP) (Goldfarb et al., 1986; 
Solin et al., 1990; Kong and Byun, 2013). In fact, ACPP is the most abundant phosphatase in 
human prostatic tissue (Hassan et al., 2010). ACPP is a homodimer of two non-covalently 
associated subunits, each of which is approximately 50kDa. Homodimerization is necessary for 
catalytic activity (Kuciel et al., 1990).  
 ACPP is located on human chromosome 3. There are two protein isoforms, intracellular 
and extracellular, which are encoded from this single gene. The smaller of the two, isoform 1, 
has 10 exons and encodes the secreted form of ACPP found in semen. The longer of the two, 
isoform 2, with 11 exons, contains a transmembrane domain and is intracellular (Winqvist et al., 
1989, Li and Sharief, 1993). The intracellular and secreted isoproteins differ in isoelectric point 
values and biochemical properties, but are similar in that they both hydrolyze organic 
phosphomonoesters in acidic conditions (pH 4-6) (Vihnko et al., 1978; Lin et al., 1983; Lad et 
al., 1984). The secreted isoprotein is a 100kDa homodimeric glycoprotein, which is only secreted 
by columnar epithelial cells in the prostate gland at a concentration around 1mg/mL (Röhnberg 
et al., 1981; Solin et al., 1990; Lee et al., 1991; Shan et al., 2003). Each ACPP monomer has two 
domains. The larger domain is a seven-stranded β-sheet with α-helices on each side. The smaller 
domain is composed of six α-helices (Lee et al., 1991; Kuciel et al., 1996; Ortlund et al., 2003). 
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  As a member of a family of enzymes known as acid phosphatases, the phosphatase 
activity of ACPP is optimal in acidic conditions. Dephosphorylation of orthophosphoric 
monoesters and phosphorylated proteins by this enzyme are optimal in a pH range of 3-6 
(Zelivianski et al., 1998; Brillard-Bourdet et al., 2002). In addition to the phosphatase activity, 
ACPP acts as a protease, hydrolyzing the cleavage of SEMG1 substrates preferentially at 
Tyr136, Tyr292, and Gln266 amino acid residues (Brillard-Bourdet et al., 2002). The proteolytic 
role of ACPP is associated with its extracellular function related to seminal liquefaction and has 
an optimal activity around a pH of 9 (Brillard-Bourdet et al. 2002).  
 An unknown protease within seminal fluid cleaves ACPP. Cleaved peptides that remain 
stable contain amino acids 85-120 or 248-286, which then form amyloid fibrils called Semen-
derived Enhancer of Virus Infection (SEVI) (Münch et al., 2007). Amyloid fibrils, which are 
insoluble aggregates formed from cleaved fragments of ACPP or SEMG1, enhance HIV 
infectivity (Münch et al., 2007; Roan et al., 2011; 2014). SEVI increases infectivity several 
magnitudes (Münch et al., 2007), with its positively charged residues which interact with 
negatively charged HIV virions in order to target the cell membrane to promote attachment and 
uptake of the virus (Roan et al., 2011). Similarly, an amyloid fibril produced by SEMG1 (amino 
acids between 86-107), enhances HIV infection by 30-fold in vitro (Roan et al., 2011; 2014). 
This peptide possesses an overall positive charge that helps it bind to HIV-1 virions and 
augments infection (Münch et al., 2007). 
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1.5 Experimental goals 
 In this dissertation I aim to fully identify abundant seminal plasma proteins among 
multiple human, chimpanzee, and gorilla seminal plasma samples (Chapter 2). Proteins that are 
expressed in high abundance in one species compared to another species are likely important in 
producing the phenotypic differences in seminal fluid as a result of high or low sperm 
competition. I will also include a closer look at proteins (like SEMG1 and SEMG2) that have 
been predicted by others to be under positive selection and/or pseudogenization across the 
hominids.  Finally, I take a comparative approach to understand the functional molecular 
evolution of an important enzyme in semen coagulation and copulatory plug formation, prostate-
specific transglutaminase (TGM4), by examining the activity of recombinant human, 
chimpanzee, and the hypothetical human-chimpanzee ancestor proteins (Chapter 3).  
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CHAPTER 2:  Proteomic composition of seminal plasma proteins in gorilla, 
human, and chimpanzee 
2.1 Introduction 
 Many reproductive, immunological, and sensory genes appear to have evolved under 
positive selection in mammalian lineages (Kosiol et al., 2008). Specifically, male reproductive 
proteins are claimed to evolve rapidly in primates and other taxa (Torgerson, 2002; Jensen-
Seaman and Li, 2003; Dorus et al., 2004; Clark and Swanson, 2005; Panhuis, 2006, Haerty, 
2007; Carnahan and Jensen-Seaman, 2008). This rapid evolution has been attributed to forces 
including sperm competition, pathogen resistance, sexual conflict, and heterospecific avoidance 
(Swanson and Vacquier, 2002). Though many seminal proteins have shown this pattern in single 
gene studies, in large-scale computational studies, sexual selective pressures do not appear to 
affect the overall evolution of extracellular reproductive proteins (Dean et al., 2009; Findlay and 
Swanson, 2010; Wong, 2011). Rather sexual selection exerts strong pressure on proteins that are 
either tissue specific or have functions related to immunity and peptidase activity (Good et al., 
2013, Carnahan-Craig and Jensen-Seaman, 2014).  
2.1.1 Primate mating systems and sperm competition 
 Extant hominids are closely related but differ dramatically in social structure and mating 
systems. Gorilla (Gorilla gorilla) has a polygynous mating system where a female usually mates 
with a single dominant male during estrus (Watts, 1990). Chimpanzee (Pan troglodytes) has 
multi-male/multi-female mating systems, where a female will mate with multiple males in rapid 
succession during estrus (White, 1996). The human (Homo sapiens) mating system is a challenge 
to classify due to societal differences, but most humans are monogamous or polygynous, where 
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monogamy is defined as the tendency to mate with a single male during any given cycle 
(Marlowe, 2000).  
 Although these are generalizations, mating systems with higher female promiscuity are 
projected to have higher sperm competition (Karr and Picnick, 1999; Dixson and Anderson, 
2001; Birkhead and Pizzari, 2002). Primate species that experience high sperm competition have 
been shown to have larger testes to body size ratio (Harcourt et al., 1981); similarly, seminal 
vesicles are larger in species with higher sperm competition (Dixson, 1997). Concentration of 
motile sperm (Møller, 1988), volume of sperm midpiece (Dixson and Anderson, 2004), and 
movement of sperm (Nascimento et al., 2008) increases with higher sperm competition. 
Chimpanzee and closely related bonobo (Pan paniscus) are the only hominoids to form a 
copulatory plug and produce a relatively large volume of ejaculate (Dixson, 1997; Dorus et al., 
2004; Dixson and Anderson, 2004). Gorilla sperm competition is likely to be low (Dixson, 
1997), and they have relatively small ejaculate volume (Seager et al., 1982; Dixson, 1997). 
Different levels of sperm competition lead to varying levels of positive, purifying, or neutral 
evolution on reproductive genes. Genes involved in semen coagulation have been shown to be 
positively selected for in species with higher sperm competition (Dixson, 1997; Jensen-Seaman 
and Li, 2003; Dorus et al., 2004; Carnahan and Jensen-Seaman, 2008).  
2.1.2 Shotgun proteomics and seminal plasma proteins 
  As DNA sequencing becomes more efficient and economical, the increased availability 
of complete genome sequences of species has accelerated research in multiple fields, especially 
proteomics. Shotgun proteomics, a term created by Yates (1998), is a method of analyzing a 
complex mixture of proteins through liquid chromatography of proteolytically digested proteins. 
Shotgun proteomics has been used to identify proteins from reproductive fluids, including but 
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not limited to, seminal fluid, prostatic secretions, and follicular fluid (Pilch and Mann, 2006; 
Drake et al., 2010; Ambekar et al., 2013). Within primates, human seminal fluid is the only 
primate in which the proteome has been comprehensively characterized (Pilch and Mann, 2006; 
Fung et al., 2004). Proteomic studies show that seminal plasma proteins vary between 
individuals in humans and rodents (Martinez-Heredia et al., 2008; Ramm et al., 2008); however, 
there is a need for proteomic studies assessing differences between species.  
 Currently, there has only been one other study conducted on non-human primate seminal 
fluid, and as of yet, it has only been written in a dissertation (Claw, 2013). They reported that the 
most abundant proteins, across multiple primate species, were involved in semen coagulation and 
liquefaction. These proteins were SEMG1, SEMG2, TGM4, KLK3, and ACPP (all were 
discussed extensively in section 1.4.2); at least one of these proteins was within the top five most 
abundant proteins in each species, despite the associated mating system (Claw, 2013). As 
mentioned before, genes encoding proteins involved in semen coagulation have been shown to 
be positively selected for in primate species with increased female promiscuity (Dixson, 1997; 
Jensen-Seaman and Li, 2003; Dorus et al., 2004; Carnahan and Jensen-Seaman, 2008). 
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2.2 Methods 
 This methods section is broken into five subcategories: 1) Seminal plasma sample 
preparation, 2) SDS-PAGE optimization, 3) Western blot optimization, 4) Quality control 
checks, and 5) Methods for comparative proteomics among human, chimpanzee, and gorilla 
seminal plasma. Subsections 2.2.1.1. and 2.2.5 provide descriptions of optimized methods 
utilized to address my experimental goals.  
2.2.1 Seminal plasma sample preparation 
2.2.1.1 Sample preparation 
 Semen samples were provided by three healthy non-vasectomized human volunteers (Lee 
BioSystems, St. Louis, MO) and from three healthy non-vasectomized chimpanzees trained to 
voluntarily provide samples (ID#95A016, age 16; ID#99A003, age 12; and ID#95A018, age 16), 
housed at the New Iberia Research Center (New Iberia, LA). Semen was obtained from three 
gorillas (Studbook IDs 835, 883, and 612), via electrojaculation under sedation. Individuals 835 
and 883 are brothers. Human samples were obtained under approval from the Institutional 
Review Board of Lee BioSystems. Chimpanzee and gorilla samples were obtained under 
Institutional Animal Care and Use Committee approval of the University of Louisiana at 
Lafayette and the Henry Doorly Zoo (Omaha, NE), respectively. Samples were stored at -80°C 
until analysis. In the case of human and gorilla samples, an aliquot of each individual was 
centrifuged (13,000xg, 5 min, 4° C) to pellet sperm cells and the supernatant was used for further 
analysis. For chimpanzee, the coagulated semen samples were first allowed to partially liquefy at 
37°C for 3 hours. From the resulting liquid fraction of each individual an aliquot was centrifuged 
(13,000xg, 5 min, 4° C), and the supernatant was used for further analysis.  
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2.2.1.2 Protein quantification 
 Protein concentration was determined using either the Qubit® Protein Assay Kit 
(Thermofisher Scientific, Waltham, MA) or the Bradford protein assay (Bio-Rad, Hercules, CA). 
For the Qubit® Protein Assay, seminal samples were diluted 1:20 or 1:200 before assaying. 
Either 1, 5, or 10µl of diluted sample was added to Qubit® protein assay buffer (1µl reagent in 
199µl buffer) with the total volume being 200µl. Samples were vortexed, incubated for 5 
minutes, and then the fluorescence was measured with the Qubit 2.0 fluorometer (Life 
Technologies, Carlsbad, CA). This kit used three standards to generate a standard curve and 
calculated sample concentration in relation to fluorescence. In the Bradford assay, seminal 
samples were undiluted or diluted 1:20 before assaying. Then 20µl of sample was added to 1mL 
of Bio-Rad Bradford assay dye, mixed, and incubated for 5 minutes. Absorbance at 595nm was 
measured using the Genesys 10 UV spectrophotometer (Thermo Spectronic, Rochester, NY). 
Utilizing 7 BSA standards, a standard curve was manually generated relating absorbance to 
mg/mL concentration. Sample concentration was calculated by solving for “x” using the standard 
slope equation generated by the standards. For comparison purposes, 1-10 µl of the 7 BSA 
standards were cross-assayed using the Qubit® protein assay; likewise 20 µl of the 3 Qubit 
protein standards were cross-assayed using the Bradford assay.   
2.2.2 SDS-PAGE optimization 
 Chimpanzee ‘Little Joe’ seminal plasma was used initially for SDS-PAGE optimization 
of seminal fluid. A volume of seminal plasma containing 10µg of protein (1:20 diluted and 
undiluted) was mixed 1:1 with Laemmli buffer (Bio-Rad) and 5% β-mercaptoethanol; and was 
incubated at 95°C for 10 minutes. Samples were loaded onto a 10% SDS-PAGE gel (Invitrogen) 
and run at 200 volts for 20 minutes. The gel was stained with coomassie stain (0.05% coomassie 
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R-250, 50% methanol, 40% dH2O, and 10% glacial acetic acid) for thirty minutes and destained 
overnight. A pooled human semen sample (donor number: T3402; named ‘Human #4’) was 
ordered from Lee BioSystems, St. Louis, MO. Varying concentrations (5µg, 10µg, and 15µg) of 
Human #4 seminal plasma were separated on a 10% SDS-PAGE gel and stained as described 
above.  
 On several occasions, commercial gels were compared to poured 10% gels, as well as a 
poured 6-10% stacking gel. Either 10µg or 20µg of seminal plasma (human or chimpanzee) was 
mixed 1:1 with Laemmli buffer (Bio-Rad) and 10% β-mercaptoethanol and was incubated at 
95°C for 10 minutes. Samples were loaded into either a poured or commercial gel and ran at 110 
volts for 15 minutes, and then 220 volts for thirty minutes. Gels were stained and destained as 
described above. However, after 2014, a commercial coomassie (Li-COR, Lincoln, NE) stain 
was used instead, followed with an overnight destain with dH2O, and imaged on the FC odyssey 
imager (Li-COR).  
2.2.3 Western blot optimization 
2.2.3.1 Abnova primary antibodies for highly abundant seminal proteins 
 Initial Westerns were performed with a polyclonal mouse anti-SEMG1 antibody because 
SEMG1 and SEMG2 are the most abundant proteins in human semen (Lilja et al., 1989). A 
volume of human seminal plasma containing 5, 10, or 15µg of protein was separated on a 10% 
SDS-PAGE (Invitrogen), as described above. An Immuno-Blot® PVDF (Bio-Rad) membrane 
was activated in methanol for one minute, and incubated in chilled Towbin Transfer Buffer 
(25mM Tris, 192 M glycine, and 20% methanol, with a pH 8.3) with the separated gel and other 
cassette components for 10 minutes. The Western sandwich was assembled and put into the mini 
Trans-Blot® (Bio-Rad) chamber with an ice pack. The apparatus was placed on a stir plate with 
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agitation, and proteins were transferred at 95 volts for 75 minutes. After transfer several control 
checks were made. The SDS gel was stained and destained, to check if any proteins remained. 
Before continuing, the PVDF membrane was incubated in a 0.5% Ponceau S (Sigma Aldrich, St. 
Louis, MO) and 1% glacial acetic acid solution for one minute and rinsed with dH2O to observe 
transferred protein. The PVDF membrane was incubated in dH2O until all of the Ponceau S dye 
dissipated. After the control checks, the PVDF membrane was incubated in SuperBlock PBS 
(Thermofisher Scientific) for 30 to 90 minutes. Mouse anti-SEMG1 (Abnova, Jhongli, Taiwan) 
was diluted (1:5,000) in SuperBlock PBS and placed on the PVDF membrane and incubated 
overnight at room temperature. The blot was washed three times with PBS for 15 minutes. Then 
a 1:12,000 dilution of Immunopure goat anti-mouse IgG peroxidase conjugated secondary 
antibody (Thermofisher Scientific) in SuperBlock PBS was added to the PVDF membrane and 
incubated for one hour at room temperature. Afterwards the blot was washed three times with 
PBS for fifteen minutes, and detected with the Pierce ® ECL Western blotting substrate kit 
(Thermofisher Scientific) using the typhoon 8600 (Molecular Dynamics, Sunnyvale, CA). 
 Human albumin, an abundant protein in bodily serum (Pilch and Mann, 2006) was 
Western blotted. A volume of human seminal plasma containing 5, 10, or 15µg of protein was 
separated on a 10% SDS-PAGE (Invitrogen), as described above. Proteins were transferred to an 
Immuno-Blot® PVDF (Bio-Rad) and blocked in SuperBlock PBS (Thermofisher Scientific) as 
described above, except transfer occurred at 100 volts for 75 minutes. Monoclonal mouse anti-
Albumin (Abnova) was diluted (1:5,000) in SuperBlock PBS, dispensed over the PVDF 
membrane and incubated overnight at room temperature. Three different secondary antibodies 
and detection methods were tested, including Immunopure goat anti-mouse IgG peroxidase 
conjugated antibody and Piece ® ECL detection as described above. In addition, peroxidase 
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conjugated antibody incubation was combined with SIGMAFAST™ 3, 3’- Diaminobenzidine 
(Sigma Alderich) tablet detection following the product’s protocol. A different secondary 
antibody, goat anti-mouse IgG alkaline phosphatase conjugated antibody (Themofisher 
Scientific), was diluted 1:1,000 with SuperBlock PBS and covered the transferred membrane for 
one hour at room temperature. Following normal PBS washes, the PVDF membrane was washed 
with 0.05M Tris-HCL, pH 8, for ten minutes at room temperature. FastRed detection solution 
was made immediately before use and was made with 0.01g Napthol AS-MX phosphate and 
0.02g FastRed (Sigma Aldrich) in 10mL of 0.05M Tris-HCL, pH 8, solution. FastRed detection 
solution covered the membrane and once bands developed (within a few minutes), the solution 
was removed and the membrane was rinsed with dH2O, and imaged on a scanner. In addition to 
seminal plasma, purified human albumin (Sigma Aldrich) and bovine serum albumin 
(Thermofisher Scientific) were made in a dilution series (62.5ng to 5,000ng and 125ng to 
5,000ng, respectively) and separated on a 10% SDS-PAGE (Invitrogen), as described above. 
Proteins were transferred to a PVDF membrane at 100 volts for 60 minutes, and blocked with 
SuperBlock PBS for 30 minutes. The membrane was incubated in mouse anti-albumin primary 
antibody diluted in Superblock PBS (1:5,000 or 1:50,000) overnight, and detected with FastRed.  
2.2.3.2 Dot blot to confirm secondary antibody effectiveness 
 To determine if goat anti-mouse IgG alkaline phosphatase conjugated antibody 
(ThermoFisher Scientific) was active, a dot blot was performed. Both a dry PVDF membrane 
(not activated in methanol) and a dry nitrocellulose membrane absorbed 2µl of secondary 
antibody. The membrane was incubated with SuperBlock PBS for ten minutes, washed with PBS 
twice for ten minutes, and was detected with FastRed, as described above.  
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2.2.3.3 Purified actin dilution series 
 In order to compare several different Western blotting protocols and detection systems, a 
dilution series of bovine actin was detected with a monoclonal mouse anti-actin antibody. Bovine 
actin (Sigma Aldrich) was reconstituted in Tris-EDTA, pH 8, to a concentration of 1mg/mL. A 
dilution series (3ng/µl, 6 ng/µl, 12 ng/µl, 25ng/µl, 50ng/µl, and 100ng/µl) of actin was made, 
which was chosen based on Urban and Woo (2007). The dilution series (5µl) was prepared with 
2:1 Laemmli buffer and 10% β-ME separated on a 10% SDS-PAGE (Invitrogen), as described 
above. Proteins were transferred at 100 volts for 75 minutes. Post-transfer, the PVDF membrane 
was blocked in SuperBlock PBS for 30 minutes, and was incubated in monoclonal mouse anti-
actin antibody (Sigma Aldrich) overnight, which was either diluted 1:5,000 or 1:50,000 in 
SuperBlock PBS. Washes were performed in PBS for either three times for 15 minutes or three 
times for 5 minutes. Both goat anti-mouse alkaline phosphatase conjugated and peroxidase 
conjugated antibodies were diluted in SuperBlock PBS in the following dilutions: 1,1,000 or 
1:50,000. Both FastRed and Pierce® ECL detection systems were used. Several membranes were 
stripped and re-probed. After detection, the PVDF membrane was incubated in stripping buffer 
(1.5% glycine, 0.1% SDS, and 1% Tween20) twice for 10 minutes at room temperature, then 
washed twice with PBS for 10 minutes, and lastly washed twice with TBST for 5 minutes. The 
stripped membrane was incubated in SuperBlock PBS for 30 minutes and downstream 
procedures continued.  
2.2.3.4 Optimization of secondary antibodies 
 Varying concentrations of secondary goat anti-mouse IgG alkaline phosphatase 
conjugated antibody (Themofisher Scientific) were tested using 5µl of Magic Mark™ 
(Invitrogen) ladder separated on the same 10% SDS-PAGE gel and PVDF membrane. Once 
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transferred, the PVDF membrane was cut into 5 strips, blocked with SuperBlock PBS, incubated 
with the following secondary antibody dilutions: 1:1,000; 1:5,000; 1:25,000; 1:50,000; and 
1:100,000. After washes, the individual strips were detected with FastRed solution, described 
previously.  
 After several attempts with Abnova primary antibodies, rabbit polyclonal anti- SEMG1 
and rabbit polyclonal anti- SEMG2 (Abcam, Cambridge, UK) were optimized with human and 
chimpanzee seminal plasma. First 1, 5, 10, 15, 20, and 50µg of human seminal plasma were 
separated on a 10% SDS-PAGE (Invitrogen), as described above. Proteins were transferred to an 
Immuno-Blot® PVDF (Bio-Rad) membrane at 100 volts for 60 minutes and blocked in 
SuperBlock PBS (Thermofisher Scientific) for thirty minutes. Membranes were incubated with 
either 1:1,0001 or 1:5,000 primary anti-SEMG1 or anti-SEMG2 antibody diluted in SuperBlock 
PBS overnight. Membranes were washed three times for five minutes in PBS. Goat anti-rabbit 
alkaline phosphatase (Abcam) conjugated antibody was diluted (1:25,0002; 1:40,0003; 1:50,000) 
in Superblock PBS and the membrane was incubated for an hour at room temperature. FastRed 
detection was used as described above.  
2.2.3.5 Membrane transfer optimization 
 Besides optimizing wet transfer (using the mini Trans-Blot® Bio-Rad apparatus) voltage 
and times, a semi-dry iBlot® (Thermofisher Scientific) system was tested for comparison 
purposes. Volumes of human and chimpanzee seminal plasma containing 20µg of protein (in 
duplicate) were separated on a 10% SDS-PAGE (Invitrogen) at 150 volts for 90 minutes. The 
10% SDS-PAGE gel was carefully cut between lanes 5 and 6, separating identical halves. One 
                                                
1 Optimal primary antibody dilution for both anti-SEMG1 and anti-SEMG2 Abcam antibodies 
2 Optimal secondary antibody dilution for SEMG2 detection 
3 Optimal secondary antibody dilution for SEMG1 detection 
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half was transferred using the semi-dry iBlot® transfer system in seven minutes to an Immuno-
Blot® PVDF (Bio-Rad) membrane. The membrane was kept wet in dH2O, until the second half 
of the gel was transferred using the Trans-Blot® system to an Immuno-Blot® PVDF membrane 
(100 volts for 60 minutes). Both membranes were blocked for 45 minutes in SuperBlock PBS, 
rinsed three times for five minutes in PBS, and then incubated with rabbit polyclonal anti-
SEMG2 antibody (1:10,000; Abcam) overnight. After incubation, the membrane was washed 
three times with PBS for five minutes, and incubated with goat anti-rabbit alkaline phosphatase 
conjugated antibody (1:25,000) for one hour at room temperature. FastRed detection was used, 
as described above.  
 Previously my lab detected cartilage acidic protein (CRTAC1) in high abundance in 
chimpanzee seminal plasma using liquid chromatography tandem mass spectrometry (LC/MS-
MS), which was 142.2 fold higher relative abundance compared to human seminal plasma 
(Chovanec et al., unpublished). To further characterize this difference, 10µg of three human and 
three chimpanzee seminal plasma samples were separated on a 10% SDS-PAGE (Invitrogen), as 
described above. Proteins were transferred to an Immuno-Blot® PVDF (Bio-Rad) membrane at 
100 volts for 75 minutes and blocked in SuperBlock PBS (Thermofisher Scientific) for thirty 
minutes. Monoclonal mouse anti-CRTAC1 (Abnova) was diluted (1:1,0004; 1,5,000; or 
1:50,000) in SuperBlock PBS, dispensed over the PVDF membrane and incubated overnight at 
room temperature. The membrane was washed three times in PBS for five minutes. Several blots 
were incubated with goat anti-mouse alkaline phosphatase conjugated antibody (1:1,000; 
1:50,000) for one hour at room temperature. FastRed detection was used, as described above. In 
addition, a single blot was cut in half post transfer and incubated in either PBS or TBS for all the 
washes, and detected using FastRed and alkaline phosphatase conjugated secondary antibody. 
                                                
4 Optimal primary antibody dilution for anti-CRTAC1 Abnova antibody 
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Several blots were incubated with goat anti-rabbit peroxidase conjugated antibody (1:1,000; 
1:15,000; 1:20,000) for one hour at room temperature. After washes, blots were detected with 
either Pierce ® ECL or Pierce ® ECL Supersignal Western blotting kit, in a comparison study, 
using X-ray film.  
2.2.3.6 Anti-pilin detection 
 Because natural seminal plasma samples were used for our Western blots, bands were 
often not single, and multiple variants of cross-linked, monomeric, and degraded of proteins 
were detected. Furthermore, it was sometimes unclear if the signal was truly related to our 
protein of interest, or if it was background signal due to our blotting protocol. In order to address 
these concerns during our optimizations of Western blotting protocols, hospital samples of 
Pseudomonas aeruginosa isolates were borrowed from Dr. Castric’s lab, along with their 
optimized primary antibody. Samples were separated on a 10% SDS-PAGE (Invitrogen), at 150 
volts for 60 minutes. Proteins were transferred to an Immuno-Blot® PVDF (Bio-Rad) membrane 
at 100 volts for 30 minutes and blocked in SuperBlock PBS (Thermofisher Scientific) for thirty 
minutes. The PVDF membrane was incubated in primary monoclonal mouse anti-pilin (1:1,000) 
antibody overnight at room temperature, and then was washed three times in PBS for five 
minutes. The blot was incubated with either goat anti-mouse alkaline phosphatase or peroxidase 
conjugated antibody (1:10,000) for sixty minutes. FastRed or Pierce® Supersignal Western 
blotting substrate kit were used for detection with their respective secondary antibodies.  
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2.2.4 Quality control checks 
2.2.4.1 Loading control Western blot 
 All of the seminal proteins we study are extracellular proteins; therefore common 
intracellular controls, like β-actin, are not applicable. In addition, there are few, if any, published 
papers that include an extracellular protein control for seminal plasma. Using LC/MS-MS data of 
human and chimpanzee seminal plasma (Chovanec et al., unpublished), a few candidate proteins 
had similar moderate abundances in each individual and species. Each candidate protein’s NCBI 
sequence for human, chimpanzee, gorilla, orangutan, and macaque were aligned using Clustal 
Omega to identify differences among species. Clusterin was moderately abundant, conserved, 
and had several commercial antibodies available. Clusterin was Western blotted as described in 
section 2.2.5.2.  
2.2.4.2 Protease inhibitor assay 
 A new-pooled individual semen sample (donor number: T2566, named: ‘Human 5’) was 
ordered from Lee BioSystems, St. Louis, MO. The semen was frozen at -80°C upon arrival; the 
sample was thawed on ice and aliquoted (250µl) into three tubes. One tube had 2.5µl of the 
following protease inhibiters added: BCl-, apo, benzamide, and DMSF (gifted from the Cascio 
lab). Another tube had 2.5µl mammalian protease inhibitor premade cocktail (Sigma Aldrich) 
added. Subsequent aliquots (50 µl) were made and incubated at the following temperatures: 4°C, 
23°C, and 37°C for 80 minutes. Samples were quantified using the Bradford assay (Bio-Rad) and 
10µg was loaded onto a 10% SDS-PAGE gel (Invitrogen) and either coomassie stained or 
Western blotted (Li-COR method) with an anti-SEMG1 or anti-SEMG2 antibody (Abcam). 
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2.2.5 Methods for comparative proteomics among human, chimpanzee, and gorilla 
seminal plasma 
2.2.5.1 Shotgun Liquid Chromatography Tandem Mass Spectrometry LC-MS/MS 
2.2.5.1.1	LC/MS-MS	sample	preparation	
 Three human, chimpanzee, and gorilla individual seminal plasma samples (described in 
section 2.2.1.1) were precipitated as follows. Equal volume of trifluroethanol, TFE (Sigma 
Aldrich), was added to 25µl 100mM ammonium bicarbonate, pH 7.5 (Sigma Aldrich), 2.5µl 
200mM dithiothreitol, DTT (Bio-Rad), and a volume of seminal plasma containing 30µg of total 
protein. Samples were heated at 90°C for 20 minutes; 10µl of 100mM iodoacetamide, IAM 
(Sigma Aldrich), was added and incubated for 60 minutes in the dark. To destroy excess IAM, 
2.5µl of 200mM DTT was added and incubated in the dark for 60 minutes. Samples were dried 
with a speedvac and reconstituted with 100mM ammonium bicarbonate (pH 7.5). Samples were 
cold acetone (2X) precipitated, dried with a speedvac, and reconstituted in 50µl of 100mM 
ammonium bicarbonate (pH 7.5). Samples were digested with trypsin (Promega, Madison, WI) 
overnight at 37°C in a 1:50 enzyme to substrate concentration. Formic acid was added to stop 
trypsin activity and samples were dried with a speedvac; then reconstituted in 20µl of 0.1% 
formic acid.  
2.2.5.1.2	LC/MS-MS	conditions	
 A collaborator, John Thomas, working in the laboratory of Dr. Partha Basu, completed 
the analysis of generated peptides from the tryptic digestion. The system used for peptide 
analysis was a 6530 Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA), 1200 
series liquid chromatography (Agilent Technologies), HPLC-Chip Cube MS interface (Agilent 
Technologies), and an HPLC-Chip with a 160 nL enrichment column (Agilent Technologies). 
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Peptides were separated using a 150 mm × 75 mm analytical column packed with Zorbax 300 
SB-C18 (5 mm particles). For each injection, 2µl of peptides were loaded onto the enrichment 
column with 95% solvent A (95% water, 5% acetonitrile, 0.1% formic acid) with a sample flush 
out factor of 10.0 times the injection volume. The system maintained a 95% solvent A 
concentration for the first 5 minutes of the run. They were then eluted with a gradient from 5% B 
(95% acetonitrile, 5% water, 0.1% formic acid) to 55% B in 45 minutes, 80% in 55 minutes, at a 
flow rate of 0.5 µl/min. The total runtime, including column reconditioning, was 60 minutes. The 
column effluent was directly coupled to the 6530 Q-TOF mass spectrometer via a HPLC-Chip 
Cube nanospray source operated at capillary voltage 1950 V with a capillary voltage in 2GHz 
extended dynamic range. The MS data was acquired in the positive ionization mode using Mass-
Hunter Workstation (Agilent Technologies, Build 5.01.5125.1). Gas temperature, drying gas 
volume, fragmentor voltage, skimmer voltage, and octopole RF were set to 365°C, 4 L/min, 175 
V, 65 V, and 750 V, respectively. Auto MS/MS was performed with a total cycle time of 1.3 
seconds. In each cycle, MS spectra was acquired at 4 Hz (5 spectra per sec; m/z 250-2400) and 
the three most-abundant ions (with charge states +2, +3, > +3, and unknown) exceeding 1000 
counts were selected for MS/MS at 3 Hz (3 spectra per sec; m/z 50-3200). Medium isolation (4 
m/z) window was used for precursor isolation. Equation 2.1 was used to determine the collision 
energy based on charge state and precursor m/z. Table 2.1 presents the parameters for the 
calculation of the collision energy. Reference mass correction was activated using reference 
masses of 299.294437 m/z and 1221.990637. Precursors were set in an exclusion list for 0.5 min 
after two MS/MS spectra. 
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𝐶𝑜𝑙𝑙𝑖𝑠𝑜𝑛 𝐸𝑛𝑒𝑟𝑔𝑦 = 𝑠𝑙𝑜𝑝𝑒 × 𝑚𝑧100 + 𝑂𝑓𝑓𝑠𝑒𝑡 
Equation 2.1: Equation used to calculate Collision energy 
Table 2.1: Parameters for collision energy calculation. 
Charge Slope Offset 
2 3 2 
3 3.6 -4.8 
>3 3.6 -4.8 
Unknown 3.6 -4.8 
 
2.2.5.1.3	LC/MS-MS	spectra	data	processing		
 Collision induced dissociation (CID) data was searched against Homo sapiens, Pan 
troglodytes, and Gorilla gorilla gorilla databases. The data files were extracted to generate peak 
lists using Spectrum Mills Proteomic Workbench (Agilent Technologies, Rev B.04.01.141) with 
the following attributions: precursors were between 250 to 2400 Da over the scan time of 0 to 60 
minutes, scans with the same precursor ±1.4 m/z were merged within a time frame of ±30 
seconds. Precursor ions needed to have a minimum signal to noise value of 25. Charges up to a 
maximum of 7 were assigned to the precursor ion, and the 12C peak was determined by the Data 
Extractor. The databases were searched for tryptic peptides with a product mass tolerance of ±0.7 
Da for the precursor ions and a tolerance of ±1.2 Da for the fragment ions. Two missed 
cleavages were allowed and the minimum tag length was >3 with at least 4 detected peaks. The 
search mode was set to “Identity” with carboamidomethylation as fixed modification. A 
Spectrum Mills autovalidation was performed first in the protein details followed by peptide 
mode using a.) in protein details mode; protein score ≥20, peptide score (scored percent intensity 
[SPI]) charge +2 (>6, >60%), peptide charge +1 (>6, >70%), peptide charge +3 (>8, >70%), 
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peptide charge +4 (>8, >70%), peptide charge +5 (>12, >70%), peptide charge +2 (>6, >90%), 
and rank 1 minus rank 2 score threshold 2 for the first 5 rules and 1 for the final rule; b.) in 
peptide mode: SPI charge +2 (>11, >60%), peptide charge +1 (>13, >70%), peptide charge +3 
(>13, >70%), peptide charge +4 (>13, >70%), peptide charge +5 (>15, >70%), and rank 1 minus 
rank 2 score threshold ≥2. All protein hits found in a distinct database search by Spectrum Mill 
are non-redundant. When an individual peptide matched to more than one species database, it 
was prioritized as follows: a) if the database match was to a protein from the same species as the 
sample origin, that annotation was used; b) else, if the peptide matched to the human database, 
that annotation was used; c) else, if the peptide matched to another species, that annotation was 
used. 
2.2.5.1.4	Manual	mapping	of	SEMG	peptides	
 The automated mapping to NCBI databases described above misidentified SEMG1 and 
SEMG2 peptides. Therefore, all the SEMG identified peptides were manually mapped; unique 
peptides were identified to either SEMG1 or SEMG2 sequences. Table 2.2 includes the 
accession numbers to the SEMG sequences utilized for each species. Downstream quantification 
analysis used my manual SEMG assignment opposed to the computational database search 
assignment.  
Table 2.2: SEMG sequences used for peptide mapping 
Protein name Accession number 
Human SEMG1 AAB59506.1 
Human SEMG2 AAA60562.1 
Chimpanzee SEMG1 ABO52927.1 
Chimpanzee SEMG2 Q5U7N4.1 
Gorilla SEMG1 ABO52952  
Gorilla SEMG2 Q5U7N3   
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2.2.5.1.5	Protein	quantification	and	statistical	analysis	
 The resulting peptide and protein matches were filtered to produce a set of “high 
confidence” proteins by eliminating those found in only one run for any given species, and those 
found as only one unique peptide. These data were then normalized by dividing the number of 
peptides matching each protein by the total number of peptides in that run. An alternative method 
of normalization was also used, in which the number of peptides were standardized by the length 
of the protein (using the length of the longest isoform in the human UniProt database, except for 
SEMG1 in which case the length used was the species-specific length). These protein 
abundances are referred to as the “normalized spectral abundance frequencies”, or NSAF. The 
NSAFs were averaged across the three technical replicates of each individual. Two methods 
were used to assess the significance of the differences between pairs of species in protein 
abundance, for both the length-standardized and the non-standardized (“raw”) data sets. First, a 
two-tailed t-test was used with a Benjamini-Hochberg false discovery rate of 0.1 (Benjamini and 
Hochberg, 1995). Second, a power law global error method (PLGEM) commonly used for 
microarray and proteomic data described by Pavelka et al. (2008) was used. For this, the number 
of subsets sampled during the model-fitting steps was changed to 5, the number of iterations was 
increased to 10,000, and the false discovery rate was set to 0.01. Biodiversity indexes, Shannon 
and Simpson, were utilized on length and raw normalized abundances. Biodiversity index scores 
were calculated based on species averaged protein abundance, using the equations listed in Table 
2.3. Subsequently proteins were analyzed for gene ontology on Panther and DAVID online 
bioinformatic tools.  
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Table 2.3: Equations used to calculate Shannon and Simpson biodiversity indexes 
 
Diversity Index Equations 
Shannon Diversity index values 
𝐻! =  − 𝑝!!!!! ln𝑝! 𝐸! = ln (𝑛)− 𝑝!!!!! ln𝑝! 
𝑒! = 𝐿𝑛( − 𝑝!!!!! ln𝑝!  ) 
Simpson Diversity index value 
1D =  1 𝑝!!!!!!  
 
2.2.5.2 SDS PAGE and Western blot methods 
  Volumes of human, chimpanzee, and gorilla seminal plasma containing 10µg of protein 
were mixed with dH2O (to 10µl). Samples were diluted (2:1) with Laemmli buffer (Bio-Rad) and 
10% β-ME and incubated at 95°C for ten minutes. Samples were loaded into 10% SDS-PAGE 
gel (Invitrogen) in 1X NuPAGE MOPS (Invitrogen) running buffer and run at 110 volts for 15 
minutes, and then 220 volts for 30 minutes. For SDS-PAGE imaging, the gel was incubated with 
coomassie stain (Li-COR) for 30 minutes and destained with dH2O overnight. After destaining, 
the gel was imaged on the FC Odyssey imager (Li-COR) under the 700nm channel. 
 SDS-PAGE gels that underwent protein-specific antibody detection followed the protocol 
outlined below. An Immobilin®-FL PVDF (Millipore, Merck, Germany) was activated in 
methanol for one minute, and incubated in 1X NuPAGE (Invitrogen) transfer buffer with the 
separated gel and other cassette components for 10 minutes. The Western sandwich was 
assembled and put into the mini Trans-Blot® (Bio-Rad) chamber with an ice pack. The apparatus 
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was placed on a stir plate with agitation, and proteins were transferred at 100 volts for 45 
minutes. The PVDF membrane was rinsed with water, and incubated in 50%odyssey block/50% 
PBS for an hour and subsequently rinsed in dH2O, three times for five minutes. Primary antibody 
was diluted, specific to each antibody (Table 2.4), in 50%odyssey block/50% PBST. The 
membrane was incubated overnight in primary antibody, washed three times for five minutes in 
PBS, and then incubated for an hour in secondary IRDye® 680RD or 800CW (LI-COR) 
antibody diluted either 1:10,00 or 1:15,000. Following three washes in PBST for five minutes, 
the Western blot was imaged on the Odyssey FC (LI-COR) imager. Western blot samples were 
quantified using LI-COR Image Studio Lite software. All previous blots were repeated and 
detected using the Odyssey.  
Table 2.4: Primary antibodies and their dilutions 
Primary Antibody Dilution Secondary Antibody 
Mouse anti-ACPP  1:3,000 1:10,000 
Mouse anti-KLK3 1:1,000 1:10,000 
Rabbit anti-KLK3 1:1,000 1:10,000 
Mouse anti-TGM4 1:1,000 1:10,000 
Goat anti-Clusterin 1:1,000 1:15,000 
    * All antibodies were from Abcam (Cambridge, UK). 
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2.3 Results 
2.3.1 Protein quantification 
 The Bradford and Qbit protein quantification assays were compared to one another using 
each assay’s standards. The difference between means (expected and calculated concentration) 
and a paired t-test were used to analyze results, and were calculated based on three categories: 
low standards, high standards, and all standards (Table 2.5). Analysis was completed in R studio 
and is provided in the Appendix (A.1).  
 In general, the Bradford assay reported lower concentrations than expected, which were 
all significant (p≤ 0.006) for known standards under 400µg/mL. Bradford standards used for 
generating the curve are between 125 – 2,000 µg/mL, which does not explain why 200 µg/mL 
and 400 µg/mL Qbit standards would be significantly different. The Qbit assay reported higher 
concentrations than expected, and were significantly different for higher Bradford standards (or 
all standards). However, lower Bradford standards (125 µg/mL – 500 µg/mL) were not 
significantly different (p=0.09). It is important to note, that higher Bradford standards were 
diluted before assaying in order to fall within the assay’s standard range, and their calculated 
diluted concentrations were multiplied by their dilution factor to obtain their final concentration. 
It is probable that the extrapolation of the diluted concentration may have contributed to the 
significant difference between calculated concentration and expected concentration. Overall, 
each quantification assay yields a different concentration for the same sample, which is likely 
attributed to the mechanism behind quantification and the samples amino acid composition. This 
comparison indicates a trend in the Bradford assay reporting lower than known concentration 
values while the Qbit assay reports higher than known concentration, with the caveat that the 
commercial known concentrations are correct.  
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Table 2.5: Known concentrations are lower in Bradford and higher in Qbit assays than expected 
Standards Assay 
Sum of differences between 
expected ‘known’ 
concentration and calculated 
concentration.  
Paired t-test of 
differences 
between means 
Low Qbit Standards Bradford  -203.24 p = 0.006 
High Qbit Standards Bradford -95.36 p = 0.003 
All Qbit Standards Bradford -149.30 p = 0.002 
Low Bradford Standards Qbit +221.3 p = 0.09 
High Bradford Standards Qbit +1212.75 p = 0.007 
All Bradford Standards Qbit +787.85 p= 0.012 
 
 Semen samples were measured using the Bradford protein assay in order to be consistent 
for comparison studies. Concentrations are listed in Table 2.6 and the standard curve and sample 
absorbencies are graphed in Figure 2.1. The average concentration of human seminal plasma was 
9.44 ± 1.21 mg/mL, chimpanzee seminal plasma was 16.91 ± 1.97 mg/mL, and gorilla seminal 
plasma was 14.20 ± 1.63 mg/mL. The average chimpanzee seminal plasma concentration was 
significantly higher compared to human (p= 0.019), but not gorilla (p=0.331). Gorilla and human 
seminal plasma concentrations were not significantly different (p=0.059).  
Table 2.6: Hominid species seminal plasma concentrations 
Species 
Name  
Assignment 
Sample ID 
Sample concentration 
(mg/mL) 
Human 
Species average:  
9.44± 1.21 mg/mL 
“Hu#1” Donor ID: T3027 11.97 
“Hu#2” Donor ID: T3206 12.24 
“Hu#3” Donor ID: T3127 5.77 
“Hu#4” Donor ID: T3402 8.93 
“Hu#5” Donor ID: T2566 8.28 
Chimpanzee 
Species Average: 
16.91 ± 1.97 mg/mL 
“Ch#1” Kent, ID#95A016 18.05 
“Ch#2” BJ, ID#99A003 14.51 
“Ch#3” Jared, ID#95A018 13.13 
“Ch#4” Little Joe 21.95 
Gorilla 
Species Average: 
14.20 ± 1.63 mg/mL 
“Go#1” Mo, Studbook ID#835 11.53 
“Go#2” Tubby, Studbook ID#883 12.62 
“Go#3” Bom, Studbook ID#612 18.91 
“Go#4” Kit 13.71 
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Figure 2.1: Bradford assay with seminal plasma sample absorbencies 
Standard BSA samples in the Bradford assay were plotted (black outlined diamonds) in R and a linear regression 
line was calculated (y= 0. 677x + 0. 256, R2=0.93). Chimpanzee, gorilla, and human seminal plasma sample 
concentrations were calculated by inputting their diluted absorbencies for y and solving for x. Dilution 
concentrations were multiplied by 20 in order to calculate the total concentration for the sample (Table 2.6). The 
graph above has the absorbencies (of dilutions) plotted alongside the standard absorbencies. All samples fell within 
the standard range, which ensures accurate predicted concentrations.  
 
2.3.2 SDS PAGE optimization 
 Multiple attempts at pouring 6-10% stacking gels or 10% SDS-PAGE gels were 
attempted. Consistently, commercial 10% NuPAGE (Invitrogen) gels provided better sample 
separation and clarity. Figure 2.2 shows a representative experiment where human seminal 
plasma (30µg) and mock- transfected 293T media (10µg) were separated in a 10% NuPAGE and 
a 6-10% poured stacking gel in the same electrophoresis chamber. Post electrophoresis, gels 
were stained using the same coomassie stain and destain. Therefore, the only difference between 
gels was the preparation (poured or commercial).  
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Figure 2.2: Commercial NuPAGE gels yield better clarity than poured stacking gels  
Mock- transfected 293T media (10µg) and human seminal plasma (30µg) were separated in a 10% NuPAGE gel 
(left) and a 6-10% poured stacking gel (right) and stained with coomassie. The commercial NuPAGE gel (left) 
yielded better separation of samples.  
 
 
2.3.3 Western blot optimization  
2.3.3.1 Bio-Rad wet transfer system provides band clarity in Western blots compared to iBlot™ 
transfer system  
 Polyclonal rabbit anti-SEMG1 and anti-SEMG2 antibodies were ordered from ABCAM, 
and SEMG2 primary antibody was used to optimize several detection methods. An iblot™ 
(Invitrogen) dry transfer system was temporarily available in our department for trial 
experiments. The iblot™ system transfers protein from an SDS-PAGE to a membrane within 7 
minutes, whereas our Bio-Rad wet system transferred proteins between 45-75 minutes. Human 
and chimpanzee seminal plasma (20µg) in quadruplicate was separated on the same SDS-PAGE 
gel. Then the gel was cut into equal halves and proteins were transferred utilizing either the 
iblot™ system or the Bio-Rad wet transfer system. Post-transfer the PVDF membranes were 
incubated in antibodies and washes in the same container. The only difference between 
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membrane detection was the transfer system. When using the anti-SEMG2 (ABCAM) primary 
antibody, Bio-Rad wet transfer yielded cleaner results with FastRed detection (Figure 2.3). 
Distinct bands around 70kDa were detected for human seminal plasma using the wet transfer 
system, while the iblot™ transfer system did not detect the full size of SEMG2. It is important to 
note that SEMG proteins are known substrates for prostate-specific transglutaminase and for 
Kallikrein 3, and the smearing pattern of protein is probably a result of protein cross-linking and 
degradation.   
 
Figure 2.3: Bio-Rad wet transfer system has a clearer signal to background Western blot 
ratio compared to iBlot™ dry transfer  
Human and chimpanzee seminal plasma (20µg) was separated on the same SDS-PAGE gel in quadruplicate, 
transferred by the iBlot™ dry transfer system or the Bio-Rad wet transfer system, and incubated with the same 
antibodies and FastRed detection substrates.  
 
2.3.3.2 Non-specific bands are due to cross-linking and degradation of seminal proteins and 
not due to our Western blot protocol 
 In order to address the smeary appearance of our seminal plasma Western blots (seen in 
Figure 2.3), we used our protocols and equipment to blot samples that are not known to be cross-
linked or degraded. Hospital samples of nonglycosylated Pseudomonas aeruginosa isolates 
(B017, B018, and B029) were gifted from Dr. Pete Castric’s lab, along with their optimized 
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monoclonal mouse anti-pilin primary antibody. Our lab equipment and FastRed Western blot 
protocol were utilized with their samples and primary antibody. Nonglycosylated mature pilin 
protein is around 16 kDa molecular weight while glycosylated pilin protein is around 17kDa 
(Castric et al., 2001). Nonglycosylated pilin samples were detected at the expected 16kDa with 
low background signal (Figure 2.4). This Western blot confirmed that our equipment and 
protocol were sufficient for detection of protein using optimized working antibodies. In addition, 
if the protein of interest (pilin) was not susceptible to degradation and cross-linking (unlike 
SEMG1 and SEMG2), our methods would detect clean single bands within the expected 
molecular weight range.  
 
 
Figure 2.4: Nonglycosylated pilin was cleanly detected from hospital samples 
Pseudomonas aeruginosa isolates (B017, B018, and B029) from Children’s Hospital of Pittsburgh were separated 
on an SDS-PAGE and mature nonglycosylated pilin was detected around 16kDa. 
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2.3.3.3 Alkaline phosphatase conjugated secondary antibody and FastRed colorimetric 
detection reduces signal to noise ratio compared to chemiluminescent detection 
 I wanted to assay the sensitivity of chemiluminescent detection with horseradish 
peroxidase (HRP) conjugated secondary antibody and the FastRed colorimetric detection with 
alkaline phosphatase (AP) conjugated secondary antibody. For this experiment, purified human 
actin (Sigma Aldrich) with different amounts of protein (15ng, 31ng, 62.5ng, 125ng, 250ng, 
500ng, and 5,000ng) were separated and transferred to PVDF membranes under the same 
conditions. The only difference between membranes was the secondary antibody applied (either 
HRP or AP conjugated) and the detection substrate (ECL chemiluminescent or FastRed 
colorimetric, respectively). Both detection methods were able to detect 250ng of actin (Figure 
2.5), but the FastRed colorimetric Western blot had relatively less background noise compared to 
signal.  
 
Figure 2.5: Colorimetric FastRed detection has reduced background noise compared to 
chemiluminescence 
Human actin protein was Western blotted using horseradish peroxidase (HRP) conjugated secondary antibody and 
chemiluminescent ECL substrate and imaged on the typhoon (left) and was also Western blotted using alkaline 
phosphatase (AP) conjugated secondary antibody and FastRed colorimetric detection (right). Lanes are labeled with 
total amount of protein that was loaded into the SDS-PAGE gel. Both detection methods were able to visualize actin 
in greater amounts than 125ng.  
	
   15ng   31ng   62.5ng  125ng 250ng 500ng 5µg     15ng   31ng   62.5ng  125ng 250ng 500ng 5µg  
Chemiluminescence FastRed Colorimetric 
Anti-Actin 
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2.3.4 Western blot quality control checks  
2.3.4.1 Increased abundance of heterodimeric clusterin in gorilla seminal plasma prevents it 
from being an effective extracellular loading control across hominid seminal plasma  
 Currently there is no universal loading control for seminal plasma, like β- actin, or other 
housekeeping proteins, in intracellular experiments. We searched for a protein that was similar in 
expression across primate seminal plasma, which could act as a loading control between species. 
After reviewing previous shotgun Liquid Chromatography Tandem Mass Spectrometry (LC/MS-
MS) data comparing human and chimpanzee seminal plasma (Chovanec et al., unpublished), two 
candidate proteins, albumin and clusterin, were both highly abundant and similar in 
concentration between species. Both albumin and clusterin have seven amino acid differences 
between human and chimpanzee (Appendix A.2, Alignments 1 and 2). Clusterin was chosen 
because it was less likely to have false signal compared to albumin. Bovine serum albumin is 
used as a blank in LC/MS-MS and is in many blocking buffers, which could provide additional 
signal for human albumin in an experiment. When human and bovine serum albumin were 
aligned there were four fragments greater than six amino acids that could be cross identified 
between human and bovine serum albumin (Appendix A.2, Alignment 3).  
 Initially, human and chimpanzee seminal plasma (10µg and 20µg) was Western blotted 
for clusterin. Human clusterin detection was 30% higher than chimpanzee (opposite of the 
LC/MS-MS data). Both human and chimpanzee detected protein was the appropriate molecular 
weight for clusterin (Figure 2.6:A) in its monomeric form (~48kDa). When human, chimpanzee, 
and gorilla seminal plasma were Western blotted the results were less clear (Figure 2.6:B). 
Gorilla seminal plasma inconsistently blots both the monomeric form and the heterodimeric 
disulfide cross-linked form of clusterin (70-80kDa), which provides a challenge to quantify 
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clusterin signal. Human clusterin detection was 30% higher than chimpanzee and gorilla was the 
lowest signal, which is opposite of my LC/MS-MS discussed later in this chapter.  
 
Figure 2.6: Clusterin is not a reliable extracellular loading control 
Anti-clusterin antibody from ABCAM was used to detect clusterin in human, chimpanzee, and gorilla seminal 
plasma. A) Lanes 2 and 3 have 10µg of human or chimpanzee seminal plasma loaded and lanes 4 and 5 have 20µg 
of the same human or chimpanzee seminal plasma loaded. Human signal was roughly 30% higher than chimpanzee 
in both loading conditions. B) Two individuals of each species’ seminal plasma (20 µg) was loaded and detected 
with anti-clusterin antibody. Monomeric clusterin protein should be around 48kDa; however, heterodimeric clusterin 
which is disulfide cross-linked is expected to be around 70-80kDa. Though gorilla clusterin detection looks different 
than human and chimpanzee, it most likely has both monomeric and heterodimeric forms of clusterin.  
 
 2.3.4.2 Majority of proteolytic degradation of proteins, particularly the semenogelins, occurs 
before we receive semen samples 
 The semenogelins are known substrates for cross-linking and degradation, which explains 
the appearance of multiple bands in my Western blots detecting either protein (i.e., Figure 2.3). 
Protease inhibitor cocktails were added to semen samples (BCl-, apo, benzamide, and DMSF – 
“CPI-Hu#5” or Sigma mammalian protease inhibitors- “SPI-Hu#5”) to determine if a majority of 
protein degradation could be prevented. Semen with and without inhibitors was centrifuged to 
separate seminal plasma proteins from spermatozoa, and then aliquoted into different tubes and 
each tube was incubated at 4°C, 23°C, and 37°C for an hour, potentially allowing enzymatic 
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activity. Samples were quantified (Figure 2.7), and samples with protease inhibitors had a 
slightly higher concentration than without inhibitors. However, there were minimal differences 
in protein concentration across the different aliquots incubated at different temperatures.  
Figure 2.7: No significant differences in protein concentration in seminal plasma with 
and without protease inhibitors 
Human semen (Hu#5), human semen with a mix of protease inhibitors (CPI), and human semen with a commercial 
sigma protease inhibitor (SPI) cocktail were aliquoted and incubated at different temperatures, and their 
absorbencies were measured using BioRad protein assay dye. Standard BSA samples in the Bradford assay were 
plotted (diamonds) in R and a linear regression line was calculated (y= 0.661x + 0.239, R2=0.94). The average 
calculated concentration of each sample is listed on the right and their concentrations were not significantly different 
(p=0.124; see Appendix A.1.4).  
 
 There were no noticeable visual differences between samples (inhibitor vs. non-inhibitor 
or across temperature incubation) when samples were separated by SDS-PAGE (Figure 2.8) or 
blotted with anti-SEMG antibodies (Figure 2.9). Both anti-SEMG1 and SEMG2 antibodies 
detected proteins at their respective full-length molecular weights; however, they also had 
smaller portions of protein detected. Essentially, a large amount of degradation occurs before we 
receive our semen samples. Although adding protease inhibitors may prevent subsequent 
degradation, unless inhibitors are immediately added during collection, majority of proteins 
susceptible to proteolytic cleavage will be degraded.  
 
 
 
 
Sample Concentration 
Human #5 8.56 mg/mL 
CPI –Hu#5  10.82 mg/mL 
SPI –Hu#5 9.69 mg/mL 
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Figure 2.8: Seminal plasma samples with and without protease inhibitors look similar  
Human semen was aliquoted and immediately inhibitors (BCL-, apo, benzamide, and DMSF) were added (inhibitor 
cocktail/CPI) or a premade mammalian protease inhibitor cocktail (Sigma inhibitor mix/SPI) was added. 
Centrifugation removed sperm cells and seminal plasma was subjected to varying temperature (4°C, 23°C, or 37°C) 
incubations for an hour. Seminal plasma with and without protease inhibitors visually look the same when stained 
with coomassie.  
 
 
Figure 2.9: SEMG1 and SEMG2 are degraded before addition of protease inhibitors 
Human semen was aliquoted and immediately inhibitors (BCL-, apo, benzamide, and DMSF) were added (inhibitor 
cocktail/CPI) or a premade mammalian protease inhibitor cocktail (Sigma inhibitor mix/SPI) was added. 
Centrifugation removed sperm cells and seminal plasma was subjected to varying temperature (4°C, 23°C, or 37°C) 
incubations for an hour. There were minimal or no differences of anti-SEMG binding between 10µg seminal plasma 
with and without protease inhibitors. Both full length and varying sizes of degraded SEMG peptides were detected 
across samples.  
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2.3.5 LC/MS-MS and Western blot identification of seminal plasma proteins among 
human, chimpanzee, and gorilla individuals  
 A total of 7,735 peptides were identified across all three species, nine individuals, and 
twenty-seven runs. Initially, all chimpanzee semenogelin peptides were identified as SEMG2. 
Considering that genomic chimpanzee SEMG2 analysis predicts pseudogenization (discussed in 
section 1.4.2.1), but anti-SEMG2 antibody (Figure 2.3) detected protein from chimpanzee 
seminal plasma, SEMGs were manually identified by peptide sequence before further analyzing 
LC/MS-MS data.  
2.3.5.1 SEMGs, if expressed, are in relatively high abundance across hominid species with 
differences among SEMG1 and SEMG2 expression 
 For each species, semenogelin peptides were manually mapped to reference sequences 
(Table 2.2) and identified as either SEMG1 or SEMG2 (Table 2.7). Several peptides were 
ambiguous as they matched well to either paralog (Figure 2.10) in each species, and were 
removed from the data set for further quantification. There were five unique peptides identified 
in chimpanzee that appear more likely to be from SEMG2 (Figure 2.10); however, a majority of 
chimpanzee semenogelin peptides mapped to SEMG1. Only one of the three gorilla individuals 
had semenogelin peptides identified, although when peptides were identified, they were in 
relatively high abundance (Table 2.7). Using an anti-SEMG2 antibody, semenogelin expression 
was confirmed in one of the three gorillas (Figure 2.11). Previous genomic sequence analysis of 
gorilla SEMGs indicated multiple premature stop codons in the semenogelin genes that are 
polymorphic (Figure 1.5:D).  
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Table 2.7: Normalized raw spectral abundances of SEMGs are relatively high but variable 
across hominids 
 
 
 
 
 
Figure 2.10: Manual peptide mapping of SEMGs 
LC-MS/MS peptide spectra were each matched to either SEMG1 (light grey), SEMG2 (black), both SEMGs (dark 
grey) protein sequence. The signal peptide sequence is striked through, indicating that this peptide portion should 
not have been detected, and it was not. A manual coverage map was generated for gorilla semenogelins as well.  
 
 
  
Species SEMG1 
% Abundance 
SEMG2 
% Abundance 
SEMG total number 
of peptides identified 
Human (Average) 13.9 ± 6.7 % 20.3 ± 2.0 % 1,050 
Chimpanzee (Average) 43.6 ± 2.7 % 1.47 ± 0.4 % 1,258 
Gorilla (Average) 3.25 ± 3.25% 10.6 ± 10.6 % 81 
Gorilla (Individual #3) 9.74 ± 1.74 % 31.7 ± 11.5 % 81 
 
 
 
 
 
 
 
 
Human SEMG1 (AAB59506.1) 
MKPNIIFVLSLLLILEKQAAVMGQKGGSKGRLPSEFSQFPHGQKGQHYSGQKGKQQTESK 
GSFSIQYTYHVDANDHDQSRKSQQYDLNALHKTTKSQRHLGGSQQLLHNKQEGRDHDKSK 
GHFHRVVIHHKGGKAHRGTQNPSQDQGNSPSGKGISSQYSNTEERLWVHGLSKEQTSVSG 
AQKGRKQGGSQSSYVLQTEELVANKQQRETKNSHQNKGHYQNVVEVREEHSSKVQTSLCP 
AHQDKLQHGSKDIFSTQDELLVYNKNQHQTKNLNQDQQHGRKANKISYQSSSTEERRLHY 
GENGVQKDVSQSSIYSQTEEKAQGKSQKQITIPSQEQEHSQKANKISYQSSSTEERRLHY 
GENGVQKDVSQRSIYSQTEKLVAGKSQIQAPNPKQEPWHGENAKGESGQSTNREQDLLSH 
EQKGRHQHGSHGGLDIVIIEQEDDSDRHLAQHLNNDRNPLFT   
 
 
 
 
 
Human SEMG2 (AAA60562.1) 
MKSIILFVLSLLLILEKQAAVMGQKGGSKGQLPSGSSQFPHGQKGQHYFGQKDQQHTKSK 
GSFSIQHTYHVDINDHDWTRKSQQYDLNALHKATKSKQHLGGSQQLLNYKQEGRDHDKSK 
GHFHMIVIHHKGGQAHHGTQNPSQDQGNSPSGKGLSSQCSNTEKRLWVHGLSKEQASASG 
AQKGRTQGGSQSSYVLQTEELVVNKQQRETKNSHQNKGHYQNVVDVREEHSSKLQTSLHP 
AHQDRLQHGPKDIFTTQDELLVYNKNQHQTKNLSQDQEHGRKAHKISYPSSRTEERQLHH 
GEKSVQKDVSKGSISIQTEEKIHGKSQNQVTIHSQDQEHGHKENKISYQSSSTEERHLNC 
GEKGIQKGVSKGSISIQTEEQIHGKSQNQVRIPSQAQEYGHKENKISYQSSSTEERRLNS 
GEKDVQKGVSKGSISIQTEEKIHGKSQNQVTIPSQDQEHGHKENKMSYQSSSTEERRLNY 
GGKSTQKDVSQSSISFQIEKLVEGKSQIQTPNPNQDQWSGQNAKGKSGQSADSKQDLLSH 
EQKGRYKQESSESHNIVITEHEVAQDDHLTQQYNEDRNPIST  						
							
Chimpanzee SEMG1 (ABO52927.1) 
MKPNIIFVLSLLLILEKQAAVMGQKGGSKGRLPSESSQFPHGQKGQHYSGQKGKQQTESK 
GSFSIQYTYHVDANDHDQTRKSQQYDLNALHKTTKSERHLGGSQQLLHNKQEGRDHDKSK 
GHFHRVVIHHKGGKAHRWTQNPSQDQGNSPSGKGISSQYSNTEERLWVHGLSKEQTSVSG 
AQKGRKQGGSQSSYVLQTEELVANKQQRETKNSHQNKGHYQNVVEVREEHSSKVQTSLCP 
AHQDKLQHGSKDIFSTQDELLVYNKNQHQTKNLNQDQQHGRKANKTSYQSSSTEERRLHY 
GENGVQKDVSQSSIYSQTEEKAHGKSQKQITTPSQEQEHSQKANKTSYQSSSTEEGRLHY 
GENGVQKDVSQSSIYSQTEEKAHGKSQKQITIPSQEQEHSQKANKTSYQSSSTEERRLPY 
GENGVQKVVSQSSIYSQTEEKAYGKSQKQITTPSQEQEHSQKANKTSYQSSSTEERRLHY 
GENGVQKDVSQSSIYSQTEEKAHGKSQKQITTPSQEQEHSQKANKTSYQSSSTEERRLHY 
GENGVQKDVSQSSIYSQTEEKAHGKSQKQITIPSQEQEHSQKANKTSYQSSSTEERRLHY 
GENGVQKDVSQSSIYSQTEKLVGKSQIQAPNPKQEPWHGENAKGESGQSTNREQDLLSRE 
QKGRHQHGSHGGLDIVIIEEEDDSDHHLAQHLSNDRNPLFT 
 
Chimpanzee SEMG2 (Q5U7N4.1) 
MKSIILFVLSLVLILEKQAAVMGQKDGSKGQLPSGSSQFPHGQKGQHYFGQKDQQHTKSK 
GSFSIQHTYHVDINDHDQTRKSQQYDLNALHKVTKSKQHLDGSQQLLNYKQEGRDHDKSE 
GHFHMIVIHHKGGQAHCGTQNPSQDQGNSPSGKGLSSQYSNTEKRLWVHGLSKEQASASG 
AQKGRTQGGSQSSYVLQTEELVVNKQQLETKNSHQNKGHYQNVVDVREEHSGKLQTSLHP 
AHQDRLQHGPKDIFTTQDELLVYNKNQHQTKNLNQDQEHGQKAHKISYQSSRTEERQLNH 
GEKSVQKDVSKGSISIQTEEKIHGKSQNQVTIHSQDQEHGHKENKMSYQSSSTEERHLNC 
GEKGIQKGVSKGSISIQTEEQIHGKSQNXVRIPSQAQEYGRKENKIS 
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Figure 2.11: Western blot supports LC/MS-MS peptide mapping of SEMG2 in seminal 
plasma of chimpanzee individuals and one gorilla individual  
Human seminal plasma samples bound anti-SEMG2 antibody around 80kDa. Expected weight of human SEMG2 is 
between 65 -76 kDa, depending on glycosylation. Chimpanzee samples all bound anti-SEMG2 antibody at various 
molecular weights, as well as one gorilla individual.  
 
2.3.5.2 Nine proteins are shared among human, chimpanzee, and gorilla seminal plasma, with 
a vast majority of proteins being species specific contributing to distinct proteomes.  
 A protein was deemed to be present in a species if a peptide was identified in at least two 
runs and there were at least two unique peptides identified. Utilizing the ‘two-peptide’ rule, 168 
proteins were identified with high confidence; 71 seminal plasma proteins were identified for 
human, 64 proteins for chimpanzee, and 34 proteins for gorilla. Two methods for abundance 
normalization were used, which are described in section 2.2.5.1.5, the first method does not 
adjust for length of protein, while the second method is normalized incorporating the length of 
the protein. To differentiate between each method, “length” will label results normalized with 
protein length, and “raw” will be relative abundances not normalized by length.  
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 Nine proteins were shared among the three species, which include: albumin, clusterin, 
keratin 1 and 10, lacto-transferrin, serpina 1, semenogelin I and II, and titin (also known as 
connectin). Through gene ontology, these core proteins were identified as extracellular structural 
proteins or enzyme modulators (Panther). Except for the semenogelins, the core protein 
sequences are conserved (with a dN/dS < 0.5), and these proteins are expressed in various tissues 
throughout the body. There is individual variation within species, evident in SDS-PAGE (Figure 
2.12) and more specifically LC/MS-MS (Appendix A.6 tables); however, there are greater 
differences between species, emphasized by the species-specific banding patterns evident in 
SDS-PAGE (Figure 2.12). Human seminal plasma has 41 unique proteins compared to 
chimpanzee and gorilla, while chimpanzee and gorilla have 33 and 24, respectively, unique 
seminal plasma proteins.  
 
Figure 2.12: Distinct species-specific banding pattern of hominid seminal plasma 
Seminal plasma (20µg) of three individuals of each species (human, chimpanzee, and gorilla) were separated on a 
10% SDS PAGE gel and stained with coomassie.  
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2.3.5.3 Biodiversity indexes indicate moderate protein richness and evenness in human, 
chimpanzee, and gorilla seminal plasma without significant differences between species 
 Both Shannon and Simpson’s indexes are typically used to assess biodiversity of species 
within an ecological community. However, I applied these mathematical calculations to assess 
the diversity and evenness of proteins within each species seminal plasma proteome (based on 
three individuals) and for both normalization methods (Table 2.8). Simpson’s diversity index is 
sensitive to abundances of the more plentiful species in a sample, therefore, is associated as a 
measure of ‘dominant’ concentration of species (Whittaker, 1965). Simpson index (1/D) values 
are between 0 and 1, where the closer the value is to 1 the greater diversity within the population. 
Human, chimpanzee, and gorilla seminal plasma proteomes have a relatively high (1/D > 0.80 
for all samples) Simpson index value, and all three species had similar diversity values. The 
Simpson and Shannon index values did not change (not significant5) much between the length 
and raw normalization methods.  
 Normalized abundance quantifications incorporating protein length, appear to fit the data 
better when calculating Shannon’s diversity and evenness statistics, and are more consistent with 
the Simpson’s diversity index. An evenness (EH) score is between 0 and 1, where the closer the 
value is to 1 indicates an even distribution of proteins (i.e., there is not a dominant protein 
contributing to most of the sample). Human, chimpanzee, and gorilla EH values were all 0.70 ± 
0.02 (adjusting for protein length), which indicates a moderately even distribution of proteins. A 
Shannon index (H) value assesses richness and evenness of diversity within a population, and the 
higher the value the more species (or proteins) are present, which are also evenly distributed. 
However, it is argued that Shannon indexes are susceptible to sampling size (or area in 
                                                
5 A simple paired t-test with Welch’s correction for both indexes reported an insignificant p-value comparing length 
and raw normalization statistics (Simpson, p=0.848; Shannon, p=0.819). 
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ecological studies); in order to assess diversity indexes across populations, H should be adjusted. 
A common adjustment is to convert H using the natural log scale, which infers the equivalent 
or effective numbers of species by calculating eH. Moreover, eH values are comparable across 
populations because they represent the number of equally abundant species required to produce 
the same value of diversity (Hill, 1972; Peet, 1974; Jost, 2006). H and eH values are reported for 
each species with both normalization data sets in Table 2.8. Human and chimpanzee seminal 
plasma proteomes have similar diversity in the length-adjusted data set (~H=2.92, ~eH=18.6), 
while gorilla has lower diversity in the length-adjusted data set (H= 2.43, ~eH=11.4). 
 
Table 2.8: Diversity indexes indicate relatively high protein diversity and moderately even 
distribution of seminal plasma proteomes for hominids. 
Species Shannon Index Simpson Index 
 Raw Length Raw Length 
Human 
EH = 0.71 
H =3.04 
eH = 20.90 
EH = 0.69 
H = 2.92 
eH = 18.54 
1/D = 0.92 1/D = 0.90 
Chimpanzee 
EH = 0.62 
H = 2.57 
eH = 13.07 
EH = 0.71 
H = 2.93 
eH = 18.72 
1/D = 0.80 1/D = 0.90 
Gorilla 
EH = 0.78 
H = 2.78 
eH = 16.12 
EH = 0.68 
H = 2.43 
eH = 11.38 
1/D = 0.92 1/D = 0.86 
 
2.3.5.4 Chimpanzee seminal plasma has increased expression of proteins involved in semen 
coagulation and prevention of liquefaction  
 Chimpanzee has multiple serpina (1, 3, and 5) protease inhibitors in a significantly higher 
concentration than human. Serpina 3 has the largest difference (~34-fold, length) between human 
and chimpanzee. In addition, only one serpina protease inhibitor, serpina 1, was detected in 
gorilla, although, it was significantly higher by ~3-fold (length) compared to human (Table 2.9; 
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Figure 2.13). Prolactin inducible protein (PIP) was not detected in chimpanzee seminal plasma, 
even though it is high in abundance (~28%, length) in human and has moderate abundance (~4%, 
length) in gorilla (Table 2.9). In addition, human is significantly 7-fold higher (length) than 
gorilla seminal plasma (Figure 2.13). Interestingly, Cartilage Acidic Protein 1 (CRTAC1) was 
found in chimpanzee seminal plasma ~1.3% (length) abundance (Table 2.9), and not detected in 
either human or gorilla seminal plasma. A follow up Western blot confirmed CRTAC1 
abundance in chimpanzee, which was ~100.8-fold higher compared to human (Figure 2.14).  
2.3.5.5 Gorilla seminal plasma has loss of proteins involved in semen coagulation and 
liquefaction pathways 
 Prostate-specific transglutaminase, TGM4, was not detected in gorilla seminal plasma, 
which supports pseudogenization shown in genomic studies. Moreover, TGM4 is in a 
significantly higher concentration (~7-fold, length) in chimpanzee compared to human (Table 
2.9). A follow up Western blot confirmed our LC/MS-MS findings, where chimpanzees had ~7-
fold higher expression compared to human seminal plasma, and gorilla TGM4 was not detected 
(Figure 2.15). 
 Prostatic acid phosphatase (ACPP) was found around 3-4% (length) abundance for both 
human and chimpanzee seminal plasma, and was not detected in gorilla. There was no significant 
difference between human and chimpanzee (Table 2.9). A follow up Western confirmed similar 
abundance between human and chimpanzee ACPP; however, one of the gorilla samples also had 
ACPP antibody bind around its respective molecular weight, but was much lower in abundance, 
approximately 17-fold lower than human (Figure 2.15).  
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 Alternatively, gorilla has a significant 4- 6.6 fold increase of albumin compared to 
chimpanzee and human. Likewise, gorilla has a significant 2-4.5 fold increase of clusterin 
compared to chimpanzee and human seminal plasma. Additionally, proteins like ARNT (1.6%, 
length), BCL3 (1.63%, length), CCDC88C (1.96%, length), NDUFS1 (1.41%, length), PAEP 
(26.74%, length), TSSC1 (2.01%, length), and ZCCHC11 (1.11%, length) are found in relatively 
high abundance in gorilla but are either not detected or in low abundance in the other species.  
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Table 2.9: Relative abundance of proteins detected in hominid seminal plasma 
Proteina Methodb Human Averagec Chimp Averagec  Gorilla Averagec 
ACE 
Length 0.00% ± 0.00% 0.16% ± 0.10% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.43% ± 0.27%* 0.00% ± 0.00% 
ACO2 
Length 0.00% ± 0.00% 0.04% ± 0.02% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.07% ± 0.04% 0.00% ± 0.00% 
ACOT13 
Length 0.00% ± 0.00% 0.53% ± 0.34%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.15% ± 0.10% 0.00% ± 0.00% 
ACPP 
Length 3.86% ± 1.03%* 3.04% ± 0.97%* 0.00% ± 0.00% 
Raw 4.12% ± 0.92%* 2.37% ± 0.78%* 0.00% ± 0.00% 
ACR 
Length 0.00% ± 0.00% 0.18% ± 0.06% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.15% ± 0.05% 0.00% ± 0.00% 
ACRBP 
Length 0.00% ± 0.00% 0.56% ± 0.10%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.60% ± 0.12%* 0.00% ± 0.00% 
ACTA2 
Length 0.54% ± 0.05%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.58% ± 0.05%* 0.00% ± 0.00% 0.00% ± 0.00% 
ACTB 
Length 0.00% ± 0.00% 0.93% ± 0.23%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.68% ± 0.14%* 0.00% ± 0.00% 
ALB 
Length 3.37% ± 0.65% 6.70% ± 1.13%* 24.71% ± 10.51%* 
Raw 5.66% ± 0.81% 8.03% ± 1.29%* 25.91% ± 10.07%* 
AMY2B 
Length 0.00% ± 0.00% 1.10% ± 0.12%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 1.13% ± 0.15%* 0.00% ± 0.00% 
ANPEP 
Length 0.25% ± 0.11% 0.06% ± 0.06% 0.00% ± 0.00% 
Raw 0.72% ± 0.32%* 0.12% ± 0.12% 0.00% ± 0.00% 
APOB 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.34% ± 0.15%* 
Raw 0.07% ± 0.04% 0.00% ± 0.00% 2.71% ± 1.09%* 
ARHGAP31 
Length 0.02% ± 0.01% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.07% ± 0.04% 0.00% ± 0.00% 0.00% ± 0.00% 
ARNT 
Length 0.00% ± 0.00% 0.00% ± 0.00% 1.60% ± 0.87%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.82% ± 0.91%* 
ASAP2 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.33% ± 0.24% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.58% ± 0.32%* 
AZGP1 
Length 2.85% ± 0.57%* 1.53% ± 0.64%* 0.00% ± 0.00% 
Raw 2.43% ± 0.48%* 0.92% ± 0.39%* 0.00% ± 0.00% 
B2M 
Length 0.82% ± 0.40%* 0.45% ± 0.30% 0.00% ± 0.00% 
Raw 0.24% ± 0.11% 0.11% ± 0.07% 0.00% ± 0.00% 
B4GALT1 
Length 0.00% ± 0.00% 0.26% ± 0.14% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.20% ± 0.11% 0.00% ± 0.00% 
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BCL3 
Length 0.00% ± 0.00% 0.00% ± 0.00% 1.63% ± 0.91%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.09% ± 0.62%* 
BIRC6 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
CAP1 
Length 0.15% ± 0.09% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.19% ± 0.10% 0.00% ± 0.00% 0.00% ± 0.00% 
CCDC88C 
Length 0.00% ± 0.00% 0.00% ± 0.00% 1.96% ± 1.20%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 6.14% ± 3.96%* 
CEP162 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.53% ± 0.29%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.38% ± 0.89%* 
CFAP69 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.32% ± 0.23% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.68% ± 0.44%* 
CKB 
Length 0.22% ± 0.15% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.23% ± 0.16% 0.00% ± 0.00% 0.00% ± 0.00% 
CLEC11A 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.63% ± 0.63%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.59% ± 0.59%* 
CLIP2 
Length 0.03% ± 0.03% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
CLU 
Length 1.85% ± 0.29% 4.54% ± 1.10% 8.27% ± 1.23%* 
Raw 2.36% ± 0.53% 4.57% ± 0.94% 7.09% ± 0.42%* 
CPE 
Length 0.37% ± 0.19% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.45% ± 0.20% 0.00% ± 0.00% 0.00% ± 0.00% 
CPSF1 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.37% ± 0.37% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.74% ± 0.74%* 
CRISP1 
Length 1.38% ± 0.27%* 0.33% ± 0.16% 0.00% ± 0.00% 
Raw 0.96% ± 0.26%* 0.17% ± 0.08% 0.00% ± 0.00% 
CRTAC1 
Length 0.00% ± 0.00% 1.35% ± 0.09%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 1.76% ± 0.17%* 0.00% ± 0.00% 
CST2 
Length 0.09% ± 0.09% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.09% ± 0.05% 0.00% ± 0.00% 0.00% ± 0.00% 
CST3 
Length 0.56% ± 0.32%* 1.79% ± 0.23%* 0.00% ± 0.00% 
Raw 0.19% ± 0.15% 0.52% ± 0.08%* 0.00% ± 0.00% 
CST4 
Length 1.40% ± 0.53%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.57% ± 0.24%* 0.00% ± 0.00% 0.00% ± 0.00% 
CTSB 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.40% ± 0.40% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.34% ± 0.34% 
CTSD 
Length 0.29% ± 0.19% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.32% ± 0.21% 0.00% ± 0.00% 0.00% ± 0.00% 
 84 
Proteina Methodb Human Averagec Chimp Averagec  Gorilla Averagec 
DEFA1 
Length 1.43% ± 0.44%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.38% ± 0.13%* 0.00% ± 0.00% 0.00% ± 0.00% 
DHX57 
Length 0.01% ± 0.01% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.05% ± 0.05% 0.00% ± 0.00% 0.00% ± 0.00% 
DNAH7 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.03% ± 0.03% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.42% ± 0.42%* 
DPEP3 
Length 0.00% ± 0.00% 0.58% ± 0.05%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.56% ± 0.04%* 0.00% ± 0.00% 
DUT 
Length 0.09% ± 0.05% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.07% ± 0.04% 0.00% ± 0.00% 0.00% ± 0.00% 
ECM1 
Length 0.46% ± 0.07%* 0.91% ± 0.08%* 0.00% ± 0.00% 
Raw 0.67% ± 0.11%* 0.97% ± 0.07%* 0.00% ± 0.00% 
ENO1 
Length 0.00% ± 0.00% 0.09% ± 0.09% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.08% ± 0.08% 0.00% ± 0.00% 
FAM184B 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.82% ± 0.28%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.04% ± 0.04%* 
FAM3D 
Length 0.00% ± 0.00% 0.12% ± 0.12% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.06% ± 0.06% 0.00% ± 0.00% 
FN1 
Length 0.39% ± 0.16% 1.13% ± 0.22%* 0.00% ± 0.00% 
Raw 2.57% ± 0.94%* 5.25% ± 0.83%* 0.00% ± 0.00% 
FOLH1 
Length 0.09% ± 0.09% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.15% ± 0.15% 0.00% ± 0.00% 0.00% ± 0.00% 
GDF15 
Length 0.42% ± 0.42% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.33% ± 0.33% 0.00% ± 0.00% 0.00% ± 0.00% 
GOLGB1 
Length 0.01% ± 0.01% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
GPI 
Length 0.00% ± 0.00% 0.26% ± 0.09% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.29% ± 0.11% 0.00% ± 0.00% 
HEXB 
Length 0.23% ± 0.10% 0.12% ± 0.12% 0.00% ± 0.00% 
Raw 0.33% ± 0.12% 0.14% ± 0.14% 0.00% ± 0.00% 
HK1 
Length 0.00% ± 0.00% 0.19% ± 0.09% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.34% ± 0.17% 0.00% ± 0.00% 
HSP90AA1 
Length 0.00% ± 0.00% 0.07% ± 0.07% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.11% ± 0.11% 0.00% ± 0.00% 
HSPA1A 
Length 0.00% ± 0.00% 0.11% ± 0.01%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.14% ± 0.02%* 0.00% ± 0.00% 
HSPA1L 
Length 0.13% ± 0.04% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.23% ± 0.09% 0.00% ± 0.00% 0.00% ± 0.00% 
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HSPA5 
Length 0.11% ± 0.03%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.20% ± 0.03%* 0.00% ± 0.00% 0.00% ± 0.00% 
IDH1 
Length 0.17% ± 0.05% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.18% ± 0.05% 0.00% ± 0.00% 0.00% ± 0.00% 
IGHG1 
Length 0.52% ± 0.26%* 2.21% ± 0.32%* 0.00% ± 0.00% 
Raw 0.47% ± 0.21% 1.44% ± 0.18%* 0.00% ± 0.00% 
IGKC 
Length 0.00% ± 0.00% 4.03% ± 1.28%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.83% ± 0.25%* 0.00% ± 0.00% 
KLK3 
Length 2.83% ± 0.36%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 2.09% ± 0.29%* 0.00% ± 0.00% 0.00% ± 0.00% 
KRT1 
Length 0.32% ± 0.08% 0.38% ± 0.20% 2.93% ± 2.23%* 
Raw 0.54% ± 0.09% 0.50% ± 0.27% 3.74% ± 2.75%* 
KRT10 
Length 0.29% ± 0.23% 0.09% ± 0.09% 0.23% ± 0.23% 
Raw 0.44% ± 0.32% 0.12% ± 0.12% 0.34% ± 0.34% 
KRT2 
Length 0.47% ± 0.33% 0.08% ± 0.08% 0.00% ± 0.00% 
Raw 0.78% ± 0.53%* 0.11% ± 0.11% 0.00% ± 0.00% 
LAMP2 
Length 0.31% ± 0.12% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.24% ± 0.13% 0.00% ± 0.00% 0.00% ± 0.00% 
LCP1 
Length 0.14% ± 0.07% 0.17% ± 0.07% 0.00% ± 0.00% 
Raw 0.40% ± 0.12% 0.22% ± 0.10% 0.00% ± 0.00% 
LDHC 
Length 0.00% ± 0.00% 0.57% ± 0.57%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.39% ± 0.39%* 0.00% ± 0.00% 
LGALS3BP 
Length 1.19% ± 0.35%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 1.94% ± 0.52%* 0.00% ± 0.00% 0.00% ± 0.00% 
LRPPRC 
Length 0.01% ± 0.01% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.00% ± 0.00% 
LRRK1 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.24% ± 0.24% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.72% ± 0.72%* 
LTF 
Length 3.53% ± 0.68% 2.96% ± 1.74% 3.48% ± 1.39% 
Raw 7.27% ± 1.80% 3.99% ± 2.21% 4.25% ± 1.38% 
MDH2 
Length 0.00% ± 0.00% 0.48% ± 0.48%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.34% ± 0.34% 0.00% ± 0.00% 
MGAM 
Length 0.00% ± 0.00% 0.05% ± 0.03% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.18% ± 0.10% 0.00% ± 0.00% 
MME 
Length 0.00% ± 0.00% 0.04% ± 0.04% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.06% ± 0.06% 0.00% ± 0.00% 
MSMB 
Length 1.61% ± 1.14%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.46% ± 0.31%* 0.00% ± 0.00% 0.00% ± 0.00% 
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MUC6 
Length 0.37% ± 0.09%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 2.53% ± 0.62%* 0.00% ± 0.00% 0.00% ± 0.00% 
NBPF3 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.94% ± 0.78%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.79% ± 0.57%* 
NDUFS1 
Length 0.00% ± 0.00% 0.00% ± 0.00% 1.41% ± 0.97%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.51% ± 0.87%* 
NEMF 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.13% ± 0.13% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.34% ± 0.34% 
NPC2 
Length 3.17% ± 0.93%* 6.58% ± 0.76%* 0.00% ± 0.00% 
Raw 1.36% ± 0.40%* 1.98% ± 0.28%* 0.00% ± 0.00% 
ORM1 
Length 0.24% ± 0.24% 0.40% ± 0.40% 0.00% ± 0.00% 
Raw 0.14% ± 0.14% 0.17% ± 0.17% 0.00% ± 0.00% 
OXCT2 
Length 0.00% ± 0.00% 0.12% ± 0.07% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.13% ± 0.07% 0.00% ± 0.00% 
PAEP 
Length 0.00% ± 0.00% 1.50% ± 0.79%* 26.74% ± 5.05%* 
Raw 0.00% ± 0.00% 0.55% ± 0.28%* 10.68% ± 3.61%* 
PATE1 
Length 0.53% ± 0.53%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.21% ± 0.21%* 0.08% ± 0.08% 0.00% ± 0.00% 
PGAM2 
Length 0.00% ± 0.00% 0.16% ± 0.16% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.00% ± 0.00% 
PGC 
Length 0.22% ± 0.06% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.26% ± 0.06%* 0.00% ± 0.00% 0.00% ± 0.00% 
PGK2 
Length 0.00% ± 0.00% 0.19% ± 0.14% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.15% ± 0.11% 0.00% ± 0.00% 
PIP 
Length 28.40% ± 6.23%* 0.00% ± 0.00% 3.71% ± 3.71%* 
Raw 11.80% ± 3.22%* 0.00% ± 0.00% 1.40% ± 1.40%* 
PKM 
Length 0.00% ± 0.00% 0.48% ± 0.24% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.49% ± 0.25%* 0.00% ± 0.00% 
PLA1A 
Length 0.00% ± 0.00% 0.17% ± 0.13% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.15% ± 0.11% 0.00% ± 0.00% 
PLS3 
Length 0.00% ± 0.00% 0.10% ± 0.06% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.12% ± 0.07% 0.00% ± 0.00% 
PPIB 
Length 0.00% ± 0.00% 1.07% ± 0.48% 1.57% ± 1.57% 
Raw 0.00% ± 0.00% 0.47% ± 0.21% 0.90% ± 0.90% 
PRDX6 
Length 0.71% ± 0.32% 0.91% ± 0.28% 0.00% ± 0.00% 
Raw 0.42% ± 0.17% 0.39% ± 0.11% 0.00% ± 0.00% 
PSAP 
Length 1.07% ± 0.20%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 1.52% ± 0.18%* 0.00% ± 0.00% 0.00% ± 0.00% 
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PSCA 
Length 0.00% ± 0.00% 2.67% ± 0.56%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.66% ± 0.15%* 0.00% ± 0.00% 
QSOX1 
Length 0.09% ± 0.06% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.18% ± 0.11% 0.00% ± 0.00% 0.00% ± 0.00% 
RLTPR 
Length 0.00% ± 0.00% 0.03% ± 0.03% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.08% ± 0.08% 0.00% ± 0.00% 
RNASET2 
Length 0.00% ± 0.00% 1.68% ± 0.06%* 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.84% ± 0.01%* 0.00% ± 0.00% 
S100A8 
Length 1.13% ± 0.72%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.33% ± 0.21%* 0.00% ± 0.00% 0.00% ± 0.00% 
SEMG1 
Length 10.96% ± 5.32%* 28.61% ± 2.50%* 1.90% ± 1.90% 
Raw 13.88% ± 6.73%* 43.62% ± 2.70%* 3.25% ± 3.25% 
SEMG2 
Length 12.46% ± 1.60%* 1.86% ± 0.63% 7.44% ± 7.44%* 
Raw 20.29% ± 2.00%* 1.47% ± 0.44% 10.58% ± 10.58%* 
SERPINA1 
Length 0.90% ± 0.03% 2.24% ± 0.53%* 3.08% ± 1.99%* 
Raw 1.05% ± 0.09% 1.88% ± 0.47%* 2.50% ± 1.37%* 
SERPINA3 
Length 0.06% ± 0.06% 2.16% ± 0.54%* 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 1.84% ± 0.50%* 0.00% ± 0.00% 
SERPINA5 
Length 1.70% ± 0.45%* 4.29% ± 0.81%* 0.00% ± 0.00% 
Raw 1.91% ± 0.39%* 3.47% ± 0.71%* 0.00% ± 0.00% 
SERPINF2 
Length 0.13% ± 0.10% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.19% ± 0.15% 0.00% ± 0.00% 0.00% ± 0.00% 
SLC9B2 
Length 0.08% ± 0.04% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.13% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
SMG1 
Length 0.01% ± 0.01% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
SOD2 
Length 0.00% ± 0.00% 0.15% ± 0.08% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.07% ± 0.03% 0.00% ± 0.00% 
SOD3 
Length 0.13% ± 0.13% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.07% ± 0.07% 0.00% ± 0.00% 0.00% ± 0.00% 
SORD 
Length 0.21% ± 0.05%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.19% ± 0.04%* 0.00% ± 0.00% 0.00% ± 0.00% 
SRCAP 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.10% ± 0.07% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.52% ± 0.32%* 
TF 
Length 0.85% ± 0.32%* 0.71% ± 0.38%* 0.00% ± 0.00% 
Raw 1.64% ± 0.55%* 0.95% ± 0.48%* 0.00% ± 0.00% 
TGM4 
Length 0.19% ± 0.06% 1.35% ± 0.60%* 0.00% ± 0.00% 
Raw 0.36% ± 0.13% 1.88% ± 0.87%* 0.00% ± 0.00% 
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TIMP1 
Length 0.96% ± 0.22%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.56% ± 0.12%* 0.00% ± 0.00% 0.00% ± 0.00% 
TKFC 
Length 0.00% ± 0.00% 0.05% ± 0.05% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.06% ± 0.06% 0.00% ± 0.00% 
TMPRSS2 
Length 0.17% ± 0.12% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.25% ± 0.20% 0.00% ± 0.00% 0.00% ± 0.00% 
TRRAP 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.09% ± 0.06% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.49% ± 0.28%* 
TSSC1 
Length 0.00% ± 0.00% 0.00% ± 0.00% 2.01% ± 1.76%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.28% ± 0.99%* 
TTLL5 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.41% ± 0.41% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 1.11% ± 1.11%* 
TTN 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.01% ± 0.01% 
Raw 0.20% ± 0.14% 0.07% ± 0.04% 0.70% ± 0.35%* 
TUBA1A 
Length 0.00% ± 0.00% 0.24% ± 0.13% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.22% ± 0.12% 0.00% ± 0.00% 
TUBB 
Length 0.00% ± 0.00% 0.12% ± 0.12% 0.00% ± 0.00% 
Raw 0.00% ± 0.00% 0.11% ± 0.11% 0.00% ± 0.00% 
UBA1 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.47% ± 0.24% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.73% ± 0.36%* 
UBA52 
Length 1.35% ± 0.68%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.52% ± 0.27%* 0.00% ± 0.00% 0.00% ± 0.00% 
WFDC2 
Length 0.68% ± 0.27%* 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.24% ± 0.09% 0.00% ± 0.00% 0.00% ± 0.00% 
WTIP 
Length 0.06% ± 0.06% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.08% ± 0.08% 0.00% ± 0.00% 0.00% ± 0.00% 
YWHAB 
Length 0.33% ± 0.33% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.19% ± 0.19% 0.00% ± 0.00% 0.00% ± 0.00% 
ZCCHC11 
Length 0.00% ± 0.00% 0.00% ± 0.00% 1.11% ± 0.75%* 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 2.94% ± 1.98%* 
ZFHX2 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.05% ± 0.05% 
Raw 0.00% ± 0.00% 0.00% ± 0.00% 0.34% ± 0.34% 
ZNF148 
Length 0.00% ± 0.00% 0.00% ± 0.00% 0.00% ± 0.00% 
Raw 0.07% ± 0.07% 0.00% ± 0.00% 0.00% ± 0.00% 
a) Proteins listed in this table were detected with high confidence (utilizing the ‘two-peptide’ rule) and are organized 
by alphabetical order b) Normalization method (length adjusted or raw) is specified in this column for the adjacent 
relative abundance values. c) Values in this column represent species relative protein abundance with standard error 
of the mean (among three individuals) and are different depending on normalization method. Values with a “*” were 
significantly higher in abundance compared to one or both species. Refer to Table A.9 for statistical comparison.  
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Figure 2.13: Pairwise PLGEM graphs with raw normalization 
Normalized spectral abundance frequencies (NSAF) of high-confidence proteins 
identified in human, chimpanzee, and gorilla seminal plasma. Dashed lines 
indicate the margins of two-fold difference in abundance. Circled points 
indicate those proteins whose abundance differed significantly between these 
species, as inferred from PLGEM analysis and applying a 1% FDR. For clarity, 
inset plots show proteins whose NSAF values are less than 0.05 for both 
species, indicated by the black square in the larger plot; this inset plot does not 
obscure any data points in the larger plot. Names are given for proteins with 
significant differences and found at NSAF values greater than 0.01. 
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Figure 2.14: Chimpanzee seminal plasma has an excess of CRTAC1 
Seminal plasma (20µg) of three individuals of human and chimpanzee were separated on a 10% SDS PAGE and 
proteins were transferred to a PVDF and Western blotted with an anti-CRTAC1 antibody. Only one of three human 
seminal plasma samples bound to anti-CRTAC1 antibody while all three chimpanzee seminal plasma samples bound 
to anti-CRTAC1 (100.8-fold higher than human). 
 
  
Figure 2.15: Western blots confirm LC/MS-MS results 
In both LC-MS/MS and Western blot methods, TGM4 was not detected in gorilla seminal plasma; chimpanzee 
seminal plasma had 7-fold higher expression than human that was significant via Western blot (and significant using 
PLGEM for LC/MS-MS). ACPP was only detected in only one gorilla’s seminal plasma via Western blot and was 
not detected in any gorilla individual’s seminal plasma via LC-MS/MS. ACPP is expressed 1.5 fold higher in human 
seminal plasma compared to chimpanzee, which was significant via Western blot (*p<0.05, Holm-Sidak method).  
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2.4 Discussion 
 Seminal plasma is a complex mixture of proteins, sugars, lipids, and ions. Our LC-
MS/MS data in conjunction with the use of biodiversity indexes support that the seminal plasma 
proteome is diverse (Table 2.8; 2.9). There were no significant differences in overall diversity of 
proteins between human, chimpanzee, and gorilla seminal plasma. In addition, gene ontology 
analysis did not reveal any species-specific differences in proteome molecular function, 
biological process, or protein classes (further analyzed in Appendix A.7).  
 We observed a statistically significant difference in average concentration of chimpanzee 
seminal plasma (14.20 ± 1.63 mg/mL) compared to human seminal plasma (9.44 ± 1.21 mg/mL). 
This difference is likely attributed to sample collection, such as pooling semen samples from the 
same individual, and all subsequent reactions (LC/MS-MS and Western blots) had the same total 
protein concentration loaded for each sample. Therefore detection and relative abundance 
differences were not accounted for by total protein content. There were over >50% (detection 
only, not factoring in abundance) of proteins identified being unique to each species (human 
41/71; chimpanzee 33/64; gorilla 24/34) and separation of seminal plasma in SDS-PAGE has 
species-specific banding patterns (Figure 2.12). It is abundantly clear that these species 
proteomes are quite different. The challenge is interpreting which differences are responding to 
sexual selective pressures and generating the different semen consistencies observed in these 
species. The following subsections will focus on seemingly striking differences which functions 
are unknown or biologically relevant to fertilization or semen coagulation. It is likely that our 
analysis may have missed proteins that play an important role, which are not highly abundant nor 
significantly different between species.  
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2.4.1 Semenogelins 
SEMG1 and SEMG2 are among the most abundant proteins in human seminal plasma, 
together accounting for 23.4% of MS spectra identified across the three human samples (Table 
2.7). Similarly, these two proteins account for 30.9% of spectra from chimpanzees. However, 
whereas SEMG1 and SEMG2 are found in nearly equal abundance in human semen, nearly all of 
the semenogelin protein in chimpanzees is derived from the longer SEMG1 gene (Figure 1.5:C). 
Considering previous studies have shown a fixed premature stop codon in the SEMG2 gene 
(Figure 1.5:D; Jensen-Seaman and Li, 2003) for chimpanzees, it was surprising that SEMG2 was 
even detected. However, another study analyzing a single chimpanzee individual also detected 
SEMG2 with an approximate abundance of 2.8% (and ~15.9% of SEMG1) in a separate lab run 
under their conditions (Claw, 2013).  
 Western blots of seminal plasma revealed high-molecular weight targets of anti-
semenogelin antibodies especially in chimpanzees (Figure 2.11). This is consistent with covalent 
cross-linking of semenogelin monomers to form large insoluble protein complexes. It is therefore 
possible that the high-molecular weight proteins bound by anti-SEMG2 and seen in our Western 
blots are similarly produced. Among the three species examined in this study, chimpanzees are 
the only one to produce a firm copulatory plug (Dixson and Anderson, 2001). In a proteomic 
study analyzing the copulatory plug, a common phenotype in mice, 63 different proteins were 
identified (Dean et al., 2011), including the semenogelins paralog, SVS2. It is likely that the 
detection of high molecular weight semenogelins is a result of their cross-linking interaction with 
themselves and other unknown proteins.  
With both LC-MS/MS and Western blotting, only one of the three gorilla individuals 
sampled possessed peptides derived from the semenogelin genes, although in this individual the 
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amount produced was substantial (Table 2.7; Figure 2.11), ~28% relative abundance. This 
variation of expression among gorillas correlates to the presence of polymorphic stop codons in 
both their semenogelin genes (Figure 1.5:D). 
 Western blots of all three hominid species also show smaller, low molecular weight 
peptides when probed with anti-SEMG1 or anti-SEMG2 (Figure 2.11), consistent with 
degradation by endogenous seminal proteases, as seen in other studies (Lwaleed et al., 2004; de 
Lamirande, 2007). Attempts to use protease inhibitors to prevent or stop degradation were 
largely unsuccessful (Figure 2.8, 2.9), indicating that at least a large amount of this proteolytic 
degradation is happening almost immediately upon ejaculation. 
2.4.2 Up-regulation and pseudogenization of seminal coagulation pathway 
Serpina1, Serpina3, Serpina5, SEMG1, Fibronectin (FN1), CRTAC1, and TGM4 were 
expressed higher in chimpanzees compared to humans and have functions related to semen 
coagulation and copulatory plug formation (Figure 2.16). Serpina5, or Protein C Inhibitor, is 
known to inactivate Kallikrein related peptidase 3 (KLK3) (Lwaleed et al., 2004). KLK3 is an 
important serine protease involved in cleavage of semenogelin peptides to release spermatozoa, 
which also liquefies semen. The up regulation of serine protease inhibitors may delay the 
dissolution of the copulatory plug formed in chimpanzees.  
SEMG1 is a known substrate of TGM4, and is one of the major components, along with 
FN1, in forming viscosity, or the copulatory plug in chimpanzees. Cross-linking of the rodent 
paralogs SVS1, 2 and 3 to form a copulatory plug is mediated by the rodent TGM4 paralog 
(Tseng et al., 2008, 2011). Tgm4 or Svs2 knockout male mice are unable to form a copulatory 
plug, indicating that both are required, even though additional proteins are present in the 
copulatory plug (Dean et al., 2011; Dean et al., 2013; Kawano et al., 2014). CRTAC1 is an 
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extracellular matrix protein in cartilage tissue, and may help form the copulatory plug; however, 
functional studies would need to support this hypothesis. 
Prolactin inducible protein (PIP) was not detected in our chimpanzee samples, though it 
was in moderate to high abundance in human and gorilla (Table 2.9). However, PIP was detected 
in one chimpanzee individual in another LC/MS-MS data set around 2.5% abundance (Claw, 
2013). Human and mouse tissue expression data suggest that PIP is expressed from the prostate 
(Unigene). PIP has been shown to cleave FN1 (Caputo, 2000), which may aid in the dissolution 
of the copulatory plug. Subsequently, PIPs down regulation or absence in chimpanzee semen 
may be connected to its interaction with FN1.  
Multiple proteins in this pathway were not detected in gorilla, such as: TGM4, KLK3, 
Serpina3, and Serpina5 (Figure 2.16). In addition, the SEMGs were only found in one individual, 
and ACPP was only detected in one individual via Western blot (Figure 2.15). As discussed in 
Chapter 1, gorilla ejaculate is “liquidy” and in a smaller volume compared to human and 
chimpanzee. This semen phenotype may be a result of gene loss involved in the coagulation 
pathway. Gorilla has increased expression of albumin and clusterin compared to human and 
chimpanzees, and possibly these two proteins are making up the consistency of gorilla semen.  
Intriguingly, Progestagen-associated endometrial protein (PAEP) nearly accounts for 
~26% (length-adjusted) of the gorilla seminal plasma proteome. PAEP is significantly higher in 
abundance in gorilla than chimpanzee (~1.5%, length adjusted), and PAEP was not detected in 
human at all. However, other studies have detected PAEP in human seminal fluid and there is 
some gene expression of PAEP in human testes, although expression is mainly associated with 
human mammary glands, uterus, and cervix (Unigene). PAEP is the official gene symbol, but has 
numerous identifiers in literature, the most common being Glycodelin, which is indicative of it 
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being a glycoprotein. PAEP has four forms, with the same protein backbone but different 
glycosylation profiles, likely influencing its function and are named after their location 
(Glycodelin-A; amniotic fluid, Glycodelin-C; cumulus cells, Glycodelin-F; follicular fluid, 
Glycodelin-S; semenial fluid). These forms have essential roles in regulating a uterine 
environment for embryo implantation and development (Uchida et al., 2013). Glycodelin-S, 
likely the form we detected from gorilla and chimpanzee seminal plasma, binds spermatozoa 
immediately after ejaculation, subsequently preventing capacitation, until is disassociated 
(Uchida et al., 2013). This increased abundance of PAEP in gorilla seminal plasma is interesting, 
and perhaps it is playing a role in delaying capacitation of spermatozoa to lengthen the viability 
time of sperm, as capacitation is required for fertilization of the ova, but sperm are not functional 
two hours post capacitation (Cohen-Dayag et al., 1995).   
Only SEMG2 and PIP are expressed in higher abundance in human compared to the other 
species (Figure 2.16). However, human has maintained expression of all the proteins involved in 
the semen coagulation and liquefaction pathway. This is not surprising, as human ejaculate is 
moderate compared to chimpanzee and gorilla, and retaining proteins in both coagulation and 
liquefaction would lead to this phenotype.  
In conclusion, chimpanzee has an up regulation of proteins that are likely involved in 
semen coagulation and copulatory plug formation. Likewise, serene protease inhibitors have 
increased expression that may slow the dissolution of the copulatory plug, while proteases (like 
KLK3 and ACPP) are absent or under-expressed. Copulatory plug formation is thought to be 
advantageous, by either aiding in fertilization or preventing subsequent males sperm from 
fertilizing the females egg. Likely this seminal phenotype is a response to increased sperm 
competition due to their multi-male/multi-female mating system. Contrarily, gorillas with 
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relatively low sperm competition have many proteins lost in both the coagulation and 
liquefaction pathways. This may be due to a relaxation of selective pressures on semen, while 
other sexual selective pressures are at play increasing their ability to combat other males for 
access to females. The high abundance of PAEP in gorilla seminal plasma, was unexpected, but 
likely is important in the sperm capacitation process and timing of fertilization, which may be 
unique to gorillas. Human, with perceived moderate sperm competition, has all proteins involved 
in the semen coagulation and liquefaction pathway, likely contributing to a comparatively 
average semen consistency and proteome. 
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Figure 2.16: Expression differences in seminal coagulation and liquefaction pathways of 
hominds: human, chimpanzee, and gorilla  
Proteins involved in the semen coagulation (TGM4 and “coagulants” proteins) and semen liquefaction (“proteases”; 
“protease inhibitors”) are represented for each species: human, chimpanzee, and gorilla. Proteins are color-coded 
based on their function. Proteins that are black, PIP and CRTAC1, have unknown functions directly related to semen 
coagulation/liquefaction pathways, however related functions and observed differences in abundance suggest 
involvement in the liquefaction and coagulation pathway, respectively. PIP has been shown to have proteolytic 
activity on fibronectin in vitro, therefore, its unknown function in this pathway is likely associated with cleaving 
fibronectin and liquefaction of semen. CRTAC1 is an extracellular matrix protein involved in cartilage formation 
and may be a coagulant in semen. All the proteins were detected in human seminal plasma (either by LC/MS-MS or 
Western blot). Subsequently, protein names that are listed in human and not listed in another species indicate that 
they were not detected via LC/MS-MS in that species. Protein names, which are bolded, are in the species that had 
the highest significant expression of that particular protein compared to other species.  Protein names with an *, 
were not identified in all individuals of the same species. Arrows and blunt end lines have either proteolytic or 
inhibitory activity, respectively, on the proteins that they are pointed to.  
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2.5 Future Directions  
 It is strikingly clear that there are differences among these seminal plasma proteomes, 
and the presence of all the proteins detected in this study likely have some physiologic function 
in seminal plasma which is a result of multiple selective forces. In essence, there are 171 
different future directions this study could continue – the same number of proteins identified 
with high confidence. This study and previous studies suggest that the proteins involved in 
semen coagulation and liquefaction (Figure 2.16) may be of most interest. Specifically, I 
followed up with TGM4 (Chapter 3), but recently I have been thinking about the importance of 
proteins unique to one species and not the other. Where did they come from? What is their 
function?   
 Anne-Ruxandra Carvunis coined the term ‘proto-gene hypothesis’, which proposes that 
de novo genes arise from ancestral promoters driving constitutive expression of non-genic 
sequences (2012). The constitutive promoters are signatures left from ancestral genes, which 
have become pseudogenized or lost. The nongenic short transcripts in front of these promoters 
are quickly degraded if they do not provide a benefit, but if they are functionally advantageous, 
can rapidly evolve into a functional gene generating a novel protein in a species. In essence, a 
gene is preserved until it is no longer needed; then it becomes a pseudogene, in which its 
sequence can primitively become a new gene with a different function. I hypothesize that the 
pseudogenization events in both SEMG1 and SEMG2 of gorilla have occurred relatively recently, 
and in accordance with the model proposed by Carvunis, the promoter is still very active—as 
evidenced by the high expression in one gorilla who lacks a premature stop codon. If possible, I 
would like to sequence the DNA of the same gorilla individuals, whose semen was assayed, to 
determine: 1) if they had premature stop codons corresponding to their proteomic expression and 
 99 
2) if their promoter sequences were conserved. I would then follow up with an in vitro model 
whereby reporter constructs carrying the promoter sequence found in front of expressed and non-
expressed SEMG genes are transfected into mammalian cells in culture to assay their promoter 
strength. If possible, SEMG mRNA transcripts could be analyzed through RT-PCR of gorilla 
testes tissue.  
 CRTAC1 expression in chimpanzee seminal plasma and its relative high abundance is 
intriguing to me. I have hypothesized that its roles in cartilage formation may have functions in 
the construction of the copulatory plug, but how, I am unsure. There are a few pilot experiments 
I would design to assay its importance. First, is CRTAC1, or its paralogs present in other species, 
known to form copulatory plugs? If in mice, do Crtac1 knockout mice produce a plug? Or are 
male mice unable to form plugs like Svs2 and Tgm4 knockout mice? Second, is CRTAC1 a 
substrate for prostate specific transglutaminase? I would use either recombinant chimpanzee 
CRTAC1 or commercially available CRTAC1 (most likely human) in the TGM4 assays to 
determine if CRTAC1 is cross-linked.  
 I recently went to a lecture where Mark Chance, Ph.D., was presenting on his team’s 
innovative project, CrosstalkerTM, which is a bioinformatics tool to search interactive gene-
protein networks. He claimed that users could input a list of genes, proteins, or metabolites, and 
search multiple connected resources, like String, to identify additional genes/proteins/metabolites 
involved in associated pathways. The generation of these large ‘Omics’ data sets is a tremendous 
advancement in research; however, the bioinformatic tools and expertise for analysis is lagging 
behind. I think there are still biologically interesting proteins which are present in these data but 
not resolved through our current analysis. The largest future direction of this project should be to 
utilize these data as a resource for future bioinformatic tools to identify interesting leads.  
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CHAPTER 3: Prostate specific transglutaminase TGM4 activity 
3.1 Introduction 
 Humans and chimpanzees diverged approximately 6 million years ago. Our last common 
ancestor with chimpanzees is extinct and the fossils they left behind can only allude to 
behavioral and social organization. There is debate about what our last common ancestor’s 
mating system was, and several models have been proposed using anatomical fossil evidence, 
proposing either a chimpanzee-like mating system or a gorilla-like mating system. A 
chimpanzee-like mating system model transitions from polyandry to increased pair-bonded 
monogamy driven by female choice and male provisioning, concealed ovulation, and greater 
paternal care in the hominin lineage (Lovejoy et al, 2009; Lovejoy, 2009; Gavrilets, 2012). A 
monoandrous gorilla-like mating system model requires reduced aggression between males first 
within social groups and then between groups, while simultaneously shifting toward mate pair-
bonding (Nakahashi and Horiuchi, 2012; Chapais, 2013). Either model is plausible, but many 
researchers tend to favor the chimpanzee-like mating system (Dixson, 2009; Chapais, 2009).  
 Ancestral sequence reconstruction (ASR) enables restoration of an extinct common 
ancestor sequence through maximum likelihood comparison of extant species and genetic 
engineering to produce the ancestral protein (Harms and Thornton, 2010). ASR has not been 
commonly used in human evolutionary studies, but has been implemented in studies of other 
species (Chang et al., 2002; Yokoyama et al., 2008). For example, the common ancestor of 
reptiles and birds, the archosaur, was determined to have nocturnal behavior, after its rhodopsin 
protein was reconstructed and compared to extant vertebrate rhodopsins (Chang et al., 2002). My 
study reconstructs the human-chimpanzee ancestral prostate specific transglutaminase (TGM4) 
and aims to assay its activity compare to human and chimpanzee TGM4s.  
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 TGM4 is a calcium-dependent enzyme involved in semen coagulation and copulatory 
plug formation in chimpanzee by crosslinking semenogelin (SEMG1 and SEMG2) proteins at 
glutamine and lysine residues (Greenberg et al., 1991; Folk, 1983; Esposito and Caputo, 2004). 
In gibbons, gorillas, and other species with relatively low sperm competition, TGM4 has become 
a pseudogene (Clark and Swanson, 2005; Carnahan and Jensen-Seaman, 2008; Tian et al., 2009). 
After seminal coagulation, the semenogelin proteins are cleaved by KLK3 (Kallikrein related 
peptidase 3, Lilja, 1985) and to a lesser extent by ACPP (Prostate acid phosphatase; Brillard-
Bourdet, et al., 2002) facilitating liquefaction of semen. The cleavage of semenogelin releases 
bound and trapped spermatozoa (Robert et al., 1997; Flori et al., 2008). (Figure 3.1)  
 TGM4 is approximately 7 fold higher in chimpanzee seminal plasma compared to 
humans (discussed in Chapter 2), and it is important in copulatory plug formation (Dean, 2013). 
Because of these attributes, TGM4’s activity is an excellent choice to study in order to assess 
mating system behavior in our last common ancestor with chimpanzee. If the ancestral TGM4 
functions more like chimpanzee TGM4 compared to human TGM4, then a chimpanzee-like 
mating system with polyandry would be supported. However, if ancestral TGM4 activity is more 
like human TGM4 activity, then the gorilla-like mating system model would be supported.  
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Figure 3.1: Proteins involved in semen coagulation and liquefaction upon ejaculation 
SEMG1 and SEMG2 proteins are transcribed and translated in the seminal vesicle. Subsequently they are cross-
linked together by TGM4 (expressed from the prostate gland) at glutamine and lysine residues forming an 
extracellular matrix that traps spermatozoa. Proteases, like ACPP and the KLKs, cleave SEMGs, releasing 
spermatozoa and liquefying semen within 5-20 minutes upon ejaculation.  
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3.2 Methods 
 This section incorporates methods for cloning TGM4, SEMG1, SEMG2, and KLK3 cDNA 
into expression vectors with the objective to produce recombinant proteins with the human, 
chimpanzee, or the human-chimpanzee ancestor amino acid sequence. TGM4 constructs were 
subsequently analyzed in this dissertation; however, the other constructs will be part of a larger 
project.  
 
3.2.1 Cloning of Human SEMGs and TGM4 into pFastBac1 vector 
3.2.1.1 Traditional and TOPO® cloning 
 Dr. Hiroshi Miyamoto from the University of Rochester Medical Center, generously 
donated pSG5 plasmids containing full-length human SEMG1 and SEMG2 cDNA. A clone 
containing the full coding sequence of human TGM4 (IMAGE clone ID:3950865; GenBank 
ID:BC007003.1) was purchased from ThermoFisher Scientific (Waltham, MA). I designed 
primers that matched the beginning and end of SEMG1, SEMG2, and TGM4 sequence with the 
addition of restriction enzyme sites (SEMG1: SalI/PstI; XhoI/SphI, SEMG2: SalI/XbaI; 
XhoI/SphI, TGM4: SalI/XbaI; XhoI/SphI) matching pFastBac1 (Invitrogen, Carlsbad, CA) vector, 
a C-terminal HIS tag sequence, and random nucleotides on the ends to allow restriction enzymes 
to work properly (Table 3.1). The semenogelins and TGM4 were amplified with iProof™ DNA 
polymerase (BioRad, Hercules, CA) under the following conditions: (98°C, 30”)/(98°C, 10”/ 
55°C, 15”/ 72°C, 1’)35 /(72°C, 10’)/(4°C, ∞). Initially, traditional cloning (digestion, ligation, 
and transformation) of the PCR products was attempted, but was unsuccessful. Subsequently, the 
gene amplified products were purified with the Wizard® SV gel and PCR clean-up system 
(Promega, Madison, WI), and incubated at 72°C for 15 minutes with Taq polymerase, thus 
incorporating additional A’s to the 3’ ends before TOPO® TA cloning (Invitrogen) and plating 
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onto LB kanamycin/IPTG/X-gal plates. TOPO® transformants were grown overnight at 37°C in 
LB ampicillin and DNA was extracted using the IBI high speed plasmid mini kit (Midsci, St. 
Louis, MO). Candidates were sequenced with BigDye® Terminator v3.1 (Thermofisher 
Scientific) with the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and 
analyzed on the Avant 3100 sequencer (Applied Biosystems, Foster City, CA). Vector and gene 
specific sequencing primers were used and are included in Appendix A.7 (Table A.14).  
 
Table 3.1: Modified primers used for human gene construct cloning 
Gene Primer Sequence 
Human 
SEMG1 
 
Forward: 5’- CAGAATGCCGTCGACCTGCAGATGAAGCCCAACATCATCTTTGTACTTTCCCTG-3’ 
Reverse: 5’- ACGGTGATCGCATGCCTCGAGTTAATGGTGATGGTGATGGTGTGTAAATAATGGGTTT 
CGGTCGTTGTTAAG-3’ 
Human 
SEMG2 
 
Forward: 5’- GGCTATCGATCGTCGACTCTAGAATGAAGTCCATCATCCTCTTTGTCC-3’ 
Reverse: 5’- GCCTATGCGCATGCCTCGAGTTAATGGTGATGGTGATGGTGTGTAGATATTGGATTTC 
TGTCTTCATTATA-3’ 
Human 
TGM4 
 
Forward: 5’- CGAGTCAGGTCGACTCTAGAATGATGGATGCATCAAAAGAGCTGC-3’ 
Reverse: 5’- TAGACTCATCGGCATGCCTCGAGTTAATGGTGATGGTGATGGTGCTTGGTGATGAGAA 
CAATCTTCTGAGCATTAATC-3’ 
 
 SEMGs and TGM4 gene orientation in the TOPO® vector was determined; and 20µl of 
the TOPO® - SEMG1, SEMG2, or TGM4 clone (approximately 1.5- 7µg DNA) was digested 
with NotI / SalI or NotI/ Acc65I in multicore buffer (Promega) as well as 20µl of pFastBac1 
(Invitrogen) vector (about 3.5 µg of vector DNA), for four hours at 37°C and then terminated at 
65°C for ten minutes. The pFastBac1 vector was then incubated with alkaline phosphatase 
(Promega) at 37°C for one hour. Alkaline phosphatase removes 5’ phosphates in order to prevent 
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re-circularization of the vector. The digested and/or dephosphorylated products were extracted 
with the Wizard® SV gel and PCR clean-up system (Promega) and quantified with the Qubit® 
dsDNA BR assay kit on the Qubit® 2.0 fluorometer (Invitrogen). Both 1:1 and 3:1 
(insert:vector) DNA ratios (~100-200ng DNA total) were added to separate ligation reactions 
(total volume 10µl)  and incubated with T4 ligase (Promega) in the thermocycler at the following 
increasing temperatures for sixty minute increments (4°C, 6°C, 8-16°C). Entire ligation reactions 
(10µl) were transferred to 200µl of thawed TG1 chemically competent E. coli cells and put on 
ice for 20 minutes. Cells were heatshocked at 42°C for 45 seconds and immediately transferred 
to ice for two minutes. Cells were added to 500µl of LB broth in a culture tube and incubated at 
37°C and 250 rpm for one hour. After incubation, 50µl and 250µl of each culture were spread 
onto LB carbenicillin plates and incubated 16-18 hours at 37°C. Single colonies were transferred 
to a 3mL LB ampicillin tube, and to an LB carbenicillin replicate plate, and incubated overnight 
at 37°C. Freezer stocks were made from 750µl of culture with 250µl 60% glycerol and stored at -
80°C. The remaining 2.25mL culture’s DNA was extracted with the IBI high-speed plasmid mini 
kit (Midsci). Candidates were sequenced with BigDye® Terminator (Thermofisher Scientific) at 
the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and analyzed on the Avant 
3100 sequencer (Applied Biosystems). Verified constructs were grown in 50mL LB ampicillin 
cultures and DNA was extracted using the Pureyield™ plasmid midiprep system (Promega).  
3.2.1.2 Site-directed mutagenesis of human TGM4 
 The pcDNA-TGM4 plasmid used to subclone human TGM4 into pFastBac1 had one 
nonsynonymous mutation at 1125 bases in the sequence. This missense variant converts a proline 
(CCG) codon to a serine (TCG) codon. After searching for common single nucleotide 
polymorphisms (SNPs) in humans for TGM4, this variant did not appear to be present. In 
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addition, PolyPhen and SIFT missense effect indexes indicated this mutation would most likely 
be deleterious. Therefore, QuickChange II Site-directed mutagenesis (Agilent Technologies, 
Santa Clara, CA) was utilized to modify the mutated human TGM4 to the common proline 
(CCG) variant in the population.   
 Human TGM4 pFastBac1 template (10ng and 50ng) was amplified with 5.7µl of 20nM 
mutagenetic primers (Table 3.2) at the following conditions: (95°C, 1’)/(95°C, 50”/60°C, 50”/ 
68°C, 16’)18 /(68°C, 8’) /(4°C, ∞). Then 1µl of DpnI was added to each reaction and incubated at 
37°C for 2 hours and 80°C for 20 minutes. XL1-Blue chemically competent E. coli cells (Agilent 
Technologies) were aliquoted (50µl) into pre-chilled tubes and incubated on ice for several 
minutes. Then 1µl (5ng reaction) or 4µl (10ng reaction) of DpnI digested DNA was added to the 
cells and incubated on ice for thirty minutes. Cells were heat shocked at 42°C for 45 seconds, 
and immediately incubated on ice for two minutes. Transformed cells were transferred to a 
0.5mL NZY+ broth (preheated to 42°C) and incubated at 37°C and 250 rpm for one hour. After 
incubation, 250µl of cells were spread onto LB carbenicillin/ 2%XGAL/ 10mM IPTG plates and 
grown overnight at 37°C. Freezer stocks were made from 750µl of culture with 250µl 60% 
glycerol and stored at -80°C. The remaining 2.25mL culture’s DNA was extracted with the IBI 
high speed plasmid mini kit (Midsci). Candidates were sequenced with BigDye® Terminator 
(Thermofisher Scientific) at the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, 
∞), and analyzed on the Avant 3100 sequencer (Applied Biosystems). Verified constructs were 
grown in 50mL LB ampicillin cultures and DNA was extracted using the Pureyield™ plasmid 
midiprep system (Promega).  
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Table 3.2: Mutagenic primers used for human TGM4 modification 
Gene Mutagenic Primer Sequence 
Human TGM4  
1: 5’– GCTGTGGACGCAACGCCGCAGGAGCGAAGCC–3’ 
2: 5’– GGCTTCGCTCCTGCGGCGTTGCGTCCACAGC–3’ 
 
3.2.2 Gibson assembly of human and chimpanzee KLK3s and chimpanzee and 
human-chimpanzee ancestor TGM4s into the pFastBac1 vector 
3.2.2.1 Designing of gBlocks 
 Human and chimpanzee KLK3s were cloned using Gibson assembly of DNA fragments. 
Double stranded DNA fragments, called gblocks, were ordered through Integrated DNA 
Technologies (IDT). Currently, 125-3,000 base pairs of DNA can be synthesized; however, 
during the production of these clones, only up to 700 base pairs were commercially available. 
Because KLK3 mRNA with a HIS-tag would be more than 800 base pairs, three gblocks were 
designed by Jennifer (Vill) Doyle and Michael Seaman (Figure 3.2) to clone human and 
chimpanzee KLK3. Because species-specific nucleotide differences (that are nonsynonymous) 
occur in the first half of KLK3 mRNA, a human specific gblock “A” and a chimpanzee specific 
gblock “A” were designed (Figure 3.2). Since no nonsynonymous mutations occur in the second 
half of KLK3 mRNA, a combined human and chimpanzee gblock “B” was designed with a HIS-
tag sequence inserted before the stop codon (Figure 3.2).  Both gblocks include restriction 
enzyme sites and the end of block A and beginning of block B overlapped (underlined in Figure 
3.2) approximately 60 nucleotides (for Gibson assembly to work).  
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Figure 3.2: Human and chimpanzee KLK3 gblock design  
Human KLK3 gblock A and chimpanzee gblock A have two nonsynonymous differences highlighted in yellow. 
Both gblock As overlap with HumanChimpKLK3 gblock B where the sequence is underlined. The combined gblock 
B has a HIS-tag sequence (in blue) inserted before the stop codon (red). Restriction enzyme sites (EcoRI and 
Acc65I) were included before the start codon (green) and after the stop codon (red) and are bolded. 
 
 Chimpanzee and human-chimpanzee ancestor TGM4s were cloned using Gibson 
assembly of DNA fragments.  At the time, Integrated DNA Technologies (IDT) could synthesize 
up to 2,000 base pairs of DNA, which was just shy of the 2,100 base pair minimum requirement 
to design HIS-tag TGM4s. Therefore each TGM4 would have to be assembled using two gblocks 
with a forty base pair overlap. Nonsynonymous mutations between chimpanzee and human-
chimpanzee ancestor are throughout the mRNA sequence, therefore, a total of four gblocks were 
required (Ancestor Block A, Ancestor Block B, Chimpanzee Block A, and Chimpanzee Block B) 
and were otherwise designed similar to the KLK3 gblocks (Figure 3.3). Human-chimpanzee 
ancestor sequence was determined by comparing the amino acid sequence between human, 
chimpanzee, and orangutan as an outgroup (Appendix A.8). 
HumanKLK3_blockA 
AGGTGACAGAGCTAGCGTCGAATTCATGTGGGTCCCGGTTGTCTTCCTCACC
CTGTCCGTGACGTGGATTGGTGCTGCACCCCTCATCCTGTCTCGGATTGTGG
GAGGCTGGGAGTGCGAGAAGCATTCCCAACCCTGGCAGGTGCTTGTGGCCTC
TCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTC
ACAGCTGCCCACTGCATCAGGAACAAAAGCGTGATCTTGCTGGGTCGGCACA
GCCTGTTTCATCCTGAAGACACAGGCCAGGTATTTCAGGTCAGCCACAGCTT
CCCACACCCGCTCTACGATATGAGCCTCCTGAAGAATCGATTCCTCAGGCCA
GGTGATGACTCCAGCCACGACCTCATGCTGCTCCGCCTGTCAGAGCCTGCCG
AGCTCACGGATGCTGTGAAGGTCATGGACCTGCCCACCCAGGAGCCAGCACT
GGGGACCACCTGCTAC 
 
ChimpKLK3_blockA 
AGGTGACAGAGCTAGCGTCGAATTCATGTGGGTCCCGGTTGTCTTCCTCACC
CTGTCCGTGACGTGGATTGGTGCTGCACCCCTCATCCTGTCTCGGATTGTGG
GAGGCTGGGAGTGCAAGAAGCATTCCCAACCCTGGCAGGTGCTTGTGGCCTC
TCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTC
ACAGCTGCCCACTGCATCAGGAACAAAAGCGTGATCTTGCTGGGTCGGCACA
GCCTGTTTCATCCTGAAGACACAGGCCAGGTATTTCAGGTCAGCCACAGCTT
CCCACACCCGCTCTACGATATGAGCCTCCTGAAGAATCGATTCCTCAGGCCA
GGTGATGACTCCAGCCACGACCTCATGCTGCTCCGCCTGTCAGAGCCTGCCG
AGATCACGGATGCTGTGAAGGTCATGGACCTGCCCACCCAGGAGCCAGCACT
GGGGACCACCTGCTAC 
 
HumanChimpKLK3_blockB 
GATGCTGTGAAGGTCATGGACCTGCCCACCCAGGAGCCAGCACTGGGGACCA
CCTGCTACGCCTCAGGCTGGGGCAGCATTGAACCAGAGGAGTTCTTGACCCC
AAAGAAACTTCAGTGTGTGGACCTCCATGTTATTTCCAATGACGTGTGTGCG
CAAGTTCACCCTCAGAAGGTGACCAAGTTCATGCTGTGTGCTGGACGCTGGA
CAGGGGGCAAAAGCACCTGCTCGGGTGATTCTGGGGGCCCACTTGTCTGTAA
TGGTGTGCTTCAAGGTATCACGTCATGGGGCAGTGAACCATGTGCCCTGCCC
GAAAGGCCTTCCCTGTACACCAAGGTGGTGCATTACCGGAAGTGGATCAAGG
ACACCATCGTGGCCAACCCCCACCATCACCATCACCATTGAGGTACCGAGAT
CAAGGCTCCATCTCC
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Figure 3.3: Human-chimpanzee ancestor and chimpanzee TGM4 gblock design  
Human-chimpanzee ancestor TGM4 gblock A and B and chimpanzee gblock A and B have different sequences, 
highlighted in yellow. Both gblock As overlap with their respective gblock Bs where the sequence is underlined. 
Both gblock Bs have a HIS-tag sequence (in blue) inserted before the stop codon (red). Restriction enzyme sites 
(SalI and NotI) were included before the start codon (green) and after the stop codon (red) and are bolded. In 
addition, the surrounding sequence matched the pFastBac1 vector sequence.   
 
 
Human/ChimpAncestorTGM4_BlockA 
GGATCCCGGTCCGAAGCGCGCGGAATTCAAAGGCCTACGTCG
ACATGATGGATGCATCAAAAGAGCTGCAAGTTCTCCACGTTG
ACTTCTTGAAGCAGGACAACGCCGTTTCTCACCACACATGGG
AGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGT
TTCACCTGCGGCTGGTGCTGAACCAGCCCCTACAATCCTACC
ACCAACTGAAACTGGAATTCAGCACAGGGCCGAATCCTAGCA
TCGCCAAACACACCCTGGTGGTGCTCGACCCGAGGACGCCCT
CAGACCACTACAACTGGCAGGCAACCCTTCAAAATGAGTCTG
GCAAAGAGGTCACAGTGGCTGTCACCAGTTCCCCCAATGCCA
TCCTGGGCAAGTACCAACTAAATGTGAAAACTGGAAACCACA
TCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACC
CATGGTGTAAAGAGGACATGGTTTTCATGCCTGATGAGGACG
AGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACG
TGGGGGCTGCCAGAAGTATCAAATACAAACCCTGGAACTTTG
GTCAGTTTGAGAAAAATGTCCTGGACTGCTGCATTTCCCTGC
TGACTGAGAGCTCCCTCAAGCCCACAGATAGGAGGGACCCCG
TGCTGGTGTGCAGGGCCATGTGTGCTATGATGAGCTTTGAGA
AAGGCCAAGGCGTGCTCATTGGGAATTGGACTGGGGACTACG
AAGGTGGCACAGCCCCATACAAGTGGACAGGCAGTGCCCCGA
TCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTG
GCCAGTGCTGGGTGTTTGCTGGGATCCTGACTACAGTGCTGA
GAGCGTTGGGCATCCCAGCACGCAGTGTGACAGGCTTCGATT
CAGCTCACGACACAGAAAGGAACCTCACGGTGGACACCTATG
TGAATGAGAATGGCGAGAAAATCACCAATATGA 
 
 
 
 
 
 
 
Human/ChimpAncestorTGM4_BlockB 
ACACCTATGTGAATGAGAATGGCGAGAAAATCACCAATATGACCC
ACGACTCTGTCTGGAATTTCCATGTGTGGACGGATGCCTGGATGA
AGCGACCGGATCTGCCCAAGGGCTACGACGGCTGGCAGGCTGTGG
ACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGC
CATCACCACTGACCGCCATCCGCAAAGGTGACATCTTTATTGTCT
ATGACACCAGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCA
TCTGGTTGGTGAAGATGGTGAATGGGCAGGAGGAGTTACACGTAA
TTTCAATGGAGACCACAAGCATCGGGAAAAACATCAGCACCAAGG
CAGTGGGCCAAGACAGGCGGAGAGATATCACCTATGAGTACAAGT
ATCCAGAAGGCTCCTCTGAGGAGAGGCAGGTCATGGATCATGCCT
TCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAG
AGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGG
GAAACCCTGTTAATTTCACCGTGATTCTTAAAAGGAAGACCGCTG
CCCTACAGAATGTCAACATCTTGGGCTCCTTTGAACTACAGTTGT
ACACTGGCAAGAAGGTGGCAAAACTGTGTGACCTCAATAAGACCT
CGCAGATCCAAGGTCAAGTATCAGAAGTGACTCTGACCTTGGACT
CCAAGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAG
TTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGTCTAAGGAAA
TCATGGCCTCTGAAGTATTCACGTCTTTCCAGTACCCTGAGTTCT
CTATAGAGTTGCCTAACACAGGCAGAATTGGCCAGCTACTTGTCT
GCAATTGTATCTTCAAGAATACCCTGGCCATCCCTTTGACTGACG
TCAAGTTCTCTTTGGAAAGCCTGGGCATCTCCTCACTACAGACCT
CTGACCATGGGACGGTGCAGCCTGGTGAGACCATCCAATCCCAAA
TAAAATGCACCCCAATAAAAACTGGACCCAAGAAATTTATCGTCA
AGTTAAGTTCCAAACAAGTGAAAGAGATTAATGCTCAGAAGATTG
TTCTCATCACCAAGCACCATCACCATCACCATTAACGCGGCCGCT
TTCGAATCTAGAGCCTGCAGTCTCGAGGCATGCGGTACCAAGC 
 			
ChimpTGM4_BlockA 
GGATCCCGGTCCGAAGCGCGCGGAATTCAAAGGCCTACGTCGAC
ATGATGGATGCATCAAAAGAGCTGCAAGTTCTCCACGTTGACTT
CTTGAAGCAGGACAACGCCGTTTCTCACCACACATGGGAGTTCC
AAACGAGCACTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTG
CGGCTGGTGCTGAACCAGCCCCTACAATCCTACCACCAACTGAA
ACTGGAATTCAGCACAGGGCCGAATCCTAGCATCGCCAAACACA
CCGTGGTGGTGCTCGACCTGAGGACGCCCTCAGACCACTACAAC
TGGCAGGCAACCCTTCAAAATGAGTCTGGCAAAGAGGTCACAGT
GGCTGTCACCAGTTCCCCCAATGCCATCCTGGGCAAGTACCAAC
TAAATGTGAAAACTGGAAACCACATCCTTAAGTCTGAAGAAAAC
ATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGT
TTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATG
ACACGGGCTGCCATTACGTGGGGGCTGCCAGAAGTATCAGATAC
AAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCCTGGACTG
CTGCATTTCCCTGCTGACTGAGAGCTCCCTCAAGCCCACAGATA
GGAGGGACCCCGTGCTGGTGTGCAGGGCCATGTGTGCTATGATG
AGCTTTGAGAAAGGCCAAGGCGTGCTCATTGGGAATTGGACTGG
GGACTACGAAGGTGGCACAGCCCCATACAAGTGGACAGGCAGTG
CCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGC
TTTGGCCAGTGCTGGGTGTTTGCTGGGATCCTGACTACAGTGCT
GAGAGCGTTGGGCATCCCAGCACGCAGTGTGACAGGCTTCGATT
CAGCTCACGACACAGAAAGGAACCTCACGGTGGACACCTATGTG
AATGAGAATGGCGAGAAAATCACCAATATGA 
 
 
 
 
 
 
 
 
ChimpTGM4_BlockB 
ACACCTATGTGAATGAGAATGGCGAGAAAATCACCAATATGACCCA
CGACTCTGTCTGGAATTTCCATGTGTGGACGGATGCCTGGATGAAG
CGACCGGATCTGCCCAAGGGCTACGACGGCTGGCAGGCTGTGGACG
CAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGCCATC
ACCACTGACCGCCATCCGCAAAGGTGACATCTTTATTGTCTATGAC
ACCAGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTGGT
TGGTGAAGATGGTGAATGGGCAGGAGGAGTTACACGTAATTTCAAT
GGAGACCACAAGCATCGGGAAAAACATCAGCACCAAGGCAGTGGGC
CAAGACAGGCGGAGAGATATCACCTATGAGTACAAGTATCCAGAAG
GCTCCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCT
CAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAGAGAACTTTCTT
CACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACCCTGTTA
ATTTCACCGTGATTCTTAAAAGGAAGACCGCTGCCCTACAGAATGT
CAACATCTTGGGCTCCTTTGAACTACAGTTGTACACTGGCAAGAAG
GTGGCAAAACTGTGTGACCTCAATAAGACCTCGCAGATCCAAGGTC
AAGTATCAGAAGTGACTCTGACCTTGGACTCCAAGACCTACATCAA
CAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATC
ATTGCGGAAATTGTGGAGTCTAAGGAAATCATGGCCTCTGAAGTAT
TCACGTCTTTCCAGTACCCTGAGATCTCTATAGAGTTGCCTAACAC
AGGCAGAATTGGCCAGCTACTTGTCTGCAATTGTATCTTCAAGAAT
ACCCTGGCCATCCCTTTGACTGACGTCAAGTTCTCTTTGGAAAGCC
TGGGCATCTCCTCACTACAGACCTCTGACCATGGGACGGTGCAGCC
TGGTGAGACCATCCAATCCCAAATAAAATGCACCCCAATAAAAACT
GGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACAAGTGAAAG
AGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCA
TCACCATTAACGCGGCCGCTTTCGAATCTAGAGCCTGCAGTCTCGA
GGCATGCGGTACCAAGC 
 113 
 The ordered gblocks (Figures 3.2 and 3.3) from Integrated DNA Technology (IDT) came 
lyophilized and were reconstituted with 20µl TrisEDTA (10ng/µl). The gblocks were diluted 
(1:100) and amplified with 1µl of 20nmol gblock primers (Table 3.3) using 0.5µl TaKaRa DNA 
polymerase (Clonetech, Mountain View, CA) under the following conditions: (94°C, 2’)/(98°C, 
15”/ 55°C, 15”/ 72°C, 1’)35 /(4°C, ∞) in a 50µl reaction. The amplified gblocks were separated 
on a 1% agarose gel with 0.1% crystal violet buffer, and the amplified products were extracted 
with the Wizard® SV gel and PCR clean-up system (Promega) and quantified with the Qubit® 
dsDNA BR assay kit on the Qubit® 2.0 fluorometer (Invitrogen).  
 
Table 3.3: gBlock primers of KLK3 and TGM4 used for gibson assembly 
Gene gBlock Primer Sequence 
KLK3  
Block A_Fwd: 5’– AGGTGACAGAGCTAGCGTC–3’ 
Block A_Rev: 
Block B_Fwd: 
Block B_Rev: 
5’– GTAGCAGGTGGTCCCCAG–3’ 
5’– GATGCTGTGAAGGTCATGGA–3’ 
5’– GGAGATGGAGCCTTGATCTC–3’ 
TGM4   
Block A_Fwd: 5’– GGATCCCGGTCCGAAGCGCGCGG–3’ 
Block A_Rev: 
Block B_Fwd: 
Block B_Rev: 
5’– CATATTGGTGATTTTCTCGCCATTC–3’ 
5’– CACCTATGTGAATGAGAATGGCGAG–3’ 
5’– GCTTGGTACCGCATGCCTCG–3’ 
3.2.2.2 Gibson assembly 
 Chimpanzee KLK3 gblocks were amplified separately by Jennifer (Vill) Doyle and were 
incubated with Gibson assembly mix (New England Biolabs®, Ipswich, MA) for an hour at 
50°C and then 80°C for 20 minutes. Gibson assembled chimpanzee KLK3 and pFastBac1 
(Invitrogen) vector were digested with EcoRI/Acc65I in multicore buffer (Promega), as well as 
20µl of pFastBac1 (Invitrogen) vector for four hours at 37°C and then terminated at 65°C for ten 
minutes. The pFastBac1 vector was then incubated with alkaline phosphatase (Promega) at 37°C 
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for one hour. Ligation, transformation, and verification of chimpanzee KLK3 pFastBac1 was 
similar to human SEMGs and human TGM4 described previously.  
 Human KLK3 gblocks A and B were amplified together with Block A forward primer and 
Block B reverse primer using iProof™ DNA polymerase (BioRad) under the following 
conditions: (98°C, 2’)/(98°C, 10”/ 55°C, 15”/ 72°C, 1’)35 /(72°C, 10’)/(4°C, ∞). Amplified 
human KLK3 gblocks AB DNA and pFastBac1 (Invitrogen) were digested with fast EcoRI and 
Acc65I (Thermofisher Scientific) at 37°C for 45 minutes and terminated at 80°C for 20 minutes. 
The pFastBac1 vector was simultaneously dephosphorylated with Fast Alkaline Phosphatase 
(Thermofisher Scientific). The digested and/or dephosphorylated products were extracted with 
the Wizard® SV gel and PCR clean-up system (Promega) and quantified with the Qubit® 
dsDNA BR assay kit on the Qubit® 2.0 fluorometer (Invitrogen). Different insert:vector DNA 
ratios (1:1, 1:3 and 3:1) were added to separate ligation reactions (total volume 10µl)  and 
incubated with Fast T4 ligase (Thermofisher Scientific) in the thermocycler at the following 
temperatures: (22°C, 10’)/(21°C, 5’)/ (20°C, 5’)/ (18°C, 5’)/ (16°C, 5’)/ (14°C, 5’) /(65°C, 
10’)/(4°C, ∞). Half of each ligation reaction (5µl) was transferred to 200µl of thawed TG1 
chemically competent E. coli cells and put on ice for 20 minutes. Cells were heatshocked at 42°C 
for 45 seconds and immediately transferred to ice for two minutes. Cells were added to 500µl of 
LB broth in a culture tube and incubated at 37°C and 250 rpm for one hour. After incubation, 
50µl and 250µl of each culture were spread onto LB carbenicillin plates and incubated 16-18 
hours at 37°C. Single colonies were transferred to a 3mL LB ampicillin tube, and to an LB 
carbenicillin replicate plate, and incubated overnight at 37°C. Freezer stocks were made from 
750µl of culture with 250µl 60% glycerol and stored at -80°C. The remaining 2.25mL culture’s 
DNA was extracted with the IBI high speed plasmid mini kit (Midsci). Candidates were 
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sequenced with BigDye® Terminator (Thermofisher Scientific) at the following conditions: 
(96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and analyzed on the Avant 3100 sequencer (Applied 
Biosystems). Verified constructs were grown in 50mL LB ampicillin cultures and DNA was 
extracted using the Pureyield™ plasmid midiprep system (Promega).  
 Two to three molar excess of ancestor and chimpanzee TGM4 gblocks were incubated 
with NotI/SalI digested pFastBac1, Gibson assembly mix (New England Biolabs), and water for 
an hour at 50°C and terminated at 80°C for 10 minutes. NEB® 5-alpha competent E. coli (high 
efficiency) cells were thawed on ice for approximately thirty minutes. Then 10µl of chimpanzee 
or ancestor TGM4 gibson mixed DNA was added to the cells and incubated for another thirty 
minutes on ice. Cells were heatshocked at 42°C for 45 seconds, and 0.5mL of LB broth was 
added to the cells and incubated at 37°C and 250 rpm for one hour. After incubation, 50µl and 
200µl were plated on LB carbenicillin plates and incubated overnight at 37°C. Single colonies 
were transferred to a 3mL LB ampicillin tube, and to an LB carbenicillin replicate plate, and 
incubated overnight at 37°C. Freezer stocks were made from 750µl of culture with 250µl 60% 
glycerol and stored at -80°C. The remaining 2.25mL culture’s DNA was extracted with the IBI 
high speed plasmid mini kit (Midsci). Candidates were sequenced with BigDye® Terminator 
(Thermofisher Scientific) at the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, 
∞), and analyzed on the Avant 3100 sequencer (Applied Biosystems). Verified constructs were 
grown in 50mL LB ampicillin cultures and DNA was extracted using the Pureyield™ plasmid 
midiprep system (Promega). 
3.2.2.3 Site-directed mutagenesis of chimpanzee and ancestor TGM4s in pFastBac1 vector 
 Gibson assembly of chimpanzee and ancestor TGM4 into the pFastBac1 plasmid 
produced a nonsynonymous mutation in each construct. Therefore, Quick-change lightening site-
 116 
directed mutagenesis (Agilent Technologies) was utilized to modify the mutated TGM4s to 
normal. Table 3.4 provides the mutagenic primer sequences. Ancestor and chimpanzee TGM4 
template (5ng, 25ng, and 50ng) was amplified with 125ng of respective mutagenetic primers at 
the following conditions: (95°C, 2’)/(95°C, 20”/60°C, 10”/ 68°C, 5’)18 /(68°C, 5’) /(4°C, ∞). 
Then 2µl of DpnI was added to each reaction and incubated at 37°C for 5 minutes. XL10-gold 
chemically competent E. coli cells (Agilent Technologies) were aliquoted (45µl) into pre-chilled 
tubes and 2µl of β-mercaptoethanol was added to the cells and incubated on ice for two minutes. 
Then 2µl of DpnI digested DNA was added to the cells and incubated on ice for thirty minutes. 
Cells were heat shocked at 42°C for 30 seconds, and immediately incubated on ice for two 
minutes. Transformed cells were transferred to 0.5mL NZY+ broth and incubated at 37°C and 
250 rpm for one hour. After incubation, 250µl of cells were spread onto LB carbenicillin plates 
and grown overnight at 37°C. Freezer stocks were made from 750µl of culture with 250µl 60% 
glycerol and stored at -80°C. The remaining 2.25mL culture’s DNA was extracted with the IBI 
high speed plasmid mini kit (Midsci). Candidates were sequenced with BigDye® Terminator 
(Thermofisher Scientific) at the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, 
∞), and analyzed on the Avant 3100 sequencer (Applied Biosystems). Verified constructs were 
grown in 50mL LB ampicillin cultures and DNA was extracted using the Pureyield™ plasmid 
midiprep system (Promega). 
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Table 3.4: Mutagenic primers used for chimpanzee and ancestor TGM4 modification 
Gene Mutagenic Primer Sequence 
Chimpanzee TGM4  
1: 5’– CAAGCCCACAGATAGGAGGGACCCCGTGCTGGTGTGCAGGGCC–3’ 
2: 5’– GGCCCTGCACACCAGCACGGGGTCCCTCCTATCTGTGGGCTTG–3’ 
Human-chimpanzee 
ancestor TGM4  
 
1: 5’– CAGATGATGTGCTGCTGGGAAACCCTGTTAATTTCACCG–3’ 
2: 5’– CGGTGAAATTAACAGGGTTTCCCAGCAGCACATCATCTG–3’ 
 
3.2.3 Cloning of chimpanzee SEMGs into pFastBac1 
 The coding portion of SEMG1 in exon 2 from chimpanzee genomic DNA was amplified 
using TaKaRa DNA polymerase (Clonetech) under the following conditions: (98°C, 30”)/(98°C, 
10”/ 57°C, 15”/ 72°C, 1’)10 /(98°C, 10”/ 55°C, 15”/ 72°C, 1’)20 /(72°C, 10’) /(4°C, ∞) in a 50µl 
reaction. This PCR is a modified nested PCR, where four primers were added, two external 
primers to amplify a larger region of SEMG1, and two internal primers to amplify a smaller 
section of SEMG1 with added restriction sites and addition of a HIS tag (Table 3.5). In addition, 
TaKaRa taq (0.5µl) and dH2O (5µl) were added to the reaction immediately before the first 
cycle’s 57°C annealing stage, which is often referred to a “Hot start” PCR.  
 The coding portion of SEMG2 in exon 2 from chimpanzee genomic DNA was amplified 
using Phusion High Fidelity polymerase (Thermofisher Scientific) under the following 
conditions: (98°C, 30”)/(98°C, 10”/ 57°C, 15”/ 72°C, 1’)10 /(98°C, 10”/ 55°C, 15”/ 72°C, 1’)20 
/(72°C, 10’) /(4°C, ∞) in a 50µl reaction with provided GC buffer. This PCR is a modified nested 
PCR, where four primers were added, two external primers to amplify a larger region of SEMG2, 
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and two internal primers to amplify a smaller section of SEMG2 with added restriction sites and 
addition of a HIS tag (Table 3.5). Like SEMG1 amplification, 0.5µl of Phusion polymerase and 
5µl of dH2O was added to the reaction during the first primer annealing cycle. 
Table 3.5: Primers used for chimpanzee SEMG1 and SEMG2 amplification 
Gene Primer Sequence 
Chimpanzee SEMG1  
(External)  
MS_11F: 5’– GAAAGCTGCTCAGACAGCTA–3’ 
MS_12R: 5’– AGATATCTCCCCTATTTGCTA–3’ 
(Internal)  
2CS1_PvuIIEx1/2 Fwd: 5’- CGATGACTAGCAGCTGTGATGGGACAAAAAGGTGGATCAAAAG 
GCCGATTACCAAGTGAAT–3’ 
2CS1_HISstopNotIRev: 5’– GATCGATGACGCGGCCGCTTAATGGTGATGGTGATGGTGTGTA 
AATAATGGGTTTCGGTCGTTG–3’ 
Chimpanzee SEMG2   
(External)  
MS_21F: 5’– TCTCCACCCAACGCTGTAGGC–3’ 
MS_22R: 5’– CCTGACATTGCAAGTGTCC–3’ 
(Internal)  
2CS2_PvuIIEx1/2 Fwd: 5’– CGTTGCAAGGCAGCTGTGATGGGACAAAAAGATGGATCAAAAG 
GCCAATT– 3’ 
2CS2_HISstopKpnIRev: 5’– GATGGCATGGGTACCTTAATGGTGATGGTGATGGTGTGTAGAT 
ATTGGATTTCTGTCTTCATTATATTGTTGTGTC– 3’ 
 
 Multiple attempts to digest SEMGs PCR products (SEMG1: PvuII/NotI, SEMG2: 
PvuII/Acc65I) and extract with the Wizard® SV gel and PCR clean-up system (Promega) were 
attempted. However, after quantification with the Qubit® dsDNA BR assay kit on the Qubit® 
2.0 fluorometer (Invitrogen), concentrations were too low for ligation. We decided instead of 
amplifying from genomic DNA, specificity and yield might be higher if amplification was from 
BAC (Bacterial Artificial Chromosome) DNA known to contain the chimpanzee SEMGs (Hurle 
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et al., 2007; PubMed ID 17267810). An E. coli culture harboring the CH251-562O11 BAC 
(BACPAC Resources/CHORI, Oakland, CA) was streaked onto a 2XYT (1.6% Bactotryptone, 
1% yeast, and 0.5% NaCl) chloramphenicol plate and grown overnight at 37°C for 20 hours and 
at 22°C for 48 hours. Single CH251-562O11 colonies were transferred to 3mL of 2XYT 
chloramphenicol broth and incubated at 37°C overnight with 250 rpm agitation. Freezer stocks 
were made from 750µl of culture with 250µl 60% glycerol and stored at -80°C. The remaining 
2.25mL culture’s BAC DNA was extracted with the ZR BAC DNA miniprep kit (Zymo 
Research, Irvine, CA). Then 1µl of CH251-562O11 BAC DNA was amplified under the same 
conditions described above for both SEMG1 and SEMG2.  
 Chimpanzee SEMG1 PCR and human SEMG1 pFastBac1 were digested with PvuII and 
NotI for 45 minutes at 37°C and terminated at 72°C for 10 minutes. Chimpanzee SEMG2 PCR 
and human SEMG2 pFastBac1 were digested with PvuII and Acc65I for 45 minutes at 37°C and 
terminated at 72°C for 10 minutes. Both digested human SEMG1 and SEMG2 pFastBac1 were 
dephosphorylated with 2µl of FastAP (Thermofisher Scientific) for 15 minutes at 37°C and 
terminated at 75°C for 5 minutes. Digested products were separated on a 1% agarose gel with 
0.1% crystal violet buffer and were purified with the Zymoclean gel DNA recovery kit (Zymo 
Research). Samples were quantified with the Qubit® dsDNA BR assay kit on the Qubit® 2.0 
fluorometer (Invitrogen). Different insert:vector DNA ratios (1:1, 1:3 and 3:1) were added to 
separate ligation reactions (total volume 10µl)  and incubated with Fast T4 ligase (Thermofisher 
Scientific) in the thermocycler at the following temperatures: (22°C, 10’)/(21°C, 5’)/ (20°C, 5’)/ 
(18°C, 5’)/ (16°C, 5’)/ (14°C, 5’) /(65°C, 10’)/(4°C, ∞). Half of each ligation reaction (5µl) was 
transferred to 200µl of thawed TG1 chemically competent E. coli cells and put on ice for 20 
minutes. Cells were heatshocked at 42°C for 45 seconds and immediately transferred to ice for 
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two minutes. Cells were added to 500µl of LB broth in a culture tube and incubated at 37°C and 
250 rpm for one hour. After incubation, 50µl and 200µl of each culture were spread onto LB 
carbenicillin plates and incubated 16-18 hours at 37°C. Single colonies were transferred to a 
3mL LB ampicillin tube, and to an LB carbenicillin replicate plate, and incubated overnight at 
37°C. Freezer stocks were made from 750µl of culture with 250µl 60% glycerol and stored at -
80°C. The remaining 2.25mL culture’s DNA was extracted with the IBI high speed plasmid mini 
kit (Midsci). Candidates were sequenced with BigDye® Terminator (Thermofisher Scientific) at 
the following conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and analyzed on the Avant 
3100 sequencer (Applied Biosystems). Only chimpanzee SEMG2 was verified via sequencing 
and size analysis through gel electrophoresis. TA TOPO cloning of chimpanzee SEMG1 
products was attempted, but also yielded shorter constructs.  
 
3.2.4 Site directed mutagenesis to produce chimpanzee SEMG2-TYR mutant and 
human-chimpanzee ancestor KLK3 in pFastBac1 vector 
 Quick-change lightening site-directed mutagenesis (Agilent Technologies) was utilized to 
make both human-chimpanzee ancestor KLK3 and the chimpanzee SEMG2 Tyrosine mutant in 
pFastBac1 (Invitrogen). Human KLK3 and chimpanzee SEMG2 constructs in pFastBac1 (5ng, 
25ng, and 50ng) were amplified with 125ng mutagenic primers (Table 3.6) at the following 
conditions: (95°C, 2’)/(95°C, 20”/60°C, 10”/ 68°C, 5’)18 /(68°C, 5’) /(4°C, ∞). DpnI digestion, 
transformation, and verification were performed similar to chimpanzee and ancestor TGM4 site-
directed mutagenesis described previously.  
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Table 3.6: Mutagenic primers used for chimpanzee and ancestor TGM4 modification 
Gene Mutagenic Primer Sequence 
Chimpanzee  
SEMG2-TYR 
 
1: 5’– GGAAAATAAAATATCATACCAATCTTCGAGTAC–3’ 
2: 5’– GTACTCGAAGATTGGTATGATATTTTATTTTCC–3’ 
Human-
chimpanzee 
ancestor KLK3  
 
1: 5’– CCTGTCAGAGCCTGCCGAGATCACGGATGCTGTGAAGGTC–3’ 
2: 5’– GACCTTCACAGCATCCGTGATCTCGGCAGGCTCTGACAGG–3’ 
 
3.2.5 Transfer of pFastBac1 clones to pCMV mammalian expression vectors 
3.2.5.1 Chimpanzee SEMG1 
 After multiple attempts to clone full-length chimpanzee SEMG1, we ordered a construct 
cloned into pCMV-3Tag-3a (Agilent Technologies) from GenScript (Piscataway, NJ) containing 
chimpanzee SEMG1-HIS sequence (Hurle et al., 2007; Accession number: DP000037). First we 
received 4µg of DNA, which 20, 40, or 60ng of DNA was transformed into One Shot® TOP10 
chemically competent cells (Thermofisher Scientific) and 75µl or 250µl of culture was spread 
onto LB kanamycin plates. Plates were incubated overnight at 37°C; however, there was no 
growth. We requested a glycerol stock of chimpanzee SEMG1-HIS pCMV-3Tag-3a from 
GenScript. The stock was labeled as TOP10 E. coli cells, but I confirmed with the company that 
the cells were Stbl3 cells, which aid in reduced recombination between repetitive regions. The 
glycerol stock was streaked onto LB kanamycin plates and grown at 37°C for approximately 26 
hours. A single colony was transferred to 3mL of LB kanamycin broth and grown overnight at 
37°C with 250rpm agitation. Freezer stocks were made from 750µl of culture with 250µl 60% 
glycerol and stored at -80°C. In addition, 30µl was transferred from the overnight culture to 
another 3mL LB kanamycin broth and grown for 6 hours. Then 50µl of the starter culture was 
transferred to a 50mL LB kanamycin broth and grown at 37°C (250rpm) for 18 hours. DNA was 
extracted using the Pureyield™ plasmid midiprep system (Promega). Midipreps were digested 
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with HindIII and XhoI to determine size compared to other digested semenogelins. However, 
midipreps grown at 37°C were the incorrect size (smaller), I decided to restart from the 
GenScript glycerol stock and grow all cultures at 30°C. Midiprep digestion with HindIII and 
XhoI showed the 30°C were also the incorrect size; however, the original 4µg stock DNA from 
GenScript when digested, was the correct size.  
 The Puthenveedu lab from Carnegie Mellon Research Institute provided chemically 
competent Stbl3 cells, and 1µl (200ng) of chimpanzee SEMG1-HIS pCMV-3tag-3a DNA was 
added to thawed Stbl3 competent cells. Cells were incubated on ice for 30 minutes and then 
heatshocked at 42°C for 45 seconds and immediately placed on ice for 2 minutes. Transformed 
cells were added to 500µl of LB broth and incubated at 30°C for one hour at 250 rpm. Then 
200µl of culture was transferred to three LB kanamycin plates and incubated at three different 
temperatures: 22°C, 30°C, and 37°C. In addition, 100µl of cells were grown on LB plates at 
30°C to determine if the Stbl3 cells were viable. Single colonies were picked from 22°C and 
30°C plates and grown in 3mL LB kanamycin at either 22°C or 30°C, respectively, overnight 
with agitation. DNA was extracted using the IBI high speed plasmid mini kit (Midsci), and 250µl 
of culture was mixed with 750µl of 60% glycerol and stored at -80°C. Both 22°C and 30°C 
grown cultures were digested with HindIII and XhoI to determine size. Candidates were 
sequenced with BigDye® Terminator (Thermofisher Scientific) at the following conditions: 
(96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and analyzed on the Avant 3100 sequencer (Applied 
Biosystems). Verified constructs were grown in 50mL LB kanamycin cultures at 22°C for 48-72 
hours and DNA was extracted using the Pureyield™ plasmid midiprep system (Promega). 
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3.2.5.2 KLK3s, TGM4s, and SEMGs subcloning procedure into pCMV vector 
 Human, chimpanzee, and human-chimpanzee ancestor KLK3 in pFastBac1 constructs and 
pCMV-flag vector (with GFP) were digested with Fast EcoRI and Acc651. Human, chimpanzee, 
and human-chimpanzee ancestor TGM4 in pFastBac1 were amplified using Phusion High 
Fidelity polymerase (Thermofisher Scientific) under the following conditions: (98°C, 1’)/(98°C, 
10”/ 60°C, 30”/ 72°C, 1’)30/ (72°C, 8’) /(4°C, ∞) in a 50µl reaction with provided HF buffer and 
with universal primers (Table 3.7). Amplified TGM4 products and pCMV-flag vector (with 
GFP) were digested with Fast BglII6 and Acc65I (Thermofisher Scientific). Human SEMG1 in 
pFastBac1 was digested with SalI, and then incubated with 0.2µl of C-dNTP and T-dNTPs and 
2µl Klenow polymerase (Promega) at room temperature for 30 minutes and terminated at 75°C 
for 10 minutes. Likewise, pCMV-flag vector (with GFP) was digested with BglII, and then 
incubated with 0.2µl of G-dNTP and A-dNTPs and 2µl of Klenow polymerase at room 
temperature for 30 minutes and terminated at 75°C for 10 minutes. Both Klenow base-filled in 
digests were redigested with Acc65I, and the pCMV-flag vector was dephosphorylated with Fast 
Alkaline Phosphatase (Thermofisher Scientific). Human SEMG2, chimpanzee SEMG2, and 
chimpanzee SEMG2-Tyr constructs in pFastBac1 and pCMV-flag (with GFP) were digested with 
NotI and Acc65I. All digestions were carried out at 37°C for 90 minutes with termination at 80°C 
for 20 minutes. All pCMV-flag vectors were dephosphorylated with Fast Alkaline Phosphatase 
(Themofisher Scientific), simultaneously. Products were separated on a 1% agarose gel with 
0.1% crystal violet buffer and were purified with the IBI high speed plasmid mini kit (Midsci). 
Samples were quantified with the Qubit® dsDNA BR assay kit on the Qubit® 2.0 fluorometer 
(Invitrogen). A 1:1 (insert:vector) DNA molar ratio was added to separate ligation reactions 
                                                
6 Chimpanzee TGM4 mRNA has a BglII cut site. These constructs were not correct. Subsequently, pCMVscript-
cTGM4 was digested and transferred to pCMV-flag vector and used for reported TGM4 assays 
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(total volume 10µl)  and incubated with Fast T4 ligase (Thermofisher Scientific) in the 
thermocycler at the following temperatures: (22°C, 20’)/(21°C, 5’)/ (20°C, 5’)/ (18°C, 5’)/ 
(16°C, 5’)/ (14°C, 5’) /(65°C, 10’)/(4°C, ∞). All of each ligation reaction (10µl) was transferred 
to 200µl of thawed TG1 chemically competent E. coli cells and put on ice for 20 minutes. Cells 
were heatshocked at 42°C for 45 seconds and immediately transferred to ice for two minutes. 
Cells were added to 500µl of LB broth in a culture tube and incubated at 37°C and 250 rpm for 
one hour. After incubation, 50µl and 200µl of each culture were spread onto LB carbenicillin 
plates and incubated 16-18 hours at 37°C. Single colonies were transferred to 3mL LB ampicillin 
broth and to an LB carbenicillin replicate plate, and incubated overnight at 37°C. Freezer stocks 
were made from 750µl of culture with 250µl 60% glycerol and stored at -80°C. The remaining 
2.25mL culture’s DNA was extracted with the IBI high speed plasmid mini kit (Midsci). 
Candidates were sequenced with BigDye® Terminator (Thermofisher Scientific) at the following 
conditions: (96.0°C, 10”/50°C 5”/60°C, 4’)35 /(4°C, ∞), and analyzed on the Avant 3100 
sequencer (Applied Biosystems).   
Table 3.7: Universal primers used for pFastBac1 TGM4 amplification 
Gene Primer Sequence 
TGM4 in 
pFastBac1 
 
Forward: 5’– GTACGATGACAGATCTAAAGGCCTACGTCGACATGATGGATGCATCAAAAGAGCTG–3’ 
Reverse: 5’– TCCTCTAGTACTTCTCGACAAGCTTGGTACCGCATGCCTCGA–3’ 
  
 Our pCMV-flag (with GFP) vector worked with all our constructs; however, it was 
challenging to clone into because of the position of GFP. We ordered pCMV-script (Agilent 
Technologies) vector for easier cloning. TG1 chemically competent cells were thawed on ice, 
and 1µl of pCMV-script vector was transferred to the cells using a filtered tip. Cells were 
incubated on ice for 20 minutes, heat shocked at 42°C for 45 seconds, and then immediately 
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placed on ice for 2 minutes. The transformed mixture was transferred to 500µl of LB media in a 
culture tube and incubated for an hour at 37°C and 250 rpm. Both 50µl and 250µl were plated on 
LB kanamycin plates and incubated at 37°C overnight. pCMV-script colonies were selected and 
streaked onto a LB kanamycin replicate plate and grown overnight at 37°C. Two replicates were 
selected and grown overnight in 3mL of LB kanamycin broth, 250µl of each culture was mixed 
with 750µl of 60% glycerol and stored at -80°C. A 2mL LB kanamycin broth was inoculated and 
grown at 37°C for 6 hours before transferring 50µl into a 50mL LB kanamycin broth. 50mL 
cultures were grown at 37°C for 18 hours and DNA was extracted with the Pureyield™ plasmid 
midiprep system (Promega).  
 Chimpanzee TGM4, human-chimpanzee ancestor TGM4, and chimpanzee SEMG2-Tyr in 
pFastBac1 were cloned into the pCMV-script vector. First pCMV-script was digested with 
SalI/Acc65I and NotI/Acc65I, with and without fast Alkaline Phosphatase (Thermofisher 
Scientific). However, none of the single Acc65I digests worked. Then pCMV-script, chimpanzee 
TGM4, human-chimpanzee ancestor TGM4, and chimpanzee SEMG2-Tyr were digested with 
SalI/KpnI (TGM4s) and NotI/KpnI (SEMG2-Tyr). KpnI single digests worked for the pCMV-
script vector. Gel-purification, ligation, transformation, and verification processes were exactly 
like pCMV-Flag (with GFP) cloning.  
 Subsequently, chimpanzee TGM4 in pCMV-script was subcloned into pCMV-flag vector 
because the original pCMV-flag chimpanzee TGM4 was incorrect (see footnote 6, page 123). 
Both pCMV-script chimpanzee TGM4 and pCMV-flag human TGM4 were digested with SalI 
and KpnI. Both the chimpanzee TGM4 and pCMV-flag backbone bands were gel-purified, 
ligated, and transformed as described previously.  
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3.2.6 Production/Purification of recombinant proteins 
3.2.6.1 Gene expression in insect cell culture 
 Our pFastBac1 constructs were sent to our collaborators to transfect in Sf9 insect cells. 
Media containing viral particles for human TGM4, chimpanzee KLK3, and human SEMG1 were 
received. Samples were heated at 95°C for 5 minutes, and amplified with GoTaq® (Promega) at 
the following conditions: (95°C, 30”)/(95°C, 10”/ 55°C, 15”/ 72°C, 1’)35 / (72°C, 10’) / 4°C, ∞) 
using the primers listed in Table 3.8. PCR products were separated on a 0.8% agarose gel with 
0.008% ethidium bromide and imaged under UV light. 
Table 3.8: Primers used for viral particle amplification 
Gene Primer Sequence 
TGM4  
F420: 
R720: 
5’– CCCCCAATGCCATCCTGGGCAAGTACCAAC–3’ 
5’– CACACATGGCCCTGCACACCAGCACGGGG–3’ 
R1020: 5’– TGGTGATTTTCTCGCCATTCTCATTCAC–3’ 
SEMG1 
F450: 
R950: 
R1200: 
 
5’– CATCTGGAAAGGGAATATCCAG–3’ 
5’– GGGATACATCTTTCTGCACACC–3’ 
5’– GCCATGGCTCTTGCTTAGGA–3’ 
KLK3 
SeqInternal_Fwd: 
Block_B_F: 
His_Rev: 
 
5’– CTCATCCTGTCTCGGATTG–3’ 
5’– GATGCTGTGAAGGTCATGGA–3’ 
5’– AATGGTGATGGTGATGGTG–3’ 
 
3.2.6.2 LNCaP cell culture 
 Androgen sensitive human metastatic prostate LNCaP cells were ordered from ATCC 
(Manassas, Virginia, lot number: 59410738). Cells were grown at 37°C with 5% CO2 in 
Dulbeccos Modified Eagle’s Medium, DMEM (GE Healthcare, Little Chalfont, United 
Kingdom) with 10% FBS (Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin 
streptomycin (Cellgro, Corning, New York). Cells were dispersed by Trypsin EDTA (Life 
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Technologies) every 3-4 days and transferred to a new 25cm2 flask (Sarstedt, Nümbrecht, 
Germany) in a 1:4 dilution.  
 Endogenous Kallikrein 3 should be expressed from LNCaP cells (Väisänen et al, 1999). 
Approximately 3µg of protein from LNCaP media was separated in a 10% SDS-PAGE 
(Invitrogen).  An Immobilin®-FL PVDF (Millipore, Merck, Germany) was activated in 
methanol for one minute, and incubated in 1X NuPAGE (Invitrogen) transfer buffer with the 
separated gel and other cassette components for 10 minutes. The Western sandwich was 
assembled and put into the mini Trans-Blot® (Bio-Rad) chamber with an ice pack. The apparatus 
was placed on a stir plate with agitation, and proteins were transferred at 100 volts for 45 
minutes. The PVDF membrane was rinsed with water, and incubated in 50%odyssey block/50% 
PBS for an hour and subsequently rinsed in dH2O, three times for five minutes. Polyclonal rabbit 
anti-KLK3 and mouse anti-TGM4 primary antibodies (ABCAM) were diluted (1:1,000) in 
50%odyssey block/50% PBST. The membrane was incubated overnight in primary antibody, 
washed three times for five minutes in PBS, and then incubated for an hour in secondary donkey 
anti-mouse IRDye® 680RD and anti-rabbit IRDye® 800CW (Licor, Lincoln, NE) antibodies 
(1:15,000). Following three washes in PBST for five minutes, the Western blot was imaged on 
the Odyssey FC (Licor) imager.  
 Approximately 80,000 LNCaP cells were plated in each well of a 12 well plate (Corning, 
Corning, NY) 24 hours before transfection. SEMG1 and SEMG2 (1µg) in pSG5 (provided by 
Miyamoto) were mixed with 7.5µl of FuGENE (Promega), and DMEM media up to 250µl, and 
were incubated at room temperature for 5 minutes. Then 50µl of each mixture was slowly 
dropped in a circular fashion to a designated well. The plate was returned to the incubator (37°C 
and 5% CO2). 24 hours after transfection, 1mL of media was removed from each well and 
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replaced with 0.5mL of DMEM with 1% penicillin streptomycin. Media was collected and saved 
after 48 hours post transfection. Media was quantified, acetone precipitated, and Western blotted 
described later.  
3.2.6.3 293T mammalian cell culture 
 Human embryonic kidney cells with T antigen (293T) were ordered from ATCC (lot 
number: 59587035). Cells were grown at 37°C with 5% CO2 in DMEM (GE Healthcare), with 
10% FBS (Atlanta Biologicals) and 1% penicillin streptomycin (Cellgro). Cells were dispersed 
by Trypsin EDTA (Life Technologies) every 2-5 days and transferred to a new 25cm2 flask 
(Sarstedt) in a 1:4 or 1:10 dilution. Initially, SEMG1 and SEMG2 in pSG5 vectors were 
transfected as described for LNCaP cells. However, Jennifer (Vill) Doyle, optimized 
transfections with pCMV-GFP with polyethylinamine (PEI) transfection reagent.  
 Between 200,000-250,000 293T cells were plated with 1mL of DMEM, 10% FBS, and 
1% penicillin streptomycin in a BioLite 12 well plate (Thermofisher Scientific) 24 hours before 
transfection. Then 1-2µg of pCMV- DNA, 1.63µl of PEI, and DMEM media up to 160µl was 
mixed together and incubated at room temperature for 20 minutes and then dropped into a 
designated well.  Between 16-20 hours post transfection, total media was removed from the cells 
and replaced with 0.6 mL DMEM and 1% penicillin streptomycin. Media was collected at 
various time points (48, 72, 96, and 120 hours) post transfection. During optimization, cell lysate 
was also collected at various time points using Promega passive lysis buffer.  
 Transfections were up-scaled by plating 1,500,000 cells in 5mL DMEM, 10% FBS, and 
1% penicillin streptomycin in a 25cm2 flask. 5µg of pCMV-DNA, 1µg of pCMV-GFP DNA, 
8.2µl of PEI, and DMEM media up to 800µl was mixed together and incubated for 20 minutes in 
a 15mL conical tube. To ensure a uniform transfection, media was removed from the 25cm2 flask 
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and then 4.2mL of total media was added to the mixture and added to the 25cm2 flask. GFP 
expression was imaged 48-72 hours post transfection using the confocal microscope. Media and 
lysate were quantified, purified, and assayed described later.  
3.2.6.4 Protein quantification  
 Protein concentration was determined using either the Qubit® Protein Assay Kit 
(Thermofisher Scientific) or the Bradford protein assay (Bio-Rad). For the Qubit® Protein 
Assay, samples were undiluted and diluted 1:20 before assaying. 2µl of diluted sample was 
added to Qubit® protein assay buffer (1µl reagent in 199µl buffer) with the total volume being 
200µl. Samples were vortexed, incubated for 5 minutes, and then protein concentration was 
measured with the Qubit 2.0 (Life Technologies). In the Bradford assay, samples were undiluted 
before assaying. Then 20µl of sample was added to 1mL of Bio-Rad Bradford assay dye, mixed, 
and incubated for 5 minutes. Absorbance at 595nm was measured using the Genesys 10 UV 
spectrophotometer (Thermo Spectronic, Rochester, NY). Utilizing 7 BSA standards, a standard 
curve was generated relating absorbance to mg/mL concentration. Sample concentration was 
calculated by solving for “x” using the standard slope equation generated by the standards.  
3.2.6.5 Acetone precipitation 
 Some transfected media from both LNCaP and 293T cell lines were acetone precipitated. 
Four times the volume of -20°C acetone was added to the sample in a 15mL conical tube and 
incubated on ice for an hour. Samples were centrifuged at 4°C for 10 minutes at 14,000 rpm. The 
supernatant was decanted and the pellet was dried. Once dried, PBS was used to re-suspend the 
sample to its original volume.  
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3.2.6.6 His purification and dialysis 
 Transfected media from 293T cells was purified with His-Pur™ cobalt columns 
(Thermofisher Scientific). After purification, columns were washed with regeneration MES 
buffer (20mM 2-(N-morpholine)-ethanesulfonic acid, 0.1M sodium chloride: pH 5.0) and stored 
with 20% ethanol. Columns were labeled with the species and protein name and were only re-
used with the same species/protein sample. Samples were dialyzed with slide-a-lyzer™ dialysis 
cassettes (Thermofisher Scientific). TGM4 proteins were dialyzed in 7.5mM CaCl2 and 5mM 
Tris (pH 7.5) buffer because it was the reaction buffer used in downstream applications.  
3.2.6.7 Antibody detection of recombinant proteins 
 Media and cell lysate from transfected 293T cells were analyzed with traditional Western 
and dot blotting methods, with primary antibodies specific to the protein, or most commonly, an 
anti-HIS primary antibody (Gen Script). 10µg of media or lysate was separated in a 10% SDS-
PAGE (Invitrogen). An Immobilin®-FL PVDF (Millipore, Merck, Germany) was activated in 
methanol for one minute, and incubated in 1X NuPAGE (Invitrogen) transfer buffer with the 
separated gel and other cassette components for 10 minutes. The Western sandwich was 
assembled and put into the mini Trans-Blot® (Bio-Rad) chamber with an ice pack. The apparatus 
was placed on a stir plate with agitation, and proteins were transferred at 100 volts for 45 
minutes. The PVDF membrane was rinsed with water, and incubated in 50%odyssey block/50% 
PBS for an hour and subsequently rinsed in dH2O, three times for five minutes. Primary 
antibodies specific to TGM4, KLK3, SEMG1, SEMG2, or HIS were diluted (1:1,000) in 
50%odyssey block/50% PBST. The membrane was incubated overnight in primary antibody, 
washed three times for five minutes in PBST, and then incubated for an hour in secondary 
donkey anti-mouse IRDye® 680RD or anti-rabbit IRDye® 800CW (Licor) antibodies, diluted 
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1:15,000. Following three washes in PBST for five minutes, the Western blot was imaged on the 
Odyssey FC (Licor) imager.  
 Media and cell lysate samples (10µl, 100µl, and 200µl) were added to a dot blot 
apparatus (BioRad) over a dry nitrocellulose-FL (Licor) membrane. Samples were absorbed 
using a vacuum pump attached to a faucet. The membrane was blocked with 50% odyssey 
block/50% PBS for one hour, and rinsed three times with dH2O for five minutes. Anti-HIS (or 
anti-TGM4) antibody, diluted 1:1,000 in 50%PBST/50% odyssey block, covered the membrane 
and was incubated overnight. The membrane was washed three times for five minutes in PBST, 
and then incubated for an hour in secondary goat anti-mouse IRDye® 800CW (Licor) antibody 
(diluted 1:15,000). After three washes in PBST for five minutes, the dot blot was imaged on the 
Odyssey FC (Licor) imager.  
3.2.7 TGM4 assays 
3.2.7.1 1D gel based assay 
 Peter et al. utilized monodansylcaverdine (MDC), calcium chloride reaction buffer, and 
dimethylcasein to assay prostate specific transglutaminase (TGM4) activity (1998). This assay 
was initially optimized using guinea pig transglutaminase (gpTGM). gpTGM (0.001µg, 0.001µg, 
0.01µg, 0.5µg7, or 1µg) was incubated with either 2.5 or 5µg of casein (Sigma-Aldrich) in 10µl 
of reaction buffer (0.3mM MDC8, 7.5mM CaCl2, 5mM Tris: pH 7.5) for one, two, or three9 
hours at 37°C. 10µl of human seminal plasma, TGM4 transfected media, or TGM4 transfected 
cell lysate were incubated with 2.5µg of casein (Sigma-Aldrich) in 6µl of reaction buffer (0.3mM 
MDC, 7.5mM CaCl2, 5mM Tris: pH 7.5) for three hours at 37°C. Each reaction was prepared in 
duplicate, and one had 2µl of 500mM EDTA (pH 8), which prevented enzymatic activity. 
                                                
7 0.5µg gpTGM is optimal when comparing activity to transfected media or cell lysate 
8 Monodansylcaverdine (MDC) solubility is 10 mg/mL 
9 Incubation for three hours was preferred  
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 After enzyme/substrate incubation, 2µl of 500mM EDTA (pH 8) was added to all 
reactions to ensure enzyme termination. Then 5µl of loading buffer (Lammeli buffer (BioRad) 
with 10% β- Mercaptoethanol (Sigma Aldrich)) was added to each reaction and incubated at 
95°C for 10 minutes. Samples were loaded into a 10% NuPAGE gel (Invitrogen) and 
electrophoresed at 150 volts for approximately 45 minutes. The gel was imaged under UV and 
then stained with coomassie (Licor) for thirty minutes. The gel was destained with dH2O 
overnight and then imaged on the Odyssey FC (Licor) imager.  
3.2.7.2 96 well plate reader assay  
 Zedira transglutaminase fluorescent assay was modified for a 96 well plate format 
(Darmstadt, Germany). Total volume of the reaction was adjusted to 250µl for each well 
(opposed to 1mL). First, 125µl of reaction buffer was warmed at 37°C (for a minimum of 10 
minutes) in the Spectramax® i3x platform (Molecular Devices, Sunnyvale, CA) in a Corning® 
96 well flat clear bottom black polystyrene plate (Thermofisher Scientific). Transfected 
media/lysate, HIS purified media/lysate, or guinea pig transglutaminase (Sigma Aldrich) was 
aliquoted into 0.2mL tubes with a 125µl total volume. Using a multichannel pipette, 
transglutaminase enzymes were transferred to the reaction buffer immediately before 
measurements were taken on the Spectramax® i3x platform under the parameters in Table 3.9. 
Table 3.9: Spectramax® i3x parameters for TGM assays 
Parameter Specification 
Excitation wavelength 332nm 
Emission wavelength 500nm 
Emission slit 15nm 
Excitation slit 15nm 
Read height (from top) 4.35- 4.53 mm 
Time intervals between reads 1 minute 
Total time 3.5 – 7 hours 
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3.3 Results 
3.3.1 Generation of recombinant plasmids with human, chimpanzee, and human-
chimpanzee ancestral mRNA sequences 
  TGM4 and KLK3 cDNA (or gBlocks) were cloned into pFastBac1 for human, 
chimpanzee, and the hypothetical human-chimpanzee ancestor and then transferred into the 
pCMV vector with methods described in section 3.2.1 (Table 3.10). Alignments for human, 
chimpanzee, and human-chimpanzee ancestor TGM4 in pCMV are included in the appendix 
(A.14), since these constructs’ enzymatic activity (post-expression) were assayed. Human and 
chimpanzee SEMG1 and SEMG2 cDNAs (with the exception of chimpanzee SEMG1) were 
cloned into pFastBac1, sequence confirmed, and transferred into the pCMV vector with methods 
described in section 3.2.1 (Table 3.10). All pCMV constructs were transfected into mammalian 
293T cells and some of them had confirmed expression, in the media or lysate (summarized in 
Table 3.10; expanded on in section 3.3.2). 
Table 3.10: Summary of recombinant plasmids 
Clone pFastBac1 pCMV vector 
Human TGM4-HIS Sequence confirmed Sequence confirmed; protein expressed in 
the lysate 
Human SEMG1-HIS Sequence confirmed Sequence confirmed; protein expressed in 
the media 
Human SEMG2-HIS Sequence confirmed Sequence confirmed; protein expressed in 
the media 
Human KLK3-HIS Sequence confirmed Sequence confirmed  
Chimp TGM4-HIS Sequence confirmed Sequence confirmed; protein probably 
expressed in the lysate 
Chimp SEMG1-HIS ---------- Sequence confirmed; protein expressed in 
the media  
Chimp SEMG2-HIS Sequence confirmed Sequence confirmed; protein expressed in 
the media 
Chimp SEMG2 Tyr-HIS Sequence confirmed Sequence confirmed  
Chimp KLK3-HIS Sequence confirmed Sequence confirmed 
H/C Anc TGM4-HIS Sequence confirmed Sequence confirmed; protein expressed in 
the lysate 
H/C Anc KLK3-HIS Sequence confirmed  Sequence confirmed 
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3.3.2 Expression of recombinant proteins in mammalian cell culture 
 Seminal proteins by nature are extracellular; therefore, their coding sequence should 
contain a secretion signal peptide. All of our recombinant plasmids (Table 3.10) were cloned 
with a HIS-tag before the native stop codon but were otherwise natural in sequence. In early 
optimization experiments, recombinant plasmids containing GFP had intercellular expression 
peaking between 48 and 72 hours post-transfection (data not shown). However, expression of 
our recombinant proteins in media occurred at different time points. Recombinant TGM4 
proteins are first detected in media 72 hours post-transfection but have increased expression at 96 
hours post-transfection (Figure 3.4). Recombinant SEMG proteins were detected in the media 48 
hours post-transfection (Figure 3.4).  
 
Figure 3.4: Differential timing of secretion of recombinant proteins 
An anti-HIS antibody was used to detect recombinant proteins (designed with a HIS tag) from transfected cell media 
aliquoted onto a nitrocellulose membrane. Mock media, where no DNA was transfected in 293T cells was used as a 
negative control in each experiment. Human TGM4 (hTGM4) and human SEMG1 (hSEMG1) are representative 
orthologs of other recombinant proteins (H/C ancestor TGM4, human SEMG2, chimpanzee SEMG1, and 
chimpanzee SEMG2). TGM4s are first detected in media collected 96 hours after transfection; whereas, SEMGs are 
detected in the media collected from 48 hours after transfection.  
  1µl      5µl     10µl   50µl    100µl   250µl 
 1µl   10µl     25µl     50µl   100µl  250µl  
 1µl    10µl     100µl   200µl  
hTGM4 media 
48 hours 
hTGM4 media 
96 hours 
Mock media 
96 hours 
10µl      100µl     200µl  
Mock Media 
96 hours 
 
hSEMG1 Media 
48 hours 
 
 
hSEMG1 Media 
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3.3.3 Transglutaminase assay  
3.3.3.1 Optimization of the 1D gel assay 
 This assay was initially optimized using 1µg of guinea pig transglutaminase (gpTGM) in 
reaction buffer containing either 2.5µg or 5µg of casein. Either amount of casein yielded a 
positive reaction, and visually there was not a large difference between reactions (data not 
shown). For subsequent reactions, 2.5µg of casein was used. gpTGM (0.001µg, 0.01µg, 0.1µg, 
1µg) was incubated with reaction buffer/casein for one hour at 37°C, and activity was only visible 
for 0.1µg and 1µg of gpTGM (Figure 3.5).  
 
Figure 3.5: Transglutaminase activity detected as low as 0.1µg of gpTGM enzyme 
Human seminal plasma (Hu#2) does not appear to have functional transglutaminase activity. Both 0.1µg and 1µg of 
gpTGM is able to cross-link MDC to casein.  
 
 Incubation at 37°C for variable lengths of time (one hour, two hours, or three hours) was 
tested with 0.01µg, 0.1µg, and 1µg of gpTGM and activity was visualized on a 1D gel. 
Transglutaminase activity was detected after one hour of incubation for 0.1(faintly) and1µg of 
enzyme; however, activity was easier to detect after a two hour incubation. Transglutaminase 
activity was not detected after 3 hours of incubation (at 37°C) for 0.01µg gpTGM (data not 
shown).  
   Hu#2                        gpTGM 
  -     +         -        +       -       -         -       
            1µg             0.1µg    0.01µg  0.001µg 
EDTA 
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3.3.3.2 Human SEMG1 Ia peptides are cross-linked by transglutaminases 
Megan Hockman, a previous undergraduate in our lab produced human SEMG1.Ia 
fragments for her honors thesis. The SEMG Ia fragments are enriched with glutamine and lysine 
resides and are the substrates for TGM4. Likely, SEMG Ia fragments would be a substrate for 
gpTM. In fact after a 3 hour incubation at 37°C, gpTGM was able to crosslink hSEMG1.Ia 
proteins together (Figure 3.6). However, enzyme efficiency was noticeably lower than 
crosslinking casein. Transfected human TGM4 media was able to crosslink casein, but not 
hSEMG1.Ia peptides.  
 
Figure 3.6: Guinea pig transglutaminase has activity on hSEMG1.Ia peptides and 
transfected hTGM4 media has activity with casein 
A) GpTGM is able to crosslink casein (Gp/Cas); gpTGM is able to weakly crosslink hSEMG1.Ia (Gp/H1.Ia), and as 
expected, the reaction is terminated in the presence of EDTA. Human TGM4 media is able to crosslink casein 
(hT4/Cas), but not hSEMG1.Ia (hT4/h1.Ia). B) The SDS-PAGE gel was stained with coomassie and imaged on the 
Licor odyssey imager after UV detection. 
 
  Rxn   EDTA    Rxn   EDTA   Rxn   EDTA   Rxn 
      Gp/Cas       Gp/H1.Ia     hT4/h1.Ia  hT4/Cas 
A)  B) 
  Rxn   EDTA    Rxn   EDTA   Rxn   EDTA   Rxn 
     Gp/Cas      Gp/H1.Ia    hT4/h1.Ia  hT4/Cas 
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3.3.3.3 Recombinant TGM4 proteins lose function after HIS purification 
 TGM4 loses activity after HIS-tag purification (Figure 3.7), even though multiple 
Western and dot blots confirmed retention of the protein (Figure 3.8). Dialysis was attempted to 
regain activity of TGM4, but was not successful (data not shown).  
 
Figure 3.7: Recombinant human and ancestor TGM4 have enzymatic activity before but 
not after HIS purification 
Guinea pig transglutaminase (gpTGM) is able to crosslink casein (gpTGM/-) and as expected, the reaction is 
terminated in the presence of EDTA (gpTGM/+). Human TGM4 media is able to crosslink casein (hT4/-); however, 
post-HIS purification activity is lost (hE1, hE2, and hE2). Ancestor TGM4 media actively crosslinks casein 
(aTGM4/-), but activity is lost after HIS purification (aE1, aE2, and aE3). Mock transfected media has no detectable 
cross-linking activity. A) SDS-PAGE gel detected under UV light. B) The same SDS-PAGE gel stained with 
coomassie and imaged on the Licor Odyssey FC.  
 
EDTA  -   +   -    +   -  +    -  +  -   +     -  +    -    -    -     - 
gpTGM   hTGM4     hE1      hE2       hE3     aTGM4  aE1 aE2  aE3 Mock 
A) 
B) 
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Figure 3.8: Recombinant human TGM4 is purified from media using HIS columns 
Anti-TGM4 Western blot detects TGM4 in human seminal plasma (HS+), human transfected media (HT4), HT4 
diluted 1:1 with equilibrium buffer (1:1), as well as in elution 2 (E2) post HIS purification. Nothing is detected in 
the flow through (FT- proteins unbound to cobalt resin) or washes. 
 
 
3.3.4 Comparison of TGM4 enzymatic activity of human and the human-chimp 
ancestor 
 Consistently, transfected TGM4 lysates have more MDC cross-linked to casein (brighter 
banding) compared to transfected media (Figure 3.9). In addition, mock-transfected lysates do 
not have any enzymatic activity (no banding), which supports that all the activity shown in 
TGM4 transfected lysate is from TGM4. Chimpanzee TGM4 transfected media or lysates 
yielded no or minimal activity (Figure 3.9) despite multiple attempts. Human-chimpanzee 
ancestor TGM4 has significantly (p<	0.0007632, Welch’s two sample t-test) higher activity 
compared to human TGM4 (Figure 3.10; 3.11).  
HS+  HT4  1:1   FT   WASH    E1   E2   E3 
40 
50 
60 
80 
100 
hTGM4 media through HIS purification 
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Figure 3.9: Human and ancestor TGM4 lysates are more efficient than media 
Guinea pig transglutaminase (gpTGM) was used as a positive control. Any reaction in the presence of EDTA (+) 
should not have activity. Equal volumes of transfected TGM4 media or lysate were assayed with MDC and casein. 
Mock media and lysate have no activity. Chimpanzee TGM4 lysate has very little activity. Both human and ancestor 
TGM4 lysates have a lot of activity, and have some activity in their transfected media.  
  
EDTA      -      +       -        +        -       +       -      +       -      +      -     +      -        -       -           
hT4 media aT4 media hT4 Lys aT4 Lys gpTGM cT4 media cT4 Lys 
Mock  
Media 
Mock  
Lys 
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Figure 3.10: Human-chimpanzee ancestor TGM4 has significantly higher enzymatic 
activity compared to human TGM4. 
Equal concentrations of TGM4 enzymes were assayed with MDC and casein and fluorescence was measured 
overtime. All samples were from transfected cell lysates. Graphs A and B are from the same data set, but differ in 
the length of the x-axis. All human-chimpanzee ancestor TGM4 transfected recombinant protein replicates (2, 4, 6, 
8) are blue lines, and represent the average fluorescence across four technical replicates. Likewise, human TGM4 
transfected recombinant protein replicates (2, 4, 6, 8) are green lines, and data points represent the average 
fluorescence across four technical replicates. Mock lysate, the black line, is from one mock- transfection, but 
represents the average of four technical replicates. Slopes derived from samples in the linear phase of the assay 
(Graph A) are proportional to the enzyme’s ability to catalyze MDC-casein cross-linkage. A steeper slope indicates 
greater velocity.  The average slope of human TGM4 was 183914.5 while the average slope of ancestor TGM4 was 
212935.24.  Ancestor TGM4 has ~1.2 fold increase in velocity, which is significant (p< 0.0007632, Welch’s two 
sample t-test), compared to human TGM4s activity. 
0 
10000000 
20000000 
30000000 
40000000 
50000000 
60000000 
0 30 60 90 120 150 180 
R
el
at
iv
e 
Fl
uo
re
sc
en
t U
ni
ts
 (R
FU
s)
 
Time (minutes) 
Mock 
HT4#2 
HT4#4 
HT4#6 
HT4#8 
AT4#2 
AT4#6 
AT4#4 
AT4#8 
y = 66537x + 1E+07 
y = 176553x + 1E+07 
y = 188651x + 1E+07 
y = 209999x + 9E+06 
y = 160455x + 1E+07 
y = 274709x + 2E+07 
y = 267600x + 2E+07 
y = 277383x + 2E+07 
y = 320494x + 1E+07 
0 
5000000 
10000000 
15000000 
20000000 
25000000 
30000000 
35000000 
0 10 20 30 40 50 60 
R
el
at
iv
e 
flu
or
es
ce
nt
 u
ni
ts
 (R
FU
s)
 
Time (minutes) 
Mock HT4.2 HT4.6 HT4.4 HT4.8 AT4.2 AT4.6 AT4.4 AT4.8 
*** 
 141 
 
Figure 3.11: Recombinant human-chimpanzee ancestor TGM4 has more activity than 
recombinant human TGM4 
Samples assayed in Figure 3.10, were separated on an SDS PAGE gel after their fluorescence was measured over 
time. This gel confirms that mock lysate does not have any activity. Human-chimpanzee ancestor TGM4 reactions 
have cross-linked more MDC to casein compared to human TGM4. Numbers under human or ancestor TGM4 titles 
identify the transfected recombinant protein replicate. Each lane has two of the four assay reaction technical 
replicates loaded.  
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3.4 Discussion 
 Both human and human-chimpanzee ancestor TGM4s express more activity in lysates 
from transfected 293T cells than the media (Figure 3.9). My initial experiments concluding that 
TGM4 activity was present 96 hours after transfection in the media, may be a result of dead cells 
lysing and releasing the proteins, opposed to the TGM4s being slowly secreted into the media 
(Figure 3.4). Signal peptide sequence analysis of TGM4s did not recognize a secretion signal 
peptide. TGM4s are secreted from the prostate gland, and it is possible that they have an 
unknown tissue-specific signal peptide for secretion. Therefore, LnCAP (derived from prostate) 
cells may be able to natively secrete transfected TGM4s better than 293T cells. However, we 
initially chose to use 293T cells because of their transfection efficiency. Alternatively, a 
secretion signal peptide sequence could be genetically engineered into the current pCMV 
constructs to increase secretion in our optimized 293T cells.  
 Production of recombinant chimpanzee TGM4 has consistently been less than both 
human and ancestor TGM4 (Figure 3.9). I have thoroughly analyzed the DNA sequence, in both 
the TGM4 and vector promoter sequences for any mutations that could cause this effect 
(Appendix A.10). I have cloned chimpanzee TGM4 several times, have transformed it into two 
different types of competent E. coli strains, and I have attempted recombinant plasmid 
purification with multiple methods. There are a few synonymous differences between my clones, 
which could account for variation if there was codon usage bias. Upon review, some codons had 
decreased usage in human cell lines, although all codons were utilized. My hypothesis is that 
chimpanzee TGM4 is incorrectly folding in vitro; this could either be because the native protein 
needs additional chaperones to fold correctly, or potentially the HIS tag is interfering with 
folding.  
 143 
 Recombinant human-chimpanzee ancestor TGM4 significantly has ~1.2 fold greater 
velocity compared to recombinant human TGM4. This indicates that our last common ancestor 
with chimpanzee had a functional TGM4 with faster cross-linking activity than extant humans. It 
would have been ideal if we were able to produce and assay chimpanzee TGM4’s activity, which 
would have provided a more complete picture.  
 However, we do know that gorillas have presumably a functionless TGM4, as it was not 
identified in seminal plasma (Chapter 2) and an 11bp deletion in its gene sequence has predicted 
pseudogenization (Clark and Swanson, 2005; Carnahan and Jensen-Seaman, 2008). The relative 
abundance of TGM4 in our ancestor’s seminal plasma will always be unknown; however, we 
know that chimpanzees have 7-fold higher expression of TGM4 compared to humans (Chapter 
2). It is likely that over the past 6Mya, humans have decreased expression of TGM4 and have 
also reduced transglutaminase activity. Considering that TGM4 is important in semen 
coagulation and the formation of the copulatory plug in chimpanzees, increased efficiency and/or 
abundance may be associated with high levels of sperm competition. The increased activity of 
human-chimpanzee ancestor TGM4 compared to human TGM4 indicates that the ancestor may 
have had higher sperm competition. This study supports a more chimpanzee-like mating system, 
with polyandrous females, in our last common ancestor with chimpanzee. 
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3.5 Future Directions 
 First and foremost, I would make a few experimental changes to have all the TGM4s 
secreted into the media and elevate chimpanzee TGM4 protein expression to relatively similar 
levels as human TGM4. I would clone all the TGM4s into a new vector that included a secretion 
signal peptide, or I would insert a secretion signal peptide in front of the TGM4 sequence in the 
current vectors. The addition of the signal peptide should allow expression of TGM4s to be 
secreted from mammalian cells and into the media. Concurrently, these changes may increase the 
expression of chimpanzee TGM4, but if not, I would first remove the HIS-tag sequence from the 
recombinant DNA plasmid. The positively charged HIS-tag may be interacting strangely with 
the chimpanzee TGM4 protein causing it to misfold and be degraded.  
 In addition to optimizing production of TGM4 proteins, I would make a few 
modifications to the plate-reader assay. Initially, I attempted to make my own reaction mixture 
for the plate reader, but was unsuccessful. Once I began using the Zedira transglutaminase assay 
kit, I was able to see enzymatic activity and presented those results in this dissertation. However, 
I would want to experimentally test different amounts of substrate, different substrates, change 
the pH conditions, or change the calcium concentrations of the reaction buffer. Therefore, I 
would revisit developing my own reaction mixture that worked as well as the Zedira 
transglutaminase assay kit. I would start by reducing the concentration of MDC or increasing the 
concentration of calcium in my original reaction base.  
 Currently this study only looked at the enzymatic activity of two recombinant TGM4s on 
a common substrate, casein. However, I would want to assay the activity of recombinant TGM4s 
on physiological substrates like SEMG1, SEMG2, and possibly CRTAC1. In addition, I would 
design an experiment to increase the amount of substrate to determine the Km as well as the 
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Vmax of TGM4. I would want to look at the specificity of enzyme/substrate pairings, by testing 
same species TGM4/substrate activity in comparison to one species TGM4 with another species 
substrate activity. 
 This study focused on human and human/chimpanzee ancestor TGM4 activity. Besides 
assaying chimpanzee TGM4 activity, it would be interesting to generate the chimpanzee/gorilla 
ancestor TGM4, the orangutan TGM4, and the macaque TGM4. These species TGM4s would 
provide a more complete picture of the evolution of TGM4 across species with differing sexual 
selection. Depending on these findings, I would suggest looking at “transitional” TGM4 proteins, 
by using site-directed mutagenesis to modify TGM4 one evolutionary step (amino acid change) 
at a time to either its derived or ancestral protein.  
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APPENDIX 
A.1 Script in R for protein quantification and protease inhibitor analysis 
A.1.1 Quantification method mini-comparison 
#BRADFORD	STANDARDS	to	generate	standard	curve	
BR_known_Std_conc	<-	c(0.125,	0.25,	0.5,	0.75,	1,	1.5,	2)	
BR_Std_Abs	<-	c(0.176,	0.397,	0.635,	0.846,	1.021,	1.261,	1.481)	
BRStdDF	<-	data.frame(BR_known_Std_conc,	BR_Std_Abs)	
BRStd_reg	<-	lm(BR_Std_Abs	~	BR_known_Std_conc)	
summary(BRStd_reg)	
##		
##	Call:	
##	lm(formula	=	BR_Std_Abs	~	BR_known_Std_conc)	
##		
##	Residuals:	
##							1							2							3							4							5							6							7		
##	-0.1540	-0.0165		0.0545		0.0985		0.1065		0.0125	-0.1015		
##		
##	Coefficients:	
##																			Estimate	Std.	Error	t	value	Pr(>|t|)					
##	(Intercept)								0.24650				0.06992			3.525	0.016822	*			
##	BR_known_Std_conc		0.66800				0.06484		10.303	0.000148	***	
##	---	
##	Signif.	codes:		0	'***'	0.001	'**'	0.01	'*'	0.05	'.'	0.1	'	'	1	
##		
##	Residual	standard	error:	0.1081	on	5	degrees	of	freedom	
##	Multiple	R-squared:		0.955,		Adjusted	R-squared:		0.946		
##	F-statistic:	106.1	on	1	and	5	DF,		p-value:	0.0001482	
conc.calc	<-	function(Slope,	Intercept,	Abs,	DF)	
{((Abs-Intercept)/(Slope))*DF}	
	
#TEST	SAMPLES	qbit	standards	in	Bradford	
qbSamplenames	<-	c("200ug/mL",	"200ug/mL",	"200ug/mL",		"400ug/mL",	"400ug/mL
",	"400ug/mL")	
qbAbsorbances	<-	c(0.265,	0.234,	0.234,	0.445,	0.448,	0.457)	
qbSampleconcs	<-	conc.calc(BRStd_reg$coefficients[2],	BRStd_reg$coefficients[
1],	qbAbsorbances,	1)	
qbSampleconcs_in_ug_mL	<-	qbSampleconcs	*1000	
Qb_concs_DF	<-	data.frame	(qbSamplenames,	qbAbsorbances,	qbSampleconcs,	qbSam
pleconcs_in_ug_mL)	
	
#Stats	
two_qbitstds	<-	c(200,	200,	200)		
two_qbit_measured_concs	<-	c(27.69,	-18.71,	-18.71)	#in	ug/ml	
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Twoqt	<-	t.test(two_qbitstds,	two_qbit_measured_concs,	paired=TRUE)	
Twoqt		
	
##		Paired	t-test	
##		
##	data:		two_qbitstds	and	two_qbit_measured_concs	
##	t	=	13.141,	df	=	2,	p-value	=	0.005741	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		136.6956	269.7910	
##	sample	estimates:	
##	mean	of	the	differences		
##																203.2433	
four_qbitstds	<-c(400,	400,	400)	
four_qbit_measured_concs	<-c(297.15,	301.65,	315.12)	
fourqt	<-	t.test(four_qbitstds,	four_qbit_measured_concs,	paired=TRUE)	
fourqt		
##		
##		Paired	t-test	
##		
##	data:		four_qbitstds	and	four_qbit_measured_concs	
##	t	=	17.664,	df	=	2,	p-value	=	0.00319	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##			72.13161	118.58839	
##	sample	estimates:	
##	mean	of	the	differences		
##																			95.36	
all_qbitstds	<-c	(200,	200,	200,	400,	400,	400)	
all_qbit_measured_concs	<-c(27.69,	-18.71,	-18.71,	297.15,	301.65,	315.12)	
allqt	<-	t.test(all_qbitstds,	all_qbit_measured_concs,	paired=TRUE)	
allqt		
##		
##		Paired	t-test	
##		
##	data:		all_qbitstds	and	all_qbit_measured_concs	
##	t	=	5.922,	df	=	5,	p-value	=	0.001957	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##			84.49377	214.10956	
##	sample	estimates:	
##	mean	of	the	differences		
##																149.3017	
library(ggplot2)	
library(ggthemes)	
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#Qbit	in	Bradford	Graph	
ggplot(data=	BRStdDF,		
							aes(x=	BR_known_Std_conc,	
												y=	BR_Std_Abs))	+	
		geom_point()	+	
		geom_smooth(method	=	lm,	
															se	=	FALSE,	size	=	0.25,	color	=	"black")	+		
		geom_point(data	=	Qb_concs_DF,	
													aes(x	=	qbSampleconcs,	
																	y	=	qbAbsorbances,	
																	color	=	qbSamplenames,	
																	shape=	qbSamplenames))	+		
		theme_gdocs()	+	scale_color_calc()	+	
		theme(legend.title=element_blank())	+		
		labs(x="Concentration	mg/mL")	+	labs(y=	"Absorbances")	+	
		theme(text=element_text(size=10,	family="Arial"))	
	
#Bradford	standards	in	qbit	
Brstandards_in_ug_ml	<-	c(125,	250,	500,	750,	1000,	1500,	2000)	
Brstandards_measured_concs	<-	c(328,	605,	606,	1451,	2200,	3000,	3450)	
BRinqb	<-	data.frame(Brstandards_in_ug_ml,	Brstandards_measured_concs)	
BRinQBt	<-	t.test(Brstandards_in_ug_ml,	Brstandards_measured_concs,	paired=TR
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UE)	
BRinQBt	
##		
##		Paired	t-test	
##		
##	data:		Brstandards_in_ug_ml	and	Brstandards_measured_concs	
##	t	=	-3.5089,	df	=	6,	p-value	=	0.01269	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-1337.2574		-238.4569	
##	sample	estimates:	
##	mean	of	the	differences		
##															-787.8571	
LowBRinQB	<-	data.frame("lstd"=	c(125,	250,	500),	"lmeasured"=	c(328,	605,	60
6))	
lBRinQBt	<-	t.test(LowBRinQB$lstd,	LowBRinQB$lmeasured,	paired=TRUE)	
lBRinQBt	
##		
##		Paired	t-test	
##		
##	data:		LowBRinQB$lstd	and	LowBRinQB$lmeasured	
##	t	=	-3.0545,	df	=	2,	p-value	=	0.09255	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-533.11323			90.44657	
##	sample	estimates:	
##	mean	of	the	differences		
##															-221.3333	
HighBRinQB	<-	data.frame("hstd"=	c(750,	1000,	1500,	2000),	"hmeasured"=	c(145
1,	2200,	3000,	3450))	
HBRinQBt	<-	t.test(HighBRinQB$hstd,	HighBRinQB$hmeasured,	paired=TRUE)	
HBRinQBt	
##		
##		Paired	t-test	
##		
##	data:		HighBRinQB$hstd	and	HighBRinQB$hmeasured	
##	t	=	-6.6355,	df	=	3,	p-value	=	0.006973	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-1794.4001		-631.0999	
##	sample	estimates:	
##	mean	of	the	differences		
##																-1212.75	
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A.1.2 Seminal plasma concentrations 
#	STANDARDS	
seStd_conc	<-	c(0.125,	0.25,	0.5,	0.75,	1,	1.5,	2)	
seStd_Abs	<-	c(0.212,	0.34,	0.621,	0.9,	1.099,	1.313,	1.46)	
seStdDF	<-	data.frame(seStd_conc,	seStd_Abs)	
seStd_reg	<-	lm(seStd_Abs	~	seStd_conc)	
summary(seStd_reg)	
##		
##	Call:	
##	lm(formula	=	seStd_Abs	~	seStd_conc)	
##		
##	Residuals:	
##								1								2								3								4								5								6								7		
##	-0.12934	-0.08600		0.02569		0.13537		0.16506		0.04043	-0.15120		
##		
##	Coefficients:	
##													Estimate	Std.	Error	t	value	Pr(>|t|)					
##	(Intercept)		0.25668				0.08906			2.882	0.034504	*			
##	seStd_conc			0.67726				0.08259			8.200	0.000439	***	
##	---	
##	Signif.	codes:		0	'***'	0.001	'**'	0.01	'*'	0.05	'.'	0.1	'	'	1	
##		
##	Residual	standard	error:	0.1377	on	5	degrees	of	freedom	
##	Multiple	R-squared:		0.9308,	Adjusted	R-squared:		0.917		
##	F-statistic:	67.25	on	1	and	5	DF,		p-value:	0.0004388	
#SEMEN	SAMPLES	
seSamplenames	<-	c("H1",	"H2",	"H3",	"H4",	"H5",	"C1",	"C2",	"C3",	"CLJ",	"G1
",	"G2",	"G3",	"G4")	
seAbsorbances	<-	c(0.662,	0.671,	0.452,	0.559,	0.537,	0.868,	0.748,	0.701,	1.
00,	0.647,	0.684,	0.897,	0.721)	
seSpecies	<-	c("Human",	"Human",	"Human",	"Human",	"Human",	"Chimpanzee",	"Ch
impanzee",	"Chimpanzee",	"Chimpanzee",	"Gorila",	"Gorila",	"Gorila",	"Gorila"
)	
	
conc.calc	<-	function(Slope,	Intercept,	Abs,	DF)	
{((Abs-Intercept)/(Slope))*DF}	
	
seSampleconcs	<-	conc.calc(seStd_reg$coefficients[2],	seStd_reg$coefficients[
1],	seAbsorbances,	1)	
seSampleconcs20	<-	conc.calc(seStd_reg$coefficients[2],	seStd_reg$coefficient
s[1],	seAbsorbances,	20)	
Semen_concs_DF	<-	data.frame(seSpecies,	seSamplenames,	seAbsorbances,	seSampl
econcs,	seSampleconcs20)	
library(ggplot2)	
library(ggthemes)	
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ggplot(data=	seStdDF,		
							aes(x=	seStd_conc,	
												y=	seStd_Abs))	+	
		geom_point(shape=5)	+	
		geom_smooth(method	=	lm,	
															se	=	FALSE,		
														size	=	0.25,		
														color	=	"black")	+		
		geom_point(data	=	Semen_concs_DF,	
													aes(x	=	seSampleconcs,	
																	y	=	seAbsorbances,	
																	color	=	seSpecies,	
																	shape	=	seSpecies))	+		
		theme_gdocs()	+	scale_color_calc()	+	
		theme(legend.title=element_blank())	+		
		labs(x="Concentration	mg/mL")	+	labs(y=	"Absorbances")	+	
		theme(text=element_text(size=10,	family="Arial"))	
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A.1.3 Statistical comparison of seminal concentration across species 
#HumanSEM	
Human_concentrations	<-	c(11.97,12.24,5.77,8.93,8.28)	
Mean_Human	<-	mean(Human_concentrations)	
Human_SD	<-	(sd(Human_concentrations))	
Human_SE	<-	Human_SD/sqrt(length(Human_concentrations))	
	
#ChimpSEM	
Chimp_concentrations	<-	c(18.05,14.51,13.13,21.95)	
Mean_Chimp	<-	mean(Chimp_concentrations)	
Chimp_SD	<-	(sd(Chimp_concentrations))	
Chimp_SE	<-	Chimp_SD/sqrt(length(Chimp_concentrations))	
	
#GorillaSEM	
Gorilla_concentrations	<-c(11.53,12.62,18.91,13.71)	
Mean_Gorilla	<-	mean(Gorilla_concentrations)	
Gorilla_SD	<-	(sd(Gorilla_concentrations))	
Gorilla_SE	<-	Gorilla_SD/sqrt(length(Gorilla_concentrations))	
	
SemenMeans_DF	<-	data.frame("Species"=	c("Human",	"Chimp",	"Gorilla"),	"Means
"	=c(Mean_Human,	Mean_Chimp,	Mean_Gorilla),	"SEs"=	c(Human_SE,	Chimp_SE,	Gori
lla_SE))	
SemenMeans_DF		
##			Species			Means						SEs	
##	1			Human		9.4380	1.210692	
##	2			Chimp	16.9100	1.973778	
##	3	Gorilla	14.1925	1.634250	
#ANOVA	
Semenanova	<-	aov(seSampleconcs20	~seSpecies,	data=	Semen_concs_DF)	
summary(Semenanova)	
##													Df	Sum	Sq	Mean	Sq	F	value	Pr(>F)			
##	seSpecies				2		129.8			64.90			5.998	0.0194	*	
##	Residuals			10		108.2			10.82																		
##	---	
##	Signif.	codes:		0	'***'	0.001	'**'	0.01	'*'	0.05	'.'	0.1	'	'	1	
t.test(Chimp_concentrations,	Gorilla_concentrations)	
##		
##		Welch	Two	Sample	t-test	
##		
##	data:		Chimp_concentrations	and	Gorilla_concentrations	
##	t	=	1.0605,	df	=	5.7982,	p-value	=	0.3311	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-3.606071		9.041071	
##	sample	estimates:	
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##	mean	of	x	mean	of	y		
##			16.9100			14.1925	
t.test(Human_concentrations,	Gorilla_concentrations)	
##		
##		Welch	Two	Sample	t-test	
##		
##	data:		Human_concentrations	and	Gorilla_concentrations	
##	t	=	-2.3377,	df	=	5.8704,	p-value	=	0.05896	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-9.7579078		0.2489078	
##	sample	estimates:	
##	mean	of	x	mean	of	y		
##				9.4380			14.1925	
t.test(Chimp_concentrations,	Human_concentrations)	
##		
##		Welch	Two	Sample	t-test	
##		
##	data:		Chimp_concentrations	and	Human_concentrations	
##	t	=	3.2269,	df	=	5.1368,	p-value	=	0.0224	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##			1.567154	13.376846	
##	sample	estimates:	
##	mean	of	x	mean	of	y		
##				16.910					9.438	
	
A.1.4 Protease Inhibitor Bradford Assay 
#STANDARDS	
piStd_conc	<-	c(0.125,	0.25,	0.5,	0.75,	1,	1.5,	2)	
piStd_Abs	<-	c(0.198,	0.33,	0.607,	0.833,	1.061,	1.279,	1.416)	
piStdDF	<-	data.frame(piStd_conc,	piStd_Abs)	
piStd_reg	<-	lm(piStd_Abs	~	piStd_conc)	
summary(piStd_reg)	
##		
##	Call:	
##	lm(formula	=	piStd_Abs	~	piStd_conc)	
##		
##	Residuals:	
##								1								2								3								4								5								6								7		
##	-0.12394	-0.07457		0.03717		0.09791		0.16066		0.04814	-0.14538		
##		
##	Coefficients:	
 156 
##													Estimate	Std.	Error	t	value	Pr(>|t|)					
##	(Intercept)		0.23931				0.08238			2.905	0.033598	*			
##	piStd_conc			0.66103				0.07639			8.653	0.000341	***	
##	---	
##	Signif.	codes:		0	'***'	0.001	'**'	0.01	'*'	0.05	'.'	0.1	'	'	1	
##		
##	Residual	standard	error:	0.1274	on	5	degrees	of	freedom	
##	Multiple	R-squared:		0.9374,	Adjusted	R-squared:		0.9249		
##	F-statistic:	74.88	on	1	and	5	DF,		p-value:	0.0003406	
#SAMPLES	
piTemperatures	<-	c("4C",	"23C",	"37C",	"4C",	"23C",	"37C",	"4C",	"23C",	"37C
")	
piSamplenames	<-	c("H5",	"H5",	"H5",	"CPI",	"CPI",	"CPI",	"SPI",	"SPI",	"SPI"
)	
piAbsorbances	<-	c(0.516,	0.513,	0.538,	0.56,	0.609,	0.622,	0.528,	0.529,	0.6
22)	
conc.calc	<-	function(Slope,	Intercept,	Abs,	DF)	
		{((Abs-Intercept)/(Slope))*DF}	
piSampleconcs	<-	conc.calc(0.66103,	0.23931,	piAbsorbances,	1)	
piSampleconcs20	<-	conc.calc(piStd_reg$coefficients[2],	piStd_reg$coefficient
s[1],	piAbsorbances,	20)	
ProteaseDF	<-	data.frame(piTemperatures,	piSamplenames,	piAbsorbances,	piSamp
leconcs,	piSampleconcs20)	
Graph in ggplots 
library(ggplot2)	
library(ggthemes)	
	
ggplot(data=	piStdDF,		
							aes(x=	piStd_conc,	
												y=	piStd_Abs))	+	
		geom_point(shape=5)	+	
		geom_smooth(method	=	lm,	
															se	=	FALSE,	size	=	0.25,	color	=	"black")	+		
		geom_point(data	=	ProteaseDF,	
													aes(x	=	piSampleconcs,	
																	y	=	piAbsorbances,	
																	color	=	piSamplenames,	
																	shape	=	piSamplenames))	+		
		theme_gdocs()	+	scale_color_calc()	+	
		theme(legend.title=element_blank())	+		
		labs(x="Concentration	mg/mL")	+	labs(y=	"Absorbances")	+	
		theme(text=element_text(size=10,	family="Arial"))	
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Semenanova	<-	aov(piSampleconcs20	~piSamplenames,	data=	ProteaseDF)	
summary(Semenanova)	
##															Df	Sum	Sq	Mean	Sq	F	value	Pr(>F)	
##	piSamplenames		2		7.655			3.828			3.008		0.124	
##	Residuals						6		7.634			1.272	
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A.2 Protein sequence alignments 
Alignment	1:	Human	and	chimpanzee	clusterin	sequences	
>HumanClus gi|355594753|ref|NP_001822.3| clusterin preproprotein [Homo sapiens] 
MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALN
ETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHM
LDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAM
DIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNEL
LKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKF
METVAEKALQEYRKKHREE 
>ChimpClus gi|410340483|gb|JAA39188.1| clusterin [Pan troglodytes] 
MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSDQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALN
ETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHM
LDVMQDHFSRASSIMDELFQDRFFAREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAM
DIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSASNPSQAQLRRELDESLQVAEKLTRKYNEL
LKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDIPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKF
METVAEKALQEYRKKHREE 
 
HumanClus     MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLI 
ChimpClus     MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSDQGSKYVNKEIQNAVNGVKQIKTLI 
              ***********************************:************************ 
HumanClus     EKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQT 
ChimpClus     EKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQT 
              ************************************************************ 
HumanClus     CMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHF 
ChimpClus     CMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHF 
              ************************************************************ 
HumanClus     SRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNF 
ChimpClus     SRASSIMDELFQDRFFAREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNF 
              ******:*********:******************************************* 
HumanClus     HAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKD 
ChimpClus     HAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKD 
              ************************************************************ 
HumanClus     QCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLE 
ChimpClus     QCDKCREILSVDCSASNPSQAQLRRELDESLQVAEKLTRKYNELLKSYQWKMLNTSSLLE 
              **************:.*****:*************:************************ 
HumanClus     QLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVP 
ChimpClus     QLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDIPSGVTEVVVKLFDSDPITVTVP 
              *************************************:********************** 
HumanClus     VEVSRKNPKFMETVAEKALQEYRKKHREE 
ChimpClus     VEVSRKNPKFMETVAEKALQEYRKKHREE 
              ***************************** 
 
::: indicates amino acid differences between human and chimpanzee clusterin which may 
affect antibody detection 
*** indicates where the ab104652 antibody binds 
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Alignment	2:	Human	and	chimpanzee	albumin	sequences	
>HumanALB gi|4502027|ref|NP_000468.1| serum albumin preproprotein [Homo sapiens] 
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENC
DKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPY
FYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKL
VTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYA
EAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNA
LLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALE
VDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAA
SQAALGL 
>ChimpALB gi|332819547|ref|XP_517233.3| PREDICTED: serum albumin [Pan troglodytes] 
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLVAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENC
DKSLHTLFGDKLCTVATLREKYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEGTFLKKYLYEVARRHPY
FYAPELLFFAERYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKL
VTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCLAEVENDEMPADLPSLAADFVESKEVCKNYA
EAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNA
LLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALE
VDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAA
SQAALGL 
HumanALB      MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF 
ChimpALB      MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLVAFAQYLQQCPF 
              ************************************************:*********** 
HumanALB      EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP 
ChimpALB      EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLREKYGEMADCCAKQEP 
              **********************************************.************* 
HumanALB      ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF 
ChimpALB      ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEGTFLKKYLYEVARRHPYFYAPELLF 
              *********************************** *********:************** 
HumanALB      FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV 
ChimpALB      FAERYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV 
              **:********************************************************* 
HumanALB      ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK 
ChimpALB      ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK 
              ************************************************************ 
HumanALB      ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR 
ChimpALB      ECCEKPLLEKSHCLAEVENDEMPADLPSLAADFVESKEVCKNYAEAKDVFLGMFLYEYAR 
              *************:***********************:********************** 
HumanALB      RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE 
ChimpALB      RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE 
              ************************************************************ 
HumanALB      QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV 
ChimpALB      QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV 
              ************************************************************ 
HumanALB      LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL 
ChimpALB      LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL 
              ************************************************************ 
HumanALB      SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV 
ChimpALB      SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV 
              ************************************************************ 
HumanALB      AASQAALGL 
ChimpALB      AASQAALGL 
              ********* 
::: indicates amino acid differences between human and chimpanzee albumin 
which may affect antibody detection 
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Alignment	3:	Human	and	bovine	albumin	sequences	
>BSA sp|P02769|ALBU_BOVIN Serum albumin OS=Bos taurus 
MKWVTFISLLLLFSSAYSRGVFRRDTHKSEIAHRFKDLGEEHFKGLVLIAFSQYLQQCPFDEHVKLVNELTEFAKTCVADESHAGC
EKSLHTLFGDELCKVASLRETYGDMADCCEKQEPERNECFLSHKDDSPDLPKLKPDPNTLCDEFKADEKKFWGKYLYEIARRHPYF
YAPELLYYANKYNGVFQECCQAEDKGACLLPKIETMREKVLASSARQRLRCASIQKFGERALKAWSVARLSQKFPKAEFVEVTKLV
TDLTKVHKECCHGDLLECADDRADLAKYICDNQDTISSKLKECCDKPLLEKSHCIAEVEKDAIPENLPPLTADFAEDKDVCKNYQE
AKDAFLGSFLEYSRRHPEYAVSVLLRLAKEYEATLEECCAKDDPHACYSTVFDKLKHLVDEPQNLIKQNCDQFEKLGEYGFQNALI
VRYTRKVPQVSTPTLVEVSRSLGKVGTRCCTKPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKCCTESLVNRRPCFSALTPD
ETYVPKAFDEKLFTFHADICTLPDTEKQIKKQTALVELLKHKPKATEEQLKTVMENFVAFVDKCCAADDKEACFAVEGPKLVVSTQ
TALA 
>HSA sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens 
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENC
DKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPY
FYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKL
VTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYA
EAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNA
LLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALE
VDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAA
SQAALGL 
 
CLUSTAL O(1.2.1) multiple sequence alignment    
BSA      MKWVTFISLLLLFSSAYSRGVFRRDTHKSEIAHRFKDLGEEHFKGLVLIAFSQYLQQCPF  
HSA      MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF                   
**********:**************:****:**********.**.******:********   
BSA      DEHVKLVNELTEFAKTCVADESHAGCEKSLHTLFGDELCKVASLRETYGDMADCCEKQEP  
HSA      EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP  
        ::*******:************   *:*********:**.**:******:***** ****   
BSA      ERNECFLSHKDDSPDLPKL-KPDPNTLCDEFKADEKKFWGKYLYEIARRHPYFYAPELLY  
HSA      ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF           
    *******.****.*:**:* :*: :.:*  *: :*:.*  *******************:   
BSA      YANKYNGVFQECCQAEDKGACLLPKIETMREKVLASSARQRLRCASIQKFGERALKAWSV  
HSA      FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV           
    :*::*:..* ***** **.******:: :*::  ****:***:***:*******:***:*   
BSA      ARLSQKFPKAEFVEVTKLVTDLTKVHKECCHGDLLECADDRADLAKYICDNQDTISSKLK  
HSA      ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK           
    *****:******.**:**********.**********************:***:******   
BSA      ECCDKPLLEKSHCIAEVEKDAIPENLPPLTADFAEDKDVCKNYQEAKDAFLGSFL-EYSR  
HSA      ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR           
    ***:**************:* :* :** *:***.*.******* ****.*** ** **:*   
BSA      RHPEYAVSVLLRLAKEYEATLEECCAKDDPHACYSTVFDKLKHLVDEPQNLIKQNCDQFE  
HSA      RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE           
    ***:*:* :****** **:***:***  *** **:.***::* **:**********: **   
BSA      KLGEYGFQNALIVRYTRKVPQVSTPTLVEVSRSLGKVGTRCCTKPESERMPCTEDYLSLI  
HSA      QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV           
    :**** *****:****:***************.*****::**.:**::****:*****::   
BSA      LNRLCVLHEKTPVSEKVTKCCTESLVNRRPCFSALTPDETYVPKAFDEKLFTFHADICTL  
HSA      LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL           
    **:***********::*******************  ******* *: : **********   
BSA      PDTEKQIKKQTALVELLKHKPKATEEQLKTVMENFVAFVDKCCAADDKEACFAVEGPKLV  
HSA      SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV               
:.*:***********:*******:****:**::*.***:*** *****:*** ** ***   
BSA      VSTQTALA-  
HSA      AASQAALGL          
   .::*:**.  
 
*** indicates trypsin digested fragments that are the same between human and 
bovine serum albumin 
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A.3 Outline of LC/MS-MS data sorting, labeling, and normalization 
Please note that the initial data processing and normalization was done by Michael I. Jensen-
Seaman. Below is his outline on the files and Pearl scripts he used. 
 
Data analysis of human, chimpanzee, and gorilla shotgun proteomics. 
Experiments performed in February 2015. All analyses done on data set 
“All_Data_JThomas_02112016”, located in 
“Projects/Proteomics/HCG_Shotgun_2015/All_Data_JThomas_02110216/”. 
This “re-run” is using cutoff score of 11, and “parent charge” up to 7. 
A.3.1 Annotation and Normalization: 
Initial annotation is by matching peptides from each species to all species with SpectrumMill 
software. 
 
Results from each run (three runs per individual) and each individual (three individuals per 
species) and each “cross-matching annotation” are a separate file. Data files are in folder 
“Projects/Proteomics/HCG_Shotgun_2015/All_Data_JThomas_02110216/”, with the names 
“Chimp_SMReRun”, “Gorilla_SMReRun”, and “Human_SMReRun”. Within each folder there 
are three files (e.g., Ch_Ch, Ch_Go, Ch_Hu); these refer to the species that was run, and the 
species against which it was annotated. Within each of these folders are four folders, with “Pep” 
and “Prot” for peptide and protein data, and “T” and “NT” for truncated and not truncated by 
score cutoff of 11. 
 
We are using “T” data, and “Pep” data. 
 
Step 1: Concatenate all peptide files for each species and cross-match (e.g., combining nine runs 
of self-match into one file). Now have three files for each species (e.g., C_H_T_all.ssv is all nine 
runs of chimp annotated against human). 
 
Step 2: Concatenate three files into one: 
 (e.g., cat C_C_T_all.ssv C_G_T_all.ssv C_H_T_all.ssv > C_T_all.ssv) 
 
Step 3: Add gene name and length from UniProt (accessed February 2016), using perl script 
“addgene_peptide.pl”: e.g., perl addgene_peptide.pl C_T_all.ssv 
Prot_Pan_UP000002277.tab) 
Resulting files are *.outnew (e.g., C_T_all.ssv.outnew). 
 
Step 4: Prioritize annotation as follows: 
1. If match to self-species, take it. 
2. Else, if match to human, take it. 
3. Else, if match to third species, take it. 
This is done using prioritize.pl, where command line defines priority order 
e.g., perl prioritize.pl C_T_all.ssv.outnew PANTR HUMAN GORGO 
Resulting files are *.prior (e.g., C_T_all.ssv.outnew.prior) 
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Results from annotation: 
Species Total Pep Total named Human annot Chimp annot Gorilla annot 
Human 3469 3455 3229 155 71 
Chimp 3275 3256 208 2998 50 
Gorilla 991 967 200 67 724 
 
Step 5: Filter by confidence in hits: 
To be considered “high-confidence ID”, protein must: 
a) Be found in two or more runs for that species 
b) Be found as two or more unique peptide 
 
Results from filtering: 
Species Peptides/Protein Protein Found in >1 
run? 
Protein ID’d from >1 
peptide? 
Human, peptide 3469 2861  
Human, protein 475 140 71 
Chimp, peptide 3275 2849  
Chimp, protein 332 111 64 
Gorilla, peptide 991 359  
Gorilla, protein 503 81 36 
 Note: This reduced the number of proteins a lot. 
These proteins are now called “high confidence” proteins. They are found in *.uniq file (e.g., 
“C_T_HiConf.uniq”, in folder 
Projects/Proteomics/HCG_Shotgun_2015/All_Data_JThomas_02110216/Annotation/Final_Ann
otations/) 
 
After adding Amanda’s manual curation of the semenogelin annotation, I have the three files: 
C_T_all_anno_MJS_02222016.xlsx (“keep” tab of spreadsheet) 
G_T_all_anno_MJS_02222016.xlsx (“keep” tab of spreadsheet) 
H_T_all_anno_MJS_02222016.xlsx (“keep” tab of spreadsheet) 
 
Step 6: Normalize data (without accounting for length): 
Re-splitting into separate files for each run (e.g., C12.T.spec.anno), where the first letter is the 
species, the first number is the individual, and the second number is the run). Using 
“normalize.pl” as follows: 
perl normalize.pl *spec.anno 
output is *spec.anno.norm 
 
This divides the spectral count for each protein by the total spectral count of each run. 
 
These are now placed into a spreadsheet “HCG_compiled.normal_new.xlsx”. 
There are 131 unique proteins among human, chimp, and gorilla. 
 
Step 7: Repeat above but accounting for length.  
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For this, combine number of spectra across the three technical replicates, to get a sum of spectra 
for each biological replicate. To produce a normalized length-controlled NSAF for each protein k 
for each biological replicate: 
 𝑁𝑆𝐴𝐹 ! =  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑐𝑡𝑟𝑎/𝑙𝑒𝑛𝑔𝑡ℎ !(𝑛𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑐𝑡𝑟𝑎/𝑙𝑒𝑛𝑔𝑡ℎ) !!!!!  
 
note: lengths for all species were taken from the human protein database (because annotation for 
other species is incomplete and unreviewed). The exception is SEMG1 and SEMG2. 
 
Results are now given as “NSAF_length” in three spreadsheets: 
C123.spec.anno.length.xlsx, G123.spec.anno.length.xlsx, H123.spec.anno.length.xlsx  
 
And combined into HCG.nsaf.length 
 
Step 8: Statistics. 
1. Simple t-test where each individual is a value. 
2. Count two-fold or greater as ‘interesting’. 
3. PLGEM analysis, in R. 
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A.4 Script in R for PLGEM statistics 
A.4.1 Load libraries and set working directory 
library(plgem)	
##		
##	Welcome	to	plgem	version	1.46.0	
library(Biobase)	
##	Loading	required	package:	BiocGenerics	
##	Loading	required	package:	parallel	
##		
##	Attaching	package:	'BiocGenerics'	
##	The	following	objects	are	masked	from	'package:parallel':	
##		
##					clusterApply,	clusterApplyLB,	clusterCall,	clusterEvalQ,	
##					clusterExport,	clusterMap,	parApply,	parCapply,	parLapply,	
##					parLapplyLB,	parRapply,	parSapply,	parSapplyLB	
##	The	following	objects	are	masked	from	'package:stats':	
##		
##					IQR,	mad,	xtabs	
##	The	following	objects	are	masked	from	'package:base':	
##		
##					anyDuplicated,	append,	as.data.frame,	cbind,	colnames,	
##					do.call,	duplicated,	eval,	evalq,	Filter,	Find,	get,	grep,	
##					grepl,	intersect,	is.unsorted,	lapply,	lengths,	Map,	mapply,	
##					match,	mget,	order,	paste,	pmax,	pmax.int,	pmin,	pmin.int,	
##					Position,	rank,	rbind,	Reduce,	rownames,	sapply,	setdiff,	
##					sort,	table,	tapply,	union,	unique,	unsplit,	which,	which.max,	
##					which.min	
##	Welcome	to	Bioconductor	
##		
##					Vignettes	contain	introductory	material;	view	with	
##					'browseVignettes()'.	To	cite	Bioconductor,	see	
##					'citation("Biobase")',	and	for	packages	'citation("pkgname")'.	
setwd("~/Desktop/PLGEM")	#all	files	listed	in	this	script	must	be	in	the	same
	folder	without	any	of	the	output	'result'	files.		
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A.4.2 Length adjusted pairwise PLGEM of human and chimp 
esetLCH	<-	readExpressionSet("length.HC.txt",	"phenoDataFile_CH_L.txt")	
	
NSAFfitLCH	<-	plgem.fit(data=esetLCH,	covariate	=	1,	fitCondition	=	'human',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##									species	
##	H1_NSAF			human	
##	H2_NSAF			human	
##	H3_NSAF			human	
##	replacing	36	non-positive	means	with	smallest	positive	mean...	
##	replacing	36	zero	standard	deviations	with	smallest	non-zero	standard			de
viation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
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##	done	with	fitting	PLGEM.	
NSAFobsSTNLCH	<-	plgem.obsStn(data=esetLCH,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitLCH,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	human	...	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	working	on	condition	chimp	...	
##	C1_NSAF	C2_NSAF	C3_NSAF		
##	done	with	calculating	PLGEM-STN	statistics.	
set.seed(123)	
NSAFresampledStnLCH	<-	plgem.resampledStn(data=esetLCH,	plgemFit	=	NSAFfitLCH
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	resampling	on	samples:	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesLCH	<-	plgem.pValue(observedStn	=	NSAFobsSTNLCH,	plgemResampledStn
	=	NSAFresampledStnLCH,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListLCH	<-	plgem.deg(observedStn	=	NSAFobsSTNLCH,	plgemPval	=	NSAFpVal
uesLCH,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		chimp_vs_human		
##	delta:	0.01	condition:	chimp_vs_human	found	28	DEG	
##	done	with	selecting	significant	DEG.	
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plgem.write.summary(NSAFdegListLCH,	prefix	=	"CH_length_PLGEM",	verbose	=	TRU
E)	
##	Writing	files...	
##					CH_length_PLGEM_fit.csv		
##					CH_length_PLGEM_stn_p-value.csv		
##					CH_length_PLGEM_chimp_vs_human_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGEM	
A.4.3 Length adjusted pairwise PLGEM of human and gorilla 
esetLHG	<-	readExpressionSet("length.HG.txt",	"phenoDataFile_GH_L.txt")	
	
NSAFfitLHG	<-	plgem.fit(data=esetLHG,	covariate	=	1,	fitCondition	=	'human',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##									species	
##	H1_NSAF			human	
##	H2_NSAF			human	
##	H3_NSAF			human	
##	replacing	25	non-positive	means	with	smallest	positive	mean...	
##	replacing	25	zero	standard	deviations	with	smallest	non-zero	standard	devi
ation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
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##	done	with	fitting	PLGEM.	
NSAFobsSTNLHG	<-	plgem.obsStn(data=esetLHG,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitLHG,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	human	...	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	working	on	condition	gorilla	...	
##	G1_NSAF	G2_NSAF	G3_NSAF		
##	done	with	calculating	PLGEM-STN	statistics.	
set.seed(123)	
NSAFresampledStnLHG	<-	plgem.resampledStn(data=esetLHG,	plgemFit	=	NSAFfitLHG
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	resampling	on	samples:	
##	H1_NSAF	H2_NSAF	H3_NSAF		
##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesLHG	<-	plgem.pValue(observedStn	=	NSAFobsSTNLHG,	plgemResampledStn
	=	NSAFresampledStnLHG,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListLHG	<-	plgem.deg(observedStn	=	NSAFobsSTNLHG,	plgemPval	=	NSAFpVal
uesLHG,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		gorilla_vs_human		
##	delta:	0.01	condition:	gorilla_vs_human	found	35	DEG	
##	done	with	selecting	significant	DEG.	
 169 
plgem.write.summary(NSAFdegListLHG,	prefix	=	"HG_length_PLGEM",	verbose	=	TRU
E)	
##	Writing	files...	
##					HG_length_PLGEM_fit.csv		
##					HG_length_PLGEM_stn_p-value.csv		
##					HG_length_PLGEM_gorilla_vs_human_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGEM	
 
A.4.4 Length adjusted pairwise PLGEM of chimp and gorilla 
esetLCG	<-	readExpressionSet("length.CG.txt",	"phenoDataFile_CG_L.txt")	
	
NSAFfitLCG	<-	plgem.fit(data=esetLCG,	covariate	=	1,	fitCondition	=	'chimp',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##									species	
##	C1_NSAF			chimp	
##	C2_NSAF			chimp	
##	C3_NSAF			chimp	
##	replacing	24	non-positive	means	with	smallest	positive	mean...	
##	replacing	24	zero	standard	deviations	with	smallest	non-zero	standard	devi
ation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
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##	done	with	fitting	PLGEM.	
NSAFobsSTNLCG	<-	plgem.obsStn(data=esetLCG,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitLCG,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	chimp	...	
##	C1_NSAF	C2_NSAF	C3_NSAF		
##	working	on	condition	gorilla	...	
##	G1_NSAF	G2_NSAF	G3_NSAF		
##	done	with	calculating	PLGEM-STN	statistics.	
set.seed(123)	
NSAFresampledStnLCG	<-	plgem.resampledStn(data=esetLCG,	plgemFit	=	NSAFfitLCG
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	C1_NSAF	C2_NSAF	C3_NSAF		
##	resampling	on	samples:	
##	C1_NSAF	C2_NSAF	C3_NSAF		
##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
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##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesLCG	<-	plgem.pValue(observedStn	=	NSAFobsSTNLCG,	plgemResampledStn
	=	NSAFresampledStnLCG,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListLCG	<-	plgem.deg(observedStn	=	NSAFobsSTNLCG,	plgemPval	=	NSAFpVal
uesLCG,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		gorilla_vs_chimp		
##	delta:	0.01	condition:	gorilla_vs_chimp	found	33	DEG	
##	done	with	selecting	significant	DEG.	
plgem.write.summary(NSAFdegListLCG,	prefix	=	"CG_length_PLGEM",	verbose	=	TRU
E)	
##	Writing	files...	
##					CG_length_PLGEM_fit.csv		
##					CG_length_PLGEM_stn_p-value.csv		
##					CG_length_PLGEM_gorilla_vs_chimp_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGEM	
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A.4.5 Raw normalization pairwise PLGEM of human and chimp 
esetRCH	<-	readExpressionSet("NSAF_CH_10042016.txt",	"phenoDataFile_CH_R.txt"
)	
	
NSAFfitRCH	<-	plgem.fit(data=esetRCH,	covariate	=	1,	fitCondition	=	'human',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##								species	
##	H1_ave			human	
##	H2_ave			human	
##	H3_ave			human	
##	replacing	36	non-positive	means	with	smallest	positive	mean...	
##	replacing	36	zero	standard	deviations	with	smallest	non-zero	standard	devi
ation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
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##	done	with	fitting	PLGEM.	
NSAFobsSTNRCH	<-	plgem.obsStn(data=esetRCH,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitRCH,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	chimp	...	
##	C1_ave	C2_ave	C3_ave		
##	working	on	condition	human	...	
##	H1_ave	H2_ave	H3_ave		
##	done	with	calculating	PLGEM-STN	statistics.	
set.seed(123)	
NSAFresampledStnRCH	<-	plgem.resampledStn(data=esetRCH,	plgemFit	=	NSAFfitRCH
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	C1_ave	C2_ave	C3_ave		
##	resampling	on	samples:	
##	H1_ave	H2_ave	H3_ave		
##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesRCH	<-	plgem.pValue(observedStn	=	NSAFobsSTNRCH,	plgemResampledStn
	=	NSAFresampledStnRCH,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListRCH	<-	plgem.deg(observedStn	=	NSAFobsSTNRCH,	plgemPval	=	NSAFpVal
uesRCH,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		human_vs_chimp		
##	delta:	0.01	condition:	human_vs_chimp	found	24	DEG	
##	done	with	selecting	significant	DEG.	
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plgem.write.summary(NSAFdegListRCH,	prefix	=	"CH_raw_PLGEM",	verbose	=	TRUE)	
##	Writing	files...	
##					CH_raw_PLGEM_fit.csv		
##					CH_raw_PLGEM_stn_p-value.csv		
##					CH_raw_PLGEM_human_vs_chimp_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGEM	
A.4.6 Raw normalization pairwise PLGEM of human and gorilla 
esetRHG	<-	readExpressionSet("NSAF_GH_10042016.txt",	"phenoDataFile_GH_R.txt"
)	
	
NSAFfitRHG	<-	plgem.fit(data=esetRHG,	covariate	=	1,	fitCondition	=	'human',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##								species	
##	H1_ave			human	
##	H2_ave			human	
##	H3_ave			human	
##	replacing	26	non-positive	means	with	smallest	positive	mean...	
##	replacing	26	zero	standard	deviations	with	smallest	non-zero	standard	devi
ation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
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##	done	with	fitting	PLGEM.	
NSAFobsSTNRHG	<-	plgem.obsStn(data=esetRHG,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitRHG,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	gorilla	...	
##	G1_ave	G2_ave	G3_ave		
##	working	on	condition	human	...	
##	H1_ave	H2_ave	H3_ave		
##	done	with	calculating	PLGEM-STN	statistics.	
set.seed(123)	
NSAFresampledStnRHG	<-	plgem.resampledStn(data=esetRHG,	plgemFit	=	NSAFfitRHG
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	G1_ave	G2_ave	G3_ave		
##	resampling	on	samples:	
##	H1_ave	H2_ave	H3_ave		
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##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesRHG	<-	plgem.pValue(observedStn	=	NSAFobsSTNRHG,	plgemResampledStn
	=	NSAFresampledStnRHG,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListRHG	<-	plgem.deg(observedStn	=	NSAFobsSTNRHG,	plgemPval	=	NSAFpVal
uesRHG,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		human_vs_gorilla		
##	delta:	0.01	condition:	human_vs_gorilla	found	40	DEG	
##	done	with	selecting	significant	DEG.	
plgem.write.summary(NSAFdegListRHG,	prefix	=	"HG_raw_PLGEM",	verbose	=	TRUE)	
##	Writing	files...	
##					HG_raw_PLGEM_fit.csv		
##					HG_raw_PLGEM_stn_p-value.csv		
##					HG_raw_PLGEM_human_vs_gorilla_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGEM	
A.4.7 Raw normalization pairwise PLGEM of chimp and gorilla 
esetRCG	<-	readExpressionSet("NSAF_CG_10042016.txt",	"phenoDataFile_CG_R.txt"
)	
	
NSAFfitRCG	<-	plgem.fit(data=esetRCG,	covariate	=	1,	fitCondition	=	'chimp',	
p=5,	q=0.5,	plot.file	=	FALSE,	fittingEval	=	TRUE,	verbose	=	TRUE)	
##	Fitting	PLGEM...	
##	samples	extracted	for	fitting:	
##								species	
##	C1_ave			chimp	
##	C2_ave			chimp	
##	C3_ave			chimp	
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##	replacing	25	non-positive	means	with	smallest	positive	mean...	
##	replacing	25	zero	standard	deviations	with	smallest	non-zero	standard	devi
ation...	
##	determining	modelling	points...	
##	fitting	data	and	modelling	points...	
##	Warning	in	plgem.fit(data	=	esetRCG,	covariate	=	1,	fitCondition	=	
##	"chimp",	:	Adjusted	r^2	is	lower	than	0.95	
##	Warning	in	plgem.fit(data	=	esetRCG,	covariate	=	1,	fitCondition	=	
##	"chimp",	:	Pearson	correlation	coefficient	is	lower	than	0.85	
##	done	with	fitting	PLGEM.	
NSAFobsSTNRCG	<-	plgem.obsStn(data=esetRCG,	covariate=1,	baselineCondition	=	
1,	plgemFit	=	NSAFfitRCG,	verbose	=	TRUE)	
##	calculating	observed	PLGEM-STN	statistics:found	1	condition(s)	to	compare	
to	the	baseline.	
##	working	on	baseline	chimp	...	
##	C1_ave	C2_ave	C3_ave		
##	working	on	condition	gorilla	...	
##	G1_ave	G2_ave	G3_ave		
##	done	with	calculating	PLGEM-STN	statistics.	
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set.seed(123)	
NSAFresampledStnRCG	<-	plgem.resampledStn(data=esetRCG,	plgemFit	=	NSAFfitRCG
,	iterations	=	10000,	verbose	=	TRUE)	
##	calculating	resampled	PLGEM-STN	statistics:found	1	condition(s)	to	compare
	to	the	baseline.	
##	baseline	samples:	
##	C1_ave	C2_ave	C3_ave		
##	resampling	on	samples:	
##	C1_ave	C2_ave	C3_ave		
##	Using	10000	iterations...	
##	working	on	cases	with	3	replicates...	
##						Iterations:	100		200		300		400		500		600		700		800		900		1000			
##	1100		1200		1300		1400		1500		1600		1700		1800		1900		2000			
##	2100		2200		2300		2400		2500		2600		2700		2800		2900		3000			
##	3100		3200		3300		3400		3500		3600		3700		3800		3900		4000			
##	4100		4200		4300		4400		4500		4600		4700		4800		4900		5000			
##	5100		5200		5300		5400		5500		5600		5700		5800		5900		6000			
##	6100		6200		6300		6400		6500		6600		6700		6800		6900		7000			
##	7100		7200		7300		7400		7500		7600		7700		7800		7900		8000			
##	8100		8200		8300		8400		8500		8600		8700		8800		8900		9000			
##	9100		9200		9300		9400		9500		9600		9700		9800		9900		10000			
##		
##	done	with	calculating	resampled	PLGEM-STN	statistics.	
NSAFpValuesRCG	<-	plgem.pValue(observedStn	=	NSAFobsSTNRCG,	plgemResampledStn
	=	NSAFresampledStnRCG,	verbose	=	TRUE)	
##	calculating	PLGEM	p-values...	done.	
NSAFdegListRCG	<-	plgem.deg(observedStn	=	NSAFobsSTNRCG,	plgemPval	=	NSAFpVal
uesRCG,	delta=	0.01,	verbose=	TRUE)	
##	selecting	significant	DEG:found	1	condition(s)	compared	to	the	baseline.	
##	Delta	=		0.01		
##		Condition	=		gorilla_vs_chimp		
##	delta:	0.01	condition:	gorilla_vs_chimp	found	47	DEG	
##	done	with	selecting	significant	DEG.	
plgem.write.summary(NSAFdegListRCG,	prefix	=	"CG_raw_PLGEM",	verbose	=	TRUE)	
##	Writing	files...	
##					CG_raw_PLGEM_fit.csv		
##					CG_raw_PLGEM_stn_p-value.csv		
##					CG_raw_PLGEM_gorilla_vs_chimp_0.01.txt		
##	...to	folder	/Users/Amanda/Desktop/PLGE
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A.5 Shannon and Simpson diversity index calculations 
Shannon and Simpson diversity indexes were hand calculated in excel. Calculation tables are shown only for raw normalization, 
however the same process was utilized for length adjusted normalized data. A t-test in R determined that the biodiversity statistics 
were not significantly different between raw and length adjust normalizations. The script and analysis follows the tables.  
 
Table A.1: Shannon diversity calculation with raw normalization 
Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
ACE 0.0000     0.0043 -5.4400 -0.0236 0.0000     
ACO2 0.0000     0.0007 -7.2813 -0.0050 0.0000     
ACOT13 0.0000     0.0015 -6.4696 -0.0100 0.0000     
ACPP 0.0412 -3.1895 -0.1314 0.0237 -3.7439 -0.0886 0.0000     
ACR 0.0000     0.0015 -6.4930 -0.0098 0.0000     
ACRBP 0.0000     0.0060 -5.1154 -0.0307 0.0000     
ACTA2 0.0058 -5.1489 -0.0299 0.0000     0.0000     
ACTB 0.0000     0.0068 -4.9839 -0.0341 0.0000     
ALB 0.0566 -2.8714 -0.1626 0.0803 -2.5222 -0.2025 0.2591 -1.3504 -0.3499 
AMY2B 0.0000     0.0113 -4.4844 -0.0506 0.0000     
ANPEP 0.0072 -4.9315 -0.0356 0.0012 -6.7649 -0.0078 0.0000     
APOB 0.0000     0.0000     0.0271 -3.6069 -0.0979 
ARHGAP31 0.0007 -7.2592 -0.0051 0.0000     0.0000     
ARNT 0.0000     0.0000     0.0182 -4.0086 -0.0728 
ASAP2 0.0000     0.0000     0.0058 -5.1499 -0.0299 
AZGP1 0.0243 -3.7154 -0.0905 0.0092 -4.6876 -0.0432 0.0000     
B2M 0.0024 -6.0318 -0.0145 0.0011 -6.7957 -0.0076 0.0000     
B4GALT1 0.0000     0.0020 -6.2141 -0.0124 0.0000     
BCL3 0.0000     0.0000     0.0109 -4.5215 -0.0492 
BIRC6 0.0008 -7.1208 -0.0058 0.0000     0.0000     
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Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
CAP1 0.0019 -6.2644 -0.0119 0.0000     0.0000     
CCDC88C 0.0000     0.0000     0.0614 -2.7902 -0.1713 
CEP162 0.0000     0.0000     0.0138 -4.2827 -0.0591 
CFAP69 0.0000     0.0000     0.0068 -4.9967 -0.0338 
CKB 0.0023 -6.0635 -0.0141 0.0000     0.0000     
CLEC11A 0.0000     0.0000     0.0059 -5.1324 -0.0303 
CLIP2 0.0008 -7.1495 -0.0056 0.0000     0.0000     
CLU 0.0236 -3.7450 -0.0885 0.0457 -3.0859 -0.1410 0.0709 -2.6462 -0.1877 
CPE 0.0045 -5.4066 -0.0243 0.0000     0.0000     
CPSF1 0.0000     0.0000     0.0074 -4.9053 -0.0363 
CRISP1 0.0096 -4.6425 -0.0447 0.0017 -6.3955 -0.0107 0.0000     
CRTAC1 0.0000     0.0176 -4.0375 -0.0712 0.0000     
CST2 0.0009 -7.0091 -0.0063 0.0000     0.0000     
CST3 0.0019 -6.2688 -0.0119 0.0052 -5.2584 -0.0274 0.0000     
CST4 0.0057 -5.1665 -0.0295 0.0000     0.0000     
CTSB 0.0000     0.0000     0.0034 -5.6785 -0.0194 
CTSD 0.0032 -5.7346 -0.0185 0.0000     0.0000     
DEFA1 0.0038 -5.5677 -0.0213 0.0000     0.0000     
DHX57 0.0005 -7.5609 -0.0039 0.0000     0.0000     
DNAH7 0.0000     0.0000     0.0042 -5.4744 -0.0230 
DPEP3 0.0000     0.0056 -5.1798 -0.0292 0.0000     
DUT 0.0007 -7.2734 -0.0050 0.0000     0.0000     
ECM1 0.0067 -5.0042 -0.0336 0.0097 -4.6349 -0.0450 0.0000     
ENO1 0.0000     0.0008 -7.0866 -0.0059 0.0000     
FAM183B 0.0000     0.0000     0.0036 -5.6312 -0.0202 
FAM184B 0.0000     0.0000     0.0104 -4.5661 -0.0475 
FAM3D 0.0000     0.0006 -7.4713 -0.0043 0.0000     
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Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
FN1 0.0257 -3.6602 -0.0942 0.0525 -2.9474 -0.1547 0.0000     
FOLH1 0.0015 -6.4737 -0.0100 0.0000     0.0000     
GDF15 0.0033 -5.7272 -0.0186 0.0000     0.0000     
GOLGB1 0.0008 -7.1245 -0.0057 0.0000     0.0000     
GPI 0.0000     0.0029 -5.8387 -0.0170 0.0000     
HEXB 0.0033 -5.7142 -0.0189 0.0014 -6.5573 -0.0093 0.0000     
HK1 0.0000     0.0034 -5.6719 -0.0195 0.0000     
HSP90AA1 0.0000     0.0011 -6.7907 -0.0076 0.0000     
HSPA1A 0.0000     0.0014 -6.5987 -0.0090 0.0000     
HSPA1L 0.0023 -6.0936 -0.0138 0.0000     0.0000     
HSPA5 0.0020 -6.2242 -0.0123 0.0000     0.0000     
IDH1 0.0018 -6.3232 -0.0113 0.0000     0.0000     
IGHG1 0.0047 -5.3524 -0.0254 0.0144 -4.2413 -0.0610 0.0000     
IGKC 0.0000     0.0083 -4.7873 -0.0399 0.0000     
KLK3 0.0209 -3.8660 -0.0810 0.0000     0.0000     
KRT1 0.0054 -5.2261 -0.0281 0.0050 -5.2935 -0.0266 0.0374 -3.2848 -0.1230 
KRT10 0.0044 -5.4236 -0.0239 0.0012 -6.7592 -0.0078 0.0034 -5.6785 -0.0194 
KRT2 0.0078 -4.8523 -0.0379 0.0011 -6.7907 -0.0076 0.0000     
LAMP2 0.0024 -6.0485 -0.0143 0.0000     0.0000     
LCP1 0.0040 -5.5241 -0.0220 0.0022 -6.1143 -0.0135 0.0000     
LDHC 0.0000     0.0039 -5.5342 -0.0219 0.0000     
LGALS3BP 0.0194 -3.9417 -0.0765 0.0000     0.0000     
LRPPRC 0.0005 -7.5791 -0.0039 0.0000     0.0000     
LRRK1 0.0000     0.0000     0.0072 -4.9381 -0.0354 
LTF 0.0727 -2.6208 -0.1907 0.0399 -3.2222 -0.1285 0.0425 -3.1587 -0.1342 
MDH2 0.0000     0.0034 -5.6918 -0.0192 0.0000     
MGAM 0.0000     0.0018 -6.3335 -0.0112 0.0000     
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Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
MME 0.0000     0.0006 -7.4966 -0.0042 0.0000     
MSMB 0.0046 -5.3809 -0.0248 0.0000     0.0000     
MUC6 0.0253 -3.6772 -0.0930 0.0000     0.0000     
NBPF3 0.0000     0.0000     0.0079 -4.8419 -0.0382 
NDUFS1 0.0000     0.0000     0.0151 -4.1928 -0.0633 
NEMF 0.0000     0.0000   0.0000 0.0034 -5.6785 -0.0194 
NPC2 0.0136 -4.2951 -0.0586 0.0198 -3.9200 -0.0778 0.0000     
ORM1 0.0014 -6.6030 -0.0090 0.0017 -6.3850 -0.0108 0.0000     
OXCT2 0.0000     0.0013 -6.6615 -0.0085 0.0000     
PAEP 0.0000     0.0055 -5.2115 -0.0284 0.1068 -2.2368 -0.2389 
PATE1 0.0021 -6.1658 -0.0129 0.0000   0.0000 0.0000     
PGAM2 0.0000     0.0008 -7.1566 -0.0056 0.0000     
PGC 0.0026 -5.9390 -0.0156 0.0000   0.0000 0.0000     
PGK2 0.0000     0.0015 -6.5251 -0.0096 0.0000     
PIP 0.1180 -2.1369 -0.2522 0.0000   0.0000 0.0140 -4.2722 -0.0596 
PKM 0.0000     0.0049 -5.3089 -0.0263 0.0000     
PLA1A 0.0000     0.0015 -6.5313 -0.0095 0.0000     
PLS3 0.0000     0.0012 -6.7067 -0.0082 0.0000     
PPIB 0.0000     0.0047 -5.3597 -0.0252 0.0090 -4.7118 -0.0424 
PRDX6 0.0042 -5.4655 -0.0231 0.0039 -5.5408 -0.0217 0.0000     
PSAP 0.0152 -4.1844 -0.0637 0.0000     0.0000     
PSCA 0.0000     0.0066 -5.0223 -0.0331 0.0000     
QSOX1 0.0018 -6.3376 -0.0112 0.0000     0.0000     
RLTPR 0.0000     0.0008 -7.1566 -0.0056 0.0000     
RNASET2 0.0000     0.0084 -4.7741 -0.0403 0.0000     
S100A8 0.0033 -5.7281 -0.0186 0.0000     0.0000     
SEMG1 0.1388 -1.9750 -0.2741 0.4362 -0.8297 -0.3619 0.0325 -3.4271 -0.1113 
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Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
SEMG2 0.2029 -1.5953 -0.3236 0.0147 -4.2226 -0.0619 0.1058 -2.2462 -0.2376 
SERPINA1 0.0105 -4.5594 -0.0477 0.0188 -3.9753 -0.0746 0.0250 -3.6906 -0.0921 
SERPINA3 0.0008 -7.1208 -0.0058 0.0184 -3.9952 -0.0735 0.0000     
SERPINA5 0.0191 -3.9594 -0.0755 0.0347 -3.3617 -0.1166 0.0000     
SERPINF2 0.0019 -6.2688 -0.0119 0.0000     0.0000     
SLC9B2 0.0013 -6.6701 -0.0085 0.0000     0.0000     
SMG1 0.0008 -7.1245 -0.0057 0.0000     0.0000     
SOD2 0.0000     0.0007 -7.3065 -0.0049 0.0000     
SOD3 0.0007 -7.1971 -0.0054 0.0000     0.0000     
SORD 0.0019 -6.2593 -0.0120 0.0000     0.0000     
SRCAP 0.0000     0.0000     0.0052 -5.2501 -0.0275 
TF 0.0164 -4.1131 -0.0673 0.0095 -4.6590 -0.0441 0.0000     
TGM4 0.0036 -5.6166 -0.0204 0.0188 -3.9724 -0.0748 0.0000     
TIMP1 0.0056 -5.1880 -0.0290 0.0000     0.0000     
TKFC 0.0000     0.0006 -7.4580 -0.0043 0.0000     
TMPRSS2 0.0025 -6.0040 -0.0148 0.0000     0.0000     
TRRAP 0.0000     0.0000     0.0049 -5.3218 -0.0260 
TSSC1 0.0000     0.0000     0.0128 -4.3545 -0.0560 
TTLL5 0.0000     0.0000     0.0111 -4.4998 -0.0500 
TTN 0.0020 -6.2359 -0.0122 0.0007 -7.2855 -0.0050 0.0070 -4.9614 -0.0347 
TUBA1A 0.0000     0.0022 -6.1051 -0.0136 0.0000     
TUBB 0.0000     0.0011 -6.7715 -0.0078 0.0000     
UBA1 0.0000     0.0000     0.0073 -4.9215 -0.0359 
UBA52 0.0052 -5.2623 -0.0273 0.0000     0.0000     
WFDC2 0.0024 -6.0501 -0.0143 0.0000     0.0000     
WTIP 0.0008 -7.1351 -0.0057 0.0000     0.0000     
YWHAB 0.0019 -6.2420 -0.0121 0.0000     0.0000     
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Protein 
Human 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Chimp 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
Gorilla 
pi=sample/
sum Ln(pi) pi*Ln(pi) 
ZCCHC11 0.0000     0.0000     0.0294 -3.5268 -0.1037 
ZFHX2 0.0000     0.0000     0.0034 -5.6785   
ZNF148 0.0007 -7.2755 -0.0050 0.0000     0.0000     
  Sums 71.0000 -3.0438   64.0000 -2.5728   36.0000 -2.7769 
 
Human 
 
Chimp 
 
Gorilla 
 
Hmax = Ln(71) 4.26 Hmax = Ln(64) 4.16 Hmax = Ln(35) 3.56 
H (diversity) 3.04 H (diversity) 2.57 H (diversity) 2.78 
Eveness = Hmax/E(pi*Ln(pi)) 0.71 Eveness = Hmax/E(pi*Ln(pi)) 0.62 Eveness = Hmax/E(pi*Ln(pi)) 0.78 
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Table A.2: Simpson diversity calculation with raw normalization 
Protein Human Avg n n(n-1) Chimp Avg n n(n-1) Gorilla Avg n n(n-1) 
ACE 0.0000 0.0000 0.0000 0.0043 0.2777 -0.2006 0.0000 0.0000 0.0000 
ACO2 0.0000 0.0000 0.0000 0.0007 0.0440 -0.0421 0.0000 0.0000 0.0000 
ACOT13 0.0000 0.0000 0.0000 0.0015 0.0992 -0.0894 0.0000 0.0000 0.0000 
ACPP 0.0412 2.9247 5.6293 0.0237 1.5144 0.7790 0.0000 0.0000 0.0000 
ACR 0.0000 0.0000 0.0000 0.0015 0.0969 -0.0875 0.0000 0.0000 0.0000 
ACRBP 0.0000 0.0000 0.0000 0.0060 0.3842 -0.2366 0.0000 0.0000 0.0000 
ACTA2 0.0058 0.4122 -0.2423 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
ACTB 0.0000 0.0000 0.0000 0.0068 0.4382 -0.2462 0.0000 0.0000 0.0000 
ALB 0.0566 4.0200 12.1401 0.0803 5.1380 21.2607 0.2591 9.0694 73.1841 
AMY2B 0.0000 0.0000 0.0000 0.0113 0.7222 -0.2006 0.0000 0.0000 0.0000 
ANPEP 0.0072 0.5123 -0.2498 0.0012 0.0738 -0.0684 0.0000 0.0000 0.0000 
APOB 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0271 0.9497 -0.0478 
ARHGAP31 0.0007 0.0500 -0.0475 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
ARNT 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0182 0.6355 -0.2316 
ASAP2 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0058 0.2030 -0.1618 
AZGP1 0.0243 1.7285 1.2592 0.0092 0.5894 -0.2420 0.0000 0.0000 0.0000 
B2M 0.0024 0.1705 -0.1414 0.0011 0.0716 -0.0665 0.0000 0.0000 0.0000 
B4GALT1 0.0000 0.0000 0.0000 0.0020 0.1281 -0.1117 0.0000 0.0000 0.0000 
BCL3 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0109 0.3805 -0.2357 
BIRC6 0.0008 0.0574 -0.0541 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CAP1 0.0019 0.1351 -0.1169 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CCDC88C 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0614 2.1493 2.4703 
CEP162 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0138 0.4832 -0.2497 
CFAP69 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0068 0.2366 -0.1806 
CKB 0.0023 0.1652 -0.1379 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CLEC11A 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0059 0.2066 -0.1639 
CLIP2 0.0008 0.0558 -0.0526 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CLU 0.0236 1.6781 1.1379 0.0457 2.9241 5.6263 0.0709 2.4823 3.6796 
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Protein Human Avg n n(n-1) Chimp Avg n n(n-1) Gorilla Avg n n(n-1) 
CPE 0.0045 0.3186 -0.2171 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CPSF1 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0074 0.2593 -0.1920 
CRISP1 0.0096 0.6840 -0.2162 0.0017 0.1068 -0.0954 0.0000 0.0000 0.0000 
CRTAC1 0.0000 0.0000 0.0000 0.0176 1.1291 0.1457 0.0000 0.0000 0.0000 
CST2 0.0009 0.0642 -0.0600 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CST3 0.0019 0.1345 -0.1164 0.0052 0.3330 -0.2221 0.0000 0.0000 0.0000 
CST4 0.0057 0.4050 -0.2410 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
CTSB 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0034 0.1197 -0.1053 
CTSD 0.0032 0.2295 -0.1768 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
DEFA1 0.0038 0.2712 -0.1976 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
DHX57 0.0005 0.0370 -0.0356 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
DNAH7 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0042 0.1468 -0.1252 
DPEP3 0.0000 0.0000 0.0000 0.0056 0.3602 -0.2305 0.0000 0.0000 0.0000 
DUT 0.0007 0.0493 -0.0468 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
ECM1 0.0067 0.4764 -0.2494 0.0097 0.6213 -0.2353 0.0000 0.0000 0.0000 
ENO1 0.0000 0.0000 0.0000 0.0008 0.0535 -0.0507 0.0000 0.0000 0.0000 
FAM183B 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0036 0.1254 -0.1097 
FAM184B 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0104 0.3639 -0.2315 
FAM3D 0.0000 0.0000 0.0000 0.0006 0.0364 -0.0351 0.0000 0.0000 0.0000 
FN1 0.0257 1.8267 1.5100 0.0525 3.3584 7.9202 0.0000 0.0000 0.0000 
FOLH1 0.0015 0.1096 -0.0976 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
GDF15 0.0033 0.2312 -0.1777 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
GOLGB1 0.0008 0.0572 -0.0539 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
GPI 0.0000 0.0000 0.0000 0.0029 0.1864 -0.1517 0.0000 0.0000 0.0000 
HEXB 0.0033 0.2342 -0.1794 0.0014 0.0909 -0.0826 0.0000 0.0000 0.0000 
HK1 0.0000 0.0000 0.0000 0.0034 0.2203 -0.1717 0.0000 0.0000 0.0000 
HSP90AA1 0.0000 0.0000 0.0000 0.0011 0.0719 -0.0668 0.0000 0.0000 0.0000 
HSPA1A 0.0000 0.0000 0.0000 0.0014 0.0872 -0.0796 0.0000 0.0000 0.0000 
HSPA1L 0.0023 0.1603 -0.1346 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
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Protein Human Avg n n(n-1) Chimp Avg n n(n-1) Gorilla Avg n n(n-1) 
HSPA5 0.0020 0.1407 -0.1209 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
IDH1 0.0018 0.1274 -0.1112 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
IGHG1 0.0047 0.3363 -0.2232 0.0144 0.9209 -0.0728 0.0000 0.0000 0.0000 
IGKC 0.0000 0.0000 0.0000 0.0083 0.5335 -0.2489 0.0000 0.0000 0.0000 
KLK3 0.0209 1.4869 0.7240 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
KRT1 0.0054 0.3816 -0.2360 0.0050 0.3216 -0.2182 0.0374 1.3107 0.4072 
KRT10 0.0044 0.3132 -0.2151 0.0012 0.0743 -0.0687 0.0034 0.1197 -0.1053 
KRT2 0.0078 0.5545 -0.2470 0.0011 0.0719 -0.0668 0.0000 0.0000 0.0000 
LAMP2 0.0024 0.1677 -0.1396 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
LCP1 0.0040 0.2833 -0.2030 0.0022 0.1415 -0.1215 0.0000 0.0000 0.0000 
LDHC 0.0000 0.0000 0.0000 0.0039 0.2528 -0.1889 0.0000 0.0000 0.0000 
LGALS3BP 0.0194 1.3785 0.5217 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
LRPPRC 0.0005 0.0363 -0.0350 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
LRRK1 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0072 0.2509 -0.1879 
LTF 0.0727 5.1650 21.5124 0.0399 2.5516 3.9591 0.0425 1.4869 0.7239 
MDH2 0.0000 0.0000 0.0000 0.0034 0.2159 -0.1693 0.0000 0.0000 0.0000 
MGAM 0.0000 0.0000 0.0000 0.0018 0.1137 -0.1007 0.0000 0.0000 0.0000 
MME 0.0000 0.0000 0.0000 0.0006 0.0355 -0.0343 0.0000 0.0000 0.0000 
MSMB 0.0046 0.3269 -0.2200 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
MUC6 0.0253 1.7958 1.4291 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
NBPF3 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0079 0.2762 -0.1999 
NDUFS1 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0151 0.5286 -0.2492 
NEMF 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0034 0.1197 -0.1053 
NPC2 0.0136 0.9681 -0.0309 0.0198 1.2698 0.3426 0.0000 0.0000 0.0000 
ORM1 0.0014 0.0963 -0.0870 0.0017 0.1080 -0.0963 0.0000 0.0000 0.0000 
OXCT2 0.0000 0.0000 0.0000 0.0013 0.0819 -0.0752 0.0000 0.0000 0.0000 
PAEP 0.0000 0.0000 0.0000 0.0055 0.3490 -0.2272 0.1068 3.7381 10.2350 
PATE1 0.0021 0.1491 -0.1269 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
PGAM2 0.0000 0.0000 0.0000 0.0008 0.0499 -0.0474 0.0000 0.0000 0.0000 
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Protein Human Avg n n(n-1) Chimp Avg n n(n-1) Gorilla Avg n n(n-1) 
PGC 0.0026 0.1871 -0.1521 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
PGK2 0.0000 0.0000 0.0000 0.0015 0.0938 -0.0850 0.0000 0.0000 0.0000 
PIP 0.1180 8.3794 61.8348 0.0000 0.0000 0.0000 0.0140 0.4883 -0.2499 
PKM 0.0000 0.0000 0.0000 0.0049 0.3166 -0.2164 0.0000 0.0000 0.0000 
PLA1A 0.0000 0.0000 0.0000 0.0015 0.0933 -0.0846 0.0000 0.0000 0.0000 
PLS3 0.0000 0.0000 0.0000 0.0012 0.0782 -0.0721 0.0000 0.0000 0.0000 
PPIB 0.0000 0.0000 0.0000 0.0047 0.3010 -0.2104 0.0090 0.3146 -0.2156 
PRDX6 0.0042 0.3003 -0.2101 0.0039 0.2511 -0.1881 0.0000 0.0000 0.0000 
PSAP 0.0152 1.0814 0.0881 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
PSCA 0.0000 0.0000 0.0000 0.0066 0.4217 -0.2439 0.0000 0.0000 0.0000 
QSOX1 0.0018 0.1256 -0.1098 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
RLTPR 0.0000 0.0000 0.0000 0.0008 0.0499 -0.0474 0.0000 0.0000 0.0000 
RNASET2 0.0000 0.0000 0.0000 0.0084 0.5405 -0.2484 0.0000 0.0000 0.0000 
S100A8 0.0033 0.2310 -0.1776 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SEMG1 0.1388 9.8521 87.2112 0.4362 27.9169 751.4343 0.0325 1.1368 0.1556 
SEMG2 0.2029 14.4024 193.025 0.0147 0.9383 -0.0579 0.1058 3.7028 10.0082 
SERPINA1 0.0105 0.7432 -0.1908 0.0188 1.2016 0.2422 0.0250 0.8735 -0.1105 
SERPINA3 0.0008 0.0574 -0.0541 0.0184 1.1778 0.2095 0.0000 0.0000 0.0000 
SERPINA5 0.0191 1.3544 0.4799 0.0347 2.2192 2.7056 0.0000 0.0000 0.0000 
SERPINF2 0.0019 0.1345 -0.1164 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SLC9B2 0.0013 0.0900 -0.0819 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SMG1 0.0008 0.0572 -0.0539 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SOD2 0.0000 0.0000 0.0000 0.0007 0.0430 -0.0411 0.0000 0.0000 0.0000 
SOD3 0.0007 0.0532 -0.0503 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SORD 0.0019 0.1358 -0.1174 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
SRCAP 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0052 0.1836 -0.1499 
TF 0.0164 1.1614 0.1874 0.0095 0.6064 -0.2387 0.0000 0.0000 0.0000 
TGM4 0.0036 0.2582 -0.1915 0.0188 1.2050 0.2470 0.0000 0.0000 0.0000 
TIMP1 0.0056 0.3964 -0.2393 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
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Protein Human Avg n n(n-1) Chimp Avg n n(n-1) Gorilla Avg n n(n-1) 
TKFC 0.0000 0.0000 0.0000 0.0006 0.0369 -0.0356 0.0000 0.0000 0.0000 
TMPRSS2 0.0025 0.1753 -0.1446 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
TRRAP 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0049 0.1709 -0.1417 
TSSC1 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0128 0.4497 -0.2475 
TTLL5 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0111 0.3889 -0.2377 
TTN 0.0020 0.1390 -0.1197 0.0007 0.0439 -0.0419 0.0070 0.2451 -0.1850 
TUBA1A 0.0000 0.0000 0.0000 0.0022 0.1428 -0.1224 0.0000 0.0000 0.0000 
TUBB 0.0000 0.0000 0.0000 0.0011 0.0733 -0.0680 0.0000 0.0000 0.0000 
UBA1 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0073 0.2551 -0.1900 
UBA52 0.0052 0.3680 -0.2326 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
WFDC2 0.0024 0.1674 -0.1394 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
WTIP 0.0008 0.0566 -0.0534 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
YWHAB 0.0019 0.1382 -0.1191 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
ZCCHC11 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0294 1.0290 0.0298 
ZFHX2 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0034 0.1197 -0.1053 
ZNF148 0.0007 0.0492 -0.0467 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 
 
 
 
 
 n n(n-1)  n n(n-1)  n n(n-1) 
Sum of columns 71 380.85 
 
64 788.12 
 
35 96.17 
        
 Human   Chimp   Gorilla  
Statistics D= 0.08 
 
D= 0.20 
 
D= 0.08 
 1/d= 0.92 
 
1/d= 0.80 
 
1/d= 0.92 
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A.5.1 Script in R for comparing biodiversity index statistics between raw and length 
adjusted data 
setwd("~/Desktop")	
ShannonsDI	<-	read.csv("Shannon_csv.csv")	
SimpsonDI	<-	read.csv("Simpson_csv.csv")	
ShannonsDI	
##						Species	Index		Raw	Length	
##	1					Human						H	3.04			2.92	
##	2					Human					EH	0.71			0.69	
##	3	Chimpanzee					H	2.57			2.93	
##	4	Chimpanzee				EH	0.62			0.71	
##	5				Gorilla					H	2.78			2.43	
##	6				Gorilla				EH	0.78			0.68	
SimpsonDI	
##						Species	Index		Raw	Length	
##	1					Human				1/D	0.92			0.90	
##	2	Chimpanzee			1/D	0.80			0.90	
##	3				Gorilla			1/D	0.92			0.87	
Shannon_tTEST	<-	t.test(ShannonsDI$Raw,	ShannonsDI$Length,	paired=TRUE)	
Simpson_tTEST	<-	t.test(SimpsonDI$Raw,	SimpsonDI$Length,	paired=TRUE)	
Shannon_tTEST	
##		
##		Paired	t-test	
##		
##	data:		ShannonsDI$Raw	and	ShannonsDI$Length	
##	t	=	0.24078,	df	=	5,	p-value	=	0.8193	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-0.2257760		0.2724426	
##	sample	estimates:	
##	mean	of	the	differences		
##														0.02333333	
Simpson_tTEST	
##		Paired	t-test	
##		
##	data:		SimpsonDI$Raw	and	SimpsonDI$Length	
##	t	=	-0.21822,	df	=	2,	p-value	=	0.8475	
##	alternative	hypothesis:	true	difference	in	means	is	not	equal	to	0	
##	95	percent	confidence	interval:	
##		-0.2071723		0.1871723	
##	sample	estimates:	
##	mean	of	the	differences		
##																			-0.01	
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A.6 Complete tables of LC/MS-MS high confidence identified proteins 
Table A.3: All proteins identified with high confidence in each human individual 
Protein Method Hu#1 Hu#2 Hu#3 Human Avg ± SEM 
ACPP 
Length 5.87% 2.43% 3.30% 3.86% ± 1.03% 
Raw 5.77% 2.57% 4.01% 4.12% ± 0.92% 
ACTA2 
Length 0.64% 0.47% 0.53% 0.54% ± 0.05% 
Raw 0.62% 0.49% 0.64% 0.58% ± 0.05% 
ALB 
Length 4.67% 2.69% 2.75% 3.37% ± 0.65% 
Raw 7.23% 4.50% 5.26% 5.66% ± 0.81% 
ANPEP 
Length 0.40% 0.03% 0.33% 0.25% ± 0.11% 
Raw 1.06% 0.08% 1.03% 0.72% ± 0.32% 
APOB 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.12% 0.09% 0.00% 0.07% ± 0.04% 
ARHGAP31 
Length 0.03% 0.02% 0.00% 0.02% ± 0.01% 
Raw 0.12% 0.09% 0.00% 0.07% ± 0.04% 
AZGP1 
Length 3.72% 1.77% 3.07% 2.85% ± 0.57% 
Raw 2.89% 1.48% 2.94% 2.43% ± 0.48% 
B2M 
Length 1.62% 0.49% 0.33% 0.82% ± 0.40% 
Raw 0.45% 0.15% 0.12% 0.24% ± 0.11% 
BIRC6 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.00% 0.00% 0.24% 0.08% ± 0.08% 
CAP1 
Length 0.30% 0.00% 0.14% 0.15% ± 0.09% 
Raw 0.33% 0.00% 0.24% 0.19% ± 0.10% 
CKB 
Length 0.51% 0.15% 0.00% 0.22% ± 0.15% 
Raw 0.54% 0.15% 0.00% 0.23% ± 0.16% 
CLIP2 
Length 0.00% 0.00% 0.08% 0.03% ± 0.03% 
Raw 0.00% 0.00% 0.24% 0.08% ± 0.08% 
CLU 
Length 1.72% 1.43% 2.39% 1.85% ± 0.29% 
Raw 1.91% 1.77% 3.41% 2.36% ± 0.53% 
CPE 
Length 0.71% 0.06% 0.33% 0.37% ± 0.19% 
Raw 0.78% 0.09% 0.48% 0.45% ± 0.20% 
CRISP1 
Length 1.16% 1.06% 1.92% 1.38% ± 0.27% 
Raw 0.67% 0.73% 1.49% 0.96% ± 0.26% 
CST2 
Length 0.00% 0.00% 0.28% 0.09% ± 0.09% 
Raw 0.00% 0.15% 0.12% 0.09% ± 0.05% 
CST3 
Length 0.00% 0.60% 1.09% 0.56% ± 0.32% 
Raw 0.00% 0.09% 0.48% 0.19% ± 0.15% 
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Protein Method Hu#1 Hu#2 Hu#3 Human Avg ± SEM 
CST4 
Length 0.34% 1.87% 1.98% 1.40% ± 0.53% 
Raw 0.10% 0.72% 0.89% 0.57% ± 0.24% 
CTSD 
Length 0.23% 0.64% 0.00% 0.29% ± 0.19% 
Raw 0.24% 0.73% 0.00% 0.32% ± 0.21% 
DEFA1 
Length 1.54% 0.62% 2.12% 1.43% ± 0.44% 
Raw 0.38% 0.15% 0.62% 0.38% ± 0.13% 
DHX57 
Length 0.00% 0.04% 0.00% 0.01% ± 0.01% 
Raw 0.00% 0.16% 0.00% 0.05% ± 0.05% 
DUT 
Length 0.00% 0.12% 0.16% 0.09% ± 0.05% 
Raw 0.00% 0.09% 0.12% 0.07% ± 0.04% 
ECM1 
Length 0.54% 0.33% 0.52% 0.46% ± 0.07% 
Raw 0.67% 0.49% 0.85% 0.67% ± 0.11% 
FN1 
Length 0.69% 0.13% 0.35% 0.39% ± 0.16% 
Raw 4.18% 0.91% 2.62% 2.57% ± 0.94% 
FOLH1 
Length 0.26% 0.00% 0.00% 0.09% ± 0.09% 
Raw 0.46% 0.00% 0.00% 0.15% ± 0.15% 
GDF15 
Length 1.25% 0.00% 0.00% 0.42% ± 0.42% 
Raw 0.98% 0.00% 0.00% 0.33% ± 0.33% 
GOLGB1 
Length 0.03% 0.00% 0.00% 0.01% ± 0.01% 
Raw 0.24% 0.00% 0.00% 0.08% ± 0.08% 
HEXB 
Length 0.43% 0.11% 0.14% 0.23% ± 0.10% 
Raw 0.57% 0.18% 0.24% 0.33% ± 0.12% 
HSPA1L 
Length 0.15% 0.05% 0.19% 0.13% ± 0.04% 
Raw 0.22% 0.08% 0.38% 0.23% ± 0.09% 
HSPA5 
Length 0.15% 0.13% 0.06% 0.11% ± 0.03% 
Raw 0.22% 0.23% 0.14% 0.20% ± 0.03% 
IDH1 
Length 0.23% 0.07% 0.19% 0.17% ± 0.05% 
Raw 0.22% 0.08% 0.24% 0.18% ± 0.05% 
IGHG1 
Length 1.02% 0.18% 0.36% 0.52% ± 0.26% 
Raw 0.87% 0.15% 0.40% 0.47% ± 0.21% 
KLK3 
Length 3.32% 2.13% 3.05% 2.83% ± 0.36% 
Raw 2.24% 1.54% 2.50% 2.09% ± 0.29% 
KRT1 
Length 0.45% 0.32% 0.19% 0.32% ± 0.08% 
Raw 0.69% 0.55% 0.38% 0.54% ± 0.09% 
KRT10 
Length 0.74% 0.00% 0.14% 0.29% ± 0.23% 
Raw 1.06% 0.00% 0.26% 0.44% ± 0.32% 
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Protein Method Hu#1 Hu#2 Hu#3 Human Avg ± SEM 
KRT2 
Length 1.13% 0.09% 0.19% 0.47% ± 0.33% 
Raw 1.83% 0.15% 0.36% 0.78% ± 0.53% 
LAMP2 
Length 0.47% 0.07% 0.39% 0.31% ± 0.12% 
Raw 0.50% 0.09% 0.12% 0.24% ± 0.13% 
LCP1 
Length 0.08% 0.28% 0.06% 0.14% ± 0.07% 
Raw 0.15% 0.53% 0.52% 0.40% ± 0.12% 
LGALS3BP 
Length 1.81% 0.60% 1.16% 1.19% ± 0.35% 
Raw 2.74% 0.96% 2.13% 1.94% ± 0.52% 
LRPPRC 
Length 0.00% 0.04% 0.00% 0.01% ± 0.01% 
Raw 0.00% 0.00% 0.00% 0.00% ± 0.00% 
LTF 
Length 3.26% 2.51% 4.82% 3.53% ± 0.68% 
Raw 6.04% 4.97% 10.82% 7.27% ± 1.80% 
MSMB 
Length 3.80% 1.03% 0.00% 1.61% ± 1.14% 
Raw 1.05% 0.33% 0.00% 0.46% ± 0.31% 
MUC6 
Length 0.51% 0.19% 0.39% 0.37% ± 0.09% 
Raw 3.28% 1.31% 3.00% 2.53% ± 0.62% 
NPC2 
Length 4.47% 1.36% 3.69% 3.17% ± 0.93% 
Raw 1.78% 0.57% 1.75% 1.36% ± 0.40% 
ORM1 
Length 0.72% 0.00% 0.00% 0.24% ± 0.24% 
Raw 0.41% 0.00% 0.00% 0.14% ± 0.14% 
PATE1 
Length 0.00% 0.00% 1.58% 0.53% ± 0.53% 
Raw 0.00% 0.00% 0.63% 0.21% ± 0.21% 
PGC 
Length 0.25% 0.30% 0.10% 0.22% ± 0.06% 
Raw 0.30% 0.35% 0.14% 0.26% ± 0.06% 
PIP 
Length 16.17% 32.46% 36.55% 28.40% ± 6.23% 
Raw 5.72% 13.04% 16.65% 11.80% ± 3.22% 
PRDX6 
Length 1.29% 0.65% 0.18% 0.71% ± 0.32% 
Raw 0.72% 0.41% 0.14% 0.42% ± 0.17% 
PSAP 
Length 1.47% 0.89% 0.84% 1.07% ± 0.20% 
Raw 1.88% 1.30% 1.39% 1.52% ± 0.18% 
QSOX1 
Length 0.06% 0.20% 0.00% 0.09% ± 0.06% 
Raw 0.15% 0.38% 0.00% 0.18% ± 0.11% 
S100A8 
Length 0.52% 0.31% 2.57% 1.13% ± 0.72% 
Raw 0.15% 0.09% 0.73% 0.33% ± 0.21% 
SEMG1 
Length 7.09% 21.47% 4.31% 10.96% ± 5.32% 
Raw 8.11% 27.29% 6.23% 13.88% ± 6.73% 
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SEMG2 
Length 12.83% 15.03% 9.51% 12.46% ± 1.60% 
Raw 19.33% 24.12% 17.41% 20.29% ± 2.00% 
SERPINA1 
Length 0.92% 0.84% 0.95% 0.90% ± 0.03% 
Raw 0.96% 0.94% 1.24% 1.05% ± 0.09% 
SERPINA3 
Length 0.00% 0.00% 0.19% 0.06% ± 0.06% 
Raw 0.00% 0.00% 0.24% 0.08% ± 0.08% 
SERPINA5 
Length 2.61% 1.23% 1.28% 1.70% ± 0.45% 
Raw 2.67% 1.37% 1.68% 1.91% ± 0.39% 
SERPINF2 
Length 0.00% 0.06% 0.32% 0.13% ± 0.10% 
Raw 0.00% 0.09% 0.48% 0.19% ± 0.15% 
SLC9B2 
Length 0.09% 0.00% 0.15% 0.08% ± 0.04% 
Raw 0.10% 0.00% 0.28% 0.13% ± 0.08% 
SMG1 
Length 0.03% 0.00% 0.00% 0.01% ± 0.01% 
Raw 0.24% 0.00% 0.00% 0.08% ± 0.08% 
SOD3 
Length 0.40% 0.00% 0.00% 0.13% ± 0.13% 
Raw 0.22% 0.00% 0.00% 0.07% ± 0.07% 
SORD 
Length 0.27% 0.25% 0.11% 0.21% ± 0.05% 
Raw 0.22% 0.23% 0.12% 0.19% ± 0.04% 
TF 
Length 1.31% 1.01% 0.23% 0.85% ± 0.32% 
Raw 2.38% 1.98% 0.55% 1.64% ± 0.55% 
TGM4 
Length 0.07% 0.26% 0.23% 0.19% ± 0.06% 
Raw 0.10% 0.48% 0.51% 0.36% ± 0.13% 
TIMP1 
Length 1.40% 0.71% 0.77% 0.96% ± 0.22% 
Raw 0.80% 0.40% 0.48% 0.56% ± 0.12% 
TMPRSS2 
Length 0.10% 0.00% 0.40% 0.17% ± 0.12% 
Raw 0.10% 0.00% 0.64% 0.25% ± 0.20% 
TTN 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.47% 0.00% 0.12% 0.20% ± 0.14% 
UBA52 
Length 1.88% 0.00% 2.18% 1.35% ± 0.68% 
Raw 0.68% 0.00% 0.88% 0.52% ± 0.27% 
WFDC2 
Length 1.17% 0.24% 0.64% 0.68% ± 0.27% 
Raw 0.39% 0.08% 0.24% 0.24% ± 0.09% 
WTIP 
Length 0.00% 0.00% 0.19% 0.06% ± 0.06% 
Raw 0.00% 0.00% 0.24% 0.08% ± 0.08% 
YWHAB 
Length 0.98% 0.00% 0.00% 0.33% ± 0.33% 
Raw 0.58% 0.00% 0.00% 0.19% ± 0.19% 
ZNF148 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.21% 0.00% 0.00% 0.07% ± 0.07% 
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Table A.4: All proteins identified with high confidence in each chimpanzee individual 
Protein Method Ch#1 Ch#2 Ch#3 Chimp Average ± SEM 
ACE 
Length 0.15% 0.34% 0.00% 0.16% ± 0.10% 
Raw 0.37% 0.93% 0.00% 0.43% ± 0.27% 
ACO2 
Length 0.00% 0.05% 0.08% 0.04% ± 0.02% 
Raw 0.00% 0.08% 0.12% 0.07% ± 0.04% 
ACOT13 
Length 0.00% 1.16% 0.43% 0.53% ± 0.34% 
Raw 0.00% 0.34% 0.12% 0.15% ± 0.10% 
ACPP 
Length 1.35% 3.05% 4.71% 3.04% ± 0.97% 
Raw 0.96% 2.47% 3.67% 2.37% ± 0.78% 
ACR 
Length 0.15% 0.10% 0.29% 0.18% ± 0.06% 
Raw 0.12% 0.09% 0.25% 0.15% ± 0.05% 
ACRBP 
Length 0.48% 0.75% 0.45% 0.56% ± 0.10% 
Raw 0.47% 0.85% 0.48% 0.60% ± 0.12% 
ACTB 
Length 1.39% 0.76% 0.65% 0.93% ± 0.23% 
Raw 0.96% 0.59% 0.50% 0.68% ± 0.14% 
ALB 
Length 8.14% 7.48% 4.48% 6.70% ± 1.13% 
Raw 9.10% 9.53% 5.46% 8.03% ± 1.29% 
AMY2B 
Length 0.89% 1.11% 1.31% 1.10% ± 0.12% 
Raw 0.84% 1.19% 1.36% 1.13% ± 0.15% 
ANPEP 
Length 0.00% 0.17% 0.00% 0.06% ± 0.06% 
Raw 0.00% 0.35% 0.00% 0.12% ± 0.12% 
AZGP1 
Length 0.44% 1.50% 2.65% 1.53% ± 0.64% 
Raw 0.24% 0.93% 1.59% 0.92% ± 0.39% 
B2M 
Length 0.00% 0.34% 1.02% 0.45% ± 0.30% 
Raw 0.00% 0.09% 0.25% 0.11% ± 0.07% 
B4GALT1 
Length 0.33% 0.00% 0.46% 0.26% ± 0.14% 
Raw 0.24% 0.00% 0.36% 0.20% ± 0.11% 
CLU 
Length 6.55% 2.75% 4.33% 4.54% ± 1.10% 
Raw 6.23% 2.96% 4.51% 4.57% ± 0.94% 
CRISP1 
Length 0.00% 0.49% 0.49% 0.33% ± 0.16% 
Raw 0.00% 0.25% 0.25% 0.17% ± 0.08% 
CRTAC1 
Length 1.18% 1.48% 1.38% 1.35% ± 0.09% 
Raw 1.44% 2.03% 1.82% 1.76% ± 0.17% 
CST3 
Length 1.34% 1.95% 2.08% 1.79% ± 0.23% 
Raw 0.36% 0.60% 0.61% 0.52% ± 0.08% 
DPEP3 
Length 0.67% 0.58% 0.50% 0.58% ± 0.05% 
Raw 0.60% 0.60% 0.49% 0.56% ± 0.04% 
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Protein Method Ch#1 Ch#2 Ch#3 Chimp Average ± SEM 
ECM1 
Length 0.97% 0.75% 1.01% 0.91% ± 0.08% 
Raw 0.96% 0.85% 1.10% 0.97% ± 0.07% 
ENO1 
Length 0.00% 0.28% 0.00% 0.09% ± 0.09% 
Raw 0.00% 0.25% 0.00% 0.08% ± 0.08% 
FAM3D 
Length 0.00% 0.36% 0.00% 0.12% ± 0.12% 
Raw 0.00% 0.17% 0.00% 0.06% ± 0.06% 
FN1 
Length 1.53% 0.77% 1.09% 1.13% ± 0.22% 
Raw 6.70% 3.82% 5.22% 5.25% ± 0.83% 
GPI 
Length 0.12% 0.22% 0.43% 0.26% ± 0.09% 
Raw 0.12% 0.26% 0.49% 0.29% ± 0.11% 
HEXB 
Length 0.00% 0.37% 0.00% 0.12% ± 0.12% 
Raw 0.00% 0.43% 0.00% 0.14% ± 0.14% 
HK1 
Length 0.14% 0.35% 0.07% 0.19% ± 0.09% 
Raw 0.24% 0.68% 0.12% 0.34% ± 0.17% 
HSP90AA1 
Length 0.00% 0.22% 0.00% 0.07% ± 0.07% 
Raw 0.00% 0.34% 0.00% 0.11% ± 0.11% 
HSPA1A 
Length 0.10% 0.13% 0.09% 0.11% ± 0.01% 
Raw 0.12% 0.17% 0.12% 0.14% ± 0.02% 
IGHG1 
Length 2.77% 2.22% 1.65% 2.21% ± 0.32% 
Raw 1.68% 1.54% 1.10% 1.44% ± 0.18% 
IGKC 
Length 6.15% 4.22% 1.72% 4.03% ± 1.28% 
Raw 1.21% 0.94% 0.36% 0.83% ± 0.25% 
KRT1 
Length 0.10% 0.76% 0.28% 0.38% ± 0.20% 
Raw 0.12% 1.03% 0.36% 0.50% ± 0.27% 
KRT10 
Length 0.00% 0.28% 0.00% 0.09% ± 0.09% 
Raw 0.00% 0.35% 0.00% 0.12% ± 0.12% 
KRT2 
Length 0.00% 0.25% 0.00% 0.08% ± 0.08% 
Raw 0.00% 0.34% 0.00% 0.11% ± 0.11% 
LCP1 
Length 0.10% 0.32% 0.10% 0.17% ± 0.07% 
Raw 0.12% 0.42% 0.12% 0.22% ± 0.10% 
LDHC 
Length 0.00% 1.71% 0.00% 0.57% ± 0.57% 
Raw 0.00% 1.18% 0.00% 0.39% ± 0.39% 
LTF 
Length 6.43% 1.09% 1.37% 2.96% ± 1.74% 
Raw 8.40% 1.62% 1.95% 3.99% ± 2.21% 
MDH2 
Length 0.00% 1.44% 0.00% 0.48% ± 0.48% 
Raw 0.00% 1.01% 0.00% 0.34% ± 0.34% 
MGAM 
Length 0.11% 0.04% 0.00% 0.05% ± 0.03% 
Raw 0.36% 0.18% 0.00% 0.18% ± 0.10% 
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Protein Method Ch#1 Ch#2 Ch#3 Chimp Average ± SEM 
MME 
Length 0.00% 0.11% 0.00% 0.04% ± 0.04% 
Raw 0.00% 0.17% 0.00% 0.06% ± 0.06% 
NPC2 
Length 6.05% 8.08% 5.62% 6.58% ± 0.76% 
Raw 1.69% 2.55% 1.71% 1.98% ± 0.28% 
ORM1 
Length 0.00% 1.21% 0.00% 0.40% ± 0.40% 
Raw 0.00% 0.51% 0.00% 0.17% ± 0.17% 
OXCT2 
Length 0.00% 0.24% 0.12% 0.12% ± 0.07% 
Raw 0.00% 0.26% 0.12% 0.13% ± 0.07% 
PAEP 
Length 0.00% 1.81% 2.70% 1.50% ± 0.79% 
Raw 0.00% 0.68% 0.96% 0.55% ± 0.28% 
PATE1 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.00% 0.00% 0.23% 0.08% ± 0.08% 
PGAM2 
Length 0.00% 0.00% 0.48% 0.16% ± 0.16% 
Raw 0.00% 0.00% 0.00% 0.00% ± 0.00% 
PGK2 
Length 0.47% 0.10% 0.00% 0.19% ± 0.14% 
Raw 0.36% 0.08% 0.00% 0.15% ± 0.11% 
PIP 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.00% 0.00% 0.00% 0.00% ± 0.00% 
PKM 
Length 0.74% 0.69% 0.00% 0.48% ± 0.24% 
Raw 0.72% 0.77% 0.00% 0.49% ± 0.25% 
PLA1A 
Length 0.43% 0.09% 0.00% 0.17% ± 0.13% 
Raw 0.36% 0.08% 0.00% 0.15% ± 0.11% 
PLS3 
Length 0.10% 0.19% 0.00% 0.10% ± 0.06% 
Raw 0.12% 0.25% 0.00% 0.12% ± 0.07% 
PPIB 
Length 0.30% 0.94% 1.97% 1.07% ± 0.48% 
Raw 0.12% 0.43% 0.86% 0.47% ± 0.21% 
PRDX6 
Length 1.46% 0.73% 0.54% 0.91% ± 0.28% 
Raw 0.60% 0.34% 0.24% 0.39% ± 0.11% 
PSCA 
Length 1.59% 2.97% 3.45% 2.67% ± 0.56% 
Raw 0.36% 0.76% 0.86% 0.66% ± 0.15% 
RLTPR 
Length 0.00% 0.00% 0.08% 0.03% ± 0.03% 
Raw 0.00% 0.00% 0.23% 0.08% ± 0.08% 
RNASET2 
Length 1.78% 1.59% 1.66% 1.68% ± 0.06% 
Raw 0.83% 0.85% 0.85% 0.84% ± 0.01% 
SEMG1 
Length 31.21% 23.60% 31.01% 28.61% ± 2.50% 
Raw 44.29% 38.65% 47.92% 43.62% ± 2.70% 
SEMG2 
Length 3.05% 0.90% 1.64% 1.86% ± 0.63% 
Raw 2.28% 0.77% 1.35% 1.47% ± 0.44% 
 198 
Protein Method Ch#1 Ch#2 Ch#3 Chimp Average ± SEM 
SERPINA1 
Length 1.25% 2.43% 3.05% 2.24% ± 0.53% 
Raw 0.96% 2.12% 2.55% 1.88% ± 0.47% 
SERPINA3 
Length 1.08% 2.69% 2.72% 2.16% ± 0.54% 
Raw 0.84% 2.38% 2.31% 1.84% ± 0.50% 
SERPINA5 
Length 3.05% 4.01% 5.83% 4.29% ± 0.81% 
Raw 2.27% 3.39% 4.74% 3.47% ± 0.71% 
SOD2 
Length 0.00% 0.18% 0.27% 0.15% ± 0.08% 
Raw 0.00% 0.08% 0.12% 0.07% ± 0.03% 
TF 
Length 1.40% 0.64% 0.09% 0.71% ± 0.38% 
Raw 1.79% 0.93% 0.12% 0.95% ± 0.48% 
TGM4 
Length 0.38% 2.44% 1.24% 1.35% ± 0.60% 
Raw 0.47% 3.47% 1.70% 1.88% ± 0.87% 
TKFC 
Length 0.00% 0.14% 0.00% 0.05% ± 0.05% 
Raw 0.00% 0.17% 0.00% 0.06% ± 0.06% 
TTN 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.00% 0.09% 0.12% 0.07% ± 0.04% 
TUBA1A 
Length 0.00% 0.45% 0.27% 0.24% ± 0.13% 
Raw 0.00% 0.42% 0.25% 0.22% ± 0.12% 
TUBB 
Length 0.00% 0.37% 0.00% 0.12% ± 0.12% 
Raw 0.00% 0.34% 0.00% 0.11% ± 0.11% 
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Table A.5: All proteins identified with high confidence in each gorilla individual 
Protein Method Go#1 Go#2 Go#3 Gorilla Average ± SEM 
ALB 
Length 40.24% 29.22% 4.67% 24.71% ± 10.51% 
Raw 41.27% 29.52% 6.95% 25.91% ± 10.07% 
APOB 
Length 0.52% 0.47% 0.04% 0.34% ± 0.15% 
Raw 4.29% 3.23% 0.63% 2.71% ± 1.09% 
ARHGAP31 
Length 0.00% 0.00% 0.00% 0.00% ± 0.00% 
Raw 0.00% 0.00% 0.00% 0.00% ± 0.00% 
ARNT 
Length 3.01% 1.80% 0.00% 1.60% ± 0.87% 
Raw 2.86% 2.59% 0.00% 1.82% ± 0.91% 
ASAP2 
Length 0.79% 0.00% 0.20% 0.33% ± 0.24% 
Raw 1.11% 0.00% 0.63% 0.58% ± 0.32% 
BCL3 
Length 1.74% 3.14% 0.00% 1.63% ± 0.91% 
Raw 1.11% 2.15% 0.00% 1.09% ± 0.62% 
CCDC88C 
Length 1.56% 4.21% 0.10% 1.96% ± 1.20% 
Raw 4.13% 13.78% 0.51% 6.14% ± 3.96% 
CEP162 
Length 0.56% 1.01% 0.00% 0.53% ± 0.29% 
Raw 1.11% 3.03% 0.00% 1.38% ± 0.89% 
CFAP69 
Length 0.00% 0.76% 0.22% 0.32% ± 0.23% 
Raw 0.00% 1.52% 0.51% 0.68% ± 0.44% 
CLEC11A 
Length 0.00% 0.00% 1.89% 0.63% ± 0.63% 
Raw 0.00% 0.00% 1.77% 0.59% ± 0.59% 
CLU 
Length 10.56% 7.93% 6.33% 8.27% ± 1.23% 
Raw 7.46% 6.26% 7.56% 7.09% ± 0.42% 
CPSF1 
Length 1.10% 0.00% 0.00% 0.37% ± 0.37% 
Raw 2.22% 0.00% 0.00% 0.74% ± 0.74% 
CTSB 
Length 0.00% 0.00% 1.20% 0.40% ± 0.40% 
Raw 0.00% 0.00% 1.03% 0.34% ± 0.34% 
DNAH7 
Length 0.00% 0.00% 0.10% 0.03% ± 0.03% 
Raw 0.00% 0.00% 1.26% 0.42% ± 0.42% 
FAM184B 
Length 0.75% 1.34% 0.38% 0.82% ± 0.28% 
Raw 0.95% 1.08% 1.09% 1.04% ± 0.04% 
KRT1 
Length 7.37% 1.11% 0.32% 2.93% ± 2.23% 
Raw 9.21% 1.52% 0.51% 3.74% ± 2.75% 
KRT10 
Length 0.00% 0.00% 0.70% 0.23% ± 0.23% 
Raw 0.00% 0.00% 1.03% 0.34% ± 0.34% 
LRRK1 
Length 0.00% 0.71% 0.00% 0.24% ± 0.24% 
Raw 0.00% 2.15% 0.00% 0.72% ± 0.72% 
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Protein Method Go#1 Go#2 Go#3 Gorilla Average ± SEM 
LTF 
Length 5.57% 4.01% 0.86% 3.48% ± 1.39% 
Raw 6.35% 4.74% 1.65% 4.25% ± 1.38% 
NBPF3 
Length 2.50% 0.00% 0.32% 0.94% ± 0.78% 
Raw 1.90% 0.00% 0.46% 0.79% ± 0.57% 
NDUFS1 
Length 3.26% 0.98% 0.00% 1.41% ± 0.97% 
Raw 3.02% 1.52% 0.00% 1.51% ± 0.87% 
NEMF 
Length 0.00% 0.00% 0.38% 0.13% ± 0.13% 
Raw 0.00% 0.00% 1.03% 0.34% ± 0.34% 
PAEP 
Length 17.57% 27.69% 34.97% 26.74% ± 5.05% 
Raw 5.56% 8.85% 17.64% 10.68% ± 3.61% 
PIP 
Length 0.00% 0.00% 11.13% 3.71% ± 3.71% 
Raw 0.00% 0.00% 4.19% 1.40% ± 1.40% 
PPIB 
Length 0.00% 0.00% 4.70% 1.57% ± 1.57% 
Raw 0.00% 0.00% 2.70% 0.90% ± 0.90% 
SEMG1 
Length 0.00% 0.00% 5.69% 1.90% ± 1.90% 
Raw 0.00% 0.00% 9.74% 3.25% ± 3.25% 
SEMG2 
Length 0.00% 0.00% 22.33% 7.44% ± 7.44% 
Raw 0.00% 0.00% 31.74% 10.58% ± 10.58% 
SERPINA1 
Length 0.00% 6.81% 2.43% 3.08% ± 1.99% 
Raw 0.00% 4.74% 2.75% 2.50% ± 1.37% 
SRCAP 
Length 0.24% 0.00% 0.06% 0.10% ± 0.07% 
Raw 1.11% 0.00% 0.46% 0.52% ± 0.32% 
TRRAP 
Length 0.20% 0.00% 0.05% 0.09% ± 0.06% 
Raw 0.95% 0.00% 0.51% 0.49% ± 0.28% 
TSSC1 
Length 0.00% 5.52% 0.52% 2.01% ± 1.76% 
Raw 0.00% 3.23% 0.63% 1.28% ± 0.99% 
TTLL5 
Length 1.23% 0.00% 0.00% 0.41% ± 0.41% 
Raw 3.33% 0.00% 0.00% 1.11% ± 1.11% 
TTN 
Length 0.00% 0.02% 0.01% 0.01% ± 0.01% 
Raw 0.00% 1.08% 1.03% 0.70% ± 0.35% 
UBA1 
Length 0.75% 0.67% 0.00% 0.47% ± 0.24% 
Raw 1.11% 1.08% 0.00% 0.73% ± 0.36% 
ZCCHC11 
Length 0.48% 2.60% 0.25% 1.11% ± 0.75% 
Raw 0.95% 6.89% 0.98% 2.94% ± 1.98% 
ZFHX2 
Length 0.00% 0.00% 0.16% 0.05% ± 0.05% 
Raw 0.00% 0.00% 1.03% 0.34% ± 0.34% 
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Table A.6: Raw normalized abundances of all proteins identified in each human individual (in triplicate) arranged by prevalence 
Protein H1.1% 
H1.2
% 
H1.3
% 
Hu#1 % Avg 
± SEM 
H2.1
% 
H2.2
% 
H2.3
% 
Hu#2 % Avg 
± SEM 
H3.1 
% 
H3.2
% 
H3.3
% 
Hu#3 % Avg ± 
SEM 
Human % Avg 
± SEM 
SEMG2 22.7 18.1 17.1 19.3 ± 1.72 24.12 25.1 23.2 24.1 ± 0.54 17.4 16.3 18.6 17.4 ± 0.66 20.29 ± 2.00 
SEMG1 6.82 7.25 10.3 8.11 ± 1.09 25.75 27.5 28.6 27.3 ± 0.83 5.39 5.65 7.64 6.23 ± 0.71 13.88 ± 6.73 
PIP 4.55 3.26 9.35 5.72 ± 1.85 12.47 14.0 12.7 13.0 ± 0.48 14.1 17.7 18.2 16.7 ± 1.28 11.80 ± 3.22 
LTF 7.27 6.16 4.67 6.04 ± 0.75 5.69 3.84 5.39 4.97 ± 0.57 12.0 10.6 9.82 10.8 ± 0.65 7.27 ± 1.80 
ALB 7.27 7.25 7.17 7.23 ± 0.03 4.07 4.51 4.92 4.50 ± 0.25 5.39 5.65 4.73 5.26 ± 0.28 5.66 ± 0.81 
ACPP 5.91 5.80 5.61 5.77 ± 0.09 2.44 2.71 2.58 2.57 ± 0.08 4.15 3.89 4.00 4.01 ± 0.08 4.12 ± 0.92 
FN1 4.09 4.71 3.74 4.18 ± 0.28 1.36 0.45 0.94 0.91 ± 0.26 2.49 2.47 2.91 2.62 ± 0.14 2.57 ± 0.94 
MUC6 4.09 3.26 2.49 3.28 ± 0.46 1.63 1.13 1.17 1.31 ± 0.16 2.90 3.18 2.91 3.00 ± 0.09 2.53 ± 0.62 
AZGP1 3.64 2.54 2.49 2.89 ± 0.37 1.90 1.13 1.41 1.48 ± 0.22 4.15 2.12 2.55 2.94 ± 0.62 2.43 ± 0.48 
CLU 0.91 3.26 1.56 1.91 ± 0.70 1.63 1.81 1.87 1.77 ± 0.07 4.15 3.18 2.91 3.41 ± 0.38 2.36 ± 0.53 
KLK3 2.73 1.81 2.18 2.24 ± 0.27 1.63 1.35 1.64 1.54 ± 0.09 2.49 2.47 2.55 2.50 ± 0.02 2.09 ± 0.29 
LGALS3BP 3.18 2.54 2.49 2.74 ± 0.22 0.81 0.90 1.17 0.96 ± 0.11 2.07 2.12 2.18 2.13 ± 0.03 1.94 ± 0.52 
SERPINA5 2.73 2.17 3.12 2.67 ± 0.27 1.36 1.58 1.17 1.37 ± 0.12 2.90 1.41 0.73 1.68 ± 0.64 1.91 ± 0.39 
TF 2.73 2.54 1.87 2.38 ± 0.26 2.71 1.58 1.64 1.98 ± 0.37 1.66 0.00 0.00 0.55 ± 0.55 1.64 ± 0.55 
PSAP 0.45 3.62 1.56 1.88 ± 0.93 1.63 1.58 0.70 1.30 ± 0.30 1.66 1.41 1.09 1.39 ± 0.16 1.52 ± 0.18 
NPC2 2.27 1.81 1.25 1.78 ± 0.30 0.54 0.45 0.70 0.57 ± 0.07 1.66 1.77 1.82 1.75 ± 0.05 1.36 ± 0.40 
SERPINA1 0.91 0.72 1.25 0.96 ± 0.15 0.54 1.35 0.94 0.94 ± 0.23 0.83 1.06 1.82 1.24 ± 0.30 1.05 ± 0.09 
CRISP1 0.00 1.09 0.93 0.67 ± 0.34 0.81 0.68 0.70 0.73 ± 0.04 1.24 2.12 1.09 1.49 ± 0.32 0.96 ± 0.26 
KRT2 1.82 1.81 1.87 1.83 ± 0.02 0.00 0.23 0.23 0.15 ± 0.08 0.00 0.71 0.36 0.36 ± 0.20 0.78 ± 0.53 
ANPEP 1.82 0.72 0.62 1.06 ± 0.38 0.00 0.00 0.23 0.08 ± 0.08 1.66 0.71 0.73 1.03 ± 0.31 0.72 ± 0.32 
ECM1 0.00 1.09 0.93 0.67 ± 0.34 0.54 0.45 0.47 0.49 ± 0.03 0.41 1.41 0.73 0.85 ± 0.29 0.67 ± 0.11 
ACTA2 0.45 1.09 0.31 0.62 ± 0.24 0.54 0.45 0.47 0.49 ± 0.03 0.83 0.35 0.73 0.64 ± 0.14 0.58 ± 0.05 
CST4 0.00 0.00 0.31 0.10 ± 0.10 0.54 0.45 1.17 0.72 ± 0.23 1.24 1.41 0.00 0.89 ± 0.45 0.57 ± 0.24 
TIMP1 1.36 0.72 0.31 0.80 ± 0.31 0.27 0.45 0.47 0.40 ± 0.06 0.00 0.71 0.73 0.48 ± 0.24 0.56 ± 0.12 
KRT1 0.45 0.36 1.25 0.69 ± 0.28 0.27 0.90 0.47 0.55 ± 0.19 0.41 0.35 0.36 0.38 ± 0.02 0.54 ± 0.09 
UBA52 1.36 0.36 0.31 0.68 ± 0.34 0.00 0.00 0.00 0.00 ± 0.00 0.83 0.71 1.09 0.88 ± 0.11 0.52 ± 0.27 
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Protein H1.1% 
H1.2
% 
H1.3
% 
Hu#1 % Avg 
± SEM 
H2.1
% 
H2.2
% 
H2.3
% 
Hu#2 % Avg 
± SEM 
H3.1 
% 
H3.2
% 
H3.3
% 
Hu#3 % Avg ± 
SEM 
Human % Avg 
± SEM 
IGHG1 1.36 0.00 1.25 0.87 ± 0.44 0.00 0.23 0.23 0.15 ± 0.08 0.83 0.00 0.36 0.40 ± 0.24 0.47 ± 0.21 
MSMB 0.45 1.45 1.25 1.05 ± 0.30 0.54 0.45 0.00 0.33 ± 0.17 0.00 0.00 0.00 0.00 ± 0.00 0.46 ± 0.31 
CPE 0.00 1.09 1.25 0.78 ± 0.39 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.71 0.73 0.48 ± 0.24 0.45 ± 0.20 
KRT10 0.91 0.72 1.56 1.06 ± 0.25 0.00 0.00 0.00 0.00 ± 0.00 0.41 0.00 0.36 0.26 ± 0.13 0.44 ± 0.32 
PRDX6 0.45 1.09 0.62 0.72 ± 0.19 0.54 0.45 0.23 0.41 ± 0.09 0.41 0.00 0.00 0.14 ± 0.14 0.42 ± 0.17 
LCP1 0.45 0.00 0.00 0.15 ± 0.15 1.36 0.00 0.23 0.53 ± 0.42 0.83 0.35 0.36 0.52 ± 0.16 0.40 ± 0.12 
DEFA1 0.45 0.36 0.31 0.38 ± 0.04 0.00 0.23 0.23 0.15 ± 0.08 0.41 0.71 0.73 0.62 ± 0.10 0.38 ± 0.13 
TGM4 0.00 0.00 0.31 0.10 ± 0.10 0.27 0.45 0.70 0.48 ± 0.13 0.83 0.71 0.00 0.51 ± 0.26 0.36 ± 0.13 
HEXB 0.00 1.09 0.62 0.57 ± 0.31 0.54 0.00 0.00 0.18 ± 0.18 0.00 0.35 0.36 0.24 ± 0.12 0.33 ± 0.12 
S100A8 0.45 0.00 0.00 0.15 ± 0.15 0.27 0.00 0.00 0.09 ± 0.09 0.41 1.06 0.73 0.73 ± 0.19 0.33 ± 0.21 
GDF15 0.91 1.09 0.93 0.98 ± 0.06 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.33 ± 0.33 
CTSD 0.00 0.72 0.00 0.24 ± 0.24 0.81 0.90 0.47 0.73 ± 0.13 0.00 0.00 0.00 0.00 ± 0.00 0.32 ± 0.21 
PGC 0.91 0.00 0.00 0.30 ± 0.30 0.81 0.00 0.23 0.35 ± 0.24 0.41 0.00 0.00 0.14 ± 0.14 0.26 ± 0.06 
TMPRSS2 0.00 0.00 0.31 0.10 ± 0.10 0.00 0.00 0.00 0.00 ± 0.00 0.83 0.35 0.73 0.64 ± 0.14 0.25 ± 0.20 
WFDC2 0.45 0.72 0.00 0.39 ± 0.21 0.00 0.23 0.00 0.08 ± 0.08 0.00 0.35 0.36 0.24 ± 0.12 0.24 ± 0.09 
B2M 0.00 0.72 0.62 0.45 ± 0.23 0.00 0.23 0.23 0.15 ± 0.08 0.00 0.35 0.00 0.12 ± 0.12 0.24 ± 0.11 
LAMP2 0.45 0.72 0.31 0.50 ± 0.12 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.00 0.36 0.12 ± 0.12 0.24 ± 0.13 
HSPA1L 0.00 0.36 0.31 0.22 ± 0.11 0.00 0.23 0.00 0.08 ± 0.08 0.41 0.35 0.36 0.38 ± 0.02 0.23 ± 0.09 
CKB 0.91 0.72 0.00 0.54 ± 0.28 0.00 0.23 0.23 0.15 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.23 ± 0.16 
PATE1 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.83 1.06 0.00 0.63 ± 0.32 0.21 ± 0.21 
HSPA5 0.00 0.36 0.31 0.22 ± 0.11 0.00 0.23 0.47 0.23 ± 0.14 0.41 0.00 0.00 0.14 ± 0.14 0.20 ± 0.03 
TTN 0.00 1.09 0.31 0.47 ± 0.32 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.36 0.12 ± 0.12 0.20 ± 0.14 
SORD 0.00 0.36 0.31 0.22 ± 0.11 0.00 0.23 0.47 0.23 ± 0.14 0.00 0.35 0.00 0.12 ± 0.12 0.19 ± 0.04 
CAP1 0.00 0.36 0.62 0.33 ± 0.18 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.73 0.24 ± 0.24 0.19 ± 0.10 
CST3 0.00 0.00 0.00 0.00 ± 0.00 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.71 0.73 0.48 ± 0.24 0.19 ± 0.15 
SERPINF2 0.00 0.00 0.00 0.00 ± 0.00 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.71 0.73 0.48 ± 0.24 0.19 ± 0.15 
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Protein H1.1% 
H1.2
% 
H1.3
% 
Hu#1 % Avg 
± SEM 
H2.1
% 
H2.2
% 
H2.3
% 
Hu#2 % Avg 
± SEM 
H3.1 
% 
H3.2
% 
H3.3
% 
Hu#3 % Avg ± 
SEM 
Human % Avg 
± SEM 
YWHAB 0.45 0.36 0.93 0.58 ± 0.18 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.19 ± 0.19 
IDH1 0.00 0.36 0.31 0.22 ± 0.11 0.00 0.00 0.23 0.08 ± 0.08 0.00 0.71 0.00 0.24 ± 0.24 0.18 ± 0.05 
QSOX1 0.45 0.00 0.00 0.15 ± 0.15 0.00 0.90 0.23 0.38 ± 0.27 0.00 0.00 0.00 0.00 ± 0.00 0.18 ± 0.11 
FOLH1 0.45 0.00 0.93 0.46 ± 0.27 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.15 ± 0.15 
ORM1 0.91 0.00 0.31 0.41 ± 0.27 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.14 ± 0.14 
SLC9B2 0.00 0.00 0.31 0.10 ± 0.10 0.00 0.00 0.00 0.00 ± 0.00 0.83 0.00 0.00 0.28 ± 0.28 0.13 ± 0.08 
CST2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.23 0.23 0.15 ± 0.08 0.00 0.35 0.00 0.12 ± 0.12 0.09 ± 0.05 
BIRC6 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.73 0.24 ± 0.24 0.08 ± 0.08 
CLIP2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.71 0.00 0.24 ± 0.24 0.08 ± 0.08 
GOLGB1 0.00 0.72 0.00 0.24 ± 0.24 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.08 ± 0.08 
SERPINA3 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.73 0.24 ± 0.24 0.08 ± 0.08 
SMG1 0.00 0.72 0.00 0.24 ± 0.24 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.08 ± 0.08 
WTIP 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.35 0.36 0.24 ± 0.12 0.08 ± 0.08 
ARHGAP31 0.00 0.36 0.00 0.12 ± 0.12 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.00 0.00 0.00 ± 0.00 0.07 ± 0.04 
DUT 0.00 0.00 0.00 0.00 ± 0.00 0.27 0.00 0.00 0.09 ± 0.09 0.00 0.35 0.00 0.12 ± 0.12 0.07 ± 0.04 
SOD3 0.00 0.36 0.31 0.22 ± 0.11 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.07 ± 0.07 
ZNF148 0.00 0.00 0.62 0.21 ± 0.21 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.07 ± 0.07 
DHX57 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.47 0.16 ± 0.16 0.00 0.00 0.00 0.00 ± 0.00 0.05 ± 0.05 
LRPPRC 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.23 0.23 0.15 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.05 ± 0.05 
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Table A.7: Raw normalized abundances of all proteins identified in each chimpanzee individual (in triplicate) arranged by prevalence 
Protein C1.1% 
C1.2
% 
C1.3
% 
Ch#1 % Avg ± 
SEM 
C2.1
% 
C2.2
% 
C2.3
% 
Ch#2 % Avg 
± SEM 
C3.1 
% 
C3.2
% 
C3.3
% 
Ch#3 % Avg ± 
SEM 
Chimp % Avg 
± SEM 
SEMG1 46.81 43.4 42.7 44.3 ± 1.28 37.2 38.8 39.9 38.7 ± 0.78 51.6 44.8 47.4 47.9 ± 1.98 43.62 ± 2.70 
ALB 7.45 11.0 8.82 9.10 ± 1.04 8.35 10.4 9.85 9.53 ± 0.60 5.96 4.85 5.56 5.46 ± 0.33 8.03 ± 1.29 
FN1 5.32 8.54 6.25 6.70 ± 0.96 4.81 3.46 3.20 3.82 ± 0.50 5.61 4.48 5.56 5.22 ± 0.37 5.25 ± 0.83 
CLU 6.03 6.05 6.62 6.23 ± 0.19 3.54 2.39 2.96 2.96 ± 0.33 3.86 5.60 4.07 4.51 ± 0.55 4.57 ± 0.94 
LTF 8.87 6.76 9.56 8.40 ± 0.84 1.77 1.60 1.48 1.62 ± 0.09 1.75 2.99 1.11 1.95 ± 0.55 3.99 ± 2.21 
SERPINA5 2.13 2.85 1.84 2.27 ± 0.30 3.54 3.19 3.45 3.39 ± 0.11 4.91 5.22 4.07 4.74 ± 0.34 3.47 ± 0.71 
ACPP 0.71 1.07 1.10 0.96 ± 0.13 3.29 2.39 1.72 2.47 ± 0.45 2.46 4.48 4.07 3.67 ± 0.62 2.37 ± 0.78 
NPC2 1.06 1.42 2.57 1.69 ± 0.46 3.29 2.39 1.97 2.55 ± 0.39 1.05 1.87 2.22 1.71 ± 0.35 1.98 ± 0.28 
SERPINA1 0.71 0.71 1.47 0.96 ± 0.25 2.03 2.13 2.22 2.12 ± 0.06 2.81 1.87 2.96 2.55 ± 0.34 1.88 ± 0.47 
TGM4 0.35 1.07 0.00 0.47 ± 0.31 4.05 2.93 3.45 3.47 ± 0.33 1.75 1.49 1.85 1.70 ± 0.11 1.88 ± 0.87 
SERPINA3 1.77 0.00 0.74 0.84 ± 0.51 2.28 2.39 2.46 2.38 ± 0.05 2.46 2.61 1.85 2.31 ± 0.23 1.84 ± 0.50 
CRTAC1 1.77 1.07 1.47 1.44 ± 0.20 1.77 1.86 2.46 2.03 ± 0.22 1.75 1.49 2.22 1.82 ± 0.21 1.76 ± 0.17 
SEMG2 1.06 2.85 2.94 2.28 ± 0.61 0.76 0.80 0.74 0.77 ± 0.02 0.70 1.49 1.85 1.35 ± 0.34 1.47 ± 0.44 
IGHG1 1.77 1.07 2.21 1.68 ± 0.33 1.01 2.13 1.48 1.54 ± 0.32 1.05 1.49 0.74 1.10 ± 0.22 1.44 ± 0.18 
AMY2B 0.71 0.71 1.10 0.84 ± 0.13 0.51 1.33 1.72 1.19 ± 0.36 0.35 2.24 1.48 1.36 ± 0.55 1.13 ± 0.15 
ECM1 1.42 0.36 1.10 0.96 ± 0.32 0.76 1.06 0.74 0.85 ± 0.11 0.70 0.37 2.22 1.10 ± 0.57 0.97 ± 0.07 
TF 1.77 2.14 1.47 1.79 ± 0.19 1.01 0.53 1.23 0.93 ± 0.21 0.00 0.37 0.00 0.12 ± 0.12 0.95 ± 0.48 
AZGP1 0.35 0.36 0.00 0.24 ± 0.12 0.51 1.06 1.23 0.93 ± 0.22 1.05 2.61 1.11 1.59 ± 0.51 0.92 ± 0.39 
RNASET2 1.06 1.07 0.37 0.83 ± 0.23 0.76 1.06 0.74 0.85 ± 0.11 1.05 0.75 0.74 0.85 ± 0.10 0.84 ± 0.01 
IGKC 0.71 1.07 1.84 1.21 ± 0.33 0.25 1.33 1.23 0.94 ± 0.34 0.70 0.00 0.37 0.36 ± 0.20 0.83 ± 0.25 
ACTB 0.35 1.07 1.47 0.96 ± 0.33 0.51 0.53 0.74 0.59 ± 0.07 0.00 1.49 0.00 0.50 ± 0.50 0.68 ± 0.14 
PSCA 0.35 0.36 0.37 0.36 ± 0.00 1.27 0.27 0.74 0.76 ± 0.29 0.35 1.12 1.11 0.86 ± 0.25 0.66 ± 0.15 
ACRBP 1.06 0.36 0.00 0.47 ± 0.31 0.51 0.80 1.23 0.85 ± 0.21 0.70 0.75 0.00 0.48 ± 0.24 0.60 ± 0.12 
DPEP3 0.35 0.71 0.74 0.60 ± 0.12 0.51 0.80 0.49 0.60 ± 0.10 0.35 0.75 0.37 0.49 ± 0.13 0.56 ± 0.04 
PAEP 0.00 0.00 0.00 0.00 ± 0.00 1.01 0.53 0.49 0.68 ± 0.17 1.75 0.75 0.37 0.96 ± 0.41 0.55 ± 0.28 
CST3 0.71 0.00 0.37 0.36 ± 0.20 1.01 0.53 0.25 0.60 ± 0.22 0.70 0.37 0.74 0.61 ± 0.12 0.52 ± 0.08 
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Protein C1.1% 
C1.2
% 
C1.3
% 
Ch#1 % Avg ± 
SEM 
C2.1
% 
C2.2
% 
C2.3
% 
Ch#2 % Avg 
± SEM 
C3.1 
% 
C3.2
% 
C3.3
% 
Ch#3 % Avg ± 
SEM 
Chimp % Avg 
± SEM 
KRT1 0.35 0.00 0.00 0.12 ± 0.12 1.52 1.33 0.25 1.03 ± 0.40 0.70 0.00 0.37 0.36 ± 0.20 0.50 ± 0.27 
PKM 0.71 0.71 0.74 0.72 ± 0.01 0.76 0.80 0.74 0.77 ± 0.02 0.00 0.00 0.00 0.00 ± 0.00 0.49 ± 0.25 
PPIB 0.00 0.00 0.37 0.12 ± 0.12 0.25 0.53 0.49 0.43 ± 0.09 0.35 1.87 0.37 0.86 ± 0.50 0.47 ± 0.21 
ACE 0.00 0.00 1.10 0.37 ± 0.37 1.27 0.80 0.74 0.93 ± 0.17 0.00 0.00 0.00 0.00 ± 0.00 0.43 ± 0.27 
PRDX6 0.71 0.71 0.37 0.60 ± 0.11 0.51 0.27 0.25 0.34 ± 0.08 0.35 0.37 0.00 0.24 ± 0.12 0.39 ± 0.11 
LDHC 0.00 0.00 0.00 0.00 ± 0.00 1.01 1.06 1.48 1.18 ± 0.15 0.00 0.00 0.00 0.00 ± 0.00 0.39 ± 0.39 
HK1 0.71 0.00 0.00 0.24 ± 0.24 1.01 0.53 0.49 0.68 ± 0.17 0.35 0.00 0.00 0.12 ± 0.12 0.34 ± 0.17 
MDH2 0.00 0.00 0.00 0.00 ± 0.00 1.52 0.53 0.99 1.01 ± 0.29 0.00 0.00 0.00 0.00 ± 0.00 0.34 ± 0.34 
GPI 0.00 0.00 0.37 0.12 ± 0.12 0.51 0.27 0.00 0.26 ± 0.15 0.00 0.00 1.48 0.49 ± 0.49 0.29 ± 0.11 
LCP1 0.35 0.00 0.00 0.12 ± 0.12 0.51 0.27 0.49 0.42 ± 0.08 0.00 0.00 0.37 0.12 ± 0.12 0.22 ± 0.10 
TUBA1A 0.00 0.00 0.00 0.00 ± 0.00 0.51 0.27 0.49 0.42 ± 0.08 0.00 0.37 0.37 0.25 ± 0.12 0.22 ± 0.12 
B4GALT1 0.71 0.00 0.00 0.24 ± 0.24 0.00 0.00 0.00 0.00 ± 0.00 0.35 0.00 0.74 0.36 ± 0.21 0.20 ± 0.11 
MGAM 0.35 0.71 0.00 0.36 ± 0.21 0.00 0.53 0.00 0.18 ± 0.18 0.00 0.00 0.00 0.00 ± 0.00 0.18 ± 0.10 
CRISP1 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.27 0.49 0.25 ± 0.14 0.00 0.37 0.37 0.25 ± 0.12 0.17 ± 0.08 
ORM1 0.00 0.00 0.00 0.00 ± 0.00 0.76 0.27 0.49 0.51 ± 0.14 0.00 0.00 0.00 0.00 ± 0.00 0.17 ± 0.17 
ACR 0.00 0.36 0.00 0.12 ± 0.12 0.00 0.27 0.00 0.09 ± 0.09 0.00 0.00 0.74 0.25 ± 0.25 0.15 ± 0.05 
ACOT13 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.53 0.49 0.34 ± 0.17 0.00 0.00 0.37 0.12 ± 0.12 0.15 ± 0.10 
PGK2 0.35 0.71 0.00 0.36 ± 0.21 0.25 0.00 0.00 0.08 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.15 ± 0.11 
PLA1A 0.71 0.36 0.00 0.36 ± 0.20 0.00 0.00 0.25 0.08 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.15 ± 0.11 
HSPA1A 0.00 0.36 0.00 0.12 ± 0.12 0.25 0.27 0.00 0.17 ± 0.09 0.35 0.00 0.00 0.12 ± 0.12 0.14 ± 0.02 
HEXB 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.53 0.49 0.43 ± 0.09 0.00 0.00 0.00 0.00 ± 0.00 0.14 ± 0.14 
OXCT2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.53 0.25 0.26 ± 0.15 0.00 0.37 0.00 0.12 ± 0.12 0.13 ± 0.07 
PLS3 0.35 0.00 0.00 0.12 ± 0.12 0.25 0.00 0.49 0.25 ± 0.14 0.00 0.00 0.00 0.00 ± 0.00 0.12 ± 0.07 
ANPEP 0.00 0.00 0.00 0.00 ± 0.00 0.51 0.53 0.00 0.35 ± 0.17 0.00 0.00 0.00 0.00 ± 0.00 0.12 ± 0.12 
KRT10 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.80 0.25 0.35 ± 0.24 0.00 0.00 0.00 0.00 ± 0.00 0.12 ± 0.12 
B2M 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.27 0.00 0.09 ± 0.09 0.00 0.00 0.74 0.25 ± 0.25 0.11 ± 0.07 
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Protein C1.1% 
C1.2
% 
C1.3
% 
Ch#1 % Avg ± 
SEM 
C2.1
% 
C2.2
% 
C2.3
% 
Ch#2 % Avg 
± SEM 
C3.1 
% 
C3.2
% 
C3.3
% 
Ch#3 % Avg ± 
SEM 
Chimp % Avg 
± SEM 
HSP90AA1 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.27 0.49 0.34 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.11 ± 0.11 
KRT2 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.27 0.49 0.34 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.11 ± 0.11 
TUBB 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.53 0.25 0.34 ± 0.09 0.00 0.00 0.00 0.00 ± 0.00 0.11 ± 0.11 
PGAM2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.70 0.00 0.00 0.23 ± 0.23 0.08 ± 0.08 
RLTPR 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.70 0.00 0.00 0.23 ± 0.23 0.08 ± 0.08 
ENO1 0.00 0.00 0.00 0.00 ± 0.00 0.51 0.00 0.25 0.25 ± 0.15 0.00 0.00 0.00 0.00 ± 0.00 0.08 ± 0.08 
TTN 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.27 0.00 0.09 ± 0.09 0.35 0.00 0.00 0.12 ± 0.12 0.07 ± 0.04 
ACO2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.25 0.08 ± 0.08 0.00 0.37 0.00 0.12 ± 0.12 0.07 ± 0.04 
SOD2 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.00 0.00 0.08 ± 0.08 0.35 0.00 0.00 0.12 ± 0.12 0.07 ± 0.03 
FAM3D 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.27 0.25 0.17 ± 0.09 0.00 0.00 0.00 0.00 ± 0.00 0.06 ± 0.06 
MME 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.00 0.25 0.17 ± 0.08 0.00 0.00 0.00 0.00 ± 0.00 0.06 ± 0.06 
TKFC 0.00 0.00 0.00 0.00 ± 0.00 0.25 0.27 0.00 0.17 ± 0.09 0.00 0.00 0.00 0.00 ± 0.00 0.06 ± 0.06 
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Table A.8: Raw normalized abundances of all proteins identified in each gorilla individual (in triplicate) arranged by prevalence 
Protein G1.1% 
G1.2
% 
G1.3
% 
Go#1 % Avg ± 
SEM 
G2.1
% 
G2.2
% 
G2.3
% 
Go#2 % Avg 
± SEM 
G3.1 
% 
G3.2
% 
G3.3
% 
Go#3 % Avg ± 
SEM 
Gorilla % Avg 
± SEM 
ALB 50.00 37.1 36.7 41.4 ± 4.37 27.3 38.7 22.6 29.5 ± 4.79 9.72 1.89 9.23 6.95 ± 2.53 25.9 ± 10.1 
PAEP 7.14 2.86 6.67 5.56 ± 1.36 13.6 6.45 6.45 8.85 ± 2.39 9.72 34.0 9.23 17.6 ± 8.16 10.7 ± 3.61 
SEMG2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 52.8 13.2 29.2 31.7 ± 11.5 10.6 ± 10.6 
CLU 7.14 8.57 6.67 7.46 ± 0.57 9.09 3.23 6.45 6.26 ± 1.70 5.56 9.43 7.69 7.56 ± 1.12 7.09 ± 0.42 
CCDC88C 0.00 5.71 6.67 4.13 ± 2.08 9.09 16.1 16.1 13.8 ± 2.35 0.00 0.00 1.54 0.51 ± 0.51 6.14 ± 3.96 
LTF 7.14 8.57 3.33 6.35 ± 1.56 4.55 3.23 6.45 4.74 ± 0.94 0.00 1.89 3.08 1.65 ± 0.90 4.25 ± 1.38 
KRT1 14.29 0.00 13.3 9.21 ± 4.61 4.55 0.00 0.00 1.52 ± 1.52 0.00 0.00 1.54 0.51 ± 0.51 3.74 ± 2.75 
SEMG1 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 8.33 13.2 7.69 9.74 ± 1.74 3.25 ± 3.25 
ZCCHC11 0.00 2.86 0.00 0.95 ± 0.95 4.55 6.45 9.68 6.89 ± 1.50 1.39 0.00 1.54 0.98 ± 0.49 2.94 ± 1.98 
APOB 7.14 5.71 0.00 4.29 ± 2.18 0.00 3.23 6.45 3.23 ± 1.86 0.00 1.89 0.00 0.63 ± 0.63 2.71 ± 1.09 
SERPINA1 0.00 0.00 0.00 0.00 ± 0.00 4.55 6.45 3.23 4.74 ± 0.94 1.39 3.77 3.08 2.75 ± 0.71 2.50 ± 1.37 
ARNT 0.00 8.57 0.00 2.86 ± 2.86 4.55 0.00 3.23 2.59 ± 1.35 0.00 0.00 0.00 0.00 ± 0.00 1.82 ± 0.91 
NDUFS1 0.00 5.71 3.33 3.02 ± 1.66 4.55 0.00 0.00 1.52 ± 1.52 0.00 0.00 0.00 0.00 ± 0.00 1.51 ± 0.87 
PIP 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 4.17 3.77 4.62 4.19 ± 0.24 1.40 ± 1.40 
CEP162 0.00 0.00 3.33 1.11 ± 1.11 9.09 0.00 0.00 3.03 ± 3.03 0.00 0.00 0.00 0.00 ± 0.00 1.38 ± 0.89 
TSSC1 0.00 0.00 0.00 0.00 ± 0.00 0.00 3.23 6.45 3.23 ± 1.86 0.00 1.89 0.00 0.63 ± 0.63 1.28 ± 0.99 
TTLL5 7.14 2.86 0.00 3.33 ± 2.08 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 1.11 ± 1.11 
BCL3 0.00 0.00 3.33 1.11 ± 1.11 0.00 6.45 0.00 2.15 ± 2.15 0.00 0.00 0.00 0.00 ± 0.00 1.09 ± 0.62 
FAM184B 0.00 2.86 0.00 0.95 ± 0.95 0.00 3.23 0.00 1.08 ± 1.08 1.39 1.89 0.00 1.09 ± 0.56 1.04 ± 0.04 
PPIB 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 2.78 3.77 1.54 2.70 ± 0.65 0.90 ± 0.90 
NBPF3 0.00 5.71 0.00 1.90 ± 1.90 0.00 0.00 0.00 0.00 ± 0.00 1.39 0.00 0.00 0.46 ± 0.46 0.79 ± 0.57 
CPSF1 0.00 0.00 6.67 2.22 ± 2.22 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.74 ± 0.74 
UBA1 0.00 0.00 3.33 1.11 ± 1.11 0.00 3.23 0.00 1.08 ± 1.08 0.00 0.00 0.00 0.00 ± 0.00 0.73 ± 0.36 
LRRK1 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 6.45 2.15 ± 2.15 0.00 0.00 0.00 0.00 ± 0.00 0.72 ± 0.72 
TTN 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 3.23 1.08 ± 1.08 0.00 0.00 3.08 1.03 ± 1.03 0.70 ± 0.35 
CFAP69 0.00 0.00 0.00 0.00 ± 0.00 4.55 0.00 0.00 1.52 ± 1.52 0.00 0.00 1.54 0.51 ± 0.51 0.68 ± 0.44 
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Protein G1.1% 
G1.2
% 
G1.3
% 
Go#1 % Avg ± 
SEM 
G2.1
% 
G2.2
% 
G2.3
% 
Go#2 % Avg 
± SEM 
G3.1 
% 
G3.2
% 
G3.3
% 
Go#3 % Avg ± 
SEM 
Gorilla % Avg 
± SEM 
CLEC11A 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 3.77 1.54 1.77 ± 1.10 0.59 ± 0.59 
ASAP2 0.00 0.00 3.33 1.11 ± 1.11 0.00 0.00 0.00 0.00 ± 0.00 0.00 1.89 0.00 0.63 ± 0.63 0.58 ± 0.32 
SRCAP 0.00 0.00 3.33 1.11 ± 1.11 0.00 0.00 0.00 0.00 ± 0.00 1.39 0.00 0.00 0.46 ± 0.46 0.52 ± 0.32 
TRRAP 0.00 2.86 0.00 0.95 ± 0.95 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 1.54 0.51 ± 0.51 0.49 ± 0.28 
DNAH7 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 3.77 0.00 1.26 ± 1.26 0.42 ± 0.42 
FAM183B 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 3.23 1.08 ± 1.08 0.00 0.00 0.00 0.00 ± 0.00 0.36 ± 0.36 
CTSB 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 3.08 1.03 ± 1.03 0.34 ± 0.34 
KRT10 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 3.08 1.03 ± 1.03 0.34 ± 0.34 
ZFHX2 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 0.00 0.00 ± 0.00 0.00 0.00 3.08 1.03 ± 1.03 0.34 ± 0.34 
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Table A.9: Summary of significant differences between species 
Proteina  Statistical Testb Human – Chimpc Human – Gorillad Chimp – Gorillae 
ACE 
PLGEM     C > G (R)  
t test       
2x >  0.01       
ACOT13 
PLGEM C > H (L)     
t test       
2x >  0.01       
ACPP 
PLGEM   H > G C > G 
t test       
2x >  0.01   H > G C > G 
ACRBP 
PLGEM C > H    C > G  
t test C > H    C > G  
2x >  0.01       
ACTA2 
PLGEM H > C H > G   
t test H > C H > G   
2x >  0.01       
ACTB 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01       
ALB 
PLGEM   G > H   
t test       
2x >  0.01 C > H  G > H G > C 
ANPEP 
PLGEM   H > G  (R)    
t test       
2x >  0.01       
AMY2B 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01 C > H    C > G 
APOB 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01     G > C  (R)  
ARNT 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
ASAP2 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01       
AZGP1 
PLGEM   H > G C > G 
t test   H > G   
2x >  0.01 H > C  (R)  H > G C > G (L) 
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Proteina  Statistical Testb Human – Chimpc Human – Gorillad Chimp – Gorillae 
B2M 
PLGEM   H > G (L)   
t test       
2x >  0.01       
BCL3 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
CCDC88C 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
CEP162 
PLGEM   G > H G > C 
t test       
2x >  0.01     G > C (R)  
CFAP69 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01       
CLEC11A 
PLGEM   G > H G > C 
t test       
2x >  0.01       
CLU 
PLGEM   G > H  (R)    
t test   G > H   
2x >  0.01   G > H   
CPSF1 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01       
CRISP1 
PLGEM H > C  (R)  H > G   
t test   H > G   
2x >  0.01   H > G   
CRTAC1 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01 C > H    C > G  (R)  
CST3 
PLGEM   H > G (L) C > G 
t test     C > G 
2x >  0.01 C > H  (L)   C > G (L) 
CST4 
PLGEM H > C H > G (L)   
t test       
2x >  0.01 H > C H > G   
DEFA1 
PLGEM H > C (L) H > G (L)   
t test       
2x >  0.01 H > C H > G   
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DNAH7 
PLGEM     G > C  (R)  
t test       
2x >  0.01       
DPEP3 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01       
ECM1 
PLGEM   H > G  (R)  C > G 
t test H > C (L) H > G C > G 
2x >  0.01       
FAM184B 
PLGEM   G > H G > C 
t test     G > C  (R)  
2x >  0.01     G > C  (R)  
FN1 
PLGEM   H > G  (R)  C > G 
t test     C > G 
2x >  0.01 C > H    C > G 
HSPA1A 
PLGEM       
t test C > H    C > G 
2x >  0.01       
HSPA5 
PLGEM       
t test H > C     
2x >  0.01       
IGHG1 
PLGEM   H > G (L) C > G 
t test C > H (L)   C > G 
2x >  0.01 C > H    C > G 
IGKC 
PLGEM C > H    C > G 
t test       
2x >  0.01 C > H (L)   C > G 
KLK3 
PLGEM H > C H > G   
t test H > C H > G   
2x >  0.01 H > C H > G   
KRT1 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01   G > H G > C  
KRT2 
PLGEM   H > G  (R)    
t test       
2x >  0.01       
LDHC 
PLGEM C > H    C > G (L) 
t test       
2x >  0.01       
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LGALS3BP 
PLGEM H > C H > G   
t test       
2x >  0.01 H > C H > G   
LRRK1 
PLGEM G > H  (R)    G > C  (R)  
t test       
2x >  0.01       
MDH2 
PLGEM C > H (L)     
t test       
2x >  0.01       
MSMB 
PLGEM H > C (L) H > G   
t test       
2x >  0.01 H > C H > G   
MUC6 
PLGEM H > C  (R)  H > G  (R)    
t test H > C     
2x >  0.01 H > C  (R)      
NBPF3 
PLGEM   G > H G > C 
t test       
2x >  0.01       
NDUF51 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
NPC2 
PLGEM   H > G C > G 
t test     C > G 
2x >  0.01 C > H (L) H > G C > G 
PAEP 
PLGEM C > H  G > H G > C 
t test   G > H G > C (L) 
2x >  0.01 C > H (L) G > H G > C 
PATE1 
PLGEM H > C H > G (L)   
t test       
2x >  0.01       
PGC 
PLGEM       
t test H > C  (R)      
2x >  0.01       
PIP 
PLGEM H > C H > G G > C 
t test       
2x >  0.01 H > C H > G G > C 
PKM 
PLGEM C > H  (R)    C > G  (R)  
t test       
2x >  0.01       
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PPIB 
PLGEM C > H (L) G > H   
t test       
2x >  0.01 C > H (L) G > H   
PRDX6 
PLGEM   H > G (L) C > G (L) 
t test       
2x >  0.01       
PSAP 
PLGEM H > C H > G   
t test H > C H > G   
2x >  0.01 H > C H > G   
PSCA 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01 C > H (L)   C > G (L) 
RNASET2 
PLGEM C > H    C > G 
t test C > H    C > G 
2x >  0.01 C > H    C > G (L) 
S100A8 
PLGEM H > C (L) H > G (L)   
t test       
2x >  0.01 H > C H > G   
SEMG1 
PLGEM C > H  (R)  H > G  (R)  C > G 
t test C > H  (R)    C > G 
2x >  0.01 C > H  H > G C > G 
SEMG2 
PLGEM H > C H > G  (R)  G > C  (R)  
t test H > C     
2x >  0.01 H > C   G > C 
SERPINA1 
PLGEM       
t test       
2x >  0.01 C > H (L) G > H   
SERPINA3 
PLGEM C > H    C > G 
t test C > H (L)   C > G (L) 
2x >  0.01 C > H    C > G 
SERPINA5 
PLGEM   H > G C > G 
t test     C > G 
2x >  0.01 C > H (L) H > G C > G 
SORD 
PLGEM       
t test H > C     
2x >  0.01       
SRCAP 
PLGEM     G > C  (R)  
t test       
2x >  0.01       
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TF 
PLGEM   H > G C > G 
t test       
2x >  0.01       
TGM4 
PLGEM C > H  (R)    C > G 
t test       
2x >  0.01 C > H    C > G 
TIMP1 
PLGEM H > C H > G (L)   
t test H > C     
2x >  0.01 H > C (L)     
TRRAP 
PLGEM     G > C  (R)  
t test       
2x >  0.01       
TSSC1 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
TTLL5 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01     G > C  (R)  
TTN 
PLGEM     G > C  (R)  
t test       
2x >  0.01       
UBA1 
PLGEM   G > H  (R)  G > C  (R)  
t test       
2x >  0.01       
UBA52 
PLGEM H > C H > G (L)   
t test       
2x >  0.01 H > C (L) H > G   
WFDC2 
PLGEM H > C (L) H > G (L)   
t test       
2x >  0.01       
ZCCHC11 
PLGEM   G > H G > C 
t test       
2x >  0.01   G > H G > C 
a) Each protein listed was significantly higher in one species compared to another using at least one of three 
statistical tests. b) Statistical tests included Power Law Global Error Model with a 1% false discovery rate (PLGEM; 
Appendix A.4), traditional t-test with Benjamini-Hochberg correction with a 10% false discovery rate (t-test) and 
proteins that were all proteins absent in one species, plus those present at greater than two-fold abundance, but only 
including those found with NSAF greater than 0.01 (2x >0.01) c-d) Capital letters represent species (i.e. “H” is 
human) and the “ >” indicates that the species on the right had significantly less (or none) of that protein compared 
to the species on the left. Protein abundance is summarized for each species in Table 2.7. (L) indicates statistical 
significance was only using length-adjusted normalization; likewise (R), indicates statistical significance was only 
using raw-normalization. Without either (L) or (R) the significant difference was found in both normalization data 
sets.  
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A.7 Gene Ontology 
 
Figure A.1: Biological process functions of all identified proteins in human, 
chimpanzee, and gorilla seminal plasma 
Seminal plasma proteins (identified across all three species) are associated with 12 biological processes identified 
through gene ontology (Panther). Metabolic processes (28%) and cellular processes (17%) are the largest categories. 
  
Cellular	component	organization	or	biogenesis		9%	
Cellular	process		24%	
Localization		8%	Reproduction		3%	Biological	regulation	7%	Response	to	stimulus		8%	
Developmental	process	4%	
Multicellular	organismal	process		3%	
Biological	adhesion	1%	
Metabolic	process		28%	
Growth	0%	
Immune	system	process		5%	
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Table A.10: Significant overexpression of GO molecular functions in human seminal plasma 
compared to the human reference genome 
 GO molecular function #  Expected Fold Enrichment +/- P value 
Cysteine-type endopeptidase inhibitor activity 6 .22 27.50 + 3.27E-04 
Endopeptidase inhibitor activity 11 .66 16.62 + 2.42E-07 
Endopeptidase regulator activity 11 .68 16.07 + 3.43E-07 
Peptidase regulator activity 12 .83 14.44 + 1.55E-07 
Enzyme regulator activity 15 3.91 3.84 + 2.16E-02 
Peptidase inhibitor activity 11 .70 15.81 + 4.07E-07 
Enzyme inhibitor activity 12 1.53 7.84 + 1.36E-04 
Protease binding 12 .50 23.99 + 4.54E-10 
Enzyme binding 25 8.19 3.05 + 6.93E-04 
Protein binding 65 43.13 1.51 + 6.79E-04 
Serine-type endopeptidase activity 8 .96 8.34 + 1.80E-02 
Peptidase activity, acting on L-amino 
acid peptides 
13 2.66 4.88 + 7.50E-03 
Peptidase activity 13 2.75 4.73 + 1.06E-02 
Serine-type peptidase activity 9 1.06 8.45 + 4.06E-03 
Serine hydrolase activity 9 1.08 8.31 + 4.68E-03 
Unclassified 1 13.42 < 0.2 - 0.00E00 
GO molecular functions are hyperlinked to their functional description on Panther’s website. The “#” column 
identified how many human proteins (out of 71) were associated with that molecular function. In addition, these 
underlined numbers are hyperlinked to tables identifying which proteins matched that function.  
 
Table A.11: Significant overexpression of GO biological processes in human seminal plasma 
compared to the human reference genome 
GO biological process complete # Expected Fold enrichment +/- P value 
Antibacterial humoral response 5 .14 35.93 + 2.96E-03 
Antimicrobial humoral response 7 .36 19.18 + 8.39E-04 
Response to stimulus 56 30.13 1.86 + 3.20E-05 
Humoral immune response 9 1.16 7.77 + 2.21E-02 
Immune response 28 6.29 4.45 + 4.79E-08 
Immune system process 30 9.60 3.13 + 3.69E-05 
Defense response 23 4.62 4.98 + 7.21E-07 
Response to stress 35 12.54 2.79 + 1.92E-05 
Acute-phase response 5 .15 32.42 + 4.89E-03 
Acute inflammatory response 8 .26 30.38 + 2.78E-06 
Platelet degranulation 15 .48 31.40 + 1.71E-14 
Regulated exocytosis 29 2.58 11.25 + 4.50E-19 
Exocytosis 29 2.89 10.03 + 1.05E-17 
Secretion by cell 29 3.61 8.04 + 4.04E-15 
Secretion 29 4.01 7.24 + 6.55E-14 
Transport 41 16.58 2.47 + 1.18E-05 
Establishment of localization 41 16.99 2.41 + 2.53E-05 
Localization 47 20.68 2.27 + 3.91E-06 
Vesicle-mediated transport 33 6.71 4.92 + 1.40E-11 
Retina homeostasis 8 .27 29.95 + 3.11E-06 
Tissue homeostasis 10 .66 15.11 + 1.26E-05 
Multicellular organismal homeostasis 10 1.08 9.23 + 1.24E-03 
Multicellular organismal process 45 25.19 1.79 + 3.25E-02 
Regulation of biological quality 32 13.37 2.39 + 5.33E-03 
Anatomical structure homeostasis 11 1.10 10.01 + 1.23E-04 
Peptide cross-linking 5 .22 22.53 + 2.86E-02 
Protein metabolic process 39 16.76 2.33 + 2.50E-04 
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GO biological process complete # Expected Fold enrichment +/- P value 
Organonitrogen compound metabolic 
process 
46 20.78 2.21 + 1.88E-05 
Negative regulation of endopeptidase activity 11 .93 11.84 + 2.23E-05 
Negative regulation of peptidase activity 12 .97 12.37 + 2.44E-06 
Negative regulation of hydrolase activity 12 1.58 7.61 + 5.09E-04 
Negative regulation of catalytic 
activity 
14 3.36 4.17 + 4.90E-02 
Negative regulation of molecular function 17 4.41 3.86 + 1.21E-02 
Regulation of molecular 
function 
32 12.71 2.52 + 1.67E-03 
Regulation of catalytic activity 26 9.43 2.76 + 7.24E-03 
Regulation of hydrolase 
activity 
19 5.31 3.58 + 7.80E-03 
Regulation of peptidase activity 17 1.58 10.79 + 2.67E-09 
Regulation of proteolysis 22 3.16 6.96 + 3.24E-09 
Regulation of protein metabolic process 29 10.40 2.79 + 9.57E-04 
Regulation of biological process 63 42.80 1.47 + 1.67E-02 
Negative regulation of proteolysis 12 1.31 9.14 + 6.98E-05 
Regulation of cellular protein 
metabolic process 
27 9.48 2.85 + 2.08E-03 
Negative regulation of protein 
metabolic process 
16 4.21 3.80 + 3.17E-02 
Regulation of endopeptidase activity 15 1.47 10.17 + 1.75E-07 
Neutrophil degranulation 20 1.81 11.03 + 1.02E-11 
Neutrophil mediated immunity 20 1.87 10.72 + 1.75E-11 
Myeloid leukocyte mediated immunity 20 1.94 10.30 + 3.65E-11 
Leukocyte mediated immunity 22 2.77 7.95 + 2.34E-10 
Immune effector process 23 3.86 5.96 + 2.02E-08 
Leukocyte degranulation 20 1.89 10.57 + 2.27E-11 
Neutrophil activation involved in immune 
response 
20 1.82 10.99 + 1.11E-11 
Myeloid cell activation involved in 
immune response 
20 1.93 10.36 + 3.27E-11 
Leukocyte activation involved in immune 
response 
21 2.28 9.20 + 6.09E-11 
Leukocyte activation 22 3.31 6.65 + 8.10E-09 
Cell activation 24 3.86 6.22 + 2.40E-09 
Cell activation involved in 
immune response 
21 2.30 9.14 + 6.91E-11 
Myeloid leukocyte activation 21 2.13 9.86 + 1.57E-11 
Neutrophil activation 20 1.85 10.81 + 1.50E-11 
Granulocyte activation 20 1.86 10.74 + 1.68E-11 
Positive regulation of biological process 40 21.06 1.90 + 4.27E-02 
Unclassified 1 13.46 < 0.2 - 0.00E00 
GO biological processes are hyperlinked to their functional description on Panther’s website. The “#” column 
identified how many human proteins (out of 71) were associated with that biological process. In addition, these 
underlined numbers are hyperlinked to tables identifying which proteins matched that process.  
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Table A.12: Significant overexpression of GO molecular functions in chimpanzee seminal 
plasma compared to the human and chimpanzee reference genomes 
GO molecular function complete # Expected Fold enrichment +/- P value 
Structural constituent of epidermis 3 .05 66.18 + 4.53E-02 
Protease binding 9 .43 20.90 + 1.82E-06 
Enzyme binding 22 7.05 3.12 + 2.37E-03 
Protein binding 51 19.61 2.60 + 1.28E-11 
Binding 61 36.99 1.65 + 9.45E-07 
Serine-type endopeptidase activity 6 .50 12.05 + 3.19E-02 
Peptidase activity, acting on L-
amino acid peptides 
10 1.88 5.31 + 4.93E-02 
Catalytic activity 39 18.29 2.13 + 3.35E-04 
Hydrolase activity 24 7.71 3.11 + 5.53E-04 
Serine-type peptidase activity 7 .57 12.19 + 5.27E-03 
Serine hydrolase activity 7 .59 11.82 + 6.46E-03 
Identical protein binding 16 4.63 3.45 + 2.89E-02 
Metal ion binding 24 9.30 2.58 + 1.64E-02 
Cation binding 25 9.58 2.61 + 7.73E-03 
Ion binding 34 15.73 2.16 + 3.48E-03 
 
GO molecular functions are hyperlinked to their functional description on Panther’s website. The “#” column 
identified how many chimpanzee proteins (out of 64) were associated with that molecular function. In addition, 
these underlined numbers are hyperlinked to tables identifying which proteins matched that function.  
 
Table A.13: Significant overexpression of GO biological processes in chimpanzee seminal 
plasma compared to the human and chimpanzee reference genomes 
 
GO biological process complete # Expected Fold enrichment +/- P value 
Canonical glycolysis 5 .08 61.77 + 2.02E-04 
Glucose catabolic process to pyruvate 5 .08 61.77 + 2.02E-04 
Pyruvate metabolic process 7 .22 32.27 + 2.37E-05 
Organic substance metabolic process 51 30.72 1.66 + 4.85E-03 
Metabolic process 51 32.13 1.59 + 2.55E-02 
Cellular process 66 48.61 1.36 + 4.11E-04 
Glucose catabolic process 5 .09 53.25 + 4.20E-04 
Glucose metabolic process 6 .37 16.40 + 1.72E-02 
Hexose metabolic process 8 .51 15.74 + 4.18E-04 
Monosaccharide metabolic 
process 
8 .64 12.48 + 2.41E-03 
Carbohydrate metabolic 
process 
13 1.52 8.52 + 3.10E-05 
Primary metabolic process 48 29.56 1.62 + 4.86E-02 
Hexose catabolic process 6 .16 37.82 + 1.35E-04 
Monosaccharide catabolic 
process 
6 .19 31.41 + 4.00E-04 
Catabolic process 20 6.28 3.18 + 1.79E-02 
Carbohydrate catabolic 
process 
9 .36 24.82 + 1.12E-06 
Organic substance 
catabolic process 
19 5.33 3.56 + 6.57E-03 
NADH regeneration 5 .08 61.77 + 2.02E-04 
NADH metabolic process 6 .12 51.48 + 2.19E-05 
NAD metabolic process 6 .22 26.86 + 9.98E-04 
Nicotinamide nucleotide metabolic process 7 .36 19.48 + 7.27E-04 
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Pyridine nucleotide metabolic process 7 .36 19.48 + 7.27E-04 
Pyridine-containing compound 
metabolic process 
7 .38 18.48 + 1.04E-03 
Organonitrogen compound metabolic process 41 17.88 2.29 + 3.30E-05 
Oxidoreduction coenzyme metabolic 
process 
7 .41 17.02 + 1.79E-03 
Coenzyme metabolic process 8 .94 8.55 + 3.94E-02 
Organophosphate metabolic process 14 3.20 4.38 + 2.46E-02 
Glycolytic process through glucose-6-
phosphate 
5 .08 59.39 + 2.45E-04 
Glycolytic process through fructose-6-
phosphate 
5 .08 59.39 + 2.45E-04 
Glycolytic process 6 .12 48.77 + 3.01E-05 
ATP generation from ADP 6 .13 47.52 + 3.51E-05 
ADP metabolic process 6 .15 41.18 + 8.16E-05 
Purine ribonucleoside 
monophosphate metabolic 
process 
8 .80 9.96 + 1.28E-02 
Purine nucleoside 
monophosphate metabolic 
process 
8 .81 9.92 + 1.32E-02 
Nucleoside monophosphate 
metabolic process 
8 .89 9.02 + 2.67E-02 
Ribonucleoside 
monophosphate metabolic 
process 
8 .84 9.50 + 1.82E-02 
Purine ribonucleoside 
diphosphate metabolic process 
6 .20 30.38 + 4.86E-04 
Purine nucleoside diphosphate 
metabolic process 
6 .20 30.38 + 4.86E-04 
Nucleoside 
diphosphate 
metabolic process 
6 .27 22.60 + 2.72E-03 
Ribonucleoside diphosphate 
metabolic process 
6 .20 29.41 + 5.87E-04 
Nucleoside diphosphate 
phosphorylation 
6 .18 33.09 + 2.95E-04 
Nucleotide phosphorylation 6 .20 29.89 + 5.35E-04 
Generation of precursor metabolites and 
energy 
9 1.01 8.88 + 6.98E-03 
ATP metabolic process 8 .66 12.05 + 3.12E-03 
Purine ribonucleoside 
triphosphate metabolic 
process 
8 .76 10.51 + 8.63E-03 
Ribonucleoside triphosphate 
metabolic process 
8 .78 10.30 + 1.01E-02 
Retina homeostasis 8 .23 34.80 + 9.09E-07 
Tissue homeostasis 9 .57 15.79 + 5.56E-05 
Multicellular organismal homeostasis 9 .93 9.65 + 3.52E-03 
Multicellular organismal process 43 21.68 1.98 + 9.47E-04 
Homeostatic process 17 4.76 3.57 + 2.82E-02 
Regulation of biological quality 28 11.51 2.43 + 1.78E-02 
Anatomical structure homeostasis 10 .95 10.58 + 3.25E-04 
Acute inflammatory response 6 .23 26.47 + 1.09E-03 
Defense response 18 3.97 4.53 + 4.06E-04 
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GO biological process complete # Expected Fold enrichment +/- P value 
Response to stress 29 10.79 2.69 + 1.22E-03 
Peptide cross-linking 5 .19 26.17 + 1.36E-02 
Platelet degranulation 9 .41 21.89 + 3.34E-06 
Regulated exocytosis 27 2.22 12.17 + 1.16E-18 
Exocytosis 27 2.49 10.84 + 2.23E-17 
Secretion by cell 27 3.11 8.70 + 5.98E-15 
Secretion 28 3.45 8.12 + 6.41E-15 
Transport 36 14.27 2.52 + 5.84E-05 
Establishment of localization 37 14.62 2.53 + 2.68E-05 
Localization 43 17.80 2.42 + 1.34E-06 
Vesicle-mediated transport 30 5.77 5.20 + 4.40E-11 
Neutrophil degranulation 21 1.56 13.46 + 2.16E-14 
Neutrophil mediated immunity 22 1.61 13.70 + 1.97E-15 
Myeloid leukocyte mediated immunity 22 1.67 13.17 + 4.50E-15 
Leukocyte mediated immunity 25 2.38 10.49 + 2.16E-15 
Immune effector process 27 3.32 8.13 + 3.25E-14 
Immune system process 32 8.26 3.87 + 1.24E-08 
Leukocyte degranulation 21 1.63 12.89 + 5.06E-14 
Neutrophil activation involved in immune 
response 
21 1.57 13.40 + 2.35E-14 
Myeloid cell activation involved in 
immune response 
21 1.66 12.64 + 7.48E-14 
Leukocyte activation involved in 
immune response 
22 1.97 11.19 + 1.32E-13 
Leukocyte activation 23 2.85 8.07 + 2.25E-11 
Cell activation 25 3.32 7.53 + 4.83E-12 
Cell activation involved in 
immune response 
22 1.98 11.12 + 1.51E-13 
Immune response 28 5.42 5.17 + 6.06E-10 
Myeloid leukocyte activation 22 1.83 12.00 + 3.09E-14 
Neutrophil activation 21 1.59 13.18 + 3.25E-14 
Granulocyte activation 21 1.60 13.10 + 3.67E-14 
Regulation of endopeptidase activity 9 1.27 7.09 + 4.33E-02 
Regulation of peptidase activity 11 1.36 8.11 + 9.25E-04 
Regulation of proteolysis 16 2.72 5.88 + 7.46E-05 
Multi-organism process 27 7.56 3.57 + 9.91E-06 
GO biological processes are hyperlinked to their functional description on Panther’s website. The “#” column 
identified how many chimpanzee proteins (out of 64) were associated with that biological process. In addition, these 
underlined numbers are hyperlinked to tables identifying which proteins matched that process.  
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Table A.13: Significant overexpression of GO biological processes in gorilla seminal plasma 
compared to the human and chimpanzee reference genomes 
GO biological process complete # Expected Fold enrichment +/- P value 
Antimicrobial humoral response 5 .18 28.49 + 8.02E-03 
Positive regulation of serine-type 
endopeptidase activity 
2 .00 > 100 + 1.52E-02 
Positive regulation of serine-type 
peptidase activity 
2 .00 > 100 + 1.52E-02 
Neutrophil degranulation 4 .01 > 100 + 3.68E-07 
Neutrophil mediated immunity 4 .03 > 100 + 2.92E-04 
Myeloid leukocyte mediated 
immunity 
4 .06 70.33 + 2.69E-03 
Leukocyte mediated 
immunity 
6 .24 25.25 + 1.05E-03 
Leukocyte degranulation 4 .03 > 100 + 2.26E-04 
Regulated exocytosis 7 .18 39.61 + 3.96E-06 
Exocytosis 7 .29 24.44 + 1.07E-04 
Secretion by cell 7 .57 12.31 + 1.07E-02 
Secretion 7 .71 9.85 + 4.60E-02 
Neutrophil activation involved in immune 
response 
4 .01 > 100 + 1.08E-05 
Myeloid cell activation involved in 
immune response 
4 .05 72.94 + 2.33E-03 
Leukocyte activation involved in 
immune response 
5 .22 22.58 + 2.17E-02 
Cell activation involved in 
immune response 
5 .23 21.79 + 2.58E-02 
Myeloid leukocyte activation 5 .15 32.82 + 3.52E-03 
Neutrophil activation 4 .04 > 100 + 4.66E-04 
Granulocyte activation 4 .04 98.47 + 7.08E-04 
Platelet degranulation 4 .01 > 100 + 1.08E-05 
Antimicrobial humoral response 5 .10 52.38 + 3.55E-04 
Humoral immune response 6 .22 27.61 + 6.25E-04 
Retina homeostasis 4 .11 37.16 + 3.33E-02 
Interspecies interaction between organisms 6 .40 15.15 + 2.01E-02 
Protein complex assembly 9 1.33 6.78 + 3.82E-02 
Protein complex biogenesis 9 1.33 6.77 + 3.87E-02 
Unclassified 4 9.00 .44 - 0.00E00 
GO biological processes are hyperlinked to their functional description on Panther’s website. The “#” column 
identified how many gorilla proteins (out of 34) were associated with that biological process. In addition, these 
underlined numbers are hyperlinked to tables identifying which proteins matched that process.  
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Figure A.2: Biological process functions of all 
identified proteins in each species: human, 
chimpanzee, and gorilla seminal plasma 
 
Seminal plasma proteins are associated with 12 biological 
processes identified through gene ontology (Panther). These three 
pie charts indicate the species specific percentage distribution of 
the biological processes that are summarized in Figure A.1.  
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A.8 Sequencing and PCR primers  
Table A.14: Vector and gene specific sequencing primers 
Vector Primer 
Ebv_Rev_pFB 5’– GATGAGTTTGGACAAACCAC–3’ 
pFLAG_N-CMV-30_For 5’– AATGTCGTAATAACCCCGCCCCGTTGACGC–3’ 
pFLAG_C-CMV-24_Rev 5’– TATTAGGACAAGGCTGGTGGGCAC–3’ 
HIS_Reverse 5’– AATGGTGATGGTGATGGTG–3’ 
AC_M13_Rev 5’– AACAGCTATGACCATG–3’ 
AC_M13-20_Fwd 5’- GTAAAACGACGGCCAGT–3’ 
Poly_Fwd_pFB 5’– AAATGATAACCATCTCGC–3’ 
AC_pSG5_Rev 5’– AGTTTGGACAAACCACAACTAG–3’ 
SG5_RevMCS 5’– CTGCAATAAACAAGTTCTGC–3’ 
T3_Fwd 5’- AATTAACCCTCACTAAAGGG-3’ 
T7_Rev 5’- CATTATGCTGAGTGATATCCCG-3’ 
Gene Primer 
R_KLK3_80 5’- CACTCCCAGCCTCCCACAATC–3’ 
KLK3_SeqInternal_Fwd 5’– CTCATCCTGTCTCGGATTG–3’ 
KLK3_SeqInternal_Rev  5’- GAGGGTGAACTTGCGCAC-3’ 
R_SEMG_100 5’- GCTGCTTGCTTCTCCAAG-3’ 
AC_SgI_450_Reverse   5’- CTTTCTTCTGTGTTTGAATATTG-3’ 
AC_SgI_mRNA_Forward_450 5’- CATCTGGAAAGGGAATATCCAG-3’ 
AC_SgI_mRNA_Forward_650 5’- AGCTAACAAACAACAACGTGAGA-3’ 
AC_SgI_mRNA_Reverse_950 5’- GGGATACATCTTTCTGCACACC-3’ 
AC_SgI_mRNA_Reverse_1200 5’- GCCATGGCTCTTGCTTAGGA-3’ 
AC_SgI_Fwd_1200 5’- CAAATCCTAAGCAAGAGCCATG-3’ 
AC_SgII_Rev_480 5’- GTTTGAACATTGACTGGATAATCC-3’ 
AC SgII mRNA Forward 480 5’- GGATTATCCAGTCAATGTTCAAAC-3’ 
AC SgII mRNA Forward 673 5’- GGGCATTACCAAAATGTGGTTGACGTG-3’ 
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Gene Primer 
AC SgII mRNA Reverse 976 5’- CAGTTTGGATAGAAATGCTGCCTTTGG-3’ 
AC SgII mRNA Reverse 1209 5’- GCTTGACTAGGAATTCTTACCTGG-3’ 
AC_SGII_Fwd_1290 5’- GCTTGACTAGGAATTCTTACCTGG-3’  
TGM4_R80 5’- CTCCCATGTGTGGTGAG-3’ 
AC_TGM4_Rev420 5’- GTTGGTACTTGCCCAGGATGGCATTGGGGG-3’ 
AC_TGM4_Fwd 420 5’- CCCCCAATGCCATCCTGGGCAAGTACCAAC-3’  
AC_TGM4_Fwd720 5’- CCCCGTGCTGGTGTGCAGGGCCATGTGTG-3’  
AC_TGM4_Rev720 5’- CACACATGGCCCTGCACACCAGCACGGGG-3’ 
AC_TGM4_Fwd1020 5’- GTGAATGAGAATGGCGAGAAAATCACCA-3’ 
AC_TGM4_Rev1020 5’- TGGTGATTTTCTCGCCATTCTCATTCAC-3’ 
AC_TGM4_Fwd1620 5’- CCTTTGAACTACAGTTGTACACTGGCAAG-3’ 
AC_TGM4_Rev1620 5’- CTTGCCAGTGTACAACTGTAGTTCAAAGG-3’ 
AC_TGM4_Fwd1920  5’- CAAGAATACCCTGGCCATCCCTTTGA-3’ 
AC_TGM4_Rev1920 5’- TCAAAGGGATGGCCAGGGTATTCTTG-3’ 
AC_TGM4_Fwd2220 5’- CAGATTATGGATGATTAAATTTGATGAC-3’ 
AC_TGM4_Fwd2520 5’- CCCTTGAGAAGCTGCCATATCTTCAGGCC-3’ 
 
Table A.15: Control PCR primers for genomic DNA 
Gene Primer 
CFTR_ex10_F 5’– CATGTCCTCTAGAAACCGTATGC–3’ 
CFTR_ex10_R 5’– CCCATACATTCTCCTAATGCTCA–3’ 
Mt_5269_F 5’– CCYCTGTCTTTAGATTTACAGTCC–3’ 
Mt_6266_R 5’– GCGAGYCAGCTRAATACTTTGACG–3’ 
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A.9 Human-chimpanzee TGM4 ancestor sequence reconstruction 
Human Change 
Chimp Change  
HumanTGM4           MMDASKELQVLHIDFLNQDNAVSHHTWEFQTSSPVFRRGQVFHLRLVLNQPLQSYHQLKL 60 
ChimpanzeeTGM4      MMDASKELQVLHVDFLKQDNAVSHHTWEFQTSTPVFRRGQVFHLRLVLNQPLQSYHQLKL 60 
OrangutanTGM4       MMDTSKELQVLHVDFLKQENAVSHHTWEFQTSSPVFRRGQVFHLRLVLNQPLQSYHQLKL 60 
GibbonTGM4          MMDTSKELQVLHVDFLKQENAVSHHTWEFQTSSPVFRRGQVFHLRLVLNQPLQSYHQLKL 60 
                    ***:********:***:*:*************:*************************** 
 
HumanTGM4           EFSTGPNPSIAKHTLVVLDPRTPSDHYNWQATLQNESGKEVTVAVTSSPNAILGKYQLNV 120 
ChimpanzeeTGM4      EFSTGPNPSIAKHTVVVLDLRTPSDHYNWQATLQNESGKEVTVAVTSSPNAILGKYQLNV 120 
OrangutanTGM4       EFSTGPNPSLAKHTLVVLDPRTXXDHYNWQATLQNESXKEVTVAVTSTPNAILGEYQLNV 120 
GibbonTGM4          EFSTGPNPSIAKHTLVVLDPRMPSAHYNWQAALQNESGKEVTVAVTSTPNAILGKYQLNV 120 
                    *********:****:**** *    ******:***** *********:******:***** 
 
HumanTGM4           KTGNHILKSEENILYLLFNPWCKEDMVFMPDEDERKEYILNDTGCHYVGAARSIKCKPWN 180 
ChimpanzeeTGM4      KTGNHILKSEENILYLLFNPWCKEDMVFMPDEDERKEYILNDTGCHYVGAARSIRYKPWN 180 
OrangutanTGM4       KTGNHILKSEENILYLLFNPWCKEDMVFMPDEDERKEYILNDTGCHYVGAARSIKYKPWN 180 
GibbonTGM4          KTGNHILKSEENILYLLFNPWCKEDMVFMPDEDERKEYILNDTGCHYVGAARSIKYKPWN 180 
                    ******************************************************: **** 
 
HumanTGM4           FGQFEKNVLDCCISLLTESSLKPTDRRDPVLVCRAMCAMMSFEKGQGVLIGNWTGDYEGG 240 
ChimpanzeeTGM4      FGQFEKNVLDCCISLLTESSLKPTDRRDPVLVCRAMCAMMSFEKGQGVLIGNWTGDYEGG 240 
OrangutanTGM4       FGQFEKNVLDCCISLLTESSLKPTDRRDPVLVCRAMCAMMSFEKGQGVLIGNWTGDYEGG 240 
GibbonTGM4          FGQFEENVLDCCISLLTESSLKPTDRRDPVLVCRAMSAMMSFEKGQGVLIGNWTGDYQGG 240 
                    *****:******************************.********************:** 
 
HumanTGM4           TAPYKWTGSAPILQQYYNTKQAVCFGQCWVFAGILTTVLRALGIPARSVTGFDSAHDTER 300 
ChimpanzeeTGM4      TAPYKWTGSAPILQQYYNTKQAVCFGQCWVFAGILTTVLRALGIPARSVTGFDSAHDTER 300 
OrangutanTGM4       TAPYKWTGSAPILQQYYNTKQAVXFGQCWVFAGILTTVLRALGIPARSVTAFDSAXDTER 300 
GibbonTGM4          TAPYKWTGSAPILQQYYNTKQPVCFGQCWVFAGILTTVLRALGIPARSVTAFDSAHDTER 300 
                    *********************.* **************************.**** **** 
 
HumanTGM4           NLTVDTYVNENGEKITSMTHDSVWNFHVWTDAWMKRPDLPKGYDGWQAVDATSQERSQGV 360 
ChimpanzeeTGM4      NLTVDTYVNENGEKITNMTHDSVWNFHVWTDAWMKRPDLPKGYDGWQAVDATPQERSQGV 360 
OrangutanTGM4       NLTVDTYVNENGEKITNMTHDSVWNFHVWTDAWMKRPDLPKGYDGWQAVDATPQERSQGV 360 
GibbonTGM4          NLTVDTYVNKNGEKITNMTHDSVWNFHVWTDAWMKRPDLPKGYDGWQAVDATPQERSQGV 360 
                    *********:******.***********************************.******* 
 
HumanTGM4           FCCGPSPLTAIRKGDIFIVYDTRFVFSEVNGDRLIWLVKMVNGQEELHVISMETTSIGKN 420 
ChimpanzeeTGM4      FCCGPSPLTAIRKGDIFIVYDTRFVFSEVNGDRLIWLVKMVNGQEELHVISMETTSIGKN 420 
OrangutanTGM4       FCCGPSPLTAIRKGDIFIVYDTRFVFSEVNGDRLIWLVKMVNGQEELHIISMETTSIGKN 420 
GibbonTGM4          FCCGPSPLTAIRKGDIFIVYDTRFVFSEVNGDRIIWLVKMVNGQEELHIISMETTSIGKN 420 
                    *********************************:**************:*********** 
 
HumanTGM4           ISTKAVGQDRRRDITYEYKYPEGSSEERQVMDHAFLLLSSEREHRRPVKENFLHMSVQSD 480 
ChimpanzeeTGM4      ISTKAVGQDRRRDITYEYKYPEGSSEERQVMDHAFLLLSSEREHRRPVKENFLHMSVQSD 480 
OrangutanTGM4       ISTKAVGQDRRRDITYEYKYSEGSSEERQVMDHAFLLLSSEREHRRPVKENFLHMSVQSD 480 
GibbonTGM4          ISTKAVGQDGRRDITYEYKYPEGSSEERQVMDHAFLLLSSEREHRQPVKENFLHMSVQSD 480 
                    ********* **********.************************:************** 
 
HumanTGM4           DVLLGNSVNFTVILKRKTAALQNVNILGSFELQLYTGKKMAKLCDLNKTSQIQGQVSEVT 540 
ChimpanzeeTGM4      DVLLGNPVNFTVILKRKTAALQNVNILGSFELQLYTGKKVAKLCDLNKTSQIQGQVSEVT 540 
OrangutanTGM4       DVLLGNPVNFTVILKRKTAALQNVNISGSFELQLYTGKKVAKLCDLNKTXQIQGQVSEVT 540 
GibbonTGM4          DVLLGNPVNFTVIIKRKTAALQNVNISGSFELQLYTGKKVAKLCDLNKTSQIQGQVSEVT 540 
                    ******.******:************ ************:********* ********** 
 
HumanTGM4           LTLDSKTYINSLAILDDEPVIRGFIIAEIVESKEIMASEVFTSFQYPEFSIELPNTGRIG 600 
ChimpanzeeTGM4      LTLDSKTYINSLAILDDEPVIRGFIIAEIVESKEIMASEVFTSFQYPEISIELPNTGRIG 600 
OrangutanTGM4       LTLDSKTYINSLAILDDEPVIRGFIIAEIVESNEIMASEVFXSFQYPEFSIELPNTGRIG 600 
GibbonTGM4          LTLDSKTYINSLAILDDEPVIRGFIIAEIVESNEIMASEVFTSFQYPEFSIELPNTGRIG 600 
                    ********************************:******** ******:*********** 
 
HumanTGM4           QLLVCNCIFKNTLAIPLTDVKFSLESLGISSLQTSDHGTVQPGETIQSQIKCTPIKTGPK 660 
ChimpanzeeTGM4      QLLVCNCIFKNTLAIPLTDVKFSLESLGISSLQTSDHGTVQPGETIQSQIKCTPIKTGPK 660 
OrangutanTGM4       QLLVCNCIFKNTLAIPLTDVKFSLESLGISSLQTSDHGTVQPGETIQSQIKCTPIKTGPK 660 
GibbonTGM4          QLLVCNCIFKNTLAIPLTDVKFSLESLGISSLQTSDHGTVQPGETIQSQIKCAPIKTGPK 660 
                    ****************************************************:******* 
 
HumanTGM4           KFIVKLSSKQVKEINAQKIVLITK 684 
ChimpanzeeTGM4      KFIVKLSSKQVKEINAQKIVLITK 684 
OrangutanTGM4       KFIVKLSSKQVKEINAQKIVLITK 684 
GibbonTGM4          KFIIKLSSKQVKEINAQKIVLITK 684 
                    ***:******************** 
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A.10 Human, chimpanzee, and human-chimpanzee ancestor sequences in pCMV vector  
 
10 20 30 40 50 60 70 80 90 100 110 120 130
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGG
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGpCMVpromoterseq.seq(1>508)
140 150 160 170 180 190 200 210 220 230 240 250 260 270
TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTAYGGGACTTTCCTACTTGGCAGTACATCT
TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTpCMVpromoterseq.seq(1>508)
GTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTHuT4_R80_2017-05-10_F02.ab1(12>377)
CAGTACATCTChT4_R80_2017-05-15_B01.ab1(88>357)
280 290 300 310 320 330 340 350 360 370 380 390 400 410
ACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTtGACTCACGGGGA-TTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG-TTTTGGCACCAAAATC
ACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG-TTTTGGCACCAAAATCpCMVpromoterseq.seq(1>508)
ACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGA-TTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG-TTTTGGCACCAAAATCHuT4_R80_2017-05-10_F02.ab1(12>377)
ACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTT-GACTCACGGGGA-TTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG-TTTTGGCACCAAAATCChT4_R80_2017-05-15_B01.ab1(88>357)
G-TTTTGGCACCAAAATCancT4_R80_2017-05-10_B01.ab1(10>217)
420 430 440 450 460 470 480 490 500 510 520 530 540 550
AACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCT
AACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTpCMVpromoterseq.seq(1>508)
AACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCTHuT4_R80_2017-05-10_F02.ab1(12>377)
TGGGCGGTAGGCGTGT-C-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCTHuT4_pflagFWD_2017-05-10_E02.ab(1>297)
AACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGGChT4_R80_2017-05-15_B01.ab1(88>357)
CCGCAGATCTChT4_pflagFWD_2017-05-15_A01.ab(77>352)
AACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCTancT4_R80_2017-05-10_B01.ab1(10>217)
TGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCTancT4_R420_2017-05-10_C01.ab1(70>420)
TGGGCGGTAGGCGTGTAC-GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA-CCGTCAGAATTCAAGC-T-GCGG-CCGCAGATCTancT4_pflagFWD_2017-05-10_A01.a(1>395)
560 570 580
-AAAGGCC-TACGTCGACATGATG
ATGATGHuman TGM4 Seq.seq(1>2073)
-AAAGGCC-TACGTCGACATGATGHuT4_R80_2017-05-10_F02.ab1(12>377)
-AAAGGCC-TACGTCGACATGATGHuT4_pflagFWD_2017-05-10_E02.ab(1>297)
AAAGGCC-TACGTCGACATGATGHuT4_R420_2017-05-10_G02.ab1(69>332)
ATGATGChimp TGM4 sequence#16AE75F.seq(1>2073)
-AAAGGCC-TACGTCGACATGATGChT4_pflagFWD_2017-05-15_A01.ab(77>352)
ATGATGAnc TGM4 sequence f#16AE75A.seq(7>2088)
-AAAGGCC-TACGTCGACATGATGancT4_R80_2017-05-10_B01.ab1(10>217)
-AAAGGCC-TACGTCGACATGATGancT4_R420_2017-05-10_C01.ab1(70>420)
-AAAGGCC-TACGTCGACATGATGancT4_pflagFWD_2017-05-10_A01.a(1>395)
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ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACATTGACTTCTT-G-AATCAGGACAACGCCG-TTTCTCAC
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ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACATTGACTTCTT-G-AATCAGGACAACGCCG-TTTCTCACHuman TGM4 Seq.seq(1>2073)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACATHuT4_R80_2017-05-10_F02.ab1(12>49)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACATTGACTTCTT-G-AATCAGGACAACGCCG-TTTCTCACHuT4_pflagFWD_2017-05-10_E02.ab(103>297
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACATTGACTTCTT-G-AATCAGGACAACGCCG-TTTCTCACHuT4_R420_2017-05-10_G02.ab1(69>316)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGTTGACTTCTT-G-AAGCAGGACAACGCCG-TTTCTCACChimp TGM4 sequence#16AE75F.seq(1>2073)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGTTGACTTCTT-G-AAGCAGGACAACGCCG-TTTCTCACChT4_pflagFWD_2017-05-15_A01.ab(103>352
AAGTTCTCCACGTTGACTTCT--G-AAGCAGGACAACGCCG-TTTCTCACChT4_R420_2017-05-15_C01.ab1(87>301)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGTTGACTTCTT-G-AAGCAGGACAACGCCG-TTTCTCACAnc TGM4 sequence f#16AE75A.seq(7>2088)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGT-GACancT4_R80_2017-05-10_B01.ab1(10>50)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGTTGACTTCTT-G-AAGCAGGACAACGCCG--TTCTCACancT4_R420_2017-05-10_C01.ab1(70>318)
ATGATGGATGCATCAAAA-GAGCTG-CAAGTTCTCCACGTTGACTTCTT-G-AAGCAGGACAACGCCG-TTTCTCACancT4_pflagFWD_2017-05-10_A01.a(103>395
Top
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CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCA
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CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAHuman TGM4 Seq.seq(1>2073)
CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAHuT4_pflagFWD_2017-05-10_E02.ab(103>297
CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAHuT4_R420_2017-05-10_G02.ab1(69>316)
CACACATGGGAGTTCCAAACGAGCACTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAChimp TGM4 sequence#16AE75F.seq(1>2073)
CACACATGGGAGTTCCAAACGAGCACTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAChT4_pflagFWD_2017-05-15_A01.ab(103>352
CACACATGGGAGTTCCAAACGAGCACTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAChT4_R420_2017-05-15_C01.ab1(87>301)
CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAAnc TGM4 sequence f#16AE75A.seq(7>2088)
CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAancT4_R420_2017-05-10_C01.ab1(70>318)
CACACATGGGAGTTCCAAACGAGCAGTCCTGTGTTCCGGCGAGGACAGGTGTTTCACCTGCGGCTGGTGCTGAACCAancT4_pflagFWD_2017-05-10_A01.a(103>395
Top
160 170 180 190 200 210 220 230
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-
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GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-Human TGM4 Seq.seq(1>2073)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGGHuT4_pflagFWD_2017-05-10_E02.ab(103>297
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-HuT4_R420_2017-05-10_G02.ab1(69>316)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCG-Chimp TGM4 sequence#16AE75F.seq(1>2073)
GCCCCTAC-ATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCG-ChT4_pflagFWD_2017-05-15_A01.ab(103>352
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCG-ChT4_R420_2017-05-15_C01.ab1(87>301)
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GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-
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GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-Human TGM4 Seq.seq(1>2073)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGGHuT4_pflagFWD_2017-05-10_E02.ab(103>297
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-HuT4_R420_2017-05-10_G02.ab1(69>316)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCG-Chimp TGM4 sequence#16AE75F.seq(1>2073)
GCCCCTAC-ATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCG-ChT4_pflagFWD_2017-05-15_A01.ab(103>352
GChT4_R420_2017-05-15_C 1.ab1(87>301)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-Anc TGM4 sequence f#16AE75A.seq(7>2088)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-ancT4_R420_2017-05-10_C01.ab1(70>318)
CAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-ancT4_R720_2017-05-10_F01.ab1(100>450)
GCCCCTACAATCCTACCACCAACTGAAACTGGAATTCAGCACAGGG-CCGAAT-CCTAGCATCGCCAAACACACCC-ancT4_pflagFWD_2017-05-10_A01.a(103>395
Top
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TGGT-GGTGCTCGACCCGA-GGACGCC-C-TCAGACC-ACTACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGC
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TGGT-GGTGCTCGACCCGA-GGACGCC-C-TCAGACC-ACTACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGCHuman TGM4 Seq.seq(1>2073)
TGGT-GGTGCTCGACCCGA-GGACGCCHuT4_R420_2017-05-10_G02.ab1(69>316)
GACGCC-C-TCAGACC-A-TNCAACTGGC-AGGCAACCCTTCAAAATGAGTCTNGCHuT4_R720_2017-05-10_B03.ab1(68>386)
TGGT-GGTGCTCGACCTGA-GGACGCC-C-TCAGACC-ACTACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGCChimp TGM4 sequence#16AE75F.seq(1>2073)
TGGT-GGTGCTCGACCTGA-GGACGCC-C-TCChT4_pflagFWD_2017-05-15_A01.ab(103>352
TGGT-GGTGCTCGACCTGAChT4_R420_2017-05-15_C01.ab1(87>301)
TGGT-GGTGCTCGACCCGA-GGACGCC-C-TCAGACC-ACTACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGCAnc TGM4 sequence f#16AE75A.seq(7>2088)
TGGT-GGTGCTCGACCCGA-GGACGCC-C-TancT4_R420_2017-05-10_C01.ab1(70>318)
TGGT-GGTGCTCGACCCGA-GGACGCC-C-TCAGACC-A-TACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGCancT4_R720_2017-05-10_F01.ab1(100>450)
TGGT-GGTGCTCGACCCGA-GGACGCC-C-TCAGACC-ACTACAACTGGC-AGGCAACCCTTCAAAATGAGTCTGGancT4_pflagFWD_2017-05-10_A01.a(103>395
Top
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AAAG-AGGTCAC-AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAC-GTGAA
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AAAG-AGGTCAC-AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAC-GTGAAHuman TGM4 Seq.seq(1>2073)
AAAG-AGGTCAC-AGTNGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAC-GTGAAHuT4_R720_2017-05-10_B03.ab1(68>386)
AAAG-AGGTCAC-AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAT-GTGAAChimp TGM4 sequence#16AE75F.seq(1>2073)
AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAT-GTGAAChT4_R720_2017-05-15_F01.ab1(82>319)
AAAG-AGGTCAC-AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAT-GTGAAAnc TGM4 sequence f#16AE75A.seq(7>2088)
AAAG-AGGTCAC-AGTGGCT-GTCACCAGTT-CCCCC-AATG-CCATCCT-GGGCAAGTACCAA-CTAAAT-GTGAAancT4_R720_2017-05-10_F01.ab1(100>450)
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AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGG
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AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGHuman TGM4 Seq.seq(1>2073)
AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGHuT4_R720_2017-05-10_B03.ab1(68>386)
CCCATGGTGTAAA-AGGACATGGHuT4_F420_2017-05-10_H02.ab1(62>351)
AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGChimp TGM4 sequence#16AE75F.seq(1>2073)
AACTNGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGChT4_R720_2017-05-15_F01.ab1(82>319)
ATGGChT4_F420_2017-05-15_D01.ab1(19>243)
AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGAnc TGM4 sequence f#16AE75A.seq(7>2088)
AACTGGAAACCACATCCTTAAGTCTGAAGAAAACATCCTATACCTTCTCTTCAACCCATGGTGTAAAGAGGACATGGancT4_R720_2017-05-10_F01.ab1(100>450)
ATGGancT4_F420_2017-05-10_D01.ab1(22>362)
Top
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TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGA
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TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAHuman TGM4 Seq.seq(1>2073)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAHuT4_R720_2017-05-10_B03.ab1(68>386)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAHuT4_F420_2017-05-10_H02.ab1(62>351)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAChimp TGM4 sequence#16AE75F.seq(1>2073)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAChT4_R720_2017-05-15_F01.ab1(82>319)
TTTTCATGCCTGATGAGGACGAGCGC-AAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAChT4_F420_2017-05-15_D01.ab1(19>243)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAAnc TGM4 sequence f#16AE75A.seq(7>2088)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAancT4_R720_2017-05-10_F01.ab1(100>450)
TTTTCATGCCTGATGAGGACGAGCGCAAAGAGTACATCCTCAATGACACGGGCTGCCATTACGTGGGGGCTGCCAGAancT4_F420_2017-05-10_D01.ab1(22>362)
Top
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AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACT
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AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTHuman TGM4 Seq.seq(1>2073)
AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGHuT4_R720_2017-05-10_B03.ab1(68>386)
AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTHuT4_F420_2017-05-10_H02.ab1(62>351)
TTCCCTGCTGACTHuT4_R1020_2017-05-10_D03.ab1(67>346)
AGTATCAGATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTChimp TGM4 sequence#16AE75F.seq(1>2073)
AGTATCAGATACAAACCCTGGAACTTTChT4_R720_2017-05-15_F01.ab1(82>319)
AGTATCAGATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTChT4_F420_2017-05-15_D01.ab1(19>243)
CAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATNTCC-T-GACTGCTGCA-TTTCCCTG-TGACTChT4_R1020_2017-05-15_H01.ab1(81>389)
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540 550 560 570 580 590 600 610
AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACT
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AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTHuman TGM4 Seq.seq(1>2073)
AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGHuT4_R720_2017-05-10_B03.ab1(68>386)
AGTATCAAATGCAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTHuT4_F420_2017-05-10_H02.ab1(62>351)
TTCCCTGCTGACTHuT4_R1020_2017-05-10_D03.ab1(67>346)
AGTATCAGATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTChimp TGM4 sequence#16AE75F.seq(1>2073)
AGTATCAGATACAAACCCTGGAACTTTChT4_R720_2017-05-15_F01.ab1(82>319)
AGTATCAGATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTChT4_F420_2017-05-15_D01.ab1(19>243)
N - -ChT4_R1020_2017-05-15_H01.ab1(81>389)
AGTATCAAATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTAnc TGM4 sequence f#16AE75A.seq(7>2088)
AGTATCAAATACAAACCCTGGAACTTancT4_R720_2017-05-10_F01.ab1(100>450)
AGTATCAAATACAAACCCTGGAACTTTGGTCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTancT4_F420_2017-05-10_D01.ab1(22>362)
TCAGTTTGAGAAAAATGTCC-TGGACTGCTGCA-TTTCCCTGCTGACTancT4_R1020_2017-05-10_H01.ab1(69>374)
Top
620 630 640 650 660 670 680 690
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAG
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GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGHuman TGM4 Seq.seq(1>2073)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGHuT4_F420_2017-05-10_H02.ab1(62>351)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGHuT4_R1020_2017-05-10_D03.ab1(67>346)
CTATGA-TGAGHuT4_F720_2017-05-10_A03.ab1(1>326)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGChimp TGM4 sequence#16AE75F.seq(1>2073)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAChT4_F420_2017-05-15_D01.ab1(19>243)
GAGAGCT-CC-TCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGChT4_R1020_2017-05-15_H01.ab1(81>389)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGAnc TGM4 sequence f#16AE75A.seq(7>2088)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGancT4_F420_2017-05-10_D01.ab1(22>362)
GAGAGCT-CCCTCAAG-CCCACAGATAGGA-GGGA-CCCCGTGCTGGTGTGCA-GGGCCATGTGTGCTATGA-TGAGancT4_R1020_2017-05-10_H01.ab1(69>374)
Top
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CTTTGAGAAA-GGCCAGGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACA
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CTTTGAGAAA-GGCCAGGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAHuman TGM4 Seq.seq(1>2073)
CTTTGAGAAA-GGC-AGGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACHuT4_F420_2017-05-10_H02.ab1(62>351)
CTTTGAGAAA-GGCCAGGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAHuT4_R1020_2017-05-10_D03.ab1(67>346)
CTTTGA-AAA-GGCCAGGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACNAAGGTGGCACAGCCCCATACAHuT4_F720_2017-05-10_A03.ab1(1>326)
CTTTGAGAAA-GGCCAAGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAChimp TGM4 sequence#16AE75F.seq(1>2073)
CTT-GAGAAA-GGCCAAGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAChT4_R1020_2017-05-15_H01.ab1(81>389)
AChT4_F720_2017-05-15_E01.ab1(75>316)
CTTTGAGAAA-GGCCAAGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAAnc TGM4 sequence f#16AE75A.seq(7>2088)
CTTTGAGAAA-GGCCAAGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAancT4_F420_2017-05-10_D01.ab1(22>362)
CTTTGAGAAA-GGCCAAGGCGTGCTCA-TTGGG-AA-TTGGACT-GGGG-ACTACGAAGGTGGCACAGCCCCATACAancT4_R1020_2017-05-10_H01.ab1(69>374)
AAGGTGGCACAGCCCCATACAancT4_F720_2017-05-10_E01.ab1(55>381)
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AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTG
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AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGHuman TGM4 Seq.seq(1>2073)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGHuT4_R1020_2017-05-10_D03.ab1(67>346)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGHuT4_F720_2017-05-10_A03.ab1(1>326)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGChimp TGM4 sequence#16AE75F.seq(1>2073)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGChT4_R1020_2017-05-15_H01.ab1(81>389)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGChT4_F720_2017-05-15_E01.ab1(75>316)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGAnc TGM4 sequence f#16AE75A.seq(7>2088)
AGTGGACAGGCAGTGCCC-GATCCTGCAGCAGTACTACAACACancT4_F420_2017-05-10_D01.ab1(22>362)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGancT4_R1020_2017-05-10_H01.ab1(69>374)
AGTGGACAGGCAGTGCCCCGATCCTGCAGCAGTACTACAACACGAAGCAGGCTGTGTGCTTTGGCCAGTGCTGGGTGancT4_F720_2017-05-10_E01.ab1(55>381)
Top
850 860 870 880 890 900 910 920
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCT
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TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTHuman TGM4 Seq.seq(1>2073)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAHuT4_R1020_2017-05-10_D03.ab1(67>346)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTHuT4_F720_2017-05-10_A03.ab1(1>326)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTChimp TGM4 sequence#16AE75F.seq(1>2073)
TTTGCTGGGATCCTGACTACAGTGCTGAGChT4_R1020_2017-05-15_H01.ab1(81>389)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTChT4_F720_2017-05-15_E01.ab1(75>316)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTAnc TGM4 sequence f#16AE75A.seq(7>2088)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCATancT4_R1020_2017-05-10_H01.ab1(69>374)
TTTGCTGGGATCCTGACTACAGTGCTGAGAGCGTTGGGCAT-CCCAGCAC-GCAGTGTGACAGGCTTCGATTCAGCTancT4_F720_2017-05-10_E01.ab1(55>381)
Top
930 940 950 960 970 980 990 1000
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAGTATGACCCACG
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CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAGTATGACCCACGHuman TGM4 Seq.seq(1>2073)
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAGTATGACCCACGHuT4_F720_2017-05-10_A03.ab1(1>326)
CCACGHuT4_F1020_2017-05-10_C03.ab1(4>284)
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAATATGACCCACGChimp TGM4 sequence#16AE75F.seq(1>2073)
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGANTGGCGAGAAAATCACCAATATGACCCACGChT4_F720_2017-05-15_E01.ab1(75>316)
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAATATGACCCACGAnc TGM4 sequence f#16AE75A.seq(7>2088)
CACGACACAGAAAGGAA-CCTCACGGTGGACACCTATGTGAATGAGAATGGCGAGAAAATCACCAATATGACCCACGancT4_F720_2017-05-10_E01.ab1(55>381)
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1010 1020 1030 1040 1050 1060 1070
ACTCTGTCTGGAATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACGACGG
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ACTCTGTCTGGAATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACGACGGHuman TGM4 Seq.seq(1>2073)
ACTCTGTCTGGAATTTCHuT4_F720_2017-05-10_A03.ab1(1>326)
ACTCTGTCTGGAATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACGACGGHuT4_F1020_2017-05-10_C03.ab1(4>284)
ACTCTGTCTGGAATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACGACGGChimp TGM4 sequence#16AE75F.seq(1>2073)
ACTCTGTCTGGAAChT4_F720_2017-05-15_E01.ab1(75>316)
TGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCNCCN-CTGCCCA-GGGCTACAACGGChT4_F1020_2017-05-15_G01.ab1(23>298)
ACTCTGTCTGGAATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACGACGGAnc TGM4 sequence f#16AE75A.seq(7>2088)
ACTCTGTCTGGAATTT-CATGTGTGGA-CGGATGCCTGG-ATGAAGC-GACCGG-ATCTGCCCAAGGGCTACNACGGancT4_F720_2017-05-10_E01.ab1(55>381)
CTGTCTGG-ATTTCCATGTGTGGA-CGGATGCCTGG-ATGAAGC-GNCCCCCATCTGCCC-AGGGCTACGACGGancT4_F1020_2017-05-10_G01.ab1(12>331)
Top
1080 1090 1100 1110 1120 1130 1140 1150
CT-GGCAGGCTGTGGACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGTTGTGGGCCATCACCACTGACCGCC
 L 
 W 
 G 
 A 
 Q 
 R 
 G 
 A 
 L 
 C 
 V 
 W 
 G 
 D 
 T 
 R 
 A 
 Q 
 N 
 T 
 R 
 A 
 P 
 R 
 A 
 Q 
 R 
 G 
 E 
 S 
 A 
 R 
 E 
 K 
 S 
 A 
 P 
 Q 
 R 
 G 
 G 
 V 
 C 
 V 
 S 
 L 
 F 
 S 
 L 
 C 
 V 
 L 
 C 
 V 
 W 
 G 
 G 
 A 
 P 
 H 
 I 
 S 
 H 
 T 
 P 
 H 
 T 
 L 
 • 
 D 
 T 
 P 
 R 
 A 
 P 
 H 
CT-GGCAGGCTGTGGACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGTTGTGGGCCATCACCACTGACCGCCHuman TGM4 Seq.seq(1>2073)
CT-GGCAGGCTGTGGACGC-ACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGTTGTGGGCCATCACCACTGACCGCCHuT4_F1020_2017-05-10_C03.ab1(4>284)
CT-GGCAGGCTGTGGACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGCCATCACCACTGACCGCCChimp TGM4 sequence#16AE75F.seq(1>2073)
CT-GGCAGGCTGTGGACGC-ACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGCCATCACCACTGACCGCCChT4_F1020_2017-05-15_G01.ab1(23>298)
CT-GGCAGGCTGTGGACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGCCATCACCACTGACCGCCAnc TGM4 sequence f#16AE75A.seq(7>2088)
CT-GGCAancT4_F720_2017-05-10_E01.ab1(55>381)
CT-GGCAGGCTGTGGACGCAACGCCGCAGGAGCGAAGCCAGGGTGTCTTCTGCTGTGGGCCATCACCACTGACCGCCancT4_F1020_2017-05-10_G01.ab1(12>331)
Top
1160 1170 1180 1190 1200 1210 1220 1230
ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCT
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ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTHuman TGM4 Seq.seq(1>2073)
ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTHuT4_F1020_2017-05-10_C03.ab1(4>284)
ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTChimp TGM4 sequence#16AE75F.seq(1>2073)
ATCCGCAAAGGTGACATCTTTATTGTCTATGATACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTChT4_F1020_2017-05-15_G01.ab1(23>298)
ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTAnc TGM4 sequence f#16AE75A.seq(7>2088)
ATCCGCAAAGGTGACATCTTTATTGTCTATGACACC-AGATTCGTCTTCTCAGAAGTGAATGGTGACAGGCTCATCTancT4_F1020_2017-05-10_G01.ab1(12>331)
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GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-C
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GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CHuman TGM4 Seq.seq(1>2073)
GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGAHuT4_F1020_2017-05-10_C03.ab1(4>284)
A-GACCACAAGCATCGGGAAAAA-CHuT4_R1620_2017-05-10_E03.ab1(58>281)
GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CChimp TGM4 sequence#16AE75F.seq(1>2073)
GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCA-TGGA-GACCACAAGCATCGGGAAAAAChT4_F1020_2017-05-15_G01.ab1(23>298)
ATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CChT4_R1620_2017-05-15_A02.ab1(72>289)
GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CAnc TGM4 sequence f#16AE75A.seq(7>2088)
GGTTGGTGAAGATGGTGAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CancT4_F1020_2017-05-10_G01.ab1(12>331)
GAATGGG-CAGGAGGAGTTACACGTAATTTCAATGGA-GACCACAAGCATCGGGAAAAA-CancT4_R1620_2017-05-10_A02.ab1(55>314)
Top
1310 1320 1330 1340 1350 1360 1370 1380
ATCAGC-ACCAAGG-CAGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCT
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ATCAGC-ACCAAGG-CAGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTHuman TGM4 Seq.seq(1>2073)
ATCAGC-ACCAAGG-CAGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTHuT4_R1620_2017-05-10_E03.ab1(58>281)
ATCAGC-ACCAAGG-CAGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTChimp TGM4 sequence#16AE75F.seq(1>2073)
ATCAGC-ACCAAGG-CNGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTChT4_R1620_2017-05-15_A02.ab1(72>289)
ATCAGC-ACCAAGG-CAGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTAnc TGM4 sequence f#16AE75A.seq(7>2088)
ATCAGC-AC-AAGG-CTGTGGGCCAAGAancT4_F1020_2017-05-10_G01.ab1(12>331)
ATCAGC-ACCAAGG-CTGTGGGCCAAGA-CAGG-CGGAGAGA-TATCACC-TATGA-GTACAAGTATCCAGAAGGCTancT4_R1620_2017-05-10_A02.ab1(55>314)
Top
1390 1400 1410 1420 1430 1440 1450 1460
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAA
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CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAHuman TGM4 Seq.seq(1>2073)
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAHuT4_R1620_2017-05-10_E03.ab1(58>281)
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAChimp TGM4 sequence#16AE75F.seq(1>2073)
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAChT4_R1620_2017-05-15_A02.ab1(72>289)
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAAnc TGM4 sequence f#16AE75A.seq(7>2088)
CCTCTGAGGAGAGGCAGGTCATGGATCATGCCTTCCTCCTTCTCAGTTCTGAGAGGGAGCACAGACGACCTGTAAAAancT4_R1620_2017-05-10_A02.ab1(55>314)
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1470 1480 1490 1500 1510 1520 1530 1540
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACTCTGTTAATTTCACCGTGATTCTTAA
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GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACTCTGTTAATTTCACCGTGATTCTTAAHuman TGM4 Seq.seq(1>2073)
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACTCTHuT4_R1620_2017-05-10_E03.ab1(58>281)
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACCCTGTTAATTTCACCGTGATTCTTAAChimp TGM4 sequence#16AE75F.seq(1>2073)
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTChT4_R1620_2017-05-15_A02.ab1(72>289)
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACCCTGTTAATTTCACCGTGATTCTTAAAnc TGM4 sequence f#16AE75A.seq(7>2088)
GAGAACTTTCTTCACATGTCGGTACAATCAGATGATGTGCTGCTGGGAAACCCTGancT4_R1620_2017-05-10_A02.ab1(55>314)
Top
1550 1560 1570 1580 1590 1600 1610
AAGGAAGACCGCTGCCCTACAGAATGTCAACATCTTGGGTTCCTTTGAACTACAGTTGTACACTGGCAAGAAGATGG
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AAGGAAGACCGCTGCCCTACAGAATGTCAACATCTTGGGTTCCTTTGAACTACAGTTGTACACTGGCAAGAAGATGGHuman TGM4 Seq.seq(1>2073)
AAGGAAGACCGCTGCCCTACAGAATGTCAACATCTTGGGCTCCTTTGAACTACAGTTGTACACTGGCAAGAAGGTGGChimp TGM4 sequence#16AE75F.seq(1>2073)
AAGGAAGACCGCTGCCCTACAGAATGTCAACATCTTGGGCTCCTTTGAACTACAGTTGTACACTGGCAAGAAGGTGGAnc TGM4 sequence f#16AE75A.seq(7>2088)
Top
1620 1630 1640 1650 1660 1670 1680 1690
CAAAACTGTGTGACCTCAATAAGACCTCGCAGATCCAAGG-TCAAGTATCAGAAGTG-ACTCTGACCTTGGACTCCA
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CAAAACTGTGTGACCTCAATAAGACCTCGCAGATCCAAGG-TCAAGTATCAGAAGTG-ACTCTGACCTTGGACTCCAHuman TGM4 Seq.seq(1>2073)
ACTCTGACCTTGGACTCCAHuT4_F1620_2017-05-10_F03.ab1(65>286)
CAAAACTGTGTGACCTCAATAAGACCTCGCAGATCCAAGG-TCAAGTATCAGAAGTG-ACTCTGACCTTGGACTCCAChimp TGM4 sequence#16AE75F.seq(1>2073)
AAACTGTGTGACCTCAATAAGACCTCGCAGATCCA-GG-TC-AGTATCAGAAGTG-NCNCTGACCTTGGACTCCAChT4_F1620_2017-05-15_B02.ab1(3>273)
CAAAACTGTGTGACCTCAATAAGACCTCGCAGATCCAAGG-TCAAGTATCAGAAGTG-ACTCTGACCTTGGACTCCAAnc TGM4 sequence f#16AE75A.seq(7>2088)
ACTCTGACCTTGGACTCCAancT4_F1620_2017-05-10_B02.ab1(62>362)
Top
1700 1710 1720 1730 1740 1750 1760 1770
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAG
 R 
 D 
 T 
 P 
 L 
 Y 
 T 
 H 
 I 
 S 
 Q 
 N 
 T 
 Q 
 S 
 A 
 P 
 L 
 W 
 G 
 A 
 L 
 Y 
 I 
 Y 
 I 
 L 
 • 
 R 
 D 
 M 
 • 
 D 
 M 
 • 
 E 
 S 
 A 
 P 
 Q 
 S 
 V 
 L 
 Y 
 I 
 S 
 Q 
 R 
 E 
 R 
 G 
 V 
 F 
 F 
 S 
 H 
 I 
 S 
 H 
 I 
 L 
 C 
 A 
 R 
 G 
 E 
 K 
 N 
 I 
 L 
 C 
 V 
 W 
 G 
 E 
 S 
 V 
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGHuman TGM4 Seq.seq(1>2073)
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGHuT4_F1620_2017-05-10_F03.ab1(65>286)
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1700 1710 1720 1730 1740 1750 1760 1770
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAG
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AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGHuman TGM4 Seq.seq(1>2073)T4_F1620_2017-05-10_F0 .ab1(65>286)
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGChimp TGM4 sequence#16AE75F.seq(1>2073)
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGChT4_F1620_2017-05-15_B02.ab1(3>273)
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGAnc TGM4 sequence f#16AE75A.seq(7>2088)
AGACCTACATCAACAGCCTGGCTATATTAGATGATGAGCCAGTTATCAGAGGTTTCATCATTGCGGAAATTGTGGAGancT4_F1620_2017-05-10_B02.ab1(62>362)
Top
1780 1790 1800 1810 1820 1830 1840
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACA
 S 
 L 
 • 
 K 
 R 
 G 
 E 
 K 
 N 
 I 
 S 
 H 
 M 
 W 
 G 
 A 
 P 
 L 
 S 
 L 
 • 
 E 
 K 
 S 
 V 
 Y 
 I 
 F 
 S 
 H 
 T 
 R 
 V 
 S 
 L 
 F 
 F 
 S 
 P 
 Q 
 S 
 V 
 Y 
 T 
 P 
 P 
 L 
 • 
 E 
 S 
 V 
 F 
 S 
 L 
 S 
 L 
 Y 
 I 
 • 
 R 
 E 
 S 
 V 
 L 
 C 
 A 
 P 
 L 
 • 
 N 
 T 
 H 
 T 
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACAHuman TGM4 Seq.seq(1>2073)
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACAHuT4_F1620_2017-05-10_F03.ab1(65>286)
GTTGCCTAACAHuT4_HISR_2017-05-10_G03.ab1(61>268)
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGATCTCTATAGAGTTGCCTAACAChimp TGM4 sequence#16AE75F.seq(1>2073)
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGATCTCTATAGAGTTGCCTAACAChT4_F1620_2017-05-15_B02.ab1(3>273)
TCACGTCTTTCCAGTACCCTG-AGATCTNTNTAGAGTTGCCTAACAChT4_HIISR_2017-05-15_C02.ab1(64>299)
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACAAnc TGM4 sequence f#16AE75A.seq(7>2088)
TCT-AA-GGAAATCATGGCCTCT-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACAancT4_F1620_2017-05-10_B02.ab1(62>362)
-GAAGTATTCACGTCTTTCCAGTACCCTG-AGTTCTCTATAGAGTTGCCTAACAancT4_HISR_2017-05-10_C02.ab1(66>312)
Top
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CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTHuman TGM4 Seq.seq(1>2073)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGHuT4_F1620_2017-05-10_F03.ab1(65>286)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTHuT4_HISR_2017-05-10_G03.ab1(61>268)
TTGACTGACGTHuT4_pflagR_2017-05-10_H03.ab1(66>322)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTChimp TGM4 sequence#16AE75F.seq(1>2073)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCChT4_F1620_2017-05-15_B02.ab1(3>273)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTChT4_HIISR_2017-05-15_C02.ab1(64>299)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTAnc TGM4 sequence f#16AE75A.seq(7>2088)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTancT4_F1620_2017-05-10_B02.ab1(62>362)
CAGGCAG-AATTGGCC-AGCTACTTGTCTGCAATTGTATCTTCAAGAATACCCTGG-CCATCCC-TTTGACTGACGTancT4_HISR_2017-05-10_C02.ab1(66>312)
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CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAHuman TGM4 Seq.seq(1>2073)
CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAHuT4_HISR_2017-05-10_G03.ab1(61>268)
CAAG-TTCTC-TTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAHuT4_pflagR_2017-05-10_H03.ab1(66>322)
CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAChimp TGM4 sequence#16AE75F.seq(1>2073)
CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAChT4_HIISR_2017-05-15_C02.ab1(64>299)
CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAAnc TGM4 sequence f#16AE75A.seq(7>2088)
CAAG-TTCTCTTTGGAA-GCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-ancT4_F1620_2017-05-10_B02.ab1(62>362)
CAAG-TTCTCTTTGGAAAGCCTGGGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAancT4_HISR_2017-05-10_C02.ab1(66>312)
GGCATCTCCTCACT-ACAGACCTCTGACCATGGGACGGT-GCAGCCTGGTGAGAancT4_pFlagRev_2017-05-10_D02.a(74>329)
Top
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CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACHuman TGM4 Seq.seq(1>2073)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAAHuT4_HISR_2017-05-10_G03.ab1(61>268)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACHuT4_pflagR_2017-05-10_H03.ab1(66>322)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACChimp TGM4 sequence#16AE75F.seq(1>2073)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCChT4_HIISR_2017-05-15_C02.ab1(64>299)
TAAGTTCCAAACChT4_pflagR_2017-05-15_D02.ab1(145>274)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACAnc TGM4 sequence f#16AE75A.seq(7>2088)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAancT4_HISR_2017-05-10_C02.ab1(66>312)
CCATCCAATCCC-AAATAAAATGCA-CCCCAATAAAAACTGGACCCAAGAAATTTATCGTCAAGTTAAGTTCCAAACancT4_pFlagRev_2017-05-10_D02.a(74>329)
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-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAAHuman TGM4 Seq.seq(1>2073)
-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAAC----------HuT4_pflagR_2017-05-10_H03.ab1(66>322)
-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAAChimp TGM4 sequence#16AE75F.seq(1>2073)
-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAACGCGGCCGCTTChT4_pflagR_2017-05-15_D02.ab1(145>274)
-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAACGCGGCCGCAnc TGM4 sequence f#16AE75A.seq(7>2088)
-AAGTGAAAGAGATTAATGCTCAGAAGATTGTTCTCATCACCAAGCACCATCACCATCACCATTAACGCGGCCGCTTancT4_pFlagRev_2017-05-10_D02.a(74>329)
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----------------------TCGAGGCATGCGGTACCGA-TACAAGGACGACGHuT4_pflagR_2017-05-10_H03.ab1(66>322)
TCGAATCTAGAGCCTGCAGTCTTCGAGGCATGCGGTACCGA-TChT4_pflagR_2017-05-15_D02.ab1(145>274)
TCGAATCTAGAGCCTGCAGTCT-CGAGGCATGCGGTACCGA-TACAAGGACGACGancT4_pFlagRev_2017-05-10_D02.a(74>329)
